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Abstract 
Although it is known that DNA topo IIȕ is required for the regulation of transcription during 
neural development and differentiation, it is not clear whether the enzyme is required during 
differentiation of human monocytes into macrophages and/or the subsequent transcription of 
cytokine genes. To test this, a robust model of differentiation of monocyte-like cells into 
macrophage-like cells using U937 and HL-60 cells treated with phorbol 12-myristate 13-
acetate (PMA) and Lipopolysaccharide (LPS) was validated. Differentiation was determined 
by morphological and growth characteristics and CD11b surface antigen expression as 
determined by flow cytometry. qRT-PCR was also used to measure mRNA transcript levels 
of key genes known to be up-regulated during monocyte differentiation and the secretion of 
pro-inflammatory cytokines produced by differentiated cells were measured using ELISA. 
siRNA  topo  IIȕ  knockdown  did  not  hinder  monocyte-like cells from undergoing 
differentiation, however experiments revealed a correlation between topo IIȕ knockdown and 
secreted TNFα, with the latter decreasing when topo IIȕ was reduced. This pattern was also 
noted when measuring IL-1ȕ secretion. Similar results were seen using a εurine  transgenic 
fibroblast cell  line  lacking  topo  IIȕ, which when stimulated with δPS secreted significantly 
lower levels of IL-θ compared to the wild type cells. Thus topo IIȕ expression is necessary for 
secretion  of  normal  levels  of  the  cytokines,  TNFα,  Iδ-1ȕ  and  Iδ-6 in response to LPS at 
certain time points. In addition in the macrophage-like state of the two cell lines, the relative 
levels  of  the  ȕ  isoform  (mRNA  and  protein)  were  shown  to  be  significantly  increased 
compared  to  α,  further  outlining  the  importance  of  topo  IIȕ  in  the  differentiated  state. 
Chromatin immuno-precipitation followed by qPCR showed however  that  topo  IIȕ was not 
associated at  three defined proximal promoter  regions of  either  the TNFα and  Iδ-1ȕ genes, 
although further studies are required to rule out a direct association of topo IIȕ with these and 
other regions of the genes.  
Down regulation of topo IIȕ protein using the inhibitor  ICRF-193 did not hinder monocyte-
like cells from undergoing differentiation either. However, contrary to the knockdown results, 
a 6 h pre-treatment with 1 nM ICRF-1λγ  increased TNFα  levels  in  these cells, both at the 
mRNA and the protein level, along with a slight  increase in secreted TNFα. NF-țB, EGRβ, 
TLR4 and TLR2 transcript levels were also increased under these conditions. Thus further 
studies are required to determine if these increases are due to additional cellular effects of the 
drug or whether topo IIȕ may play an inhibitory effect on transcription. 
Thus  it  is  clear  that  topo  IIȕ  plays  an  important  role  in  expression  of  cytokines  and 
understanding the exact nature of this requires further research that may yield potential new 
avenues for treatment of disease. 
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Chapter 1 
Introduction 
  
1.1 Topoisomerases – an overview  
DNA topoisomerases are ubiquitous enzymes found in all nucleated cells (Kunze et al., 
1991).  The double helical structure of DNA, where two strands are wound round one 
another gives rise to many problems in events such as replication, recombination and 
transcription where the strands require separation. In events such as this DNA can 
become tangled, intertwined or over-wound. DNA topoisomerases are a family of 
enzymes that are capable of unknotting and decatenating DNA and relaxing supercoils 
in order to maintain DNA in an under-wound and untangled state (Figure 1.1) 
(McClenndon et al., 2005; Deweese et al., 2008; Nitiss, 2009; Liu et al., 2009).  
                                  
 
 
 
 
 
 
 
 
 
Figure 1.1 Schematic Diagram of the action of DNA topoisomerases upon the 
topology of DNA (Liu et al., 2009) 
Each single line is representative of one double strand of DNA. Topoisomerases act to 
relax supercoiled DNA, unknot knotted DNA and decatenate catenated DNA. Bacterial 
gyrase and archael reverse gyrase, however have been shown to introduce negative 
supercoils into DNA.  
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Topoisomerases use two strategies to untangle DNA. They either create a strand break 
in the DNA catalysing the passage of another strand of DNA through the break before 
re-sealing, or they can perform a controlled rotation of one DNA strand around another. 
However the mechanism that they employ is dependent on the type of topoisomerase, 
this will be discussed further in Section 1.3. 
 
1.2 The catalytic effects of topoisomerase on DNA topology 
Topoisomerases can alter DNA topology by changing the linking number of DNA (Lk).  
Linking number is determined by the twist and writhe of the DNA. Twist is the number 
of times one DNA strand wraps around the other whereas writhe is a measure of how 
many times the axis of the double helix crosses over itself to form a supercoil. The sum 
of twist and writhe represents the number of times one strand wraps around the other 
and is called the linking number (Lk). A positive linking number indicates that the DNA 
is positively supercoiled (left-handed supercoils) and over-winding of the DNA, 
whereas a negative linking number corresponds with negative supercoiling (right-
handed supercoils) and under-winding of the DNA. 
The catalytic activity of topoisomerases can relieve torsional stress caused by either 
over-winding or under-winding of DNA. It achieves this by changing the linking 
number of the DNA. Type I topoisomerases alter the linking number by 1, i.e., remove 
one supercoil in one catalytic cycle (Kunze et al., 1991), and type II topoisomerases 
change the linking number by 2, i.e., remove two supercoils in one catalytic cycle 
(Garcia-Rubio et al., 2012). Presently DNA gyrase is the only enzyme capable of 
introducing negative supercoiling into DNA (Papillon et al., 2013). 
 
1.3 Classification of Topoisomerases 
DNA topoisomerases are classified by differences in their structure and biochemical 
activities.  
Type I topoisomerases act by creating a single strand break in duplex DNA, and either 
pass another intact single strand of DNA through the break or catalyse the controlled 
rotation of the strand breakage around the intact strand (Kunze et al., 1991; Stewart et 
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al., 1998). Type I topoisomerases are further sub-classified into type IA and type IB 
topoisomerases (Table 1.1). Type IA topoisomerases form a η’-phosphotyrosyl linkage 
with one target DNA strand (Changela et al., 2001), in comparison, type IB 
topoisomerases create a γ’ phosphotyrosyl linkage to one target DNA strand (Stivers et 
al., 1997). 
 
     Table 1.1 Classification of Type I topoisomerases 
Class A Class B 
Eubacterial Topo I & III Eubacterial Topo V 
Yeast Topo III Vaccinia Topo 
Eubacterial & Archael 
Reverse DNA Gyrase 
Human Topo I (I & 
1mitochondrial) 
Eubacterial Reverse Gyrase  
Human Topo III (α & ȕ)  
 
 
Type II topoisomerases act by creating a transient double strand break in a DNA duplex, 
they then catalyse the passage of another intact double strand of DNA through the break 
before resealing it (Liu et al., 1980; Roca & Wang, 1992; Roca et al., 1996). Type II 
topoisomerases are further sub-classified into type IIA and type IIB topoisomerases 
(Table 1.2). Type IIA topoisomerases all share sequence homology at the amino acid 
level. Type IIB topoisomerases share very little amino acid sequence homology with 
type IIA topoisomerases, thus leading to a separate classification (Champoux, 2001). 
 
Table 1.2 Classification of Type II topoisomerases 
Class A Class B 
Prokaryotic DNA Gyrase Archael DNA Topo VI 
Prokaryotic Topo IV   
Yeast DNA Topo II   
Eukaryotic Topo II (α & ȕ)   
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1.4 Structure of topoisomerases  
Type I topoisomerases act as monomeric enzymes (Das et al., 2002), with the exception 
being that of the eubacterial reverse gyrase found in Methanopyrus kandleri, which is 
heterodimeric, consisting of a 42 kDa subunit that interacts with DNA, and a 138 kDa 
ATP binding subunit (Krah et al., 1996). 
Type II topoisomerases all act as either dimeric or tetrameric enzymes (Nitiss, 2009). 
Eukaryotic and yeast topoisomerase II enzymes act as homodimers (A2). The 
prokaryotic DNA gyrase and archael DNA topoisomerase VI act as A2B2 tetramers. In 
contrast the prokaryotic DNA topoisomerase VI acts as a C2E2 heterodimer (Champoux, 
2001; Das et al., 2002; Corbett & Berger, 2004; Wall et al., 2004). 
1.4.1 Structure of type II topoisomerases 
Type II topoisomerases are comprised of three distinct regions as determined by limited 
digestion with Staphyloccocus aureus V8 (SV8) protease (Lindsley & Wang, 1991). 
The three distinct regions included the N terminal domain, the central domain and the C 
terminal domain. 
The tertiary structure of yeast topoisomerase II was first reported by Berger et al. 
(1996).  Berger et al. (1996) generated a crystal structure of the 92 kDa monomer of 
yeast topoisomerase II. They described the monomer as a flattened crescent structure 
that folds into β subunits, B’ and A’. The subunits were shown to possess a high amino 
acid sequence homology with E.coli DNA gyrase. The B’  subunit  corresponded with 
amino acid residues 420-θγγ of the gyrB domain of DNA gyrase, whilst the A’ subunit 
corresponded with amino acid residues 682-1178 of the gyrA domain of DNA gyrase 
(Figure 1.2). However the structure lacked an ATPase domain (residues 1-409) and a C 
terminal region (residues 1203-1429). Interestingly the monomer was still capable of 
cleaving DNA, however it was unable to facilitate transport of the duplex through the 
cleavage site. Once dimerised the crescent shaped monomers created a heart like 
structure that contained a large central hole, 55Å at the base, 25Å at the top and 60Å in 
height, a size capable of fitting a DNA duplex, thus suggesting this was the site of DNA 
cleavage (Berger et al., 1996).  
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Figure 1.2 Amino acid sequence homology in Type II topoisomerases.                                      
Type IIA topoisomerase sequence homology is compared to that of E.coli DNA gyrase. 
GyrB of DNA gyrase, ParE of E.coli topo IV and B’ (N-terminal) of eukaryotic topo II 
are shown in grey; this region is highly conserved in type IIA topoisomerases and 
contains the ATPase domain of the protein. GyrA, ParC and A’ (C-terminal) are shown 
in a diagonal striped pattern. This region is moderately conserved between similar 
species. It is this domain that contains the active site tyrosine and DNA binding domain. 
The C-terminal tail of all type IIA topoisomerases is shown in white. This domain does 
not share a high amino acid sequence identity between type IIA topoisomerases (a). 
Type IIB topoisomerases, of which there is only one to date, Sulfolobus shibatae topo 
VI contains only two domains, with very little amino acid sequence identity to type IIA 
topoisomerases. The B subunit (in black) contains the ATPase domain and the A 
subunit (striped) contains the active site tyrosine (b) (Champoux, 2001).  
 
 
 
 
 
6 
 
Further work using E.coli, yeast and mammalian type II topoisomerases identified other 
regions of the topo II structure, including particular amino acid residues (Figure 1.3) 
involved in the catalytic cycle and the homology between species.   
The N-terminal domain is the most highly conserved region of the type IIA 
topoisomerases. It contains the transducer domain that contains the ATPase region, 
capable of binding ATP or the analogue AMP-PMP (Champoux, 2001; Nitiss, 2009).  
The TOPRIM (topoisomerase primase) domain, a common domain found in DnaG-type 
primases, small-primase like proteins from bacteria and archaea, and type IA and type II 
topoisomerases (Aravind et al., 1998), is involved in divalent cation binding, and is also 
found in the N-terminal region of type II topoisomerases (Nitiss, 2009). It adopts an α/ȕ 
fold and is positioned so that it physically interacts with cleaved DNA (Figure 1.3) 
(Aravind et al., 1998).  
The core domain, containing the DNA binding and cleavage site is highly conserved 
between closely related species. It is this domain that contains the active site tyrosine 
found in the catabolite activator protein (CAP) like fold, or winged helix domain 
(WHD) close to the N termini (Champoux, 2001, Nitiss, 2009). Berger et al., (1996) 
describe a semi-circular groove in this core where the DNA duplex docks.  
The C-terminal domain of the enzyme is the least conserved, displaying only 30% 
amino acid sequence identity (Austin & Marsh, 1998). Differences in the sequence are 
believed to participate in differential protein association, drug action and regulation of 
enzymatic activity (Schoeffler & Berger, 2008; Gilroy & Austin, 2011). 
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Figure 1.3 Identification of amino acid and structural regions of topoisomerase II.          
Structural domains of Saccharomyces cerevisiae bound to ADPNP (η’-adenylyl-ȕ, Ȗ  -
imidodiphospahte (a) Particular amino acid residues of importance are; G139, G143, 
and G145 of the ATP binding domain (yellow) K367 in the transducer, ATPase domain 
(orange), the acidic triad, E449, D526 and D528 of the TOPRIM domain (red), Y782 
involved in the covalent attachment with DNA (purple), I833 of the tower domain 
involved in DNA interaction (green).The structure of the ATPase and breakage reunion 
domain of yeast topo II (b) The GHKL (gyrase, HSP90, histidine kinase, MutL) and the 
transducer domain are shown in yellow and orange respectively. The TOPRIM domain 
is shown in red. The WHD (or CAP like domain) is shown in purple, and the tower and 
coiled coil are shown in green and blue (Champoux, 2009).  
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1.5 Catalytic cycle of topoisomerase II 
1.5.1 DNA binding 
Recognition of specific sites of the genome by topoisomerase has been a vast area of 
interest.  
Topo II binds preferably to supercoiled DNA over linear, relaxed DNA (Crisona et al., 
2000). Investigations into site-specific binding have focused on primary and secondary 
DNA structure. Using specific topoisomerase II poisons and inhibitors (see section 1.8) 
short conserved nucleotide sequences have been established that reside at either side of 
the cleavage site, however these sequences appear to be species specific and dependent 
on the poison or inhibitor used.  Investigations into secondary structure recognition 
revealed that topoisomerase II binds to and stabilizes DNA crossovers, associates with 
helix-helix juxtapositions and cleaves at inverse repeat sequences within DNA hairpins 
(Zechiedrich & Osheroff, 1990; Froeslich-Ammon, 1994; Roca et al., 1993; West et al., 
1999).  
Topo II initially begins its catalytic process by binding one DNA duplex (termed the G 
segment), this causes a conformational change in the enzyme structure, allowing the G 
segment to interact with the enzyme’s cleavage domain. Upon binding of ATP (Figure 
1.4), dimerisation of the N terminal domains of each monomer occurs. This then 
captures the second DNA duplex (termed the T segment) creating a closed clamp 
structure (Corbett & Berger, 2004). 
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Figure 1.4 Diagrammatic representation of the catalytic cycle of topoisomerase II.  
A. The Topoisomerase II enzyme is shown in colour. The yellow, red and green structures 
represent the N terminal domain, core domain and C terminal domain, respectively (Nitiss, 
2009). First the Topoisomerase II binds to a DNA duplex, referred to as the G-segment. The 
enzyme introduces a double strand break in this DNA in the presence of Mg2+, forming a 
phosphotyrosine linkage between each single DNA strand and a tyrosine in each subunit 
(see part B). ATP binding causes the N-terminal domains to close which captures a second 
double DNA strand (T-segment) and also opens the cleaved DNA forming the ‘gate’. One 
ATP is hydrolysed which facilitates the enzyme to pass the T segment through the gate in 
the first double stranded DNA. The G segment is then re-sealed.  After passing through the 
break in the G segment, the T segment exits the enzyme through the bottom of the enzyme.  
The second ATP hydrolysis step (along with release of ADP and Pi) allows the clamp to re-
open, and allows release of the G segment. Alternately, the enzyme may initiate another 
catalytic cycle without dissociating from the G segment.  
B. The green line represents the topo II monomer. The hydroxyl group of the conserved 
tyrosine at the active site in the topo II monomer is responsible for the nucleophilic attack 
on the phosphodiester backbone of the DNA. This then creates a covalent phosphotyrosyl 
bond with the η’ of the DNA, leaving a hydroxyl moiety on the γ’ end, and a site of DNA 
cleavage. Diagram adapted from Cowell & Austin. (2012).  
 
A.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
B. 
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1.5.2 DNA cleavage 
Each monomer of topo II then initiates a transesterrification reaction by nucleophilic 
attack by a conserved tyrosine on the phosphodiester backbone of separate strands of 
the DNA duplex of the G segment, thus resulting in two covalent phosphotyrosyl bonds 
between the protein and DNA. A bond is formed between the CAP (catabolite activator 
protein) domain of each of the monomers and  the  η’  end  of  the  DNA,  leaving  a 
hydroxyl moiety on  the  remaining γ’  end  (Corbett & Berger, β00ζ). This  results  in  a 
4bp staggered cleavage site within the G segment (Shapiro et al., 1999). The reaction 
requires the binding of the divalent cation, Mg2+ at the TOPRIM domain for successful 
cleavage to occur (Corbett & Berger, 2004). Although it is Mg2+ that is required in vivo, 
in vitro studies have revealed that Mn2+, Ca2+ and Co2+ actually increase levels of 
double strand cleavage (Deweese et al., 2008).  
 
1.5.3 Strand Passage and DNA re-ligation 
Hydrolysis of bound ATP causes a conformational change in the enzyme and the T 
segment is then driven through the cleaved strand (Roca & Wang, 1992), however an 
electrostatic potential gradient has also been identified within the topo II structure that 
may also facilitate movement (Berger et al., 1996). Once the T segment has passed 
through the cleaved strand it leaves through the carboxy termini of the enzyme (see 
Figure 1.4) (Roca et al., 1996). The G segment is then re-ligated by a reverse 
transesterification reaction. The phosphorous of the phosphotyrosyl bond is attacked by 
the oxygen of the hydroxyl bond formed in the first transesterification reaction, thus 
breaking the bond and allowing the resealing of the DNA strands (Burden & Osheroff, 
1998; Deweese et al., 2008). Due to the nature of the covalent bonds created between 
the enzyme and the DNA strands, no recombination or rearrangement of the DNA 
occurs, leaving the integrity of nucleotide sequence intact. A second ATP hydrolysis 
step facilitates the reopening of the N terminal domain and release of the G segment, 
allowing the efficient turnover of the topo II enzyme.  
A study by Ding et al. (2013) has postulated that the entire catalytic cycle of topo II 
lasts 0.84 s. A diagrammatic representation of the full catalytic cycle of topo II is shown 
in Figure 1.4. 
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1.6 The Role of Topoisomerase II  
1.6.1 Replication and Transcription  
Genomic DNA is globally under-wound, thus enabling greater access to the DNA 
templates by replicative machinery (Gentry et al., 2011). Semi-conservative replication 
involves the separation of the DNA duplex in order for new strands to be synthesised 
(Figure 1.5A). This separation creates torsional stress in the form of positive 
supercoiling ahead of the replication fork (Figure 1.5B). As the replication machinery 
rotates around and travels along the template strand building up positive supercoils 
ahead, compensatory negative supercoils are formed behind the machinery in the newly 
replicated daughter molecules in an effort to nullify the positive supercoils (Figure 
1.5C). These are referred to as precatenanes (Lucas et al., 2001; McClendon et al., 
2005). 
              
 
 
 
 
 
 
Figure 1.5 Schematic representation of topological changes induced by replication 
machinery. 
(A) Replication machinery requires the separation of DNA strands in order to undergo 
semi-conservative replication of the DNA. (B) Replication results in positive supercoils 
ahead of the replication fork. (C) precatenanes are formed from newly synthesised DNA 
behind the replication fork. Topo II acts to resolve the catenanes. Topo I and Topo II are 
both capable of relaxing positive supercoils (McClendeon et al., 2005). 
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Resolution of such detrimental topology attributed distinct roles to type I and type II 
topoisomerases. Topo I, due to its ability to relieve torsional stress caused by positive 
supercoiling was believed to work ahead of the replication fork. Resolution of 
precatenanes was attributed to the catalytic activity of topoisomerase II. However there 
is now evidence to suggest that indeed topo II works ahead of the replication fork in 
addition to behind it (McClendon et al., 2005). This is supported by evidence 
suggesting  that  topo  IIα,  a  specific  mammalian  isoform  of  topo  II  favours  positive 
supercoiling.  
One of the first studies to suggest that topo I and II were required for DNA replication 
was that of Nelson et al. (1986) who, using the topoisomerase II targeting drug 
teniposide, and 3H-thymidine pulse-labelled topo II, showed that newly replicated DNA 
in rat prostatic adenocarcinoma cells interacted with topo II near the replication fork. 
Furthermore, Yan et al. (1987) showed that inhibition of topo I and II resulted in a 
decrease in DNA synthesis by 15-20 fold. A further study has also shown that mutation 
of the gene encoding Topo I slows the growth rate of yeast but is not lethal, suggesting 
that topo II can compensate for the activities of topo I (Levin et al., 1993). 
Interestingly depletion and catalytic inactivation of topo II has been shown to result in 
DNA damage at different time points during the cell cycle, however both depletion and 
inhibition are lethal to the cell. A study using budding yeast cells showed depletion of 
topo II by mutation of the gene with a restrictive promoter prevented decatenation 
during S phase, however cells still proceeded at the same rate through mitosis. DNA 
damage was induced when the cell underwent cytokinesis during the latter stages of 
mitosis. In contrast catalytic inhibition of topo II by mutating the active tyrosine 
residue, results in DNA damage in late S phase of the cell cycle and G2/M arrest of the 
cell (Baxter & Diffley, 2008). 
Supercoiling can also occur due to the actions of transcription (Liu & Wang, 1987). It 
has been established that a hindrance to the rotational movement of transcriptional 
machinery around its template, or movement of DNA around its axis can lead to 
formation of positive and negative supercoils at the same rate ahead and behind of the 
transcriptome, respectively (Fernandez et al., 2014). Indeed research has shown that an 
increase in Z DNA is found near the promoter of actively transcribed genes and this is 
quickly resolved by the actions of topoisomerases (Rich & Zhang, 2003). 
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1.6.2 Chromosome structure and mitotic function 
Topoisomerase II also facilitates chromosome condensation and segregation. Yan et al. 
(1987) reported that simian virus 40 purified DNA required the isolated nuclei of HeLa 
cells in order for successful segregation of newly synthesised daughter chromatids to 
occur. Further to this, studies in yeast using temperature sensitive topo II mutations 
revealed a lack of chromosome separation even when spindles had formed; additionally 
condensed chromosomes were shown to fragment during separation when topo II was 
unavailable. Further to this, the study also showed that cell viability was lost when cells 
underwent mitosis in the absence of topoisomerase II (Uemura et al., 1987).  
The role of topoisomerase II in chromosome condensation remains controversial 
however, as there is high variability between studies when using different inhibitors, 
mutants, antibodies or RNAi. Some studies suggest that topo II is necessary for 
successful chromosome condensation, however others saw little difference when topo II 
was inhibited. For example using chicken erthyrocyte nuclei, Adachi et al. (1991) 
showed that low levels of topo II contained in the nuclei correlated with an inability to 
condense chromosomes; upon addition of purified topo II, chromosome condensation 
occurred normally. In contrast, Lavoie et al. (2002) showed that topo II was not 
required for rDNA condensation establishment and maintenance in budding yeast. 
  
1.7 Mammalian topoisomerase II  
1.7.1 An overview 
Mammalian topoisomerase II, a 170 kDa protein was first discovered by Miller et al. 
(1981). A larger 180 kDa protein, possessing a similar structure but slightly different 
antigenicity was later discovered (Drake et al., 1987). Thus mammals were seen to 
possess two distinct topoisomerase II isoforms, later termed α and ȕ. The genes for the 
isoforms have been mapped to q12-21 on chromosome 17 and p24 on chromosome 3, 
respectively (Tan et al., 1992). In humans the isoforms are structurally similar, 
possessing 68% amino acid sequence identity, with 77% of that being in the conserved 
N terminal domain (Austin et al., 1993). They also appear to be biochemically similar, 
sharing the same catalytic cycle.  
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1.7.2 Cell Cycle Distribution 
Levels of topo II protein are highest in exponentially growing cells (Hsiang, 1988) and 
decrease during differentiation (Zwelling et al., 1990). This is reflected in levels of topo 
II during the cell cycle, however protein expression of the isoforms during the cell cycle 
differs greatly. Serum starved NIH 3T3 and BALB/c 3T3 cells appear to have 
undetectable levels of topo IIα protein until late S phase; levels of topo IIα then peak in 
G2/M phase before slowly declining into negligible amounts in G0 (Woessner et al., 
1λλ1; Chow & Ross, 1λκ7). This pattern of topo IIα was reflected in mRNA levels in a 
later study in HeLa cells, and attributed to changes in mRNA stability; mRNA in G1 
had a half-life of 30 mins, in contrast mRNA in late S phase had a half-life of over 4 h 
(Goswami et al.,  1λλθ).  Interestingly  levels  of  topo  IIȕ  during  the  cell  cycle  are 
described in many publications as remaining constant throughout the cell cycle 
(Kobayashi et al., 1998; de Campos-Nebel et al., 2010), despite multiple reports on the 
contrary (Woessner et al., 1991; Turley et al., 1997; Padget et al., 2000). For example 
work by Woessner et al. (1991) and Padget et al. (2000) using NIH-3T3 and Raji cells 
respectively report a decline in topo IIȕ protein expression as cells become confluent or 
enter G0,  although  in  contrast  to  topo  IIα,  topo  IIȕ  protein  remains  detectable  at  this 
time. Furthermore, Aoyama et al. (1λλκ) showed that levels of topo IIȕ increase during 
retinoic acid induced differentiation of HL60 cells from a promyelocytic cell type to a 
granulocytic cell morphology. Additionally McNamara et al. (2010) report that when 
NB4-MR2 cells are treated with phorbol-12-myrsitate-13-actetate (PMA) for two hours 
they display an increase in topo IIȕ  expression,  this  is  in contrast to Zwelling et al. 
(1990) who showed HL-60 cells induced to differentiate into macrophage like cells by 
24 h of treatment with PMA displayed a decrease in topo II protein expression, but they 
did not report on isoform specificity. However there is too much variation in 
experimental procedure to compare the results effectively. 
 
1.7.3 Cellular Distribution 
The opinion of where both topo II isoforms differentially localise within the cell differs 
from one publication to another. Petrov et al. (1993) reported that topo IIα was  seen 
exclusively in the nucleolus, whilst topo IIȕ appeared in the nucleolus, the nucleoplasm 
and at the periphery of heterchromatin. Zini et al. (1994) supported this report partially 
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by showing that they also found topo IIα in the nucleolus, but also in the nucleoplasm, 
however  they  only  saw  topo  IIȕ  at  a  nucleolar  level,  with  a  notable  absence  in  the 
heterochromatin and euchromatin. Chaly & Brown (1996) reported that distribution of 
topo IIα was similar during interphase and mitosis, however the distribution of topo IIȕ 
appeared variable during interphase, they also suggested that small amounts of topo IIȕ 
associated with internucleolar chromatin. Later work by Cowell et al. (1998) showed 
using isoform specific anti sera and an epitope tagging approach that topo IIȕ localised 
to the nucleus but not the nucleolar compartment. Further to this, later studies showed 
that  topo  IIα was actually concentrated  in  the heterochromatin  in mid to  late S phase, 
supporting its requirement for chromosome segregation.  Topo  IIȕ  was  shown  to  be 
associated with the periphery of heterochromatic regions in fixed and living cells. 
Interestingly treatment of cells with a histone deacetylase inhibitor revealed that topo 
IIȕ re-localised from heterochromatin to euchromatin (Cowell et al., 2011). Adachi et 
al. (1λλ7)  revealed  that  localisation  of  topo  IIα  in  the  mitotic  nucleus  was  lost  in 
interphase whilst conversely topo IIȕ was upregulated during interphase and that the C 
terminal domain of the enzymes was required for this nuclear localisation. Interestingly 
Kellner et al. (1997),  report that topo IIα is localised in the nucleus during interphase. 
The discrepancies between reports may be attributed to differences in sample 
preparations, for example earlier studies (Petrov et al., 1993; Zini et al., 1994) did not 
appear to account for potential differences in cell cycle distribution. It may also be due 
to differences between species or particular cell lines, for example Adachi et al. (1997) 
used mouse  topo  IIα protein  expressed in yeast, whilst Kellner et al. (1997) used the 
human cell line HL-60 to investigate localisation.  Additionally, although in all studies 
immunofluorescence microscopy was used, the antibodies used may have had different 
efficiencies and specificities, indeed Kellner et al. (1997) was the only study to generate 
and investigate the specificity of multiple monoclonal antibodies. Taken together, the 
differences in experimental procedure may account for the variation in topo II cellular 
distribution recorded in the literature.  
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1.8 Topoisomerase II targeting drugs 
1.8.1 An overview 
The nature of eukaryotic topoisomerase II and its catalytic actions in essential cell 
functions leaves it an attractive target for antineoplastic compounds. Many 
topoisomerase II drugs are readily available in the clinic treating a multitude of cancers 
including non-Hodgkin’s  lymphoma,  leukaemia and Karposi’s  sarcoma  to name but  a 
few. Etoposide (VP-16) is now the anti-cancer drug of choice for a number of human 
cancers including; testicular cancer, small-cell lung cancer and lymphoma (Bender, et 
al, 2008; Soubeyrand, et al, 2010; Tanaka, et al, 2007). Topoisomerase II drugs are split 
into two distinct categories; poisons and inhibitors. Classification is based on the mode 
of action of the drug and its interaction with topoisomerase II. 
 
1.8.2 Topoisomerase II poisons 
Topo II poisons act by stabilising the topo II cleavable complex, inhibiting the re-
ligation of the double strand break created by the enzyme (Germe & Hyrien, 2005). 
Recognition of the double strand break by the cell is required in order for apoptosis to 
occur; this will be discussed later in the chapter. Topo II poisons may be additionally 
subdivided into non-DNA intercalators and DNA intercalators.  
In 1965, aldehyde condensation of the non-purified root of the Indian plant, 
Podophyllum yielded products displaying anti-tumour properties. These products were 
further isolated to obtain the agent, demethylepipodophyllotoxin (DEPBG). DEPBG 
when applied to cells resulted in an inhibition of mitosis (Hande, 1998). Etoposide (VP-
16) and teniposide (VM-26), analogues of DEPBG were then synthesised and the Food 
and Drug Administration (FDA) approved them for clinical use in 1983 and 1993, 
respectively.  
Addition of etoposide to cell cultures induced single and double strand breaks. 
However, addition of etoposide to purified DNA yielded no single or double strand 
breaks. Interestingly addition of the drug to isolated cell nuclei saw the single and 
double strand breaks seen in whole cells return (Loike & Horwitz, 1976; Wozniak & 
Ross, 1983). This then lead to the discovery that etoposide induced DNA damage was 
mediated by the nuclear enzyme, topo II. 
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Etoposide and teniposide belong to the non-intercalating group of topo II drugs, the 
epipodophyllotoxins. Epipodophyllotoxins stabilise the topo II cleavage complex by 
binding to cleaved strands of DNA, preventing re-ligation. It has been shown the two 
molecules of etoposide are required for successful stabilisation; one at each scissile 
bond. Bromberg, (2003) propose a two-drug model of etoposide action. They revealed 
two molecules of etoposide were required for the stabilisation of a strand specific nick 
rather than a double strand break at each scissile bond. The work also suggested that in 
the presence of etoposide, there was no communication between the topoisomerase II 
protomers.  
Etoposide and teniposide have both been shown to preferentially target one 
topoisomerase II isoform over another, indeed etoposide and teniposide have both been 
shown to preferentially target  topo IIα (Fernandes et al., 1995). However neither drug 
targets this isoform exclusively (Willmore et al., 1998). The specific residues of topo II 
that etoposide has been shown to target are shown in Figure 1.6 
 
                                           
 
Figure 1.6 Interaction of Etoposide with Topo II  
DNA is shown in blue, etposide is shown in yellow, two topo IIȕ monomers are shown 
in this diagram, they are coloured pink and light purple. Key residues involved in drug 
interaction are labelled. The one that belongs to the second, pink monomer is flagged 
with a prime (Wu et al., 2011). 
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Elucidating the binding properties of etoposide with topo II has lead to the development 
of analogues of the drug with both increased effectiveness and fewer side effects. 
Furthermore, it has also aided in elucidating reasons for certain cell line resistance to 
etoposide. For example mutations in key residues of the enzyme lead to a decrease in 
binding activity of the drug, thus decreasing its ability to form cleavage complexes, and 
in turn decreasing its cytotoxicity. In addition, mutations at other sites of the enzyme 
may lead to a decrease in the binding affinity of the enzyme with the DNA or decrease 
the catalytic activity of the enzyme by hindering communication between the ATPase 
domain and the TOPRIM domain, thus reducing the capability of the drug to induce 
cleavage complexes (Wu et al., 2011). 
Other topo II poisons that act through intercalation of DNA to prevent re-ligation of the 
cleavable complex include the anthracyclines. First isolated from Streptomyces 
peucetius, the analogues; doxorubicin and daunorubicin were shown to have anti-cancer 
properties by targeting topoisomerase II. The ring structure of these compounds capable 
of intercalating DNA is important in their ability to stabilise the topoisomerase II 
cleavable complex (Fan et al., 2007). Other topo II poisons include the acridine, 
mAMSA and the anthracenedione, mitoxantrone. They also intercalate DNA, and 
during the cytotoxic response of cells to these drugs, topo IIȕ is preferentially targeted 
(Errington et al., 1999). Interestingly, a mAMSA derivative has been shown to 
intercalate at specific sites of topo II cleavage (Capranico et al., 1998). Furthermore, a 
specific amino acid residue in yeast topo II has been identified as mAMSA sensitive 
suggesting that mAMSA may also elicit a poisoning affect by directly binding to topo II 
in addition to intercalating DNA (Nitiss, 2009).  
Although used regularly in many chemotherapeutic regimens, the anthracyclines 
produce a certain amount of cardiotoxicity. For example reduction of doxorubicin by 
NADH dehydrogenase results in the formation of superoxide radicals. In addition 
formation of doxorubicin-iron complexes are shown to catalyse the Fenton reaction thus 
producing reactive oxygen species (ROS). An accumulation of free radicals induces a 
great amount of oxidative stress on cardiomyocytes which can result in heart failure 
(Volkova & Russel, 2011). When administered clinically, anthracyclines are often given 
synergistically with the topo II inhibitor ICRF-187 which also possesses iron chelating 
capabilities and therefore can reduce the generation of iron related ROS (Grausland et 
al., 2007). 
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Additionally, a rare side effect of treatment with topo II poisons is therapy related acute 
leukemia, in particular therapy related acute myeloid leukemia. This is associated with a 
translocation involving MLL locus, and it is hypothesised that this occurs due to repair 
of topo II poison induced adducts in such close proximity that the translocation occurs 
(Cowell & Austin, 2012). Thus it is important to investigate thoroughly the possible 
side effects of topo II poisons in order to be able to potentially combat them and/or 
determine the susceptibility of patients to the side effects potentially using the 
information to alter their chemotherapeutic regimen accordingly.  
 
1.8.3 Topoisomerase II inhibitors 
Topo II inhibitors act by inhibiting the catalytic activity of topo II, thus hindering its 
action in essential cell mechanisms. Several types exist including Merbarone, a 
thiobarbituric acid derivative which inhibits the catalytic action of topo II by preventing 
topo II mediated cleavage of DNA (Fortune & Osheroff, 1998). However the types of 
topo II inhibitors used in this study are a family known as the bisdioxopiperazines. 
These are a group of topo II inhibitors that non-competitively bind to topo II to prevent 
the hydrolysis of ATP, thus inhibiting their catalytic abilities. Drugs included in this 
group include ICRF-154, ICRF-187, and ICRF-193. Classen et al. (2003) showed that 
one molecule of bisdioxopiperazine was required to stabilize the ATPase region by 
binding both protomers simultaneously, thus creating a bridge and hindering the binding 
of ATP. Mutation of specific amino acid sequences in the ATPase domain have led to 
topo II inhibitor resistance thus supporting the mechanism proposed (Hu et al., 2002). 
However other site mutations in the N terminal and C terminal domains also confer 
resistance suggesting that ICRF-193 may bind to multiple sites (Larsen et al., 2003), 
possibly inducing a conformational change in the enzyme preventing ATP hydrolysis.   
The action by which the bisdioxopiperazines exude their cellular effects is still largely 
unknown. It is postulated that by inhibiting the catalytic cycle, and thus preventing 
enzyme turnover the cellular effects, such as an inability of cells to complete 
chromosome segregation, may be one action. Rattner et al. (1996) propose that in 
particular ICRF-193 inhibits the translocation of topo IIα to the centromere to aid with 
formation of solid kinetochores, indeed upon treatment of cells with ICRF-193 
kinetochores became visibly more fragile. Huang et al. (2001) used the protein 
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denaturant guanidinium chloride (GuHCL) in place of the traditional denaturant sodium 
dodecyl sulphate (SDS) to reveal, topo II cleavable complexes in the presence of ICRF-
193, thus suggesting that ICRF-193 may also act as a topo II poison. Interestingly they 
also report that using this method that ICRF-193 preferentially targets topo IIȕ. Taken 
together these studies suggest that ICRF-193 may have a dual action as a poison and 
inhibitor, however due to resistance being mediated through mutant ATPase regions it 
would be sensible to assume that it acts mainly as an inhibitor. Additionally treatment 
with ICRF-193 has been shown to result in entangled mitotic chromosomes, in contrast 
to the fragmented chromosomes caused by treatment with topo II poisons (Larsen et al., 
2003). In addition, the work of Isik et al. (2003) supports the work by Huang et al. 
(2001) with regards to the preferential targeting of topo IIȕ by ICRF-193. They report 
that treatment with ICRF-1λγ causes an increase in sumolyation of topo IIȕ leading to 
its selective degradation by the proteasome.  
ICRF-193 has also been shown to exert a p53 independent delay in G2/M cells (Ishida 
et al., 1994) often resulting in cell death. Interestingly, as this checkpoint is not ATM 
dependent it most likely is not a DNA damage checkpoint but a decatenation checkpoint 
(Deming et al, 2001). Progression of cells through G2/M cells in the presence of ICRF-
193 results in multiploid cells due to incomplete chromosome segregation (Iwai et al., 
1997), leading to activation of caspase-3 and apoptotic cell death (Larsen et al., 2003).  
The crystallisation of domains of the human topo II ATP domain has led to a better 
understanding of its structure, and therefore has facilitated the development of other 
topo II inhibitors, for example quinolone aminpurine 1 (QAP1) that has been shown to 
bind competitively to the ATP domain of the human topo II enzyme (Chene et al., 
2009). 
 
1.8.4 Processing of cleavable complexes 
The action by which topo II poisons and inhibitors lead to apoptosis has been the focus 
of much research and speculation. Indeed how does the cell recognise and process 
reversible double strand breaks induced by topo II when the double strand break is 
shielded by the topo II protein itself? Previous studies have shown that the stabilisation 
of transient cleavage complexes is not enough to induce cytotoxicity (Kaufmann et al., 
1998). This suggests that processing of the complex by another mechanism is required 
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to elicit a cytotoxic effect. Furthermore, removal or dilution of the drug results in the 
resealing of the staggered cuts by the enzyme, of which there is evidence in both in vitro 
(Tewey et al., 1984; Chen et al., 1983; Pommier et al., 1985) and in vivo models 
(Hsiang and Liu, 1989; Caldecott et al., 1990; Borgnetto et al., 1996; Binaschi et al., 
1997). For example studies using etoposide show that upon removal of the drug 50% of 
topo IIα and topo IIȕ mediated cleavage complexes are disassociated within 40 and 20 
minutes of drug removal respectively (Errington et al., 2004). However as cytotoxicity 
is still observed some of the remaining cleavage complexes must be processed to lethal 
lesions (Caldecott et al., 1990). Using the gamma H2AX assay these lethal lesions were 
induced approximately 1 to 2 h following drug exposure (Sunter et al., 2010). 
Studies using the topo II poison, teniposide (VM-26) have shown that the replication 
fork arrests when it comes into contact with the cleavable complex (Catapano et al., 
1997), indicating that replicational machinery could be physically colliding with the 
topoisomerase II enzyme, resulting in its physical disassociation from the DNA thus 
revealing the double strand break.  Furthermore non-topo II associated double strand 
breaks have also been reported at sites proximal to the replication fork arrest, induction 
of these double strand breaks has been suggested to be the result of recombination 
nucleases in an effort to repair and restart the replication fork (Barbour and Xiao, 2003; 
Andreassen et al. 2006). Thus taken together treatment of cells with topo II poisons can 
lead  to  the  indirect  generation  of  double  strand  breaks,  this  is  termed  the  ‘collateral 
damage’ model (Caldecott et al., 1990; Hong and Kreuzer, 2003; Polhaus and Kreuzer, 
2005). 
Further work has suggested that the cytotoxicity of topo II poisons is not exclusively 
reliant on the mechanism of replication. Indeed studies have shown using the replication 
inhibitor aphidicolin prior to cellular exposure to topo II poisons that it actually has no 
protective effect (3T3 fibroblasts, Chow and Ross, 1987; mouse mastrocytoma cells, 
Schneider et al., 1988 & 1989) or a very little 2 fold protective effect (V79 cells, 
D'Arpa et al., 1990; L1210 cells, Chow et al., 1988). In addition, work using a mouse 
carcinoma cell line revealed that treatment with aphidicolin only reduced the 
cytotoxicity of VP-16, teniposide and mAMSA but not daunorubicin, doxorubicin, 
idarubicin, epirubicin or mitoxantrone (Haldane et al., 1993). The difference in 
cytotoxicity between cell lines and different topo II poisons may be due to the varying 
longevity of topo II poison induced cleavage complex that still may have remained 
when replication was recovered.  
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Xiao et al. (2003) showed that transcriptional arrest caused by treatment of HL-60 cells 
with teniposide was responsible for activation of 26S proteasome degradation of topo 
IIȕ  specifically,  leading  to  a DNA damage  signal.  Further work  has  shown using  the 
transcription inhibitor, 5,6 dichlorobenzimidazole riboside that cells exposed to the topo 
II poisons, teniposide, VP-16 and mAMSA were more resistant to their cytotoxic effects 
(D’Arpa et al., 1990; Mao et al., 2001). Further to this cells were also shown to be more 
protected when transcription was inhibited during G1 phase rather S phase thus 
suggesting that certain cell cycle associated mechanisms may also contribute to drug 
sensitivity.  
When both replication and transcription are inhibited a synergistic protective effect 
against  topo  II  poisons  is  observed,  however  cell  killing  also  persists  (D’Arpa  et al., 
1990; Kaufmann, 1991), thus suggesting other cellular mechanisms are involved in the 
processing of cleavage complexes to lethal lesions. 
Further studies have shown that inhibition of protein synthesis using cyclohexamide 
results in a 8-fold protection to the cytotoxic effects of mAMSA (Schneider et al., 
1989). This is in support of previous work that has shown protection of cells against 
topo II poisons during replication when protein synthesis is reduced (Chow et al., 1988; 
Hromas et al., 1983).  
Studies have also shown that deletion of key proteins involved in the repair of topo II –
DNA complexes increase the sensitivity of cells to topo II drugs, one such protein is a 
TRAF and TNF receptor associated protein (TTRAP) with tyrosyl phosphodiesterase 
activity,  specifically  a  η’  tyrosyl  phosphpdiesterase  activity,  named  TDPβ  (Cortes-
Ledesma et al., 2009; Zeng et al., 2011). Further studies also identified a nuclease 
protein that removed topo II? from genomic DNA in vitro, and also showed that 
inhibition of MRE11 led to an increase in topo II? and ȕ – DNA complex formation in 
the absence of topo II poisons such as VP-16 (Lee et al., 2012). 
 
Taken together, replication, transcription, protein synthesis and repair of topo II-DNA 
complexes are all required for the processing of cleavage complexes to induce a 
cytotoxic effect mediated by topo II poisons. However these mechanisms do not act 
exclusively and other important cellular mechanisms such as DNA repair and chromatin 
remodelling may also play a part in mediating topo II poison induced cytotoxicity.  
 
23 
 
1.8.5     Factors involved in drug sensitivity 
The factors that govern sensitivity to topoisomerase II poisons and inhibitors are multi 
variable; the drug used, the cells treated and the time course of exposure used.  
εany studies have focused on quantification of topoisomerase IIα and ȕ to predict drug 
sensitivity of particular cells, with the aim to possibly generate personalised 
chemotherapeutic regimens (Dingemans et al., 1999; Depowski et al., 2000). Drug 
resistant cell lines such as that of the p388 leukaemia amsacrine resistant cell line 
displayed a significant deficiency in topo II (Per et al., 1987). Conversely an increase in 
topo  IIȕ  expression resulted in increased sensitivity to etoposide. In addition this 
increase  in  topo  IIȕ expression was  also correlated with chromatin  remodelling at  the 
topo IIȕ promoter.  
In addition to a decrease in topo II conferring resistance to topo II drugs, a decrease in 
catalytic activity of topo II also affects drug sensitivity. Eijdems et al. (1995) showed 
that the mAMSA resistance exhibited by SW-1η7γ cells did not correlate with topo IIα 
protein or mRNA levels, but did correlate with a decrease in topo IIα catalytic activity 
and they further proposed this to be due to an unknown post-translational modification. 
Gilroy et al. (β00θ)  further  demonstrated  that  a  mutation  in  topo  IIȕ  decreased  the 
affinity for ATP and ATP hydrolysis by 3 fold, thus conferring mAMSA resistance.  
Truncated forms of topo II have also been implicated in drug sensitivity; Feldhoff et al. 
(1994) revealed that the etoposide resistant small cell lung cancer cell line H209/V6 
possessed a truncated form of topo IIα with a molecular weight of 160 kDa (which was 
later attributed to a partial deletion in exon 34 of the TOP2A allele (Mirski et al., 2000). 
The truncation did not affect the catalytic activity of topo II, however it did affect the 
cellular localisation, with the majority of it being found in the cytoplasm, this is in 
contrast to the 170 kDa form which is found in the nucleus (Feldhoff et al., 1994).  
Thus cellular distribution of topo II also displays an influence on drug efficacy. Cowell 
et al. (2011) report that upon treatment of cells with the HDAC inhibitor, trichostatin A 
(TSA), topo IIȕ was redistributed from heterochromatin to euchromatin, thus treatment 
with TSA prior to VP-16 resulted in a more relevant target for VP-16 to exert its 
actions. 
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Errrington et al. (2004) showed that the half-life of cleavable complexes also 
contributed to drug sensitivity. A study using a doxorubicin resistant HL-60 cell line 
revealed  a  change  in  the  phosphorylation  states  of  topo  IIα  and  ȕ.  Topo  IIα  became 
hypo-phosphorylated  and  topo  IIȕ  became  hyper-phosphorylated at specific sites not 
seen in the wild type (Grabowski et al., 1999). 
High concentrations of the anthracycline and DNA intercalator, doxorubicin is shown to 
change the structure of DNA leading to the inhibition of topo II binding, and therefore a 
reduction in the formation of cleavable complexes (Vejpongsa & Yeh, 2014).  
The treatment length of cells to topo II poisons and inhibitors also affects the sensitivity 
of the cells to the drug. Indeed only a prolonged period of exposure to 
bisdioxopiperazines for long periods results in DNA damage, conversely a short 
exposure results in no DNA damage. This is not seen when using topo II poisons, which 
are shown to elicit DNA damage within a matter of minutes (Jensen et al., 2004).  
 
1.9 Role of topoisomerase IIα 
1.9.1 Replication, chromosome structure and mitotic function 
As described previously topo II has been shown to play a role in DNA replication. 
Interestingly  topo  IIα, unlike  topo  IIȕ prefers  to exert  its actions on positive supercoil 
substrates. As shown in Figure 1.5, positive super-coiling is generated ahead of the 
replication fork,  therefore it  is suggested that  topo IIα is  the main isoform involved in 
replication (McClendon et al., 2005).  
Extensive research has been undertaken to elucidate the role of topo II in chromosome 
condensation.  Isoform  specific  studies  have  revealed  that  topo  IIα  accumulates  at  the 
centromeres of condensed chromosomes during metaphase thus suggesting that topo IIα 
is the main isoform involved in chromosome condensation (Rattner et al., 1996). 
Additionally a regulated down-regulation  of  topo  IIα  transcription  by  doxycycline 
results in 99% of chromosome condensation but with slower kinetics and an increased 
amount of partially condensed chromosomes (Carpenter et al., 2004). Furthermore 
Johnson et al. (2009) report that treatment of chicken DT40 cells with short hairpin 
RNA  targeting  chicken  topo  IIα  resulted  in  longer  and  thinner  chromosomes.  
Interestingly, Grue et al. (1λλκ)  showed  that  topo  IIȕ  does  not  display  the  same 
chromatin  binding  properties  as  that  of  topo  IIα  and  actually  showed  that  topo  IIȕ 
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diffused away from the chromatin during mitosis, thus supporting previous work 
demonstrating the important role of topo IIα in chromosome condensation.  
The  role  of  topo  IIα  in  mitotic events is suggested to be essential for cell survival. 
Carpenter and Porter (β00ζ)  reported  that  synthesis  of  a  topo  IIα  knockout  cell  line, 
HTETOP, revealed that cells underwent mitosis but not anaphase or cytokinesis, thus 
leading to cell death. Interestingly when  trying  to  create  a  topo  IIα  knockout mouse 
model, embryonic cells failed to complete nuclear division and underwent a forced 
cytokinesis resulting in cell death (Akimitsu et al., 2003).  
 
1.9.2 Apoptosis 
εammalian  topo  IIα  has  also  been  shown to have a possible role in chromatin 
degradation. Varecha et al. (2012) used fluorescence resonance energy transfer (FRET) 
analysis of HeLa and SK-NSH cells to show that endonuclease G, an enzyme released 
from mitochondria that participates in chromatin degradation in apoptosis, interacts with 
topo IIα to degrade chromatin during apoptosis. This work is  in support of a previous 
study that showed topo IIα was required for the caspase-independent apoptotic pathway 
induced by staurosporine in NB-2a neuroblastoma cells (Solovyan, 2007). 
 
1.9.3 Protein-protein interactions 
Various studies have also demonstrated that topoisomerase IIα requires interaction with 
various proteins in order to promote its decatenation activity. De Haro et al. (2010) 
show that interaction of metnase, an enzyme containing methylase and nuclease 
domains with  topo  IIα promotes  topo  IIα dependent chromosome decatenation. Using 
HeLa, U2OS, WI38 and HCT116 cells lines, Ramamoothy et al. (2012) describe a 
direct  interaction with  the  helicase, RECQ1η with  topo  IIα  and  its  ability  to  increase 
topo  IIα  mediated  decatenation.  Additionally  work  by  Dykehuizen  et al., (2013) 
propose  that  topo  IIα  physically  interacts  with  the  BAF  complex  (mammalian 
SWItch/Sucrose Non Fermentable complex) and the ATPase activity of one of its 
subunits, Brg1 is required for the binding of topo IIα to the genome. Indeed the ability 
of topo IIα to bind to DNA was decreased in Brg1 mutants.  
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The  activity  of  topo  IIα  has  also  been  shown  to  be  a  requirement  for  the  Gβ 
decatenation checkpoint (Bower et al., 2010). More specifically phosphorylation of topo 
IIα  at  serine  1ηβζ  acts  as  a  binding  site  for  the  BRCT  domain  (BRCA1  C-Termini 
domain) of MDC1  (Mediator of DNA Checkpoint Activity protein) and binding of 
MDC1 is required for successful G2 decatenation checkpoint activity. This is supported 
by work showing the mutant serine 1524 correlates with a defective G2 decatenation 
checkpoint (Luo et al., β00λ). However topo IIα has not been shown to be required for 
DNA damage checkpoint activation (Luo et al., 2009; Bower et al., 2010).  
 
1.9.4 Transcription 
Interestingly a recent study by Thakurela et al. (β01γ)  report  that  topo  IIα  binds  to 
promoter regions in embryonic stem cells (ESCs) that are marked with the active 
histone mark, H3K4me2, and their association with developmental silent genes in ESCs 
could be involved in creating accessible chromatin for later activation. 
 
1.10 Role of topoisomerase IIȕ  
It  is  now  widely  reported  that  topoisomerase  IIȕ  plays  a  role  in  the  regulation  of 
transcription in mammalian cells, particularly in differentiating cells (Yang et al., 2000; 
Tsutsui et al., 2001; Chikamori et al., 2006; Ju et al., 2006; Lyu et al., 2006; Tiwari et 
al., 2012).  
Aoyama et al. (1998) reported that differentiation of HL-60 cells into granulocytic cells 
with retinoic acid caused an increase in protein and phosphorylation levels of topo IIα 
and ȕ. This effect persisted for λθ h with retinoic acid treatment and levels of topo IIȕ 
were still elevated 96 h after retinoic acid had been removed. A persistent elevation in 
topo IIȕ levels could be attributed to the decrease in the degradation rate of the protein. 
Using 35S-methionine,  the  degradation  rate  of  topo  IIȕ  in  retinoic  acid  (RA)  treated 
cells was 2 fold slower than those that had not been exposed (Aoyama et al., 1998). 
This then suggests that topo IIȕ is required for the transcription of genes involved in RA 
induced differentiation. This is supported by a further study using the same cell line that 
showed that topo IIȕ associated with a gene required for RA induced differentiation, the 
RARα gene (εcNamara et al., 2008).  
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Conversely McNamara et al. (2008) using a topo  IIȕ  targeting  inhibitor, ICRF-193 
showed that down-regulation of topo IIȕ resulted in the increase in expression of genes 
in  response  to  RA  suggesting  that  normally  topo  IIȕ  negatively modulates the 
expression of RA induced genes. However the study used the NB4 cell line, which 
contains  the  RARα  gene  fused  to  the  promyelocytic  leukaemia  gene  (Pεδ)  to  form 
Pεδ/RARα. This fusion may then change the association and therefore the role of topo 
IIȕ at this gene. 
The catalytic activity of  topo  IIȕ  has  also  been  shown  to  be  important  in  neuronal 
development.  Topo  IIȕ  knockout  mice  proved  to  be  non-viable due to defects in 
neuronal development; motor neurons did not innervate the diaphragm muscle and there 
was an absence of sensory projections in the spinal cord (Yang et al., 2000). A more 
detailed  inspection of murine brain development  in a  topo  IIȕ knockout mouse model 
revealed an aberrant lamination pattern in the developing cerebral cortex (Lyu et al., 
2003). Further investigation revealed  that  topoisomerase  IIȕ was  actually  responsible 
for the up and down regulation of 30% of all developmentally regulated genes, 
predominantly in the latter stage of neuronal development (Lyu et al., 2006). This was 
supported by work by Tiwari et al. (201β) who reported a switch from topo IIα to   IIȕ 
during neuronal differentiation. They also  found  that  topo IIȕ binds  to DNA sites  that 
are transcriptionally active as determined by an increase in methylation at lysine 4 of 
histone 3 during this time, and that topo IIȕ prefers to bind to promoter regions of gene 
targets involved in the progression of neuronal progenitor to neuron. An absence of topo 
IIȕ revealed a change in transcription due to alterations in accessibility to target genes, 
leading to premature death of post-mitotic neurons. Thus suggesting the role of topo IIȕ 
may  be  in  chromatin  rearrangement,  leading  to  an  ‘open’  chromatin  assembly, 
facilitating transcription of target genes. Also it has been shown that DNA superhelicity 
can facilitate the formation of transcription pre-initiation complexes on eukaryotic 
genes (Mizutani et al., 1991).  
A novel mechanism by which topo IIȕ facilitates transcription has been proposed by Ju 
et al. (2006). Stimulation of the breast cancer cell line, MCF-7 with 17ȕ-estradiol 
resulted  in  an  increased  association  in  topo  IIȕ  and  PARP-1, along with CBP co-
activator at the ps2 promoter. This was followed subsequently by recruitment of RNA 
polymerase II. Further investigation using co-ChIP revealed that PARP-1, DNA-PK, 
Ku86 and Ku70 were also found on the same strand of DNA, and it was proposed that 
they may function as part of a multi-protein complex. Interestingly a strand break was 
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discovered in the ps2 promoter, and the authors inferred that this was generated by topo 
IIȕ, this inference was supported by work showing that inhibition of topo IIȕ resulted in 
no strand break and no exchange of histone H1 with HMGB1/2 at nucleosome 3 
resulting in suppression of ps2 gene expression. Further to this, Ju et al. (2006) also 
investigated the promoter of other hormone responsive genes, one such gene was the 
TPA (PMA) responsive gene, AP-1, an important transcription factor involved in 
macrophage differentiation. Again they showed an increase in topo IIȕ, PARP-1, Ku86 
and Ku70 at the promoter of this gene following 10 min, 30 min and 60 min of 
treatment with TPA. Taken together these results suggest that a topo IIȕ  mediated 
double strand break is required for rearrangement of local chromatin architecture 
leading to recruitment and exchange of proteins involved in active transcription.  This 
work is supported by work by Haffner et al. (2010) who reported that androgen 
signalling resulted  in  the recruitment of  the androgen receptor and  topo  IIȕ  to sites of 
the TMPRSS2 genomic breakpoint and  that  this  triggered  topo  IIȕ  generated  double 
stranded breaks, furthermore they also reported that detectable de novo transcripts of the 
TMPRSS2 gene required topo IIȕ and other components of the double strand repair 
machinery.  Further work investigating  the  role  of  topo  IIȕ  at  the  psβ  promoter  in 
response to estrogen suggests that estrogen induced H3K9 demethylation leads to the 
generation of hydrogen peroxide and subsequent oxidation of bases. The repair of this 
oxidative DNA damage results in the removal of the oxidised bases result in single 
stranded nicks in the DNA. Interestingly, topo IIȕ is suggested to be recruited to these 
transient nicks, causing chromatin to bend allowing the RNA initiation complex to 
access the DNA and thus facilitating transcription (Perillo et al., 2008).  
Further  to  this,  proteasomal  degradation  by  the  βθS  proteasome  of  topo  IIȕ  upon 
treatment of cells with ICRF-193 is due to transcriptional arrest rather than DNA 
damage (Xiao et al., 2003). It is possible that the transcriptional arrest is occurring 
because topo IIȕ is unable to act due to inhibition with ICRF-193, thus supporting the 
increasing evidence base that topo IIȕ is required for transcriptional regulation. 
 
1.11 Protein association and post-translational modifications of topo II 
Investigations into the cell cycle distribution of the topo II isoforms revealed an 
interesting change in the molecular weight of topo IIȕ. Kimura et al. (1994) showed a 
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10 kDa increase  in  the molecular weight of  topo  IIȕ  in Heδa cells when cells entered 
metaphase.  In  addition  they  also  reported  a  return of  topo  IIȕ  to 1κ0 kDa when cells 
exited metaphase. They postulated that this increase in molecular weight could be due 
to phosphorylation of topo IIȕ. Indeed an earlier study showed that phosphorylation of 
topo IIα increased as cells reached ε phase (Sayor et al., 1992). Burden et al. (1994) 
suggested that hyper-phosphorylation  of  topo  IIȕ  in  mitosis  may  be  involved  in  the 
stabilisation of the enzyme during nucleolar disassembly. This work was supported by 
Aoyama et al. (1λλκ) who  showed  that  phosphorylation  of  topo  IIȕ was  increased  in 
retinoic acid treated cells and this correlated with a decreased rate of degradation of the 
enzyme, thus suggesting an increase in stability. In addition McNamara et al. (2010) 
speculate  that  the  increase  in  topo  IIȕ  protein  expression  displayed  upon  Phrobol 
Myristate Acetate (PMA) stimulation is due to an increase in stability caused by 
phosphorylation of the protein by Protein Kinase C (PKC).  
Post-translational modifications of topo II are also involved in the degradation of the 
enzyme upon treatment with topo II poisons and inhibitors.  Mao et al. (2001) reported 
that ubiquitination of topo II in HeLa cells treated with VM-26 lead to a 26S 
proteasome mediated degradation of topo II. Interestingly, topo IIȕ was  preferentially 
degraded over topo IIα.   Previously they had shown that SUεO-1 physically interacts 
with topo II, and an increase in SUMO-1/topo II conjugate was observed when HeLa 
cells were treated with VM-26, ICRF-193 and heat shock. They also suggested that the 
conformational change in topo II caused by VM26 and ICRF-193 may trigger binding 
of SUMO-1 (Mao, β000). A later study revealed that modification of topo IIȕ by SUεO 
2/3 and polyubiquitination occurred after cells had been treated with ICRF-193, 
resulting  in  the  degradation  of  topo  IIȕ.  Additionally  knock  down  of  the  SUεO 
conjugating enzyme Ubcλ resulted in a lack of topo IIȕ degradation (Isik et al., 2003).  
Both isoforms of topo II have also been shown to physically interact with HDAC 1/2. 
Topo  IIȕ  was  shown  to  interact  specifically  with εTAβ,  a  component  of  the  Nurrd 
complex of HDAC1, and as discussed earlier. Inhibition of HDAC causes the 
redistribution  of  topo  IIȕ  from heterochromatin  to  euchromatin  (Cowell  et al., 2011). 
Further co-localisation experiments revealed that HDACβ and topo IIα were associated 
with each other in the nucleoplasm (Tsai et al., 2000).  
Cowell et al. (2000) used the cell line MCF7 to co-immunoprecipate topo IIα and topo 
IIȕ with pηγ. They also revealed using the yeast system Sacchromyces cerevisae that 
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topo IIȕ interacts specifically with the C terminal domain of p53. Interestingly, prior to 
this, pηγ was shown to repress the gene expression of topo IIα (Wang et al., 1997). 
Nakano et al. (1996) proposed a mechanism by which CDγİ may regulate the action of 
topo  IIȕ. Using  the murine hybridoma cell  lines βBζ and DO11.10 and a  32P-labelled 
GST fusion protein  they revealed  that upon T cell activation CDγİ translocates  to  the 
nucleus and associates with topo IIȕ. This supports work with expression libraries that 
revealed topo IIȕ clone sequences bind to CDγİ. Treatment of the same cells with topo 
II inhibitors causes a super induction of Interleukin-2, a similar effect is witnessed when 
Cdγİ binds to topo IIȕ suggesting that it may regulate topo IIȕ by hindering its catalytic 
action.  
It is now widely accepted that topo II? is involved in the regulation of transcription, 
particularly so in the regulation of genes involved in neuronal development and 
differentiation. Both these cellular events require multiple changes in gene expression, 
and thus topo II? is required for such changes, including activation and repression. 
However differentiation events are not solely limited to cells of a neuronal lineage; in 
fact the innate immune system gives rise to regular differentiation events, which also 
require changes in gene expression for commitment of cell fate.  
In addition levels of topo II? are also increased in the serum of patients suffering with 
hepatitis B induced liver inflammation, thus indicating a role for topo II? in 
inflammation, indeed it is postulated that an inflammation induced up-regulation of topo 
II? may represent an initial marker of inflammation related malignancy (He et al., 
2003). 
 
1.12 The innate immune system 
The innate immune system is the first line of defence against infection. Its actions are 
immediate, non-specific and with no immunological memory. Along with recognition 
and destruction of potentially pathogenic infections it also acts to present foreign 
molecules to cells of the adaptive immune system (Mogenson, 2009). Cells of the innate 
immune system largely comprise leukocytes, and in particular a family of phagocytes 
that include, monocytes, macrophages, dendritic cells and neutrophils (Janeway & 
Medzhitov, 2002). Recognition of potentially pathogenic microbes is via conserved 
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regions of the microbe, termed pathogen associated molecular patterns (PAMPs). 
PAMPs are distinctively different from any host molecules. Mononuclear phagocytes 
recognise PAMPs through pattern recognition receptors (PRRs) (Janeway, 1989). PRRs 
of particular importance are termed the Toll like receptors (TLR) due to their high 
homology with the Drosophila receptor, Toll (Seong & Matzinger, 2004) that also 
recognise pathogens. 
1.12.1 Macrophage differentiation 
Hematpoetic differentiation leads to the generation of various different cell types 
originating from a single progenitor, the hematopoetic stem cell. From here, the 
hematopoetic stem cell differentiates into a multipotent progenitor and then into a 
dyspotent progenitor including the common lymphoid and common myeloid 
progenitors. Further differentiation of these progentitors leads to commitment into 
mature cells including B cells, T cells, natural killer (NK) cells and dendritic cells, 
macrophages and granulocytic cells respectively (Seita & Weissman, 2010). Monocytes 
are specifically derived from CD34+ progenitor cells in the bone marrow, they are then 
released into the peripheral blood where they circulate for several days before entering 
the tissues to replenish any tissue macrophages lost to apoptosis (Gordon, 2005).  
Differentiation occurs in vivo via stimulation of monocytes by macrophage colony 
stimulating factor (M-CSF). In vitro models of monocyte differentiation use phorbol 
esters such as Phorbol 12-Myrsitate 13-Acetate (PMA) to differentiate monocyte 
derived cell lines into cells that display a macrophage like phenotype. Previous work 
utilising this differentiating agent was done so in order to elucidate the transcriptional 
and post-translational mechanisms involved in differentiation and stimulation of 
monocytes and macrophages (Suzan et al., 1991; Ghosh et al., 2010). For example, 
Shelley et al. (2002) reported that an up-regulation of the CD11c integrin on the cell 
surface of cells undergoing differentiation was due to binding of the transcription factor 
Pur? to the CD11c promoter. The cell model used in this investigation was the 
monocytic cell line U937 that can be stimulated with PMA. U937 cells are of a 
monocytic lineage and express the gene encoding TNFα and secrete TNFα in response 
to PMA and LPS (Sundstrom & Nilsson, 1976). Differentiation with PMA also allows 
the investigation of the inflammatory response (Carruba et al., 2003). For example, 
Infantino et al. (2010) reported that stimulation of PMA treated U937 cells with LPS 
leads to an up-regulation of citrate carrier mRNA and protein expression and suggest 
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that the mitochondrial citrate carrier plays an important role in the inflammatory 
response. 
Differentiation of monocytes into macrophages is accompanied by changes in cell 
morphology and cell growth. Terminally differentiated macrophages lose their ability to 
proliferate (Takashiba et al., 1999), this is reflected by the G2/M arrest observed in 
various PMA treated cells (Kosaka et al., 1996; Barboule et al., 1999, Oliva et al., 
2008). During differentiation, cells become more granular, and Daigneault et al. (2010) 
attributed this to an increase in membrane bound organelles. Additionally an increase in 
intracellular organelles may also be observed due to an increase in the amount of 
mitochondria and lysosomes present within the macrophages (Valledor et al., 1999). 
PMA induces differentiation of monocytes to macrophages by activation of the protein 
kinase C (PKC) pathway (Johnson et al., 2002). This is the major pathway of activation. 
The PKC family is divided into three distinct subsets; conventional, novel and atypical. 
Conventional  PKCs  include  α,  ȕI,  ȕII and  Ȗ,  and  this  subset  of  PKCs  require  Ca2+, 
diacylglycerol (DAG) and the co factor phosphatidyl for activation. Novel PKCs 
include į, İ , ș, Ș, and ȝ. This subset of PKCs unlike the conventional PKC subset do 
not require, Ca2+ for activation. The atypical PKCs include ȗ and I/Ȝ and require PIP3, 
ceramide and phosphatidic acid for activation (Valledor et al., 1999).  
A detailed outline of PKC mediated macrophage differentiation is described in Figure 
1.7. 
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Figure 1.7 Schematic Representation of the pathways of macrophage differentiation by M-CSF and 
PMA.  
Binding of M-CSF to the tyrosine residue of the FMS receptor results in its autophosphorylation which in 
turn leads to the activation of phospholipase C and cleavage of phosphatidyl-inositol biphosphate creating 
DAG and release of Ca2+. DAG and Ca2+ along with the co factor phosphatidyl activate conventional 
protein kinases, which then lead to activation of the GTPase switch, Ras. This in turn activates Raf-1, a 
serine/threonine protein kinase. This phosphorylates and activates MEK-1, which then induces the 
phosphorylation and activation of ERK 1 and 2. Activation of ERK 1 and 2 leads to an up-regulation of 
transcription factors involved in early macrophage differentiation and a decrease in transcription factors 
involved in driving differentiation to a neutrophil like lineage. PMA is homologue of DAG and so acts 
through the same PKC dependent pathway. Conventional (α), novel (İ) and atypical (į) PKCs have been 
implicated in the activation of NF-țB either by phosphorylation of  IKK or by increasing NF-țB DNA 
binding (Valledor et al., 1999; Lee et al., 2003). 
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The primary transcription factor involved in monocyte to macrophage differentiation is 
Pu.1. Studies involving generation of Pu.1 knockout mice report death of the mice 
within 48 hr due to severe bacterial septicaemia, resulting from a lack of mature anti-
bacterial macrophages (McKercher et al., 1996). In order for differentiation to occur, 
monocytes must successfully respond to signalling by the macrophage-colony 
stimulating factor (M-CSF) via the macrophage colony stimulating factor receptor. The 
M-CSF receptor is the protein product of the c-fms gene. Pu.1 has been shown to bind 
to purine rich sites in the promoter of the c-fms gene, facilitating its transcription. 
Additionally Pu.1 has been shown to cause the up-regulation of adhesion molecules 
including CD11b, CD18 and CD14, which are all concomitant with macrophage 
differentiation (Valledor et al., 1998). Furthermore, Oshuri & Natoli (2013) propose 
that in addition to actively promoting gene expression, binding of Pu.1 to distal 
genomic regions causes nucleosome depletion and deposition of H3K4me1, resulting in 
sites of accessible chromatin thus facilitating the binding of multiple other transcriptions 
factors. Other transcription factors involved in the commitment to macrophage lineage 
include Sp1, EGR2, HOXB7 and NF-Y and members of the proto-oncogene families 
Jun/Fos (Valledor et al., 1998). Interestingly other transcription factors, for example 
EGR-1, have been shown to block the differentiation of cells towards a granulocytic 
lineage, therefore driving macrophage differentiation (Krishnaraju et al., 1998). 
Furthermore, loss of proliferation associated with a macrophage phenotype has been 
attributed to repression of the c-Myb and c-Myc genes early in the differentiation 
process (Valledor et al., 1998).  
Macrophages are a highly heterogeneous population of cells, found in all areas of the 
body. Microglia are macrophages that are found in the brain, alveolar macrophages are 
found in the lung; histiocytes are found in interstitial connective tissue and Kuppfer 
cells in the liver.  However differences in macrophage populations does not rely solely 
on location in the body. The various populations of macrophages are activated 
differently; these populations are broadly grouped into, classically activated (M1) and 
alternatively activated (M2) macrophages.  
Classically activated macrophages require a type I cytokine environment including 
interferon gamma (IFNȖ) and cytokine stimuli (TNFα,  Iδ-1ȕ) in order to be activated. 
Conversely a type II cytokine environment, comprising IL-4 and IL-13 inhibits 
classically activated macrophages (Ghassabeh et al., 2006). M1 macrophages also 
display an IL-12high, IL-23high, IL-10low phenotype (Manotovani, 2006). 
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Alternatively activated macrophages are activated in a type II cytokine environment, 
and are inhibited in a type I cytokine environment (Namagala et al., 2001). It was first 
postulated that this type of macrophage was the result of IL-4 antagonism of classically 
activated macrophages, however identification of a mannose receptor (MC1) which was 
up-regulated upon IL-4 stimulation along with an increase in expression of MHC class 
II molecules supported the distinction of this type of macrophage from a classically 
activated one (Gordon, 2003). Alternatively activated macrophages also display a 
distinguishable IL-12low, IL-23low, IL-10high phenotype (Manotovani, 2006). 
 
1.12.2 Inflammation 
Inflammation is characterised by five symptoms; swelling, redness, pain, fever and loss 
of function (Punchard et al., 2004). Inflammation in response to activation of the innate 
immune response by pathogenic stimuli, results in stimulation of resident tissue 
macrophages that then signal for the recruitment of leukocytes to the site of infection 
and their subsequent activation (Granger et al., 2010). Activation of macrophages 
occurs  via  stimulation  by  IFNȖ,  ε-CSF,  TNFα  and  lipopolysaccharide (LPS). 
Macrophages play a pleotropic role in inflammation including, phagocytosis, antigen 
presentation and immunomodulation (Fujiwara et al., 2005). Deactivation of 
macrophages requires secretion of anti-inflammatory cytokine such as IL-10 and TGFȕ 
by resting macrophages, thus leading to inhibition of inflammation that is necessary in 
order to allow repair of the affected site (Mosser et al., 2003). A dysregulation of the 
inflammatory response is associated with many disease states such as Rheumatoid 
Arthritis, Type II Diabetes and cancer (Coussens et al., 2002; Pickup et al., 2004; 
Moelants et al., 2013). 
 1.12.3 Toll Like Receptors 
There are 13 known Toll like receptors found in mammals, each recognising a distinct 
pattern associated with different pathogens either directly or indirectly (Shubolet et al., 
2007). Characterisation of Toll like receptors is based on the leucine rich repeat in the 
extracellular domain and the TIR domain in the intracellular domain (Takeda et al., 
2003). Toll like receptor 2 recognises and binds to a specific PAMP found in 
lipotechoic acid that makes up the wall of Gram-positive bacteria, and it has also been 
shown to recognise components of the herpes simplex virus. TLR3 has been shown to 
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recognise and bind viral double-stranded RNA. Toll like receptor 4 indirectly 
recognises lipopolysaccharide (LPS) found in the membrane of gram-negative bacteria. 
LPS firstly binds to LPS binding protein, which is in turn bound to the cell surface 
antigen, CD14, this then associates with the extracellular domain of TLR4. TLR5 has 
been shown to recognise bacteria flagellin, whilst TLR9 recognises unmethylated CpG 
sites on bacterial DNA (Moresco et al., 2011).  
Recognition of foreign material by TLRs causes a cascade of intracellular signalling 
leading to activation of NF-țB  and  thus  expression  of  genes  involved  in  the  innate 
immune response (Zhang et al., 2001). 
 
1.12.4 Activation of NF-țB 
NF-țB is a family of transcription factors that contain a Rel homology domain (RHD) 
which bind to discrete sequences of DNA termed țB sites. țB sites are often found in 
promoter or enhancer regions of various genes including those that encode pro-
inflammatory cytokines. There are five members of the NF-țB family identified to date, 
including RelA (p65), Rel B, C-Rel, p100 and p105. NF-țB exists as a heterodimer or 
homodimer of these components. It is synthesised and stored within the cell in its 
inactive  form; bound  to  a member of  the  inhibitor of kappa B  (IțB)  family. The  IțB 
family are a group of inhibitor proteins including IțBα, IțBȕ, IțBȖ, IțBİ, Bcl-γ, IțBȗ, 
IțBε  (Oeckingham & Ghosh,  β00λ; Lawrence 2009). It has been demonstrated that 
IțBα,  IțBȕ,  IțBȖ  and  IțBİ  inhibit  the  translocation  of  NF-țB  to  the  nucleus,  thus 
inhibiting its actions as a transcription factor (Anratha et al., 1999). The remaining 
IțB’s  are  believed  to  interact  with  NF-țB  in  the  nucleus  to  regulate  transcription 
(Yamazaki et al., 2001). Stimulation of TLRs leads to phosphorylation of serine 
residues within the IțB by the IKK complex (a complex including the catalytic domains 
IKKα  and  IKKȕ,  along  with  the  regulator  NF-țB  essential  modifier,  NEεO). 
Phosphorylation of  IțB  leads  to  its  polyubiquitination and  subsequent degradation by 
the 26S proteasome (Chen et al., 2005; Krappman et al., 2005). This then releases the 
NF-țB, allowing its translocation to the nucleus. A more detailed pathway of activation 
is described in Figure 1.8. 
Interestingly a comparatively new area of investigation with regards to NF-țB  is  the 
activation of it in response to DNA damage. In particular, elucidating the mechanism of 
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recognition of DNA damage including double strand breaks and the subsequent 
activation of NF-țB.  Studies  have  shown  that  ataxia  telangiectasia  mutated  (ATε) 
protein, a protein kinase activated by DNA damage is indispensable for the activation of 
NF-țB  in  response  to  irradiated  radiation  and  topoisomerase  poisons  that  are  able  to 
induce double strand breaks. Indeed it has been suggested that ATM does not recognise 
these double strand breaks through direct binding but through alterations in high-order 
chromatin as a result of the double strand break (Janssens & Tschopp, 2006). Activation 
of ATM then phosphorylates NEMO, a component of the IKK signalosome. 
Phosphorylation then leads to the zinc finger dependent ubiquitination of NEMO. Both 
the phosphorylation and ubiquitination of NEMO are required for NF-țB  activation. 
Upon ubiquitination of NEMO, a small amount of ATM is re-localised to the cytoplasm 
where it activates TAK1. Activation of TAK1 leads to association and activation of 
multiple proteins and protein complexes, however the exact mechanism still remains 
unclear. These interactions ultimately lead to activation of the conserved IKK thus 
leading to activation of NF-țB (εcCool & εiyamoto, β01β). 
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Figure 1.8 Schematic diagram outlining the pathway of NF-țB activation by TLR 
ligation (Kawai & Akira, 2007) 
Ligation of TLR leads to activation of the myeloid differentiation primary response 
gene 88 (MyD88) dependent pathway and the TRIF dependent pathway. For successful 
transcription of pro-inflammatory cytokines induced by NF-țB,  activation of both the 
TRIF and MyD88 pathway are required post stimulation of TLR4. Activation of 
MyD88 and TRIF is via TIR domain containing adaptors, TIRAP and TRAM 
respectively. The death domain of MyD88 then associates with the death domain of the 
protein kinases IRAK1 and IRAK4. Activation of IRAK4 leads to phosphorylation of 
IRAK1, thus causing the dissociation from MyD88. IRAK1 and 4 then interact with 
TRAF6, a ring domain E3 ubiquitin ligase, this then associates with Ubc13, E2 and 
UeV1a to ubiquitinate itself, leading to the recruitment of TAK1. This then activates the 
IKK and MAPK pathways. Activation of IKK leads to phosphorylation and subsequent 
degradation  of  IțB  leading  to  the  release  and  translocation  of NF-țB  to  the  nucleus. 
Activation of MAPK leads to the phosphorylation and activation of another 
transcription factor involved in the transcription of pro-inflammatory cytokines, AP-1.  
The TRIF pathway of activation is similar to that of MyD88, however it binds directly 
to TRAF6 via the TRAF6 binding motif in its N terminal domain. 
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1.13 Cytokines 
Cytokines are proteins released by the cell in response to a variety of stimuli, including 
UV radiation, heat shock and activation of the MAPK pathway via toll like receptor 
activation or binding of external cytokines. Cytokines possess no conserved amino acid 
sequence motifs or 3D structure similarity; instead they are identified and grouped 
according to their biological activity. Historically, cytokine is a general term used to 
describe these proteins, more specific terms used are; lymphokines, cytokines released 
by lymphocytes; monokines, cytokines released by monocytes; chemokines, cytokines 
that have chemotactic activity and interleukins, cytokines that are produced by and 
activate leukocytes. For the purposes of this work the general term, cytokine will be 
used. Cytokines are produced by all nucleated cells, however the largest source of 
cytokine production are T helper cells and macrophages (Epstein et al., 1998; Dinarello, 
2000). Different cell types may release the same cytokine; in addition these cytokines 
may act pleotropically, activating different cell types (Zhang et al., 2007). Cytokines are 
loosely grouped into those that induce a pro-inflammatory effect and those that have an 
anti-inflammatory effect, although some cytokines for example IL-6 (Schiller et al., 
2011) may have both a pro and anti-inflammatory effect depending on the environment 
they are acting in.   
The most abundant pro-inflammatory cytokines found at sites of inflammation are 
TNFα, Iδ-1 (specifically IL-1ȕ) and Iδ-6 (Cavaillon, 1993). Thus they have proven to 
be an attractive target of investigation. 
1.1γ.1 TNFα 
Tumour necrosis factor alpha (TNFα) is a type II transmembrane protein. It exists as a 
51 kDa homotrimer (Idris et al., 2000). The 17 kDa monomers consist of antiparallel ȕ 
pleated sheets along with antiparallel ȕ strands to form a beta structure (Eck & Sprang, 
1λκλ). TNFα  is  constitutively  produced by  a  variety  of  cells  including, macrophages, 
mast cells, endothelial cells and fibroblasts. The actions of TNFα are pleotropic, capable 
of inducing apoptosis, cell proliferation and cytokine production (Horiuchi et al., 2010).  
TNFα is inactive in its membrane bound form, cleavage and release of the homotrimer 
from the membrane by TNFα converting enzyme (TACE) allows the release of TNFα 
into the extracellular environment. Reactive oxygen species are shown to mediate the 
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LPS induced catalytic activity of TACE indirectly through activation of the p38 
signalling pathway (Scott et al., 2011). 
Activation of cells is via TNF receptors, TNF-R1 and TNF-R2. TNF-R1, a 55 kDa 
protein is ubiquitously expressed on most cells (Shen & Pervaiz, 2006), whilst the 75 
kDa protein TNF-R2 is expressed in low levels on cells of immune lineage (Idris et al., 
2000). Both receptors can bind membrane bound and soluble TNFα, however TNF-R2 
is only fully activated by binding of membrane bound TNFα. Binding of TNFα to TNF-
R1 and TNF-R2 results in the activation of the NF-țB survival pathway.  
Interestingly extracellular domains of TNF-R1 and R2 can be cleaved to form soluble 
fragments  that  have  been  shown  to  neutralise  soluble  TNFα.  It  has  been  shown  that 
TNF-R2 is also cleaved by TACE, however the enzyme responsible for the cleavage of 
TNF-R1 remains unknown. Studies have shown that inhibiting the cleavage of TNF-R1 
results in a disease state similar to that of an auto-inflammatory disease, thus suggesting 
that the neutralising actions of TNF-R1 fragments are required for regulation of the 
TNFα driven inflammatory response (Horiuchi et al., 2010).  
Signalling of TNFα through TNF-R1 and R2 leads to the translocation and activation of 
NF-țB  (Poyet  et al., 2000), which in turn leads to further transcription of cytokines. 
Thus  TNFα  is  able  to  perpetuate  the  pro-inflammatory response, whilst creating a 
positive feedback loop leading to further transcription of the TNFA gene. 
TNF-R1 contains a death domain that is required for the recruitment of the death 
domain containing TRADD protein. The subsequent TNF-R1-TRADD complex then 
creates a physical platform to enable the binding of TRAF2 to the receptor interacting 
kinase (RIP). TNF-R2 in comparison is able to directly recruit TRAF2, leading to gene 
expression (Wajant et al., 2003).  
Activation of both TNF-R1 and TNF-R2 in the presence of HIV infected T cells and 
peripheral blood lymphocytes has been shown to induce apoptosis of the infected cells 
and initiation of this was via cooperative signalling of TNF-R1 and TNF-R2 (Lazdins et 
al., 1λλ7). This suggests that TNFα signalling through binding of transmembrane TNFα 
is more important than first thought, thus an increasing amount of studies are focusing 
on the role of transmembrane TNFα. 
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Studies  using  transmembrane  TNFα  knock-in mice that are unable to secrete soluble 
TNFα are capable of controlling Leishmania infection (Allenbach et al., 2008). Previous 
work showed that interaction of transmembrane TNFα on CDζ+ on Leishmania infected 
macrophages resulted in the inhibition of intracellular Leishmania (Birkland et al., 
1992).  
The  requirements  for  the  transcription  of  TNFα  appear  to  differ  in variations of 
macrophages. Means et al, (β000) report that transcription of TNFα in response to δPS 
in alveolar macrophages requires ERK signalling, in contrast inhibition of ERK in non-
pulmonary macrophages cells did not affect the LPS induced transcription of TNFα. In 
addition they also identified εAPK dependent and independent elements in the TNFα 
promoter, and proposed that use of them was cell type specific.  
Transcription  of  TNFα  also  appears  to  be  dependent  on  the  type  of  stimulus  it  is 
activated by. Trede et al., (1995) showed that stimulation treatment of the monocytic 
THP-1 cells with Staphylococcal enterotoxin A caused an up-regulation of NF-țB 
binding to specific kappa γ site in the TNFα promoter. 
Additionally post-transcriptional regulation has been  attributed  to  TNFα  regulation. 
Inhibition of pγκ lead to a decrease in translation of the TNFα transcript, implying that 
pγκ may stabilise TNFα mRNA (δee et al., 1999). 
 
1.13.2 Interleukin 1  
Interleukin 1 is a family of cytokines including IL-1α and IL-1ȕ. They share only βθ% 
amino acid sequence homology, however they have been grouped together as they both 
share the same receptor, IL-1R1 (Kohira et al., 1993; Hacham et al., 2002). IL-1α   and 
ȕ exist as precursor proteins, pro-IL-1α and pro-IL-1ȕ (Fettelschoss et al., 2011). 
 
1.13.3 Interleukin-1ȕ 
Pro-IL-1ȕ is a 31 kDa precursor protein, which is then cleaved by the enzyme caspase-1 
to create the 17 kDa, mature, active IL-1ȕ  (Hailey  et al., 2009). The mature IL-1ȕ 
protein  is  a  ȕ  trefoil  fold  formed  by  1β  ȕ  strands  (Chavez  et al., 2006). IL-1ȕ  is 
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primarily produced by monocytes and macrophages, however it is also produced in 
smaller quantities in neutrophils, keratinocytes, epithelial cells and fibroblasts. The role 
of IL-1ȕ  in  the  innate  immune  system is to promote the recruitment of inflammatory 
cells, increasing the amount of adhesion molecules on endothelial cells and inducing 
stromal cells to release chemokines. 
In order for caspase-1 to cleave and thus activate IL-1ȕ, it must first be activated. This 
is regulated via the actions of the inflammasome (NALP3), a multi-protein complex 
comprised of casapse-1, the adaptor protein, ASC and the NOD like receptor, and NLR 
(Agostini et al., 2004; Gabay et al., 2010). Studies have also shown that pro-IL-1ȕ can 
also be cleaved by extracellular proteases to yield active IL-1ȕ (Fantuzzi et al., 1999). 
Interestingly, NF-țB  in addition  to activating  the  transcription of  Iδ-1ȕ has also been 
shown to inhibit caspase-1 dependent IL-1ȕ  cleavage  by  increasing  the  expression of 
anti-apoptotic genes (Greten et al., 2007).   
Binding of IL-1ȕ  to  Iδ-1R1 leads to recruitment of the IL-1R accessory protein, IL-
1RAcP. The IL-1-IL-1R1-IL1RAcP complex induces the recruitment of MyD88 which 
then as described previously (section 1.12.4), leads to activation of NF-țB, pγκ, and the 
JNK, ERK 1/2 and MAPK pathways (Gabay et al., 2010). 
Transcription of IL-1ȕ  also  relies  on  the  actions  of  specific  transcription  factors 
involved in the regulation of cytokine expression, for example, SP-1, AP-1 and NF-țB.  
However, like TNFα, variability in actions of transcription factors may be environment 
dependent. Exposure of cells to fibronectin, a protein produced by injured tissues led to 
an up-regulation of IL-1ȕ mRNA expression. An increased binding of the transcription 
factor, AP-1 was observed at the IL-1ȕ promoter, however there was no change in NF-
țB binding. Fibronectin was shown to bind to the cell surface integrin αηȕ1 which then 
activated the MAPK pathway leading to the increased binding of AP-1 (Roman et al., 
2000). Furthermore, a chronic stimulation of chondrocytes with inflammatory cytokines 
led to an increase in expression of IL-1ȕ.  This  was  associated  with  an  increase  in 
demethylation of specific CpG sites in the IL-1ȕ proximal promoter (Hashimoto et al., 
2013). 
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1.13.4 Interleukin-1α  
Pro-IL-1α is a γ1 kDa precursor protein. Removal of the N terminal amino acids by the 
protease calpain results in the 18 kDa mature form of IL-1α. Iδ-1α is mainly produced 
by macrophages and neutrophils but can also be expressed by cells of non-hematopoetic 
lineage including keratinocytes and fibroblasts (Rider et al., 2013). IL-1α  is  active  in 
both its soluble and membrane bound form. It has been hypothesised that 
phosphorylation of pro-IL-1α  leads  to  a  conformational change resulting in surface 
anchoring via lectin binding (Beuscher et al., 1988; Brody et al., 1989). Active 
membrane bound IL-1α  has  been  shown  to  allow  physical  cell  – cell signalling, 
important for activation of neighbouring cells. Activation of membrane bound IL-1α 
relies solely on activation of NF-țB.  However  activation  of  soluble  Iδ-1α  requires 
activation of NF-țB, the inflammasome and caspase-1. Interestingly, secretion of IL-1α 
requires the action of IL-1ȕ  as  a  shuttle  to  enter  the  extracellular environment 
(Fettelschoss et al., 2011). IL-1α  signals  through  the  same  receptor  ligand  as  Iδ-1ȕ, 
leading to a cascade of intracellular signalling as described in Section 1.13.3 (Hacham 
et al., 2002) 
IL-1α may  also  have  a  dual  role within  the  cell. IL-1α  contains  a  functional  nuclear 
localisation sequence that allows translocation to the nucleus where it has been shown 
to bind to histone acetyltransferases thus facilitating the expression of pro-inflammatory 
cytokines, furthermore it is able to do this independently of IL-R1 binding at the cells 
surface (Rider et al., 2013).  
Little is known with regards to the transcriptional regulation of IL-1α compared to other 
pro-inflammatory cytokines. Kameda & Sato (1994) demonstrated an up-regulation of 
IL-1α  mRNA  expression  in  keratinocytes  stimulated  with  δPS,  PεA  and  TNFα 
independently. Further to this Bailly et al. (1996) found using an electromobility shift 
assay an LPS induced AP-1 binding region in the IL-1α promoter, however no NF-țB 
binding sites were identified in the IL-1α promoter or first intron.  
IL-1α  has  also  been  shown  to  play  a  role  in  the  stimulation  of  osteoclastogenesis;  a 
dysregulation of which can result in osteosarcoma. Cao et al. (2008) used a mouse cell 
line K7M2 to show that under normal circumstances the osterix zinc finger transcription 
factor binds to an SP-1 binding site at the IL-1α promoter leading to suppression of Iδ-
1α transcription. 
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1.13.5 Interleukin 6 
Interleukin 6 (IL-6) is a cytokine with both pro and anti-inflammatory capabilities. It is 
a 28 kDa protein constructed as a 4 helix bundle, consisting of four long helices 
structured in an up-down topology. IL-6 is secreted by immune cells and non-immune 
cells, such as osteoblasts and keratinocytes (Ishimi et al., 1990; Neuner et al., 1991; 
Scheller et al., 2011). There are many roles attributed to the action of IL-6 including 
regulation in inflammation, metabolic control and bone metabolism. More specifically 
IL-6 trans-signalling leads to the recruitment of monocytes during infection. It has been 
shown to reduce neutrophil attracting chemokines, whilst up-regulating monocyte 
recruiting chemokines. It has also been shown to up-regulate adhesion molecules, such 
as Intercellular Adhesion Molecule-1 (ICAM-1) and Vascular Cell Adhesion Molecule-
1 (VCAM-1) on endothelial cells and increase M-CSF receptor expression resulting in a 
drive towards macrophage differentiation.  
 IL-6 contains three receptor-binding sites; a recognition site for the receptor IL-6R, a 
contact site for the gp130 domain and a contact domain for Ig-like molecules (Scheller 
et al., 2011). IL-6R is a transmembrane glycoprotein belonging to the family of 
membrane  bound  α  receptors.  Binding  of  Iδ-6 to membrane bound IL-6R leads to 
association with two molecules of the 150 kDa type 1 transmembrane protein, gp130. 
Creation of the IL-6R-gp130 homodimer leads to activation of the JAK/STAT, ERK 
and P13K pathways. However only macrophages, neutrophils, some T cells and 
hepatocytes express membrane bound IL-6R on their cell surface (Scheller et al., 2011). 
These cells are able to shed IL-6R, creating soluble IL-6R. This, along with IL-6 is able 
to bind gp130 that conversely is found on the surface of most cell types therefore 
activating cell types that do not constitutively express membrane bound IL-6R (Rose-
John et al., 2007; Scheller & Rose-John, 2006). Cleavage of membrane bound IL-6R to 
soluble IL-6R is via the catalytic actions of the Zn2+ - metalloproteinase family, a 
disintegrin and metalloprotease (ADAM) (Mullberg et al., 1994; Matthews et al., 2003; 
Chalaris et al., 2010). ADAM-10 is involved in the constitutive slow cleavage of 
membrane bound IL-6R to soluble IL-6R (Matthews et al., 2003). ADAM-17 in 
contrast, is activated by IL-1ȕ, TNFα and the synthetic phorbol ester, PεA to actively 
cleave IL-6R (Mullberg et al., 1993). Interestingly soluble IL-6R has also been shown 
to be synthesised as a result of alternatively spliced IL-6R mRNA (Lust et al., 1992). 
Alternative splicing of gp130 has also been shown to result in soluble gp130 (Daimant 
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et al., 1997).  It has been hypothesised that binding of soluble gp130, soluble IL-6R and 
IL-6 can lead to extracellular inhibition of IL-6 (Rose-John, 2012). 
Transcriptional regulation of IL-6 appears to be cell type dependent. A study examining 
the transcription of IL-6 in murine macrophages identified a Notch binding motif that 
overlapped with a NF-țB binding site (Wongchana & Palaga, 2012). Additionally, up-
regulation of IL-6 in this cell line required the cooperative actions of Notch and NF-țB. 
Conversely, Xiao et al., 2004 report that sites of AP-1 and C/EBP in a prostate cancer 
cell line were the most important transcription factors for IL-6 expression. Using a 
luciferase reporter assay they showed that, although there is indeed a NF-țB binding 
site and NF-țB is recruited, NF-țB  may  be  dispensable  for  Iδ-6 expression. 
Furthermore Zhang et al., (2013) suggest that LPS-mediated TLR4 activation leads to 
binding of c-Jun to activating transcription factor 4 at the promoter of the IL-6 gene and 
this is required for TLR4-mediated IL-6 expression.  
 
1.14 Chronic Inflammatory disorders and cancer. 
Rheumatoid Arthritis is a chronic inflammatory disease that affects approximately 1% 
of the population of Great Britain as reported by the National Institute for Health and 
Care Excellence (NICE). The susceptibility to Rheumatoid Arthritis is proposed to be 
due to a combination of environmental and genetic factors leading to the onset of the 
disease (Moelants et al., 2013).  
Pain, stiffness and inflammation of the synovial membrane of diarthrodial joints are the 
main symptoms of those patients suffering with Rheumatoid Arthritis (Brennan et al., 
2008). Unsurprisingly, activated macrophages are numerous in the inflamed synovial 
membranes of affected joints, characterised by an overexpression of MHC class II and 
release of pro-inflammatory cytokines (Kinne et al., 2000).  TNFα  in  particular  is 
present  in  the  majority  of  synovial  biopsies,  studies  have  shown  that  TNFα  induces 
leukocyte activation, pain receptor sensitization, angiogenesis and bone loss due to 
inhibition of osteoclast differentiation (McInnes & Schett, 2007; Moelants et al., 2013). 
Inhibition of TNFα has also been shown to suppress  the symptoms in various arthritis 
models, thus it is an attractive target in the treatment of Rheumatoid Arthritis (Brennan 
et al., 2008). 
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A further consequence of chronic inflammatory disorders is the increased risk of 
developing a multitude of cancers. Chronic inflammation has been shown to have pro-
tumourgenic effects possibly caused by a promotion in cell survival due to an increase 
in the release of the cytokines TNFα, Iδ-1 and IL-6. Patients with Rheumatoid Arthritis 
have been shown to be two-fold more likely to develop lymphoma and leukemia, whilst 
they are at 20-50% increased risk of developing respiratory tract cancers (Beyaert et al., 
2013). 
Other chronic inflammatory illnesses  include  Crohn’s  disease,  ulcerative  colitis  and 
systemic lupus erythematosus. Crohn’s disease and ulcerative colitis make up two of the 
main groups of inflammatory bowel diseases, and sufferers are at a higher risk of 
developing colorectal cancer. Further to this, systemic lupus erythematosus is associated 
with a higher risk of development of non-Hodgkin’s lymphoma (Beyaert et al., 2013). 
Thus elucidating the mechanisms that regulate the immune responses orchestrating 
inflammation are important in order to generate new therapies to treat such conditions, 
and therefore lowering the risk to inflammatory derived cancers.  
 
1.15 Aims 
Topo IIȕ is required for neuronal differentiation, more specifically it is shown to be 
required for both the up and down regulation of genes required for the early stages of 
neuronal development (Yang et al., 2000; Lyu et al., β00θ). δevels of topo IIȕ protein 
also increase during neuronal differentiation thus reflecting its essential requirement in 
this process (Tiwari et al., 2012). Otherr work has investigated the role of topo II in 
retinoic  acid  induced  granulocytic  differentiation,  suggesting  that  topo  IIȕ  may 
negatively regulate the expression of essential transcription factors required for 
differentiation to occur (Aoyama et al., 1998; McNamara et al., 2008). However there is 
nothing in the literature to date that  shows  that  topo  IIȕ  is  required  for macrophage 
differentiation . 
The overall aim of this project was to determine if topo IIȕ is required for macrophage 
differentiation and/or for pro-inflammatory cytokine production. 
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To achieve this, a reliable model of differentiation was created. Levels of both topo IIα 
and topo IIȕ mRNA and protein were measured in macrophage-like cells compared to 
monocyte-like cells.  
The effect of down-regulating  topo  IIȕ  on  various  markers  of  differentiation  and 
cytokine production was measured. Various methods of topo IIȕ down-regulation were 
employed, including siRNA, stable topo IIȕ knock-out cell lines and usage of the topo 
IIȕ specific inhibitor, ICRF-193.  
Chromatin Immunoprecipitation was also used  to elucidate any  topo  IIȕ  interaction at 
specific sites of interest.  
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Chapter 2 
Materials and Methods 
 
2.1 Sterilisation 
Sterilisation was performed by autoclaving; buffers and pipette tips were heated to 
121°C for 16 minutes at 0.14 MPa and left to cool before using. 
Sterilisation of drugs was performed by passing the solution through a 0.ββ ȝm filter. 
All tissue culture work was performed inside a laminar flow hood (Microflow class II 
biological safety cabinet) to ensure sterility. 
2.2 Tissue Culture Constituents 
Tissue culture constituents including media, foetal calf serum and 
penicillin/streptomycin were purchased from GIBCO, Life Technologies. 
Plastic ware including 25 cm3 and 75 cm3 culture flasks, multi-well plates and 
graduated pipettes for use in tissue culture were purchased from Greiner. 
2.3 Chemicals  
All chemicals were purchased from Sigma-Aldrich unless otherwise stated. 
2.4 Drugs 
Topoisomerase II drugs including ICRF-187, ICRF-193 and etoposide (VP-16) were 
purchased from Sigma-Aldrich. Dilutions of the drugs were made in 
dimethylsulphoxide (DMSO) also purchased from Sigma-Aldrich, and sterilised as 
described in Section 2.1.  
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2.5 Buffers          
 See Table 2.1 
Table 2.1. Chemical recipes for buffers used in experimental procedures. 
Buffers Ingredients 
Whole Cell Extraction Buffer 2% (w/v) SDS,,  2 µg/ml pepstatin, 2 µg/ml 
leupeptin , 1 mM DTT, 1 mM 
benzamidine, 1 mM PMSF 
4 x SDS PAGE Loading buffer 
 
20% (v/v) glycerol, 4% (w/v) SDS, 25% 
(v/v) stacking gel buffer, 10% (v/v) ?-
mercaptoethanol, 5% (v/v) H2O, 0.004% 
(w/v) bromophenol blue 
SDS-PAGE stacking gel buffer 0.25 M Tris-HCl (Melford) pH 6.8 
SDS- PAGE separating buffer 0.75 M Tris-HCl (Melford) pH 8.8 
10 X SDS-PAGE running buffer 250 mM Tris (Melford), 1.92 M Glycine 
(Melford), 1% (w/v) SDS 
5 X Tris Buffered Saline (TBS) 100 mM Tris-HCl (Melford) pH 7.5, 2.5 M 
NaCl 
TTBS 
(Probing of western blots) 
1 x TBS, 0.05% (v/v) Tween20 
Wet Western Transfer Buffer 25 mM Tris HCl (Melford) pH 8.3, 192 
mM glycine (Melford), 10% (v/v) 
Methanol, 0.1% (w/v) SDS 
Phosphate buffered saline (PBS) 1.37 M NaCl, 0.027 M KCl, 0.1 M 
Na2HPO4, 0.02 M NaH2PO4 
Coomassie Blue Stain 45% (v/v) Methanol 45 % (v/v) H20 10% 
Glacial acetic acid (v/v) 0.004% (w/v) 
Brilliant Blue R 
Coomassie Blue de-stain 45% (v/v) Methanol 45% (v/v) H2O, 10% 
(v/v) Glacial Acetic Acid  
ELISA Wash Buffer  1 X PBS 0.05%  (v/v) Tween20 
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2.6 Antibodies 
Table 2.2. Details of purchase and dilution of antibodies used in experimental 
procedures. 
Antibody Details Concentration used 
Anti-Topoisomerase IIα Rabbit polyclonal IgG       
(Sigma AV04007)           
Western Blotting 
1.25µg/ml 
Anti-Topoisomerase IIȕ Mouse Polyclonal                    
(BD Bioscience 611493) 
Western Blotting 
1/500 
Anti-GAPDH Rabbit polyclonal IgG             
(abcam ab9485) 
Western Blotting 
1ȝg/ml 
Anti-TNFα Mouse monoclonal           
(abcam ab9485) 
Western Blotting 
1/5000 
Anti- rabbit –HRP 
conjugated 
Goat polyclonal IgG           
(abcam ab6721) 
Western Blotting 
1/1000 
Anti-mouse –HRP 
conjugated 
Rabbit polyclonal IgG             
(DAKO P0260) 
Western Blotting 
1/1000 
Anti-CD11b –APC 
conjugated 
(eBioscience 17-0118-41) 
Flow Cytometry 
1/10 
Anti-HLA-DR –FITC 
conjugated 
(eBioscience 11-9956-73) 
Flow Cytometry 
1/10 
Anti-TLR4 –PE conjugated Serotech  
Flow Cytometry 
1/10 
  
 
2.7 qPCR Constituents 
Mastermix for use in qPCR with hydrolysis primer-probes was purchased from Primer-
Design (Precision-iC 2X qPCR mastermix). 
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Mastermix for use in qPCR with non-probe bound primers was purchased from BIO-
RAD (iQ- SYBR green supermix 170-886) 
Table 2.3. Details of Hydrolysis primers used for qPCR. 
Primer Details Sequence 
Homo sapiens 
topoisomerase 
(DNA) IIα 
Taqman Primer 
Design 
Forward: 
TGGATTTGGATTCAGATGAAGATTT 
Reverse:CTAAGTTTTGGGGAAGTTTTGGT 
Homo sapiens 
topoisomerase 
(DNA) IIȕ 
Taqman Primer 
Design 
Sense:ATATGTCTCTGTGGTCTCTTACTAAA 
Anti-sense:GCCGCTAAATCCTCTTTCCAA 
TLR2* Life 
technologies 
Hs00152932_m1 
Sequence not provided 
TLR4* Life 
technologies 
Hs00152939_m1 
Sequence not provided 
SP1* Life 
technologies 
Hs02786711_m1 
Sequence not provided 
NFțB* Life 
technologies 
Hs00765730_m1 
Sequence not provided 
IL-1ȕ Life 
technologies 
Hs01555410_m1 
Sequence not provided 
POLR2A* Life 
Technologies 
Hs00172187_m1 
Sequence not provided 
EGR2* Life 
Technologies 
Hs00166165_m1 
Sequence not provided 
TNFα  Life 
Technologies 
Hs01113624_g1 
Sequence not provided 
18S*    Life 
Technologies 
Hs99999901_s1 
Sequence not provided 
* Primer Probes kindly donated by Dr J Taylor, Newcastle University 
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2.8 Cell Lines 
2.8.1 Characterisation of U937 cells and maintenance in culture 
U937 cells were purchased from the American Type Culture Collection (ATCC) and are 
originally derived from a 37 year old Caucasian male suffering from histiocytic 
lymphoma. Cells were obtained originally from a pleural effusion and are characterised 
as being monocytic. U937 are suspension cells, they were maintained at a cell density 
between 1 x 105 and 6 x 105 cells/ml in RPMI-1640 medium supplemented with 10% 
(v/v) FCS, 45.5 units/ml Penicillin, 45.5 ?g/ml streptomycin and 2 mM glutamine. Cells 
were cultured in T25 or T75 flasks and incubated at 37°C, 5% (v/v) CO2 in a humidified 
atmosphere. 
2.8.2 Characterisation of HL-60 cells and maintenance in culture 
HL-60 cells were purchased from the American Type Culture Collection (ATCC) and 
are originally derived from a 36 year old Caucasian female suffering from acute 
promyelocytic leukaFemia. Cells were originally obtained from peripheral blood 
leukocytes by leukopheresis and are characterised as promyeoblasts. HL-60 are 
suspension cells, they were maintained at a cell density between 1 x 105 and 6 x 105 
cells/ml in RPMI-1640 medium supplemented with 10% (v/v) FCS, 45.5 units/ml 
penicillin, 45.5 ?g/ml streptomycin and 2 mM glutamine. Cells were cultured in T25 or 
T75 flasks and incubated at 37°C, 5% (v/v) CO2 in a humidified atmosphere. 
2.8.3 Characterisation of Mouse Embryonic Fibroblasts (Wild Type and #5) and 
maintenance in culture 
Wild type and stable topo IIȕ knock-out mouse embryonic fibroblasts (MEFs) were 
kindly provided by Prof C. A. Austin, Newcastle University. Cells were grown to 
confluency in Dulbecco’s εodified Eagle εedium (DεEε), supplemented with 10% 
(v/v) FCS, containing 45.5 units/ml penicillin, 45.5 ?g/ml streptomycin and 2 mM 
glutamine. Cells were cultured in T25 or T75 flasks and incubated at 37°C, 5% (v/v) 
CO2 in a humidified atmosphere. Passage of cells required the detachment of cells from 
the culture flask. Media was removed from the flask (T25) and cells were washed with 
5 ml of 1 x PBS (Table 2.1). 1.5 ml of 0.25% (v/v) Trypsin was then added to the flask 
and cells were incubated for 1 min at 37°C. 4 ml of fresh media was then added to the 
flask to stop the reaction. The flask was then gently agitated to facilitate the detachment 
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of the cells. The cells were then harvested and centrifuged at 500 x g for 3 min.  Media 
containing trypsin was removed and the cells were washed in 5 ml of 1 x PBS, as 
described previously. Cells were centrifuged again at 500 x g for 3 min. PBS was 
removed and cells were re-suspended in 10 ml of fresh media, and added to a new 
culture flask. 
2.9 Cell Harvesting  
Non-adherent U937 and HL-60 cells were removed from the culture flask and 
centrifuged for 5 min at 1500rpm. Media was then removed and fresh media was added 
to the cells. Cells were then placed into a fresh culture flask. If U937 and HL-60 had 
been treated with Phorbol-Myristate acetate and thus adhered to the culture flask, media 
was first gently removed from the flask and removed. 5 ml (for T25) 10 ml (for T75) of  
1 X PBS was then added to the flask. A 18 mm cell scraper (Fisher) was then used to 
gently detach the cells from the culture flask. Cells were then centrifuged for 5 min at 
500 x g. The PBS was removed and cells were re-suspended in fresh media. 
2.10 Cell Counting  
Cell counts were performed using an Improved Neubauer hemocytometer (0.1 mm, 
1/400 mm2). Briefly, a steamed cover slip was applied on top of the chambers. The 
presence of newton rings implied successful application. 12 ȝl of cell suspension was 
then added to each chamber and cells in the four large corner squares of each were 
counted. Each large square represented 104 cells/ml. By counting the cells seen in the 1 
mm2 squares, and taking the dilution factor into account the number of cells in the 
original suspension can be calculated using the equation below;  
Mean cell count per 1mm2 square x dilution factor = cells/ml x 104 
If Trypan Blue Exclusion was to be performed, a 1:1 mix of cell suspension to Trypan 
Blue was performed immediately before counting. 
2.11 Preparation of liquid nitrogen stocks 
Cells were counted as previously described (Section 2.8) and washed twice in PBS. 2 x 
106 cells/ml were then suspended in 1 ml of freezing solution (FCS containing 10% 
DMSO) and transferred to a cryovial (Nunc). Cryovials were then stored in a Mr Frosty 
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(Thermo-scientific) container and placed in an -80°C freezer for 24 h before being 
transferred to a liquid nitrogen container (Statebourne bio 36).  
2.12 Peripheral Blood Mononuclear Cell Isolation  
Peripheral blood mononuclear cell (PBMC) isolation was used to obtain primary 
monocytes. A qualified phlebotomist obtained 50 ml of venous blood from consenting 
healthy volunteers (Project Reference SUB86_AJ_0511 with regards to Ethical 
Approval) 
Specialised leucosep tubes (Greiner) were used to separate whole blood into plasma, 
buffy coat (leukocytes and platelets) and erythrocytes. The tubes were prepared prior to 
addition of whole blood by addition of 15 ml of lymphoprep (Axis-Shield). The tubes 
were then centrifuged briefly to ensure the lymphoprep was below the filter in the 
leucosep tube. Whole blood was then added to the leucosep tube and was centrifuged 
for 12 min at 700 x g with no deceleration.  
The plasma fraction was contained above the filter in the leucosep tube. This was 
carefully removed and discarded. The buffy coat layer was then transferred into a sterile 
50 ml falcon tube. The fraction containing the erythrocytes was also discarded. 50 ml of 
FCS free-RPMI-1640 was then added to the buffy coat in the tube, and the tube was 
centrifuged at 600 x g for 10 min with maximum deceleration.   
The supernatant was then discarded and the remaining cells were re-suspended in 2 ml 
of FCS free -RPMI-1640. A cell count was then performed using a Casy® Counter. 
 
2.13 CD14 selection of PBMCs 
2.13.1 Background 
Isolation of CD14+ cells from freshly isolated PBMCs was performed using magnetic 
cell sorting of human leukocytes (MACS) (Miltenyi Biotec). This method involves the 
addition of a mouse monoclonal anti-human CD14 antibody conjugated to magnetic 
microbeads. The antibodies then bind to CD14+ cells, and when the sample is applied to 
a magnetic field, these cells are attracted to the magnetic field and become firmly 
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attached to the side of the tube. Thus cell that are not antibody bound are flushed from 
the sample, leaving only CD14+ remaining.  
2.13.2 Method 
Freshly isolated PBMCs were centrifuged at 500 x g for 5 min. 1 x 107 cells were then 
re-suspended in 50 ?l of buffer (2 mM EDTA/PBS pH 7.2, 0.5% (v/v) FCS). 20 ?l of 
CD14 Microbeads (Miltenyi Biotec) were then added to the suspension of cells, which 
were then mixed and incubated for 15 min at 4°C. 1.5 ml of buffer (as previous) was 
then added to the suspension of cells, this was followed by centrifugation at 1500rpm 
for 5 min. The supernatant was removed and cells were re-suspended in 500 ȝl of buffer 
(as previous). At this time a MACS MS+/RS+ column was applied to the MACS 
separator (magnetic field) and washed with 500 ȝl of buffer (as previous). The cell 
sample was then added and any flow through was discarded. The column was then 
washed a further 3 times with 500 ȝl of buffer (as previous). The column was then 
removed from the MACS separator and 1 ml of buffer was used to flush out the CD14+ 
cells.  
2.14 Flow cytometry 
2.14.1 Background 
Flow cytometry was used to measure levels of various cell surface antigens. When a 
sample is processed by flow cytometry it is hydro-dynamically focused using sheath 
fluid to pass through a very small nozzle which then takes single cells past the laser 
light. The cells when passed across the path of the laser light cause the light to scatter. 
Detectors in front of the laser measure the forward scatter, which corresponds to the size 
of the cell and detectors to the side of the laser measure the side scatter that corresponds 
to the granularity of the cell. Thus cells in a sample containing multiple cell types can 
be identified by their size and granularity.  
If the cells have been treated with a fluorochrome-conjugated antibody raised to bind to 
a particular extracellular antigen then once the sample is excited at a particular 
wavelength, the fluorochrome will emit detectable light. For example FITC conjugated 
antibody labelled samples when excited at 519 nm will emit a detectable light. This then 
allows the detection and quantification of extracellular antigens. 
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2.14.2 Quantitation of surface antigen expression using Flow cytometry 
Cells were harvested as appropriate (Section 2.9) and washed twice with PBS 
containing 0.1% FCS (see Table 2.1). Cells were then transferred to a FACs tube 
(Sarstedt) and centrifuged at 1000rpm for 5 min. PBS was removed and cells were re-
suspended in 20 ?l of fresh PBS containing 0.1% (v/v) FCS. 2 ?l of antibody (see Table 
2.2 for antibodies used) was then added. One sample did not have antibody added to it, 
this acts as the unstained control. Cells were gently mixed and allowed to incubate for 
30 min out of visible light. Samples were then washed twice with 1 ml PBS and re-
suspended in 300 ?l PBS. Flow cytometry was then performed.  
Method of analysis of flow cytometry data is described in Figure 2.1. 
 
 
 
 
 
  
 
 
 
 
 
(a) 
 
 
 
 
 
 
 
 
 
 
 
(c) 
 
 
 
 
 
 
 
 
 
 
 
 
(e) 
 
 
 
 
 
 
 
 
 
 
 
 
 
(d) 
(b) 
Figure 2.1 Method of analysis of data obtained by flow cytometry. The first scatter 
graph obtained plots the side scatter against the forward scatter, thus the size and granularity 
of cells can be determined. A single acquired cell is represented as a dot on the scatter graph 
(a). The cell population was then gated and the gate applied to any future analysis (as shown 
by white polygon surrounding large cell population (b). The forward scatter on the X axis is 
then changed to represent the channel detecting the conjugate on the antibody bound to each 
cell. The first sample processed should be an unstained control, thus any auto-fluorescence 
produced by the cell can be gated out (as shown by the quadrant) (c). Samples that have 
been stained with antibody can then be analysed; applying the gate determined in (b) and 
then the quadrant determined in (c). Therefore only cells in the lower right quadrant are 
considered positive for the surface antigen investigated (d). Statistics can then be 
determined for each quadrant including the mean fluorescent intensity captured from the 
cells in each particular quadrant (e). It is important to note that if mean fluorescent intensity 
is reported that the quadrants are not employed. Cells used in this example were 0.1% 
DMSO (v/v) treated U937 cells.  57 
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2.14.3 Cell cycle analysis using Flow cytometry. 
Cells were harvested (Section 2.9) and washed twice with PBS. Cells were then re-
suspended in 200 ?l PBS and added drop-wise to 2ml of ice cold 70% (v/v) Ethanol in 
PBS. Cells were fixed for 30 min at 4°C. The fixative was then removed and the cells 
were resuspended in 1 ml of PBS containing 0.2 ?g/ml RNase A and 10 ?g/?l 
propidium iodide. Cells were then incubated for 30 min at 37°C. Flow cytometry was 
then performed.  
2.15 XTT Assay 
2.15.1 Background 
The XTT assay uses (2,3 –Bis- [2-methoxy-4-nitro-5-sulfophenyl] -2H-tetrazolium-5-
carboxyanilide salt (XTT) to measure cell viability. Living cells actively metabolise, 
thus the mitochondria in these cells produce NADH. NADH reduces the yellow 
tetrazolium salt, XTT into a soluble orange formazan dye in the presence of an electron-
coupling agent, PMS. The resulting colour formation can then be measured 
spectrophotometrically. As the amount of NADH directly correlates with cell viability, 
then the amount of reduced XTT is a reliable measure of cell viability (Berridge et al., 
2005). 
2.15.2 Method 
The XTT was stored at -20°C in 2.5 ml aliquots at a concentration of 1 mg/ml in RPMI-
1640. PMS was stored at -20°C in 15 ȝl aliquots at a concentration of 5 mM in PBS. 
Before use the XTT was defrosted in a water-bath at 50°C in order to dissolve any 
visible precipitate. PMS was defrosted at room temperature, 12.5 ȝl of PMS was then 
added to 2.5 ml XTT just before use. 50 ?l of the XTT/PMS reagent was then added to 
each 200 ȝl cell sample (in a 96 well plate). The plate was then incubated at 37°C, 5% 
(v/v) CO2 in a humidified atmosphere for 4 hrs. The endpoint absorbance was then read 
at 450nm on a spectrophotometer (Synergy). A further endpoint absorbance read was at 
630nm in order to be able to eliminate any smudges on the plate that may affect the end 
result.  
The value obtained for the plate read at 630nm was then subtracted from the value 
obtained for the 450nm value on the corresponding wells. The value for the well 
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containing media only was also subtracted from the values of all wells. An average of 
the experimental replicates was determined, and percentage cell viability was 
determined by calculated as follows: 
 
2.16 Quantifying protein expression 
2.16.1 Whole Cell Extraction  
Cells were washed in 5 ml of PBS containing protease inhibitors in order to reduce 
protein degradation (leupeptin, pepstatin, DTT, benzamidine, and PMSF, see Table 2.1). 
Lysis buffer containing 2% (w/v) SDS in PBS and inhibitors (leupeptin, pepstatin, DTT, 
benzamidine, and PMSF) was heated to 68°C before addition to cells. Cells were 
incubated for 5 min at 68°C in the lysis buffer before being passed through a fine gauge 
needle 10 times in order to shear DNA.  
2.16.2 Quantification of total protein 
Quantification of total protein in whole cell lysates was performed using the BCA 
Protein Assay kit (Thermo-scientific). This assay uses a two-step reaction to quantify 
protein levels. Initially addition of the bicinchoninic acid (BCA) substrate to the protein 
samples causes reduction of the cuprous ions (in the substrate) to cupric ions by the 
peptide bonds in the protein. The resulting cupric ions then chelate with the BCA in the 
substrate, creating a purple coloured complex that can be measured 
spectrophotometrically at 562nm (Smith et al., 1985).  
Standard samples were prepared by diluting bovine serum albumin in PBS to create a 
range of concentrations (125, 250, 500, 750, 100, 1500 and 2000 ng/ml). Whole cell 
lysate samples were diluted 1/10 in PBS. 10 ȝl of sample was added to a well of a λθ 
well plate in triplicate. 200 ?l of a 50:1 ratio of the BCA working reagents A and B was 
then added to each well. The plate was then incubated at 37°C for 30 min before the 
endpoint absorbance was measured at 562nm (BMG labtech).  
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Absorbance values were then plotted against the concentration of standard samples and 
linear regression of the line was used to determine concentration of protein in unknown 
samples. Results were multiplied by 10 in order to adjust for the dilution. 
 
2.16.3 Preparation of whole cell lysates for SDS- PAGE 
Lysates were prepared for separation by SDS-PAGE by addition of 2 x loading buffer 
(Table 2.1) at a 2:1 dilution. Samples were then heated for 3 min at 68°C. Heating 
above this temperature has been shown to affect levels of topoisomerase II (Woessner et 
al.,1990). 
2.16.4 SDS- PAGE 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
separate proteins in order of size. SDS-PAGE was performed using a 7.5% (v/v) gel. 
The gels made were 13 cm long, 18 cm wide and 1.55 mm thick, with a stacking gel of 
2 cm in depth. The gels were made using the recipe shown in Table 2.4. After addition 
of the resolving gel to the plates, 70% (v/v) isopropanol was layered on top to prevent 
the formation of bubbles. This was washed off with water after the gel had set and 
before the addition of the stacking gel. The gel was placed into a mini PROTEAN Tetra 
system (BIO-RAD) with SDS-PAGE running buffer (Table 2.1) Samples were loaded 
onto the gel along with a pre-stained molecular weight marker (BIO-RAD) and proteins 
were separated for 1 h at 100 V using a power pac 200 (BIO-RAD). 
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Table 2.4 Constituents of 7.5% Polyacrylamide Gel 
Resolving Gel Stacking Gel 
Separating buffer 
(Table 2.1) 
7.5 ml Stacking buffer 
(Table 2.1) 
6 ml 
30% (w/v) 
Acrylamide 
3.75 ml 30%  (w/v) 
Acrylamide 
2 ml 
H2O 3.45 ml H2O 3.7 ml 
10% (w/v) SDS 150 ?l 10% (w/v) SDS 120 ?l 
10%  (w/v) APS 100 ?l 10%  (w/v) APS 120 ?l 
TEMED 50 ?l TEMED 10 ?l 
 
2.16.5 Wet Western blot 
Wet Western blotting was used to transfer proteins vertically from the SDS-PAGE gel 
as described in Section 2.16.4 onto a 0.45 ?m nitrocellulose membrane (BIO-RAD). 
Protein was transferred from the gel onto nitrocellulose using wet Western blotting. 
Sponges, filter paper (Whatmann) and nitrocellulose were soaked in wet Western buffer 
for 10 min prior to assembly of the plates. A sponge was placed on the black plate, 
followed by filter paper (cut to the size of the gel) and the gel. Nitrocellulose also cut to 
the size of the gel was placed on the gel and any bubbles underneath were removed. A 
second sheet of filter paper was placed on the nitrocellulose followed by the second 
sponge, that plates were closed and placed into the mini trans-blot electrophoretic 
transfer cell (BIO-RAD) along with wet western buffer (Table 2.1) prior to 
electrophoresis at 100 V, 500 mA for 1 hr. 
2.16.6 Coomassie staining 
Following wet Western transfer gels were stained with Coomassie blue stain (Table 2.1) 
overnight at room temperature with gentle agitation. Coomassie blue stain was then 
removed and gels were allowed to soak in de-stain (Table 2.1) until the gels became 
transparent. The gels were then inspected for any blue bands thus indicating any 
remaining protein and an inefficient transfer. 
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2.16.7 Probing 
Blots were incubated overnight in 50 ml TTBS (see Table 2.1) with 3% (w/v) powdered 
skimmed milk at 4°C to block any non-specific protein binding sites. Blots were then 
washed 3 x 5 min in 50 ml TTBS. The primary antibody was then diluted as appropriate 
(see Table 2.2 for antibody information) in 3% (w/v) powdered skimmed milk in TTBS; 
the blot was then submerged in the diluent containing antibody and allowed to incubate 
for 2 h at room temperature with gentle agitation. The primary antibody sera was then 
removed and the blot was washed 3 x 5 min in 50 ml TTBS. The secondary antibody 
was then diluted as appropriate (Table 2.2) in 3% (w/v) powdered skimmed milk in 
TTBS. The blot was then submerged into the antibody containing diluent and allowed to 
incubate for 1 h at room temperature with gentle agitation. The antibody diluent was 
then removed and the blot was washed again 3 x 5 min in 50 ml TTBS. Detection of 
protein was then performed using an enhanced chemiluminescent substrate (45 ?l 
coumaric acid (1.5% (w/v) in DMSO), 100 ?l luminol (4.4% (w/v) in DMSO) in 10 ml 
100 mM Tris-HCl pH 8.5 combined with 6 ?l hydrogen peroxide in 10 ml 100 mM 
Tris-HCl pH 8.5). The blot was submerged in the ECL substrate for 1 min before 
exposure and capture using the G-box chemiluminescent detection system (Syngene). 
2.16.8 Densitometry 
Densitometry was performed using synergy genetools software. Bands were adjusted 
for background noise by subtracting the arbituary unit given for the background away 
from the arbituary unit given for the protein band.  
 
2.17 Quantifying mRNA expression  
2.17.1 RNA Extraction  
RNA extraction was performed using the High Pure RNA Isolation kit (Roche). Cells 
were pelleted and all supernatant was removed. 1 ml of Tri Reagent reagent was added 
to the cells and incubated for 5 min at room temperature to allow complete dissociation 
of nucleoprotein complexes. 200 ?l of chloroform was then added to each sample and 
the tubes were mixed vigorously by hand for 15 sec. Samples were then left to incubate 
for 2 min at room temperature. Samples were then centrifuged for 15 min at 13000 x g 
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and 4°C. Following this, 400 ?l of the colourless upper fraction of the sample was 
transferred to a new RNAse free tube. 400 ?l of 70% (v/v) ethanol was then added to 
the tube and the sample was then vortexed to ensure thorough mixing. 700 ?l of sample 
was then transferred to a spin cartridge with a collection tube and was centrifuged for 15 
sec at 13000 x g. The sample flow through was then discarded from the collection tube. 
350 ?l of wash buffer I (Roche) was then added to the spin cartridge and the sample 
was centrifuged for 15 sec at 13000 x g. The flow through and collection tube was then 
discarded and the spin cartridge inserted into a fresh collection tube. 80 ?l of DNase 
mixture (8 ?l of the provided 10x DNase reaction buffer, 10 ?l of the provided DNase, 
62 ?l RNase free water) was then added to each sample to digest any contaminating 
DNA in the sample. Samples were left to incubate with the DNase mixture for 15 min at 
room temperature before 350 ?l of the provided wash buffer I was added and the tubes 
centrifuged for a further 15 sec at 13000 x g. Sample flow through was then discarded 
and 500 ?l of wash buffer I was added to the tube followed by centrifugation at 13000 x 
g for 15 sec. Sample flow through was then discarded and the step using wash buffer II 
(Roche) was repeated. The spin cartridge was then centrifuged for 1 min at 13000 x g to 
dry the membrane with the bound RNA. The cartridge was then inserted into a recovery 
tube and 30 ?l of RNase free water was added to it and left to incubate for 1 min at 
room temperature. The spin cartridge/recovery tube was then centrifuged at 13000 x g 
for 1 min. The spin cartridge was then discarded and the recovery tube containing the 
sample was stored at -80°C until required. 
2.17.2 Reverse Transcription 
Synthesis of cDNA from RNA was performed using the Precision nanoscript reverse 
transcription kit (PrimerDesign). Annealing was performed by the addition of RNA to a 
0.2 ml thin walled PCR tube, along with 1 ?l of the provided random nonamer primer 
and nuclease free water in order to obtain a reaction volume of 10 ?l. The resulting 
sample was then heated at 65°C for 5 min. An ice water bath was used to immediately 
cool the sample.  
Extension was performed by the addition of 10 ?l of reverse transcription mastermix 
(Table 2.5) followed by incubation at 25°C for 5 min. A control sample was also 
performed at this time, where all components of the mastermix were added with the 
exception of the nanoscript enzyme (the transcriptase). This was performed for each 
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sample. The sample was then incubated for a further 15 min at 55°C. Heat inactivation 
of the sample was then performed by incubation at 75°C for 15 min. Samples were then 
stored at -20°C until used.  
Table 2.5. Volume of components used to generate a master-mix for reverse 
transcription.  
 
 
 
 
 
    
2.17.3 qPCR 
qPCR was performed using the C1000 Thermal Cycler BIO-RAD CFX96 Real time 
system. For each hydrolysis probe to be analysed a mastermix was made up; this  
contained 1 ?l primer/probe, 10 ?l mastermix (Precision-iC 2X qPCR mastermix) and 4 ?l of RNase/DNase free water per sample. 15 ?l of this mastermix was added to each 
well of a 96 well PCR plate (BIO-RAD, HSP-945). 5 ?l of 5 ng/?l of sample cDNA 
was added in triplicate to the plate. A no template control (RNAse/DNase free water) 
was added in duplicate to the plate for each probe used. In addition the reverse 
transcription control (without enzyme – see Section 2.17.2) was also added to the plate 
in duplicate. This was necessary to determine if any genomic DNA is present in the 
samples. The conditions for qPCR are outlined in Table 2.6.  
Analysis was performed using the comparative ΔΔCt method (Livak & Schmittgen, 
2001) to determine relative fold expression compared to the control sample.  
 
 
 
Reverse transcription 
component 
Volume required 
(final volume 10μl) 
Nanoscript 10X buffer 
(provided) 
2.0 ȝl 
dNTP mix 10 mM (each) 1.0 ȝl 
DTT 100 mM 2.0 ȝl 
RNase/ DNase Free water 4.0 ȝl 
Nanoscript enzyme 
(provided) 
1.0 ȝl 
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For example;  
ΔCt = Sample Ct value – Reference Ct value 
ΔCt expression = 2^- ΔCt 
 
 ΔΔCt expression  × 100 = Percentage fold expression 
 
Table 2.6. Reaction conditions for qPCR using Hydrolysis probes. 
PCR step Conditions 
1. Enzyme Activation 95°C 10:00 
2. Denaturation 95°C  0:15 
3. Data collection 50°C 0:30 
4. Extension 72° 0:15 
Go to step 2 (x50 times) 
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2.18 ELISAs 
All EδISA kits were purchased from eBiosciences as part of the ‘Ready-set-go’ range. 
Figure 2.2 illustrates the principle of the sandwich enzyme linked immunosorbant 
assay. 
 
Figure 2.2 Diagrammatic representation of a sandwich enzyme linked 
immunosorbant assay (ELISA) diagram taken from EIAab News.                                
This method indirectly detects the presence of the target protein. The capture antibody 
is coated onto a 96 well ELISA plate, the sample containing the target protein is added 
to the plate where it will bind to the capture antibody. A second antibody capable of 
detecting the target protein is then added and binds to the protein. In order to allow 
detection of the bound detection antibody, a horse-radish peroxidase (HRP) conjugated 
antibody  that  recognises  and  binds  to  the  detection  antibody  is  added.  A  γ,  γ’,  η,η’ 
Tetramethylbenzidine (TMB) substrate is then added, and the  (HRP) causes the 
oxidation of the substrate and thus a measurable colour change can be observed. 
2.18.1 ELISA to human TNFα  
Quantification of TNFα released into the supernatant was performed using the Ready-
Set-Go ELISA kit to human TNFα (eBioscience). A 96 well ELISA plate was coated 
with a TNFα capture antibody. 48 ?l of capture antibody was diluted in 12 ml of the 
supplied coating buffer, 100 ?l was then added to each well. The plate was then sealed 
and incubated overnight at 4°C. The wells were then aspirated and washed by 
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submerging the plate into a bath containing ELISA wash buffer (Table 2.1). This was 
repeated 5 times. The top TNFα standard was prepared by adding 6 ?l of 1.65 ?g/?l 
recombinant TNFα to 20 ml of the supplied assay diluent. A serial dilution was 
performed using assay diluent and 100 ?l of standard samples and experimental samples 
(diluted ½) were then added to the plate in triplicate. The plate was then incubated for 2 
h at room temperature. The wells were then aspirated and washed 3 times in ELISA 
wash buffer (Table 2.1). TNFα detection antibody was diluted 48 ?ls in 12 ml in the 
supplied assay diluent and 100 ?l of this was added to each well of the 96 well plate. 
The plate was incubated for a further hour at room temperature. Wells were again 
aspirated and washed 5 times in ELISA wash buffer (Table 2.1). The avidin –HRP 
enzyme was diluted 48 ?l in 12 ml of assay diluent and 100 ?l of this was added to each 
well of the 96 well plate. The plate was then incubated for 30 min at room temperature 
before the wells were aspirated and washed 7 times in ELISA wash buffer. 100 ?l of 
substrate solution was then added to each well and the plate was left to incubate for a 
further 15 min. 50 ?l of 2M H2SO4 was then added to each well to stop the reaction. 
The plate was then read at 450 nM and 570 nM on a spectrophotometer (synergy).  
2.18.2 ELISA to human IL-1ȕ 
Quantification of IL-1ȕ released into the supernatant was performed using the Ready-
Set-Go ELISA kit to human Il-1ȕ (eBioscience). This was performed using the same 
methodology as 2.18.1. However the topo IL-1ȕ standard was prepared by adding 10 ?l 
of 1 ?g/?l recombinant IL-1ȕ to 20 ml of the supplied assay diluent. 
2.18.3 ELISA to mouse IL-6 
Quantification of IL-6 released into the supernatant was performed using the Ready-Set-
Go ELISA kit to mouse IL-6 (eBioscience). This was performed using the same 
methodology as 2.18.1. However the topo IL-6 standard was prepared by adding 10 ?l 
of 1 ?g/?l recombinant IL-6 to 20 ml of the supplied assay diluent. 
2.18.4 ELISA to mouse IL-1α 
Quantification of IL-1α released into the supernatant was performed using the Ready-
Set-Go ELISA kit to mouse IL-1α. This was performed using the same methodology as 
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2.18.1. However the topo IL-1α standard was prepared by adding 10?l of 1 ?g/?l 
recombinant IL-1α to 20 ml of the supplied assay diluent. 
 
2.19 Chromatin Immunoprecipitation. 
2.19.1 Crosslinking of chromatin  
Chromatin Immunoprecipitation was performed to determine the association of topo IIȕ 
with regions of interest within the IL-1ȕ and TNFα genes. 
A Magna -EZ ChIP kit (Millipore) was kindly donated by Prof C. A Austin, Newcastle 
University.  
Media from adherent cells was removed and replaced with 30 ml of fresh media. 1.1 ml 
of fresh formaldehyde (0.925 g paraformaldehyde, 4.8 ml H2O, 35?l 1N KOH) was 
then added and cells were left to incubate for 10 min at room temperature. 2 ml of 
glycine was then added, the flask was agitated, and then allowed to incubate for a 
further 5 min. Media was then removed and replaced with cold PBS. Cells were washed 
twice in PBS. 2 ml of PBS containing protease inhibitors (2 ?g/ml pepstatin, 2 ?g/ml 
leupeptin, 1 mM DTT, 1 mM benzamidine, 1 mM PMSF) was then added and cells 
scraped and pelleted by centrifugation at 500 x g for 5 min. All PBS was then removed 
and the cell pellet was frozen at -80°C until used.  
2.19.2 Cell Lysis and Sonication 
Once the cell pellet was thawed, 0.5 ml of the supplied cell lysis buffer containing 1 x 
protease inhibitor cocktail (Millipore) was then added. The cells were left to incubate 
for 15 min and vortexed every 5 min in that time. The suspension was then centrifuged 
at 800 x g for 5 min at 4°C. The supernatant was then removed and 0.5 ml of the 
supplied Nuclear Lysis buffer containing 2.5 ?l of the provided 1 x protease inhibitor 
cocktail (Millipore) was then added to the lysed cells. The suspension was then left on 
ice and sonication was used to shear the cross-linked DNA. Sonication cycles were 
performed at 25% power for 15 sec. Following sonication cells were centrifuged at 
10000 x g for 10 min at 4°C. 
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2.19.3 Immuno-precipitation of cross-linked chromatin 
Protein A Magnetic beads (Millipore) and antibody were then prepared. Antibody was 
added to the upper liquid of 25 ?l of Protein A Beads (see Table 2.7 for dilution 
details). The suspension was then mixed and left to incubate for 30 min at room 
temperature to allow binding of the antibody to the beads.  
Chromatin suspension (the sample after sonication) was then diluted 1/10 in the 
supplied dilution buffer (with 17.5 ?l of 1 x protease inhibitors added) and split into 500 ?l aliquots. The aliquots were then added to the Protein A Magnetic beads/antibody 
suspensions. The samples were then left to incubate for 18 hat 4°C with rotation.  
Protein A Magnetic beads were then separated from the rest of the sample using a 
magnetic separator. The antibody/chromatin complex was then washed by re-
suspending it in 0.5 ml in a series of wash buffers provided in the Magna EZ ChIP kit; 
Low salt Immune Complex Wash buffer, High Salt Immune Complex Wash buffer, 
LiCl Immune Complex Wash buffer and TE Buffer (all Millipore), allowing 5 minutes 
for incubation for each wash. 
2.19.4 Reverse crosslinking 
100 ?l of the supplied ChIP Elution buffer (with 1 ?l Proteinase K) was added to all 
samples including the ‘Input’ sample and left to incubate for 3 h at 62°C with rotation. 
The samples were then heated to 95°C for 10 min. Samples were then cooled to room 
temperature. The beads were then removed from the sample using a magnet. 
2.19.5 DNA Purification 
DNA was purified by adding 0.5 ml of Bind reagent A (Millipore) to each 100 ?l DNA 
sample  (including  ‘INPUT’).  The  sample  was  then  transferred  to  spin  column  (with 
filter) in a collection tube. The column was then centrifuged for 30 sec at 10,000 x g. 
The flow through was then discarded and the column placed back into the collection 
tube. 500 ?l of Wash Reagent ‘B’ (εillipore) was then added to the spin filter and the 
sample was centrifuged for a further 30 sec at 10000 x g. The flow through was again 
discarded and the spin filter placed back into the collection tube. The spin column was 
centrifuged again at 10000 x g for 30 sec, and the flow through along with the collection 
tube was discarded. The spin filter was placed into a fresh collection tube and 50 ?l of 
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Elution buffer ‘C’ (εillipore) was added to the centre of the filter. The spin column was 
centrifuged for 30 s at 10000 x g and the sample in the collection tube was retained and 
stored at -20°C until analysis. 
 
Table 2.7. Purchase Details and Dilutions of Antibodies used in 
Immunoprecipitations 
Antibody Details Dilution 
Anti-topoisomerase IIȕ Cambridge Research Biochemicals.  
Custom made; raised in rabbit to 
CTD peptide of topoisomerase IIȕ 
1/12.5 
Anti -AcH3 Millipore magna –EZ kit 1/5 
Anti-GFP Santa Cruz #SC-8334 1/5 
 
 
2.19.6 qPCR 
qPCR was performed using primer pairs (see Chapter 6, Figure 6.1) and purchased from 
Integrated DNA Technologies. The GAPDH primer pair for use with the AcH3 positive 
control samples was part of the Magna –EZ kit. For each primer pair under investigation 
a large master mix was made up, this contained (per sample); 12.5 ?l of iQ-SYBR green 
supermix (BIO-RAD), 0.1 ?l Forward Primer, 0.1 ?l Reverse Primer, 9.3 ?l H2O. 22 ?l 
of this mastermix was added to each well of a 96 well PCR plate (BIORAD 223-9441). 
3 ?l of sample DNA was then added in triplicate to the appropriate wells to make a final 
reaction volume of 25 ?l. A no template control (RNAse/DNase free water) was added 
in triplicate to the plate for each primer pair used. qPCR was performed using the 
reaction conditions outlined in Table 2.8.  Melting curve analysis was also performed 
when running the qPCR in order to check for primer-dimer artifacts and reaction 
specificity. Analysis of qPCR data is outlined in Chapter 6, Figure 6.4. 
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Table 2.8. Reaction conditions for qPCR of samples obtained by ChIP 
PCR step Conditions 
1. Initial Denaturation 95°C 4:00 
2. Denaturation 95°C  0:15 
3. Annealing 62°C 0:25 
4. Plate read - 
5. Extension 72°  0:25 72°C 5:00 
Go to step 2 (x39 times) 
6. Extension 72°C 5:00 
7. Melt curve 65°C - 95°C at 0.5°C  
0:05 
8. Plate read - 
 
2.20 siRNA 
Cells were seeded at 1 x 105 cells/ml and allowed to incubate for 24 hr. 12 ?l of siRNA 
oligonucleotide (Table 2.9, Qiagen) was then added to 88 ?l of Optimem (Life 
Technologies) in a 1.5 ml microfuge tube. In a separate microfuge tube 2 ?l of 
lipofectamine (Life Technologies) was added to 98 ?l of Optimem. Both tubes were 
then mixed and left to incubate for 5 min.  The contents of both tubes were then mixed 
together and left to incubate for a further 20 min. The siRNA/lipofectamine mixture was 
then added to 2 ml of cells to obtain a final siRNA concentration of 10 nM. Cells were 
left to incubate for 4 hbefore media was changed. Experiments using siRNA treated 
cells were carried out 48 hafter media was last changed. 
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Table 2.9. Details of siRNA oligonucleotides. 
siRNA oligonucleotide siRNA oligonucleotide sequence Final 
concentration 
Hs_TOP2B_5 (SI02780736) TCGGGCTAGGAAAGAAGTAAA 10 nM 
Hs_TOP2B_6 (SI02781135) CAGCCGAAAGACCTAAATACA 10 nM 
Hs_TOP2B_3 (SI00021560) GTGGATTATGTGGTAGATCAA 10 nM 
Hs_TOP2B_7 (SI03109596) TACGATTAAGTTATTACGGTT 10 nM 
Ambion Silencer Select 
Negative Control #1 
(4390843) 
Sequence not provided 10 nM 
 
 
2.21 Statistical Analyses 
The mean and standard error of the mean were calculated when all experimental 
replicates were complete. This was calculated as;  
 
 ?’ is the standard deviation from the mean, and n is the number of data sets. 
The unpaired t-test (student t-test), linear regression, correlation coefficient, coefficient 
of variation, the analysis of variation (ANOVA) and Kolmogorov-Smirnov were all 
performed using Graphpad (Prism) software. The student t-test was used to test the 
difference of two means from two small sample populations. When data is presented as 
percentage of control, all controls are set as 100% when performing the student t-test. 
Standard error of the mean with regards to the control is to show the spread of data 
within control samples themselves.  
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Linear regression was used to draw a trend-line or ‘line of best fit’. The correlation co-
efficient was used to determine the strength of the linear correlation. The coefficient of 
variation was used to determine the extent of variation in a sample set. An ANOVA was 
used to determine differences between groups and the Kolmogorov-Smirnov was used 
to determine Gaussian distribution and thus to indicate whether to use parametric or 
non-parametric statistical analysis. All data however followed a Gaussian distribution 
and therefore only parametric statistical analysis was performed. 
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Chapter 3 
 
Establishing a Robust Model for the Quantitative Measurement of PMA Induced 
Differentiation. 
 
 
 
3.1 Introduction  
Peripheral blood monocytes, originally derived from myeloid progenitor cells produced 
during hematopoiesis, are the precursors to tissue macrophages (Martinez, 2006; 
Valledor, 1998). Circulating monocytes display a significant level of heterogeneity, 
once believed to be distinguished from other circulating cells by their high level of 
CD14 expression, a membrane bound surface antigen that interacts with Toll Like 
Receptor 4 (TLR4), Lymphocyte antigen 96 (MD-2) and Lipopolysaccharide binding 
protein (LBP) to recognise bacterial LPS (Akashi et al., 2003). There actually appears 
to be three subsets; classical CD14+CD16-, intermediate CD14++CD16+ and non-
classical CD14+CD16++ (Huber et al., 2014). 
 
Monocytes can be stimulated to differentiate into macrophages by various factors; by 
changes in the microenvironment, for example presence of infection, or an up-
regulation of Macrophage colony stimulating factor (M-CSF) (Krause et al., 2000; 
Daigneault et al., 2010). They may also be stimulated to differentiate to maintain 
homeostasis by replenishing resident macrophages lost by apoptosis (Rey-Giraud et al., 
2012). Upon stimulation monocytes adhere to the wall of the blood vessel, once in the 
cell wall they then differentiate into a phenotype consistent with that of a macrophage 
(Ley et al., 2011). Macrophages are also considered to display a high level of 
heterogeneity, this is a result of diversity in the differentiation programme as 
consequence of variations in the environment (Daigneault et al., 2010). Despite their 
heterogeneity all macrophages express the cell surface antigen, CD11b. CD11b is a 
subunit of the integrin heterodimer, Macrophage Antigen -1 (MAC-1) (Bullard et al., 
2005; Ahn et al., 2010). MAC-1 plays a role in cellular adhesion and leukocyte 
recruitment (Moreland et al., 2002; Gomes et al., 2010). This is in contrast to 
monocytes that express very low levels of CD11b in comparison (Garcia et al., 1999). 
Thus CD11b represents an excellent cellular marker for monocyte to macrophage 
differentiation. 
 
75 
 
There are many factors that contribute to the difficulties in working with primary 
macrophages. They can be obtained from peripheral blood but not only is this method 
invasive, the number of macrophages obtained is small and they do not survive long in 
culture thus making it difficult to perform extensive research on them (Wetzka et al., 
1997; Li et al., 2007). Additionally, the variability of cells between donors can also 
hinder any explorative research (Maeb et al., 2014). Therefore in order to determine if 
topoisomerase IIȕ plays a role in differentiation and/or a role in cytokine expression, the 
continuous human cell lines, U937 and HL-60 cells were used (see Materials and 
Methods, Section 2.8). U937 cells possess monocyte morphology and HL-60 are 
characterised as being promyeloblast. Both cell lines have been shown to differentiate 
into different cell types when treated with various chemical agents (Padilla et al., 2000; 
Passmore et al., 2001; Jacob et al., 2002; Tagliafico et al., 2002). Thus these cell lines 
represent a viable model system for exploring macrophage development and cytokine 
production. One such differentiating agent is Phorbol-Myristate Acetate (PMA), a 
synthetic phorbol ester that has been shown to differentiate both HL-60 and U937 cells 
into macrophage like cells (Padilla et al., 2000; Ciubotaru et al., 2005; Jerke et al., 
2009). PMA acts via activation of various protein kinases, which in turn lead to a 
signalling cascade resulting in an alteration in gene expression (Obara & Nakahata, 
2002) (See Introduction 1.8.1). The conditions using PMA differ greatly amongst 
publications. For example a range of concentrations between 2 – 200 nM, for durations 
between 24 hours and 120 hours has been reported (Melhem et al., 1991; Takashiba et 
al., 1999). Conditions used for exposure to PMA also appear to be cell line specific (Liu 
et al., 2009). 
 
 
3.2 Aim 
In  order  to  determine  the  effects  of  topo  IIȕ  inhibition  on  differentiation  it  was 
necessary to carry out a series of experiments to define optimum conditions for 
macrophage production for the model system that would enable the robust measurement 
of differentiation in these cell lines.  
Three variables were chosen to identify mature macrophages, these were; expression of 
the surface marker CD11b, changes in cell morphology and changes in cell 
proliferation. 
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3.3 Measurement of CD11b expression to determine optimal conditions of PMA 
exposure to generate differentiated U937 and HL-60 cells. 
The literature suggests that differentiation of monocytes will occur using concentrations 
of PMA between 1 - 125 ng/ml approximately (Melhem et al., 1991; Takashiba et al., 
1999; Padilla et al., 2000; Jerke et al., 2009; Liu et al., 2009).  
In order to determine the optimal concentration of PMA to differentiate U937 and HL-
60 monocytes, cells were exposed to varying concentrations of PMA for 72 h and levels 
of the cell surface antigen, CD11b were measured using flow cytometry. A 72 h 
exposure was chosen initially as many papers showed successful differentiation using 
this length of exposure (Ciuboaru et al., 2005; Jerke et al., 2009; Liu et al., 2009; 
Quattrorii et al., 2012). The results are shown in Figure 3.1. 
                  
 
Figure 3.1 Flow cytometric analysis of CD11b expression on PMA treated U937 
determining optimal PMA concentration.  
Cells were seeded at a density of 3 x 105/ml in a 12 well tissue culture plate in complete 
media (detailed in materials and methods) with 5, 10, 20 and 100 ng/ml PMA. Cells 
were allowed to incubate for 72 h. Cells were then labelled with anti-human CD11b-
APC conjugated antibody. Flow cytometry was performed using the Becton Dickinson 
flow cytometer (detailed in materials and methods). Results are presented as the mean 
fluorescence intensity of 1 x105 acquired cells. 
                      
Mean Fluorescence Intensity was plotted rather than percentage CD11b positive cells as 
this gave a more quantitative measurement of CD11b surface antigen. From Figure 3.1 
it is clear that cells treated with PMA, for 72 h, at all concentrations expressed higher 
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levels of CD11b than the DMSO control. However there was little difference in CD11b 
expression when comparing the different concentrations of PMA used.  
The length of exposure of cells to PMA required for differentiation is also considerably 
variable between publications (24 – 120 h) (Takashiba et al., 1999, Melhem et al., 
1991). Although a 72 h exposure was used initially, it was decided to investigate 
whether differentiation could be achieved using shorter exposures to PMA. For this 
experiment, 5 ng/ml of PMA was utilised as there was no great difference observed in 
CD11b expression at higher concentrations of PMA, in comparison. Cells were exposed 
for 24, 48 and 72 h before CD11b surface antigen expression was measured using flow 
cytometry. The results are shown in Figure 3.2. 
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Figure 3.2 Flow cytometric analysis of CD11b expression on PMA treated HL-60 
(a) and U937 (b) cells – determining optimal PMA time exposure.  
Cells were seeded at a density of 3 x 105/ml in a 12 well tissue culture plate in complete 
media (detailed in materials and methods) with 5 ng/ml PMA (grey) or 0.1% (v/v) 
DMSO (black). Cells were allowed to incubate for 24, 48 and 72 h. Cells were then 
harvested by cell scraping and were then labelled with anti-human CD11b-APC 
conjugated antibody. Flow cytometry was performed using the Becton Dickinson flow 
cytometer (detailed in materials and methods). Results are presented as the mean 
fluorescence intensity of 1 x105 captured cells. 
 
79 
 
   
Figure 3.2 shows an increase in CD11b expression between 24 and 48 h, 48 h and 72 h, 
and 24 and 72h. This is in agreement with Jerke et al. (2009) who saw a consistent 
increase in CD11b expression when cells were treated every 24 h for 72 h with PMA. 
However whilst this study used THP-1, a different monocytic cell line, the study was 
also carried out using 2 nM PMA, a much lower concentration than has been used in 
Figure 3.2. These differences in procedure may explain why the results do not correlate.  
Thus for all future experiments using both cell lines, a 72 h exposure to 5 ng/ml PMA 
was used to generate macrophage-like cells. In addition for all such experiments a 
sample of cells was taken and CD11b expression was analysed to verify successful 
macrophage differentiation. 
To verify that these conditions would generate macrophages consistently and 
reproducibly, flow cytometry was used to quantify CD11b on non-PMA and PMA 
treated U937 and HL-60 cells from three independent experiments. The results are 
shown in Figure 3.3. 
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Figure 3.3 Comparison of CD11b expression on non-PMA and PMA treated cells. 
U937 (a) and HL-60 (b) cells were seeded at a density of 3 x 105 cells/ml and incubated 
with the vehicle control 0.1% (v/v) DMSO (non-PMA) or 5 ng/ml PMA for 72 h. Cells 
were then labelled with anti-human CD11b-APC conjugated antibody. Flow cytometry 
was performed using the Becton Dickinson flow cytometer (detailed in materials and 
methods). Results are presented as the mean fluorescence intensity of 1 x105 acquired 
cells. The means of three independent experiments are shown ± standard error. *** = p 
< 0.001, ** = p < 0.01 
 
Results from Figure 3.3 showed that there was a significant difference (Figure 3.3a, p = 
0.0015, student t test. Figure 3.3b, p < 0.0001, student t test) in expression of CD11b on 
the cell surface of non-PMA treated cells compared to PMA treated cells. Indeed 
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CD11b surface antigen expression increased in response to PMA treatment in both 
U937 (Figure 3.3a) and HL-60 cells (Figure 3.3b). This is in agreement with previous 
studies that demonstrate an increase in CD11b post PMA treatment (Zhao et al., 2004; 
Basoni et al., 2005; Baek et al., 2009). 
 
 
3.4 Effects of PMA treatment on cell growth 
U937 and HL-60 cells are both cancer derived cell lines; histiocytic lymphoma and 
acute promyelocytic leukaemia, respectively. Therefore a characteristic both cell lines 
possess is a dysregulation in cell division, causing an up-regulation in cell proliferation. 
This does not reflect the behaviour of monocytes and promyelocytic cells in vivo, which 
generally do not divide unless stimulated (van Furth et al., 1979; Okabe & Yasukawa, 
1990). Baek et al. (2009) report that once U937 and HL-60 cells have undergone 
differentiation they lose their ability to proliferate. This then allows another method for 
establishing differentiation. 
In order to test whether 5 ng/ml PMA for 72 h prevented proliferation as expected, a 
cell proliferation assay was carried out. Proliferation was assayed by counting viable 
cell numbers using trypan blue exclusion. In this assay viable cells that possess an intact 
cell membrane, and thus exclude the trypan blue dye are counted. Conversely, non-
viable cells, which do not possess an intact plasma membrane are flooded with the dye, 
and are excluded from the count. 
HL-60 and U937 cells were exposed to the drug vehicle control 0.1% (v/v) DMSO or 5 
ng/ml PMA for 72 h. Cell proliferation was measured and the results are shown in 
Figure 3.4. 
Two counts were performed on PMA-treated cells; cells that were in suspension in the 
well were counted, and cells that had adhered to the bottom of the well were also 
counted. Results from both cell lines demonstrated a significant difference in the 
proliferation of cells treated with 0.1% (v/v) DMSO compared to 5 ng/ml PMA (p = < 
0.000, ANOVA). A decrease in suspension cells and increase in adherent cells can be 
observed up until 48 h. The amount of adherent cells then plateaus until 72 h where it 
then decreases gradually. This was observed in both cell lines (Figure 3.4a + b). As 
stated previously (Section 3.1) CD11b is a component of the ȕ2 integrin CD11b/CD18. 
The role of CD11b/CD18 in vivo is to mediate adhesion of cells to the endothelial lining 
and to components of the extracellular matrix (Lundahl et al., 1996). Therefore it may 
be assumed that an up-regulation of CD11b surface expression may correlate with an 
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increase in cellular adhesion. Indeed when taken together adherence data in Figure 3.4a  
& b and Figure 3.3 do correlate; after 72 h of treatment with PMA, CD11b surface 
expression is at its highest and this is accompanied with a plateau in the number of 
adherent PMA treated cells. This data is in support of previous work that has shown that 
treatment of U937 cells, HL-60 cells and peripheral blood monocytes with PMA results 
in an up-regulation of CD11b surface expression and an increase in cellular adherence 
(Baek et al., 2009; McIntire, 2004; Lundahl et al., 1996). Collation of the data thus 
confirms that 5 ng/ml PMA exposure for 72 h causes differentiation of monocytes into 
macrophage like cells, which can be used as a reliable model in future experiments. 
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Figure 3.4 Trypan Blue Proliferation Assay of HL-60 (a) and U937 (b) cells.  
Cells were seeded at a density of 3 x 105/ml in a 12 well tissue culture plate in complete 
media (detailed in materials and methods) either containing 0.1% DMSO (v/v) or 5 
ng/ml PMA. Cell number was then measured after 24, 48, 73, 96, 168 and 196 h. Cells 
exposed to 0.1% (v/v) DMSO are represented as (blue). For cells exposed to PMA, both 
the adherent (red) and the cells remaining in suspension (cyan) were counted. The total 
number of PMA treated cells is also shown on the graph (green). The means of three 
independent experiments are shown ± standard error. 
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3.5 Characterisation of differentiation by changes in morphology 
Monocytes in vivo exhibit a high level of heterogenicity (Gordon, 2005; Auffray et al., 
2009; Tsujioka et al., 2009), in comparison U937 and HL-60 cell lines appear more 
uniform (Figure 3.5a). This is due to the derivation of the cell lines from cancer, 
essentially the cell lines are clones (Sundstrom & Nilsson, 1976; Collins et al., 1977). 
However cell morphology between monocytes and macrophages is even more striking 
when utilising clonally derived cell lines such as HL-60 and U937 (ATCC) rather than 
primary monocytes, which may be partially differentiated and thus display a high level 
of heterogenicity (Gordon, 2005; Auffray et al., 2009; Tsujioka et al., 2009).  
 
 
                
 
Figure 3.5 Visual analysis of non-PMA and PMA treated  U937 cell morphology. 
Cells were seeded at 3 x 105 cells/ml with 0.1% (v/v) DMSO (a) or 5 ng/ml PMA (b) in 
a 75 cm3 tissue culture flask and allowed to incubate for 72 h. Images were then 
captured using an x20 objective on a Zeiss Axiovert 25 light microscope with attached 
Nikon Coolpix camera.  
 
U937 and HL-60 cells grow in suspension and once differentiated with PMA, 
observation of morphology revealed the resulting cells became adherent (Figure 3.5). In 
addition these cells could only be harvested from their culture vessel by cell scraping or 
trypsinization. This finding is in agreement with previous work that showed using HL-
60 and U937 cells, PMA treatment resulted in an increase in adherence (Lu & Pitha, 
2001). An increase in adherence to culture flasks and other cells to form clusters is the 
result of an increase in the expression of various surface antigens including CD11b that 
are involved in adhesion and up-regulated in response to PMA treatment (McKercher et 
al., 1996; Deszo et al., 2000).   
 
(a) (b) 
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PMA differentiated cells also display a higher level of granularity. This is determined 
by an increase in side scatter as measured by flow cytometry (Figure 3.6b) compared to 
non-PMA treated cells (Figure 3.6a). Additionally Figure 3.6b also shows an increase in 
forward scatter in a proportion of cells treated with PMA, thus reflecting an increase in 
the size of cells. Daigneault et al. (2010) describe an increase in granularity upon 
treatment of THP-1 cells with PMA. An increase in granularity is due to an increase in 
membrane bound organelles in response to PMA treatment. Furthermore an increase in 
intracellular organelles can also be observed in PMA treated cells (Figure 3.5b) 
Daigeneault et al. (2010) also used immunohistochemistry to identify an up-regulation 
of mitochondria and lysosomes in PMA-treated THP-1 cells. An increase in 
mitochondria and lysosomes reflects the functional activities of macrophages in the cell. 
Indeed macrophages may require more energy generated by mitochondria in order to 
successfully phagocytose foreign material. Also an increase in lysosomes is required to 
fulfil the role of macrophages in releasing lysosomal enzymes for particle digestion 
(Hakala et al., 2003). 
 
   
 
 
 
 
 
 
 
 
 
Figure 3.6 Flow cytometric analysis of non-PMA and PMA treated HL-60 cells. 
Cells were seeded at 3 x 105 cells/ml with 0.1% DMSO (v/v) (a) or 5 ng/ml PMA (b) in 
a 75cm3 tissue culture flask and allowed to incubate for 72 h. Cells were harvested and 
flow cytometry was performed using the Becton Dickinson flow cytometer (detailed in 
materials and methods). Results are presented as side scatter (y axis) vs forward scatter 
(x axis). Results presented are representative of 2 x 105 cells acquired cells.  
 
The morphological changes during PMA induced differentiation seen in Figure 3.5 have 
all been described previously (Hansen, 1990; Garrelds, 1999; McIntire, 2004) and are 
(a) (b) 
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useful visual signs that the cells have been successfully differentiated. Subsequent 
experiments using PMA-treated cells were visually assayed using light microscopy to 
ensure differentiation had occurred. 
 
 
3.6 Summary 
A robust model of differentiation has been achieved, which generates some of the 
features seen in monocyte to macrophage differentiation. Conditions for the treatment 
of U937 and HL-60 cells to PMA has been thoroughly investigated. This has resulted in 
a standardised method of differentiation, 5 ng/ml PMA for 72 h.  Three independent 
methods of validation have also been identified; loss of ability to proliferate (Figure 3.5) 
changes in morphology (Figure 3.6) and an increase in CD11b expression (Figure 3.3). 
The latter also allows for the quantitative measurement of differentiation.  
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Chapter 4 
Quantification of Topo IIα and Topo IIȕ in PMA and non-PMA treated cells and 
the Effects of Differentiation on Topo II Drug Sensitivity 
 
4.1 Introduction 
Quantification of topo IIα and topo IIȕ  has revealed a difference in the protein 
expression of the two isoforms during the cell cycle. Woessner et al. (1991) showed that 
levels of topo IIα protein were negligible in serum starved cells but when re-entering the 
cell  cycle  levels  of  topo  IIα  appeared  to  increase  during late S phase and peaked in 
G2/M phase before slowly declining and becoming undetectable in G0. Similarly 
Padget et al. (2000) also showed that exponentially growing Raji cells contained more 
topo  IIα protein  than  confluent Raji  cells, whilst  peripheral  blood  lymphocytes  in G0 
contained no detectable topo IIα protein. δevels of topo IIȕ protein during the cell cycle 
are described in many publications as remaining constant (Kobayashi et al., 1998; de 
Campos-Nebel et al., 2010), however multiple studies have shown a decline in levels of 
topo IIȕ when cells become confluent or enter G0 (Woessner et al., 1991; Turley et al., 
1997; Padget et al., 2000), thus suggesting that levels of topo IIȕ also vary during the 
cell cycle.  Interestingly  levels  of  topo  IIȕ  appear  to  change  during  differentiation. 
Tsutsui et al. (2001) report than  an  increase  in  the  protein  level  of  topo  IIȕ  can  be 
observed during neuronal differentiation in cerebellar Purkinje cells and granule cells.  
The requirement for an up-regulation  of  topo  IIȕ  during  neuronal  differentiation  has 
been attributed to the requirement of topo IIȕ in the regulation of transcription of genes 
in the later stages of neuronal development (Lyu et al., 2006). Additionally Aoyama et 
al. (1998) also demonstrated an up-regulation of topo IIȕ protein expression when Hδ-
60 cells were differentiated into granulocytic like cells using retinoic acid.  
In order to determine whether topo IIȕ is the predominant isoform in differentiated cells 
of the immune system, topo IIα and topo IIȕ mRNA and protein were quantified in non-
PMA and PMA treated cells. In order to verify the differences in the levels of the two 
isoforms, a topo II poison and topo II inhibitors that differentially target the two 
isoforms were used. The topo II poison, etoposide (VP-16) acts by trapping the topo II 
enzyme in the DNA cleavage part of its catalytic cycle, termed the cleavable complex 
(Montaudon et al., 1997; Willmore et al., 1998). Processing of cleavable complexes 
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causes generation of double strand breaks, which in a high enough quantity will 
eventually result in apoptosis (Li & Lui., 2001). This particular poison has been shown 
to  preferentially  target  topo  IIα  (Errington  et al., 2004; Bandele & Osheroff, 2008).  
Toyoda et al. (2008) using mutant Nalm-6 cell lines, one of which was heterozygous for 
topo IIα (TOPβα+/-) and the other homozygous null for topo IIȕ (TOPβȕ  /-) showed that 
TOPβα+/- cells were more resistant to VP-16 than the wild-type  but  that  TOPβȕ-/- 
remained just as sensitive to VP-16 as the wild-type, thus supporting previous evidence 
to suggest that VP-1θ preferentially targets the α isoform. In contrast topo II inhibitors 
act differently to topo II poisons. The topo II inhibitor, ICRF-193 acts by hindering the 
binding and hydrolysis of ATP; leaving topo II unable to complete its catalytic cycle 
(Roca et al., 1994). This ultimately causes an excess of DNA supercoiling that results in 
the inhibition of essential cellular processes such as replication and transcription.  
ICRF-1λγ has been shown to preferentially target topo IIȕ (Patel et al., 2000). 
If topo  IIα  is  reduced  it would  be  expected  that  there would  be  a  decrease  in VP-16 
sensitivity, conversely if topo IIȕ is reduced it would be expected that there would be a 
decrease in ICRF-1λγ sensitivity. In addition another topo IIȕ inhibitor, ICRF-187 was 
also used. 
4.2 Aim  
To  quantify  the  protein  and mRNA  levels  of  topo  IIα  and  topo  IIȕ  in  non-PMA and 
PMA treated HL-60 and U937 cells.  
To determine if a difference in  levels of topo  IIα and topo IIȕ between non-PMA and 
PMA treated cells affects the efficacy of the topo II poison, etoposide and the topo II 
inhibitors, ICRF-193 and ICRF-187. 
 
4.γ  Quantification  of  Topoisomerase  II  α  and  ȕ  mRNA  in  non-PMA and PMA 
treated U937 and HL-60 cells 
4.3.1 Determining the optimal reference gene to use for qPCR  
Quantitative real time PCR was used to generate reliable measurements of mRNA. 
Reference genes that have previously been used such as GAPDH and beta actin are now 
considered to be unreliable due to their variability in tissues and changes in the 
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regulation of their transcription during certain experimental procedures (Radonic et al, 
2004). 
The Minimum Information for Publication of Quantitative Real-Time PCR Experiments 
(MIQE) guidelines requires a suitable reference gene be used in order to generate 
reliable results. MIQE guidelines were introduced in order to standardise the qPCR 
method (Bustin, 2009). Therefore in order to identify a suitable reference gene to 
quantify  to  topo  IIα  and  ȕ  in  PεA  and  non-PMA treated cells, the geNORM kit 
(PrimerDesign) was utilised. This enabled the variability of multiple housekeeping 
genes to be measured between non-PMA and PMA treated cells.  
 
The geNORM kit contained hydrolysis probes for 11 genes including; GAPDH, ACTB, 
SDHA, RPL13A, UBC, B2M, TOP1, EIFA2, YWHAZ, ATP5B and CYC1. These are 
considered to be the most widely used reference genes. Levels of each of the genes were 
quantified by qPCR using cDNA generated from non-PMA and PMA treated HL-60 
samples in order to identify a suitable reference gene that did not change during PMA 
induced differentiation. 
Figure 4.1a is a box and whisker diagram presenting the variation in Ct values of the 
reference genes in non- PMA and PMA treated samples. Figure 4.1b shows the 
coefficient variance of the Ct values that were calculated to identify the gene with the 
least variability between samples. TOP1 was seen to have the lowest coefficient 
variance, and therefore this gene was the reference gene in qPCR measurements in HL-
60 cells. Interestingly, GAPDH, one of the most common reference genes used in 
western blotting (Chen et al., 2014; Li et al., 2006; Zhang et al., 2011; De Boo et al., 
2009) displays the highest coefficient variance, these results support previous findings 
that GAPDH is not a suitable reference gene in qPCR (Glare et al., 2002).  
18S RNA was used as a reference gene for U937 cells as this had previously been 
shown to be suitable (Zhao et al., 2013).   
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Figure 4.1 Determination of a suitable reference gene for use in qPCR when using 
non-PMA and PMA treated HL-60 cells, using the commercially available geNorm 
kit.  
HL-60 cells were seeded at cell density of 3 x 105 cells/ml with 5 ng/ml PMA or 0.1% 
(v/v) DMSO and left to incubate for 72 h before cells were harvested and RNA 
extracted (see Section 2.17.1). cDNA was then synthesised (Section 2.17.2) and qPCR 
was performed using PerfectProbe hydrolysis probes for GAPDH, ACTB, SDHA, 
RPL13A, UBC, B2M, TOP1, EIFA2, YWHAZ, ATP5B and CYC1. qPCR conditions 
can be found in Section 2.17.3. Results shown are the mean Ct of five independent 
experiments (a). Coefficient variance using data from (a) was calculated to determine 
amount of variability of Ct values between the non-PMA and PMA treated samples (b). 
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4.γ.β Determining the efficiency of the qPCR reaction using topo IIα, topoIIȕ and 
18S hydrolysis probes. 
Hydrolysis probes obtained  for  the quantification of  topo  IIα  and ȕ  arrived optimised 
ready for use. The efficiency of these probes within the qPCR assay was required in 
order to make a comparison between genes.  
An efficiency of 90- 105% is deemed acceptable. Genes that are to be compared to one 
another must have similar efficiencies in order for an accurate comparison to be made 
(Bustin, 2009). 
The calibration curve for the calculation of the efficiency of the topo IIα, topo IIȕ and 
18S probes is displayed in Figure 4.2. A 1:2 dilution of cDNA was used to generate 
samples for the calibration curve. 5 µl of each sample was used in a 20 µl reaction 
volume, complete reaction conditions are documented in Materials and Methods Section 
2.16.3.  
Efficiency calculations were performed using the equation shown in Appendix Figure 
A.1, based on qPCR alogorithms described in Rutledge & Côté (2003). The assay using 
the topo IIα specific (TOPβA) hydrolysis probe was calculated to have an efficiency of 
99.1%. The efficiency of the assay using the topo  IIȕ  (TOP2B) hydrolysis probe was 
calculated to be 104.2%, and the efficiency of the 18S probe was calculated to be 91%. 
The efficiencies of these assays are similar enough to be able to compare the two 
different genes being investigated (Bustin, 2009). It was expected that the hydrolysis 
probes would yield an acceptable efficiency as all gene assay kits are fully validated by 
the manufacturer (PrimerDesign) thus guaranteeing an efficiency within the acceptable 
range. Therefore efficiency for the TOP1 hydrolysis was not performed, as it was 
originally part of a fully validated kit especially designed for a comparative assay. 
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Figure 4.2 Establishing the efficiency of qPCR – Calibration Curves.  
RNA was extracted from non-PMA treated U937 cells and quantified using the 
nanodrop. cDNA was then synthesised and concentration was determined from amount 
of RNA used in the reverse transcription reaction. cDNA was then serial diluted from 
20 to 0.156 ng/ȝl. qPCR was then performed using Taqman hydrolysis probes to 
TOP2A, TOP2B and 18S (see Section 2.17.3 for qPCR conditions). Concentration of 
cDNA was converted into a logarithmic value and plotted against Ct value. Calibration 
curves were then generated for 18S (a), TOP2A (b) and TOP2B (c). A line of best fit 
was then added and the equation of the line generated using graphpad prism software.  
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4.γ.γ Quantifcation of Topoisomerase II α and ȕ mRNA in non-PMA and PMA 
treated U937 and HL-60 cells. 
Following  determination  of  the  efficiency  of  both  topo  IIα  and  topo  IIȕ  hydrolysis 
probes, the probes were then used to quantify levels of topo IIα and topo IIȕ mRNA in 
U937 and HL-60 PMA and non-PMA treated cells. To ensure only differentiated cells 
were to be analysed, any suspension cells in the PMA treated flasks were disposed of, 
and the remaining adherent cells were gently harvested using a cell scraper. To ensure 
differentiation had occurred, the levels of CD11b receptor expression for every sample 
to be analysed, was measured by flow cytometry (data not shown). δevels of topo IIα 
and  topo  IIȕ mRNA were  then quantified using qPCR. Analysis was performed using 
the comparative ΔΔCt method  to measure  fold  expression. Samples  taken  from Uλγ7 
cells were normalised to values obtained using the 18S reference gene, samples taken 
from HL-60 cells were normalised to values obtained using the TOP1 reference gene. 
The results are shown in Figures 4.3 and 4.4. Amplification efficiencies of both the 
target and reference genes were calculated and found to be approximately the same, 
falling within the acceptable range of amplification efficiency (see Figure 4.2) 
 
This is the first time under these conditions a comparison of both topo IIα and topo IIȕ 
has been made between monocytic cells and macrophage like cells at both the relative 
levels of mRNA and protein. 
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Figure 4.3 Comparing  the  relative  levels  of  Topoisomerase  IIα  and  ȕ mRNA  in 
Non-PMA vs PMA treated U937 cells. 
U937 cells were seeded at a density of 3 x 105 cells/ml with 5 ng/ml PMA or 0.1% 
DMSO (v/v) (Non-PMA) and allowed to incubate for 72 h before harvesting. RNA was 
then extracted and cDNA synthesised (Section 2.16). qPCR was then performed using 
Taqman hydrolysis probes to TOP2A (a) and TOP2B (b). 5µl of 5ng/µl cDNA was used 
for each reaction. Samples were performed in experimental triplicate Results were 
normalised to 1κS and the ΔΔCt method was used to calculate fold expression. Results 
shown are the mean of five independent experiments ± standard error.*** = p < 0.001. 
See Appendix Table A.1 for p values. 
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Figure 4.4 Comparing  the  relative  levels  of  Topoisomerase  IIα  and  ȕ mRNA  in 
Non-PMA vs PMA treated HL-60 cells. 
HL-60 cells were seeded at a density of 3 x 105 cells/ml with 5 ng/ml PMA or 0.1% 
DMSO (v/v) (Non-PMA) and allowed to incubate for 72 h before harvesting. RNA was 
then extracted and cDNA synthesised (Section 2.16). qPCR was then performed using 
Taqman hydrolysis probes to TOP2A (a) and TOP2B (b). 5µl of 5ng/µl cDNA was used 
for each reaction. Samples were performed in experimental triplicate. Results were 
normalised to TOP1 (as determined by the geNorm kit, Figure 4.1) and the ΔΔCt 
method was used to calculate fold expression. Results shown are the mean of five 
independent experiments ± standard error. * = p < 0.05, ** = p < 0.01. See Appendix 
Table A.2 for p values. 
Significant decreases in both the levels of topo IIα and topo IIȕ mRNA were observed 
in both U937 and HL-60 PMA treated cells compared to non-PMA treated cells. An 
average 91% decrease in TOP2A was observed in PMA treated U937 cells (Figure 
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4.3a), compared to an average 66% decrease in PMA treated HL-60 cells (Figure 4.4a). 
Contrary to that expected, on average a 65% decrease in TOP2B in PMA treated U937 
cells was measured. A similar 70% average decrease was observed in PMA treated HL-
60 cells.  
The large decrease in topo IIα expression when cells are treated with PεA (Figure 4.3a 
and 4.4a) is in agreement with other studies that have reported similar findings. Loflin 
et al. (1λλθ) demonstrated a down regulation of topo IIα mRNA when Kηθβ cells were 
treated with PMA. Additionally Lim et al. (1998) reported a decrease in topo IIα mRNA 
expression and decatenation activity after 24 h of PMA treatment in HL-60 cells. 
Along with  the  decrease  in  levels  of  topo  IIα  and  topo  IIȕ mRNA upon  treatment  of 
cells with PMA as shown in Figure 4.3 and Figure 4.4 a change in distribution of cells 
at certain phases in the cell cycle can also be observed upon treatment with PMA. Non-
PMA and PMA treated U937 cells were fixed, and stained with the nucleic acid stain, 
propidium iodide; analysis by flow cytometry was then performed. Approximately 58% 
of the exponentially growing, non-PMA treated cells were found to be in G0/G1, ~15% 
in S phase and ~5% in G2/M, this reflects previous studies that show that 
logarithimically growing cells follow this pattern during cell cycle analysis (Wang et 
al., 2006; Otte et al., 2011) (Figure 4.5c). In contrast, ~52% of cells that have been 
treated with PMA appear to be arrested in G2/M phase, with ~18% in S phase and ~2% 
in G0/G1 (see Figure 4.6b). This is in agreement with multiple other studies that found 
PMA arrested human umbilical vein endothelial cells, non-small lung cancer cells and 
MCF-7 cells in G2/M phase (Kosaka et al., 1996; Oliva et al., 2007; Barboule et al., 
1999). In normal, exponential growing cells levels of topo IIα mRNA increases during 
S phase, peaks at G2/M and declines as cells enter G0 (Woessner et al., 1991). However 
the results in Figures ζ.γa and ζ.ζa do not support this, as levels of topo IIα mRNA are 
down regulated during PMA induced G2/M arrest. The retinoblastoma tumour 
suppressor protein (Rb protein) has been shown to repress the expression of genes 
encoding proteins that are crucial for cell cycle progression through mitosis such as 
cdcβ and topo IIα (Siddiqui et al., 2003). Interestingly Rb protein has been shown to be 
hypo-phosphorylated and therefore activated when IEC-18 cells were treated with PMA 
for 6 h (Frey et al., 1997). Indeed this PMA induced activation of Rb may lead to the 
repression of topo IIα gene expression, leading to a down-regulation of topo IIα mRNA 
as observed in Figures 4.3a and 4.4a. Additionally existing mRNA may not be detected 
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after 72 h treatment with PεA as topo IIα mRNA stability has been shown to possess a 
finite half-life of 4 h during S phase (Goswami et al., 1996). 
There is a large difference in the percentage decrease of topo IIα mRNA between Uλγ7 
and HL-60 cells. It has previously been reported that PMA causes an up-regulation of 
p53. In turn, p53, a tumour suppressor protein, has been shown to cause a decrease in 
the expression of topo IIα mRNA (Wang et al., 1997). HL-60 cells are considered p53 
null thus this pathway would not be activated, however it may explain why there is an 
average 66% decrease in TOP2A in HL-60 cells compared to an average 91% decrease 
in p53 positive U937 cells.  
The decrease in topo IIȕ mRNA levels upon treatment with PεA is in disagreement to 
work by Tiwari et al. (β01β)  who  showed  that  topo  IIȕ  mRNA  expression  was  up-
regulated during murine neuronal  development. However  the  requirement  of  topo  IIȕ 
during growth development has been shown to be stage specific. Lyu et al. (2006) 
showed  that  topo  IIȕ  was  required  for  late  but  not  early  neuronal  development.  The 
decrease  in  topo  IIȕ mRNA seen in Figure 4.3b and 4.4b is only reflective of one 
particular stage of differentiation. Thus an up-regulation  of  topo  IIȕ  may  occur  at  a 
different stage. 
Topo  IIȕ  has  been  shown  to  be  involved  in  the  regulation  of  transcription  of  various 
genes, for example Ju et al. (β00θ)  reported  that  a  topo  IIȕ  double  strand  break was 
required for the recruitment of co-activator proteins to the pS2 promoter in response to 
17ȕ-estradiol for transcription to occur. It has also been shown to play a role in gene 
silencing, for example Huang et al. (2011) reported that inhibition of topo II using a 
variety of topo II drugs including the topo IIȕ targeting ICRF-193 caused un-silencing 
of the dominant allele Ube3a in Ube3a-yellow fluorescent protein knock-in mice. A 
previous study has shown  that  knockdown  of  topo  IIȕ  in  NBζ  cells  caused  the  up-
regulation of retinoic acid induced gene expression (McNamara et al., 2008).Therefore 
it may be postulated that a down regulation of topo IIȕ may lead to the un-silencing and 
activation of various genes; genes that may drive differentiation.  
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Figure 4.5 Cell cycle analysis of non-PMA U937 cells. 
Cells were seeded at a cell density of 3 x 105 cells/ml with 0.1% DMSO (v/v) (non-PMA) 
and allowed to incubate for 72 h at 37°C, 5% CO2 in a humidified atmosphere. Flow 
cytometry was performed using propidium iodide. Propidium iodide stains DNA and 
therefore DNA content can be measured. Analysis was first performed using lymphocytes 
kindly donated by Prof S Todryk to calibrate the flow cytometer for cells in G1, G1 was 
identified at the arbitrary unit 200 (a). A histogram to show the spread of cells with 
different amount of DNA content was then performed using the test sample (b) G2/M was 
identified at the arbiutary unit 400 (as cells in this phase have double amount of DNA). 
Percentage of 10000 captured cells in each phase was then calculated (c). 
 
(a)                                                                                (b) 
(c) 
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Figure 4.6 Cell cycle analysis of PMA treated U937 cells 
Cells were seeded at a cell density of 3 x 105 cells/ml with 5 ng/ml PMA and allowed to 
incubate for 72 h at 37°C, 5% CO2 in a humidified atmosphere. Flow cytometry was then 
performed using propidium iodide. Propidium iodide stains DNA and therefore DNA 
content can be measured. Analysis was first performed using lymphocytes kindly donated 
by Prof S Todryk to calibrate the flow cytometer for cells in G1; G1 was identified at the 
arbitrary unit 200 (Figure 4.5a). A histogram to show the spread of cells with different 
amount of DNA content was then performed using the test sample (a) G2/M was identified 
at the arbiutary unit 400 (as cells in this phase have double amount of DNA). Percentage of 
10000 captured cells in each phase was then calculated (b). 
 
(a) 
  (b) 
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To determine if there was a change in the amount of topo IIȕ in relation to topo IIα in 
non-PεA and PεA treated cell,  fold expression of  topo  IIȕ mRNA was compared  to 
topo IIα mRNA using ΔΔCt. It is important to note that the efficiencies of both the topo 
IIα and topo IIȕ probe were similar (see Section 4.3.3), and all samples were run on the 
same plate, therefore results for topo IIα and topo IIȕ were normalised to the same set of 
18S data.   
Despite  a  decrease  in  both  topo  IIα  and  topo  IIȕ  when  cells  are  treated with PMA, 
indeed a change in the relative amount of topo IIȕ to topo IIα mRNA was observed. In 
non-PεA treated cells there is no significant difference in levels of topo IIȕ mRNA to 
topo IIα mRNA in both cell lines (Figures 4.7a and 4.8a). In PMA treated cells, there is 
γ.η fold and ζ.λ fold more topo IIȕ mRNA in Uλγ7 and Hδ-60 cells respectively. This 
then identifies topo IIȕ as the predominant message in PMA treated cells. Although the 
results do not correlate with previous studies with regards to a lack of increase in topo 
IIȕ during differentiation,  it does  support  the  findings  the  topo  IIȕ  is  the predominant 
topo II isoform in differentiated cells (Tiwari et al., 2012).  
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Figure 4.7 Comparing fold expression of topo IIα and ȕ mRNA in non-PMA and 
PMA treated U937 cells.  
Data from Figure 4.3 was used to determine the fold expression of topo IIȕ to topo IIα 
in non-PMA treated cells (a) and PMA treated cells (b).  
Results shown are the mean of five independent experiments ± standard error. * = p < 
0.05. See Appendix Table A.3 for p values. 
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Figure 4.8 Comparing fold expression of topo IIα and ȕ mRNA in non-PMA and 
PMA treated HL-60 cells.  
Data from Figure 4.4 was used to determine the fold expression of topo IIȕ to topo IIα 
in non-PMA treated cells (a) and PMA treated cells (b).  
Results shown are the mean of five independent experiments ± standard error. * = p < 
0.05. See Appendix Table A.4 for p values. 
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4.3.4 Quantification of topo IIα and topo IIȕ mRNA in Primary monocytes and 
M-CSF treated monocytes 
In addition to quantifying topo IIα and topo IIβ in cell line models, primary monocytes 
were obtained and differentiated into macrophage like cells. Monocytes were isolated 
from peripheral blood by CD14+ selection. CD14+ monocytes are precursors of 
phagocytes such as macrophages (Kuwana et al., 2003). Macrophage colony stimulating 
factor (M-CSF) was then used to differentiate the selected CD14+ cells. It was decided 
M-CSF would be used rather than PMA in order to utilise a more biologically relevant 
model. M-CSF acts by indirectly activating Protein Kinase C (PKC) by inducing the 
production of diacylglycerol (DAG) (Valledor et al., 1999). The activation of PKC 
causes a cascade of events leading to activation of transcription factors, and therefore 
transcription of genes involved in differentiation. This pathway of activation is very 
similar to that of PMA as PMA is analogous to DAG (Teixeira et al., 2003), thus being 
able to stimulate PKC directly (see Introduction Section 1.12.1). 
Levels of topo IIα and topo IIȕ mRNA were then measured using qPCR. Analysis was 
performed using the comparative ΔΔCt method to measure fold expression. Samples 
taken from primary monocytes were normalised to values obtained using the 18S 
reference gene. The results are shown in Figure 4.9 and 4.10, respectively. 
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Figure 4.9 Comparison of relative levels of Topoisomerase IIα in CD14+ monocytes 
from PBMC isolation compared to M-CSF treated cells of the same lineage.  
CD14+ monocytes derived from peripheral blood were seeded at 1 x 106/ml in RPMI-
1640 with 50 ng/ml M-CSF or 0.1% DMSO (v/v). Cells treated with 0.1% DMSO (v/v) 
were left to incubate for 24 h before harvesting. M-CSF treated cells were left to 
incubate for 7 days before harvesting. RNA was extracted and cDNA synthesised from 
the cells (Section 2.17). qPCR was performed using Taqman probes to TOP2A, and 
normalised to 18S (see Section 2.17.3 for qPCR conditions) 5 µl of 3 ng/ȝl of cDNA 
was used for each reaction. Samples were performed in experimental triplicate. Results 
are shown comparing non-MCSF and MCSF treated CD14+ monocytes from each 
individual donor (a –d). 
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Figure 4.10 Comparison of relative levels of Topoisomerase IIȕ in CD14+ 
monocytes from PBMC isolation compared to M-CSF treated cells of the same 
lineage.  
CD14+ monocytes derived from peripheral blood were seeded at 1 x 106/ml in RPMI-
1640 with 50 ng/ml M-CSF or 0.1% DMSO (v/v). Cells treated with 0.1% DMSO (v/v) 
were left to incubate for 24 h before harvesting. M-CSF treated cells were left to 
incubate for 7 days before harvesting. RNA was extracted and cDNA synthesised from 
the cells (Section 2.17). qPCR was performed using Taqman probes to TOP2B, and 
normalised to 18S (see Section 2.17.3 for qPCR conditions) 5 µl of 3 ng/ȝl of cDNA 
was used for each reaction. Samples were performed in experimental triplicate. Results 
are shown comparing non-MCSF and MCSF treated CD14+ monocytes from each 
individual donor (a – d). 
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Figure  ζ.λ  shows  the  mRNA  levels  of  topo  IIα  in  non  ε-CSF and M-CSF treated 
CD14+ cells from four different donors. The results show that levels of topo IIα differ 
from donor to donor, indeed in two of the samples levels of topo IIα mRNA appear to 
be higher in non M-CSF treated cells than M-CSF treated cells, this is demonstrated by 
a  lack  of  amplification  of  topo  IIα  suggesting  that  levels  are  so  low  they  are 
undetectable (Figure 4.9a &c). In one sample set, no amplification was seen in non M-
CSF and M-CSF treated cells (Figure 4.9d). In comparison in Figure 4.9b there appears 
to be more topo IIα mRNA in ε-CSF treated cells.  The variance in data along with the 
heterogeneity of monocytes in vivo (ie. they may be at different stages of activation by 
various stimuli in vivo) makes it difficult to draw any firm conclusions, however Figure 
4.9a & c do support previous data in this chapter, i.e., figure 4.3a and 4.4a show a 
decrease  in  topo  IIα mRNA  expression  in  Uλγ7  and Hδ-60 cells differentiated with 
PMA. Unlike cancer derived cell lines, monocytes in vivo do not proliferate. Extensive 
research has shown that quiescent or cells in G0 (ie. non-proliferating) contain 
negligible  levels  of  topo  IIα  (Woessner  et al., 1991; Chow & Ross, 1987), however 
there are still detectable levels in non-proliferating differentiated cells (Figure 4.3a & 
Figure ζ.ζa),  thus suggesting an unknown role for topo IIα in differentiated cells. The 
results shown in Figure 4.9a & c are also in support of previous published work, 
Martinez, (2006) used transcriptome analysis to demonstrate a down regulation of topo 
IIα mRNA when primary monocytes cells underwent differentiation with ε-CSF.  
Figure  ζ.10  shows  the  mRNA  levels  of  topo  IIȕ  in  non ε-CSF and M-CSF treated 
CD1ζ+ cells from four different donors. The results show that levels of topo IIȕ mRNA 
decrease upon M-CSF treatment (Figure 4.10b & d), two of the data sets (Figure 4.10a 
& c) demonstrate this by a lack of amplification of topo IIȕ after treatment with M-CSF, 
suggesting that levels are so low they are undetectable.  The results support previous 
work  in  this  chapter  that  show  that  topo  IIȕ  mRNA  levels  decrease  when  cells  are 
treated with PMA (Figure 4.3b and Figure 4.4b). Unlike the cell lines, the decrease in 
topo IIȕ mRNA is not due to a decreased in demand for this isoform due to a lack of 
cell replication, as CD14+ monocytes do not proliferate (Clanchy et al., 2006). The 
environment of the CD14+ monocyte in vivo, however, may require transcription in 
response to stimuli in the micro-environment, therefore an up-regulation  of  topo  IIȕ 
mRNA would be seen in CD14+ monocytes.  
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4.γ.5 Quantification of Topoisomerase  IIα and ȕ protein  in U9γ7 and HL-60 cell 
lines. 
Levels of topo IIα and topo IIȕ protein were semi-quantified in samples from 
exponentially growing U937 and HL-60 cells (see Figure 3.4). These results were then 
compared to PMA treated U937 and HL-60 cells. To ensure only differentiated cells 
were to be analysed, any suspension cells in the PMA treated flasks were discarded, and 
the remaining adherent cells were gently harvested using a cell scraper. Following 
harvesting, whole cell extracts were performed (see Section 2.15) and total protein in 
each extract was quantified using the BCA Protein Assay kit (Thermo-scientific). A 
standard curve was then generated using bovine serum albumin; an example of which is 
demonstrated in Figure 4.11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.11 Example of BSA Standard Curve.  
A 2mgl/ml bovine serum albumin stock solution was used to generate dilutions of; 25, 
125, 250, 500, 750, 1000, 1500 and 2000 ȝg/ml. Unknown protein samples were diluted 
1/10 in PBS before all samples were added in triplicate to a 96 well plate, in addition to 
the samples PBS only was added in triplicate as the buffer control, and reagents from 
the BCA Protein Assay kit (Thermo-scientific) were added (Section 2.16.2) the plate 
was then incubated at 37°C for 30 min before endpoint absorbance was measured at 562 
nm. The mean absorbance of the standard triplicate wells was then plotted against 
concentration. Unknown samples were determined by y=mx+c and adjusted for 
dilution.  
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Once quantified an equal amount of total protein was loaded onto SDS-PAGE gels and 
western blots were performed. The blots were then probed with antibodies specific to 
topo IIα and topo IIȕ (see Section 2.16 for more information on methodology). 
Densitometry was then performed on the blots in order to semi-quantify the amount of 
topo IIα and topo IIȕ present in the samples. The results are shown in Figures 4.12 and 
4.13. 
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Figure 4.12 Semi-Quantitation of topo IIα and ȕ protein in non-PMA and PMA treated 
U937 cells. 
Cells were seeded at 3 x 105 cells/ml with 5 ng/ml PMA or 0.1% DMSO (v/v) in 75cm3 culture 
flask and allowed to incubate for 72 h before harvesting. Whole cell protein was then extracted 
and quantified (Section 2.16). 185ȝg of total protein was then loaded onto a 7.5% SDS gel and 
SDS PAGE was then performed to separate the proteins out by size (Section 2.16.4) this was 
followed by protein transfer onto nitrocellulose paper by wet western blot (Section 2.16.5). 
Nitrocellulose blots were then probed with antibodies to topo IIα (a) and topo IIȕ (b) (Section 
2.16.7). Lanes are labelled with treatment and sample number (c) Quantification of protein was 
performed using the densitometry software, Syngene genetools, data is presented as amount of 
protein in PMA treated cells as a percentage of that in non-PMA treated cells. See Appendix 
Figure A.2 and A.3 for GAPDH loading control. Results shown are the mean of two 
independent sample ± standard error.* = p < 0.05. See Appendix Table A.5 for p values. 
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(a) 
(b) 
Figure 4.13 Semi-Quantitation of topo IIα and ȕ protein in non-PMA and PMA treated  
HL-60 cells. 
Cells were seeded at 3 x 105 cells/ml with 5 ng/ml PMA or 0.1% DMSO (v/v) in 75cm3 culture 
flask and allowed to incubate for 72 h before harvesting. Whole cell protein was then extracted 
and quantified (Section 2.16.2). 185ȝg of total protein was then loaded onto a 7.5% SDS gel and 
SDS PAGE was then performed to separate the proteins out by size (Section 2.16.4) this was 
followed by protein transfer onto nitrocellulose paper by wet western blot (Section 2.16.5). 
Nitrocellulose blots were then probed with antibodies to topo IIα (a) and topo IIȕ (b) (Section 
2.16.7). Lanes are labelled with treatment and sample number (c) Quantification of protein was 
performed using the densitometry software, Syngene genetools, data is presented as amount of 
protein in PMA treated cells as a percentage of that in non-PMA treated cells. See Appendix 
Figures A.4 and A.5 for GAPDH loading control. Results shown are the mean of three 
independent samples ± standard error. *** = p < 0.001. See Appendix Table A.6 for p values. 
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From the results (Figure 4.12 and 4.13) a decrease in both topo IIα and topo IIȕ protein 
levels can be observed when both U937 and HL-60 cells are treated with PMA. This 
supports mRNA data in Figures 4.3 and 4.4. An average 69% decrease in topo IIα 
protein was observed in PMA treated U937 cells compared to non-PMA treated cells, 
similarly an average 70% decrease in topo IIα protein was seen in PMA treated HL-60 
cells compared to the non-PMA treated cells. Interestingly an average 65% decrease in 
the level of topo IIȕ protein was observed when U937 cells were treated with PMA, 
whilst a 70% decrease in topo IIȕ protein was seen in PMA treated HL-60 cells 
compared to non-PMA treated cells. These findings are in agreement with Kauffman et 
al. (1991) who reported a decrease in levels of both topo IIα and topo IIȕ protein when 
HL-60 cells underwent granulocytic differentiation. Constantinou et al. (1996) mirrored 
this finding, demonstrating a decrease in topo II catalytic activity followed by a 
decrease in phosphorylation and a subsequent decrease in protein levels when mouse 
erthryoleukemic cells (MELs) were differentiated with hexamethylene bis-acetamide 
(HMBA). This was in support of work by Bodely et al. (1987) who demonstrated a 
decrease in topo II protein and activity in HMBA differentiated MELs.  
As discussed previously (Section 4.2.1) down-regulation of topo IIα may be the result 
of an arrest in the cell cycle. Figure 4.6a shows that when cells are treated with PMA, 
cells appear to arrest in late S phase, early G2/M. This is in agreement with previous 
studies that have also reported the same G2/M arrest (Kosaka et al., 1996; Barboule et 
al., 1999; Oliva et al., 2008). Levels of topo IIα protein have previously been shown to 
increase during S phase, peaking in G2/M (Woessner, 1991). This reflects the 
importance of the role of topo IIα in the decatenation of sister chromatids during mitosis 
(Uemura et al., 1987; Adachi et al., 1991; Coelho et al., 2003; Ramamoothy et al., 
2012). It may then be expected that levels of topo IIα in PMA treated cells would be 
relatively high compared to cycling cells as the cells are arrested in G2/M. Taken 
together, the G2/M arrest seen in Figure 4.6a in PMA treated cells along with a lack of 
proliferation in PMA treated cells (Figure 3.4) it may be suggested that mitosis is not 
occurring, thus topo IIα is not required. The half-life of topo IIα has previously been 
reported to be 6.6 h. It then undergoes proteosomal degradation. A lack of progression 
through G2/M to enter the cell cycle again would result in normal degradation of topo 
IIα and a lack of topo IIα being synthesised. Thus this may explain the decrease in topo 
IIα protein in PMA treated cells compared with cycling cells. 
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The decrease in topo IIȕ protein levels is however, in contrast with work by Aoyama et 
al. (1998) who reported that differentiation of HL-60 cells using all-trans retinoic acid 
resulted in an increase in topo IIȕ protein. However in an earlier study by Kauffman et 
al. (1991) using the same cell line, levels of topo IIȕ were shown to be reduced. The 
difference in topo IIȕ levels observed between the studies may be due to the 
differentiating agent used. Kauffman et al. (1991) used 1.3% DMSO to differentiate 
HL-60 into a granulocyte like cells, in contrast Aoyama et al. (1998) used 1ȝmol/δ all-
trans retinoic acid to induce granulocytic differentiation of HL-60 cells. Additionally 
McNamara et al. (2010) reported an up-regulation of topo IIȕ protein expression when 
NB4 and NB4-MR2 cells were treated with PMA for 2 h, and that an increase in protein 
expression correlated with an increase in PMA concentration. They also postulated that 
this up-regulation could be the result of an up-regulation of protein kinase delta 
(PKCD), which is stimulated by PMA and suggest that PKCD phosphorylates topo IIȕ 
leading to an increase in stability and a decreased rate of degradation. Inhibition of 
PKCD was also shown to result in a decrease in topo IIȕ protein level. The results are 
however in agreement with Padget et al. (2000) who showed a higher abundance of 
both topo IIα and topo IIȕ protein in exponentially growing Raji cells compared to the 
confluent counterparts, thus suggesting that levels of topo IIȕ may also be cell cycle 
dependent. Therefore the decrease in topo IIȕ protein demonstrated in Figure 4.12b and 
4.13b may be due to similar scenario as that in the decrease of topo IIα. 
The difference between the levels of mRNA and protein expression with regards to 
quantification of both topo IIα and topo IIȕ may be due to changes in the stability of the 
mRNA transcript or the stability of the protein via changes in translational 
modifications upon PMA treatment. Indeed phosphorylation of topo IIα has previously 
been shown to increase the stability of the protein (Qi et al., 2011) and PMA induced 
PKCD has been suggested to modulate the stability of topo IIȕ (McNamara et al., 
2010). 
It was hypothesised that the changes in gene expression involved in the differentiation 
from monocyte to macrophage would require the actions of topo IIȕ in the regulation of 
transcription of lineage specific genes. Furthermore it was expected that an increase in 
the requirement of topo IIȕ may result in an up-regulation of its protein expression. 
However the results in Figures 4.9 and 4.10 do not support this hypothesis; levels of 
topo IIȕ are significantly less in differentiated cells than in cycling cells. McNamara et 
al. (2010) reported that topo IIȕ was increased 2 h after PMA treatment compared to a 
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non-PMA treated control. Indeed it may be suggested that the regulation of transcription 
of genes involved in differentiation occur very early on and the decrease in topo IIȕ 
after 72 h of PMA treatment may reflect a decrease in transcriptional activity within the 
cells. Certainly it is sensible to suggest that the transcriptional activity of differentiated 
cells may be less than cycling cells that require an increase in transcription in 
comparison for the synthesis of proteins for newly synthesised cells, and thus would 
contain a higher level of topo IIȕ.  
 
4.4 Effect of Topoisomerase II drugs on cell viability, using the XTT assay 
The cytotoxic assay, XTT was used to quantify the number of viable cells (see Section 
2.15 for further detail) when non-PMA and PMA treated cells were exposed to the 
topoisomerase II drugs, etoposide (VP-16), ICRF-193 and ICRF-187.  
Previous work has shown that efficacy of topo II drugs is directly related to the amount 
of topo II present in the cell (Depowski et al., 2000). Therefore this assay will be used 
to verify the levels of topo IIα and topo IIȕ determined in Section 4.2. 
 
4.4.1 Effect of etoposide 
Etoposide (VP-16) a topoisomerase II poison belongs to a group of non-intercalating 
drugs, the epipophyllotoxins. Etoposide acts by stabilising the topo II cleavable 
complex by forming a drug-DNA tertiary complex, thus preventing re-ligation of DNA 
strands. During the cell cycle the cleavable complexes are further processed and become 
permanent double strand breaks (Li & Lui, 2001). An accumulation of double strand 
breaks will eventually lead to apoptosis of the cell (Section 1.8.2). 
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Figure 4.14 Comparing the cytotoxic effect of VP-16 on non-PMA and PMA 
treated U937 cells. 
U937 cells were seeded at a density of 3 x 105 cells/ml with 5 ng/ml PMA or 0.1% 
DMSO (v/v) and allowed to incubate for 72 h. Media was then replaced with the 
addition of varying concentrations of VP-16 (0.01, 0.1, 1, 2.5, 5, 7.5 and 10 ȝM) 0.1% 
DMSO (v/v) was used as the drug vehicle control. Cells were allowed to incubate for a 
further 72 h, after which an XTT assay was performed (Section 2.15).  
Results are reported as percentage of 0.1% DMSO (v/v) vehicle control. Results shown 
are the mean of three independent experiments ± standard error. * = p < 0.05, ** = p < 
0.001, *** = p < 0.001. See Appendix Table A.7 for p values. 
 
Figure 4.14 shows the effects of various concentrations of VP-16 on U937 cells and 
PMA pre-treated U937 cells. When the concentration of VP-16 increases, there is a 
significant increase in cytotoxicity in non-PMA treated cells (p = < 0.0001), reaching an 
average 75% decrease in viable cells at 5ȝM, a similar decrease is maintained when 
cells are treated with 7.5 and 10ȝM VP-16. In comparison, PMA treated cells maintain 
at least an average 85% cell viability up to the highest concentration of VP-16, 10ȝM. 
Thus pre-treatment of cells with PMA appears to have a protective effect against the 
cytotoxic affect of VP-16.  
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Figure 4.15 Comparing the cytotoxic effect of VP-16 on non-PMA and PMA 
treated HL-60 cells. 
HL-60 cells were seeded at a density of 3 x 105 cells/ml with 5 ng/ml PMA or 0.1% 
DMSO (v/v) and allowed to incubate for 72 h. Media was then replaced with the 
addition of varying concentrations of VP-16 (0.01, 0.1, 1, 2.5, 5, 7.5 and 10 ȝM) 0.1% 
DMSO (v/v) was used as the drug vehicle control. Cells were allowed to incubate for a 
further 72 h, after which an XTT assay was performed (Section 2.15).  
Results are reported as percentage of 0.1% DMSO (v/v) vehicle control. Results shown 
are the mean of three independent experiments ± standard error. * = p < 0.05, ** = p < 
0.01. See Appendix Table A.8 for p values. 
 
A similar result is also observed in HL-60 cells (Figure 4.15); there is a significant 
decrease in cell viability in non-PMA treated cells as the concentration of VP-16 
increases (p = > 0.0001). When these cells are exposed to 10 ȝM of VP-16 they exhibit 
an average 82% decrease in cell viability. PMA treated cells, in contrast, again appear to 
be more protected against VP-16 with only a 43% average decrease in cell viability. 
This is in agreement with Jasek et al. (2008) who also saw a decrease in sensitivity to 
etoposide in PMA treated HL-60 cells. 
The results of this assay (Figures 4.14 and 4.15) may be explained by analysis of the 
cell cycle in Figure 4.6a that demonstrates a G2/M cell cycle arrest when cells are 
differentiated with PMA. Sensitivity of cells to VP-16 induced apoptosis has been 
shown to require the transition of cells from G1 to S phase (Ferraro et al., 2000). This is 
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supported  by  D’Arpa  et al., (1990) who reported that inhibition of nucleic acid 
synthesis rendered chinese hamster cells resistant to VP-16. Therefore an arrest in G2/M 
may lead to VP-16 resistance as seen in cells that undergo PMA pre-treatment (Figure 
4.13 and 4.14) due to an inability to proceed through G1 and S phase.  
Additionally, the cytotoxic action of VP-16 requires the processing of multiple 
cleavable complexes in order for enough double strand breaks to become visible to 
induce apoptosis (Li & Lui, 2001). The processing of cleavable complexes includes the 
physical collision of replication and/or transcriptional machinery with the cleavable 
complex, physically knocking topo II from the site to reveal the double strand break 
(Tammaro et al., 2013). If replication is ceased, for example in cell cycle arrested or 
differentiated cells (Moore & Wang, 1994) then it is sensible to suggest the amount of 
cleavable complexes processed will be reduced, resulting in a decrease in cytotoxicity. 
Figure 4.5b shows the cell cycle distribution of 0.1% DMSO (v/v) treated and PMA 
treated U937 cells. 0.1% DMSO (v/v) treated cells display a typical cell cycle 
distribution of exponentially growing cells (Wang et al., 2006), whilst PMA treated 
cells appear to accumulate in late S phase, G/M. This is in agreement with previous 
studies that have reported the same pattern of cell cycle distribution in PMA treated 
cells. Therefore from this data, along with the results from the growth curve in Chapter 
3 (Figure 3.4) it can be inferred that PMA treated cells do not cycle. It may then be 
postulated that the decrease in sensitivity to VP-16 in PMA pre-treated cells compared 
to non-PMA treated cells is due to a reduction in the processing of cleavable complexes 
due to a decline in replication associated with cell cycle arrest. In addition, this cell 
cycle block may facilitate the reversal and/or repair of more drug-stabilised cleavable 
complexes (Branzai & Foiani, 2008). All of these scenarios are not mutually exclusive 
and would lead to a decrease in VP-16 sensitivity. 
Furthermore Figures 4.3a, 4.4a 4.12a and 4.13a reveal a down-regulation of topo IIα 
both at the mRNA and protein level when cells are treated with PMA for 72 h compared 
to non-PMA treated cells. Indeed it has already been established that VP-16 
preferentially targets topo IIα. A study by Errington et al. (2004) investigated the 
cytotoxic importance of each isoform, relating this to the stability of the topo II-drug 
complexes. They report  that  the longevity of topo IIα – VP-16 complexes was greater 
than the topo IIȕ – VP-16 complexes.  It may be postulated that a decrease in topo IIα 
may render VP-1θ  ineffective  due  to  a  lack  of  topo  IIα  target. This is in support of 
previous work that has shown that measurement of topo II levels can predict the 
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efficacy of chemotherapeutic drugs (Durbecq et al., 2004; Deposki et al., 2000; 
Schindlbeack et al., 2010). 
Once a difference in the efficacy of VP-16 on non-PMA and PMA treated cells was 
established, an investigation into the synergistic effect of PMA and VP-16 on cell 
viability was undertaken. This co-treatment would establish the effects of VP-16 on 
cells that were undergoing differentiation in contrast to when they were terminally 
differentiated (Figure 4.16). 
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Figure 4.16 Comparing the effects of VP-16 on PMA pre-treated cells and 
PMA/VP-16 co-treated cells. 
U937 cells (a) and HL-60 cells (b) were seeded at a density of 3 x 105 cells/ml with 5 
ng/ml PMA or 0.1% DMSO (v/v) and allowed to incubate for 72 h. Media was then 
replaced with the addition of varying concentrations of VP-16 (0.01, 0.1, 1, 2.5, 5, 7.5 
and 10 ȝε) 0.1% DMSO (v/v) was used as the drug vehicle control. At this time cells 
for VP-16 co-treatment were seeded at 3 x 105 cells/ml with 5 ng/ml PMA and the 
various VP-16 concentrations. All cells were allowed to incubate for a further 72 h, 
after which an XTT assay was performed (See Section 2.15). Results are reported as 
percentage of 0.1% DMSO (v/v) control. Results shown are the mean of three 
independent experiments ± standard error. See Appendix Tables A.9 to A.12 for p 
values. 
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At VP-16 concentrations of 5, 7.5 and 10 ȝM U937 cells that had undergone PMA/VP-
16 co-treatment are less sensitive to VP-16 than non-PMA treated cells, however they 
are more sensitive to VP-16 than PMA pre-treated cells. For example, Figure 4.16a 
shows U937 cells that have been co-treated with PMA/VP-16 at a concentration of 5 
ȝM VP-16. These cells display an average 60% reduction in cell viability. In 
comparison, non-PMA treated cells exposed to 5 ȝM VP-16 display a 75% reduction in 
cell viability, these results are not significantly different (see Appendix Table A.9). 
Furthermore, cells pre-treated with PMA prior to treatment with 5ȝM VP-16 display an 
average 9% decrease in cell viability, this is significantly different from the co-treated 
cells (p=0.004). This decrease in cell viability is mirrored in the results where 7.5 ȝM 
and 10 ȝε VP-16 were used (see Appendix Table A.10).  
HL-60 cells exposed to the same conditions as U937 (Figure 4.16b) exhibit a similar 
pattern of response to co-treatment of PMA/VP-16 compared to PMA pre-treated 
samples and non-PMA treated samples. Again at VP-16 concentrations of 5, 7.5 and 10 
ȝM cells that had undergone co-treatment with PMA/VP-16 appeared more sensitive to 
VP-16 than PMA pre-treated cells as demonstrated by a larger decrease in cell viability. 
For example, Figure 4.16b shows HL-60 cells that have been co-treated with PMA/VP-
16 at a concentration of 5 ȝM VP-16. These cells display an average 69% reduction in 
cell viability. In comparison, non-PMA treated cells exposed to 5 ȝM VP-16 display a 
78% reduction in cell viability, which is significantly different from the co-treated cells 
(p=0.004). Furthermore, cells pre-treated with PMA prior to treatment with 5 ȝM VP-16 
display an average 40% decrease in cell viability, again this is significantly different 
from the co-treated cells (p=0.01). This decrease in cell viability is mirrored in the 
results where 7.5 ȝM and 10 ȝε VP-16 were used (see Appendix Table A.11).  
Barry et al. (1993) showed that 30 minutes of treatment of HL-60 cells to VP-16 
followed by varying lengths of incubation post treatment resulted in apoptosis of the 
cells within 8 h. A study using MCF-7 cells revealed that PMA induced G2/M arrest 
occurred between 6 to 9 h of PMA treatment (Barboule et al., 1999). Taken together it 
may be postulated that results seen in Figure 4.15, where co-treatment of cells with 
PMA/VP-16 renders cells more sensitive to VP-16 than cells that had been pre-treated 
with PMA prior to VP-16 exposure may be due to DNA damage and apoptosis induced 
by VP-16 in the early stages of PMA treatment when cells are continuing to cycle. As 
described previously, the cytotoxic effects of VP-16 are shown to be reliant on the 
cellular processing of VP-16 induced cleavable complexes (Li & Lui, 2001). These 
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events include for example the physical interaction of replication machinery with the 
cleavable complex, knocking topo II from the site and thus revealing a double strand 
break (Tammaro et al., 2013). As replication does not occur in non-cycling cells, such 
as those arrested in G2/M phase then it is sensible to suggest that the processing of the 
cleavable complexes is reduced. Pre-treated PMA cells are arrested in G2/M prior to 
treatment with VP-16 (Figure 4.6a), however co-treated VP-16/PMA cells have a 6-9 
hour period of VP-16 exposure before G2/M arrest occurs (Barboule et al., 1999). It 
may be that the co-treated cells are more sensitive to VP-16 than PMA pre-treated cells 
as they have a short period at the beginning of PMA treatment where cleavable 
complexes may be processed, subsequently triggering apoptosis.  
Lower doses of VP-16 (0.001 – 0.1 ȝε) appear  to have little cytotoxic effect on non-
PMA, PMA pre-treated and PMA/VP-16 co-treated cells. However in both U937 and 
HL-60 cells (Figure 4.16) cells co-treated with VP-16 at concentrations of 1 and 2.5 ȝε 
along with PMA exhibit a higher sensitivity to the cytotoxic actions of VP-16 compared 
to PMA pre-treated cells (see Appendix Tables A.9-A.12 ). 
Interestingly, low doses of VP-16 have been observed to up-regulate an early activation 
of PKC in HL-60 cells (Perez et al., 1997).  McNamara et al. (2010) reported that after 
2 h of treatment with PMA, levels of PKCD increased and this correlated with an up-
regulation of topo IIȕ, furthermore they suggest that this up-regulation of topo IIȕ is due 
to an increase in stability of the protein induced by its phosphorylation by PKCD. 
Therefore it may be possible that the results shown in Figure 4.16 with regards to the 1 
and 2.5 ȝM concentrations of VP-16 in the VP-16/PMA co-treated cells appearing more 
sensitive to VP-16 than non-PMA treated cells may be due to an attenuation effect of 
VP-16 and PMA resulting in an increased amount of PKCD resulting in an increase in 
topo IIȕ phosphorylation, a decreased rate of degradation, and therefore more target for 
VP-16 to act. This hypothesis is in agreement with work by Ritke et al. (1994) who 
showed that VP-16 resistant cells, K/VP.5 contained topo II that was 2.5 less 
phosphorylated than the K562 sensitive cells. Despite VP-16 preferentially targeting 
topo IIα (Errington et al., 2004; Bandele & Osheroff, 2008) it does also target topo IIȕ 
(Willmore et al., 1998; Errington et al., 2004). It may be that an early increase in topo 
IIȕ yields more target for VP-16 and therefore increases its cytotoxicity. Indeed it has 
been shown that levels of topo II can predict the efficacy of such drugs (Dingemans et 
al., 1999). 
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The results shown in Figure 4.14 are in agreement with a study by Zwelling et al. 
(1988) who also showed that treatment of HL-60 cells with PMA prior to exposure to 
VP-16 led to decrease in sensitivity to the drug compared to non-PMA treated cells. 
Furthermore they show that PMA causes changes in chromatin architecture; such as 
changes in nuclease sensitivity and alterations in DNA linking number, and suggest that 
this may change the interaction of topo II with the DNA and VP-16 with the DNA. 
Additionally they also show that cells are more sensitive to the topo II poison and DNA 
intercalator, mAMSA than VP-16. They suggest that as a DNA intercalator, mAMSA 
may induce local changes in DNA structure therefore overcoming any hindering 
changes caused by PMA. This is in contrast to VP-16, which does not DNA intercalate 
and therefore cannot directly influence DNA structure. Zwelling et al. (1988) also 
suggest that PMA may induce the cellular re-distribution of topo II to non-DNA regions 
or non-cleavable DNA sites therefore protecting against VP-16. Indeed this hypothesis 
is plausible; Cowell et al. (2011) showed that treatment of cell cultures with the histone 
deacetylase inhibitor, trichostatin A (TSA) induced the re-distribution of topo IIȕ from 
heterochromatin to euchromatin and suggested that this redistribution then converts 
topo IIȕ to a more effective target of topo II poisons.  
Taken together, the protective effect of PMA on VP-16 induced cytotoxicity appears to 
be multi-variant, and certainly deserves further investigation. 
 
4.4.2 Effect of ICRF-193 
ICRF-193, a topoisomerase II inhibitor from the bisdioxopiperazine family of drugs acts 
by non-competitively binding to topo II, preventing binding and hydrolysis of ATP. 
ATP hydrolysis is required for the release of the re-ligated DNA strand from the topo II 
dimer. Inhibition of ATP hydrolysis results in a closed clamp structure. The actions of 
ICRF-193 ultimately lead to prevention of enzyme turnover. Apoptosis of ICRF-193 
treated cells is a result of an inability of cells to segregate chromosomes, leading to an 
accumulation of DNA damage post mitosis. 
To investigate the effects of ICRF-193 on non-PMA and PMA pre-treated cells, cells 
were exposed to varying concentrations of ICRF-193 for 72 h. 
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Figure 4.17 Comparing the cytotoxic effect of ICRF-193 on non-PMA and PMA 
treated U937 cells. 
U937 cells were seeded at a density of 3 x 105 cells/ml with 5 ng/ml PMA or 0.1% 
DMSO (v/v) and allowed to incubate for 72 h. Media was then replaced with the 
addition of varying concentrations of ICRF-193 (0.001, 0.01, 0.02, 0.04, 0.06, 0.08, 0.1, 
2.5, 5 and 7.5 ȝM) 0.1% DMSO (v/v) was used as the vehicle control. Cells were 
allowed to incubate for a further 72 h, after which an XTT assay was performed 
(Section 2.15).  
Results are reported as percentage of 0.1% DMSO (v/v) vehicle control. Results shown 
are the mean of three independent experiments ± standard error. * = p < 0.05, ** = p < 
0.01. See Appendix Table A.13 for p values. 
 
 
The results in Figure 4.17 show that ICRF-193 exhibits a cytotoxic effect on non-PMA 
treated U937 cells from a concentration of 1ȝM. Non – PMA treated U937 cells exhibit 
an average 32% decrease in cell viability when treated with 1 ȝM ICRF-193 for 72 h. 
This decrease in cell viability is similar when non-PMA treated cells are treated with 
higher concentrations of ICRF-193 including 2.5, 5 and 7.5 ȝM. In comparison PMA 
treated U937 cells appear to be protected against the effects of ICRF-193 as the largest 
decrease in cell viability is on average, 11% seen when cells are treated with 1 and 5 
ȝM ICRF-193. 
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Figure 4.18 Comparing the cytotoxic effect of ICRF-193 on non-PMA and PMA 
treated HL-60 cells. 
HL-60 cells were seeded at a density of 3 x 105 cells/ml with 5 ng/ml PMA or 0.1% 
DMSO (v/v) and allowed to incubate for 72 h. Media was then replaced with the 
addition of varying concentrations of ICRF-193 (0.001, 0.01, 0.02, 0.04, 0.06, 0.08, 0.1, 
2.5, 5 and 7.5ȝM) 0.1% DMSO (v/v) was used as the vehicle control. Cells were 
allowed to incubate for a further 72 h, after which an XTT assay was performed 
(Section 2.15).  
Results are reported as percentage of 0.1% DMSO (v/v) vehicle control. Results shown 
are the mean of three independent experiments ± standard error. ** = p < 0.01, *** = p 
<0.001. See Appendix Table A.14 for p values. 
 
The results shown in Figure 4.18 reveal a similar pattern to that in Figure 4.17; ICRF-
193 appears to have a cytotoxic effect on non-PMA treated HL-60 cells from a 
concentration of 0.04ȝM, displaying an average decrease in cell viability of 21%. This 
effect on cell viability appears to peak at 1ȝM ICRF-193 when non-PMA treated cells 
display an average decrease in cell viability of 72% upon exposure to the drug. This 
decrease in cell viability is similar when non-PMA treated cells are exposed to higher 
concentrations of ICRF-193, including 2.5, 5 and 7.5 ȝM. In contrast, PMA treated HL-
60 cells appear to be protected against the effects of ICRF-193. At the highest 
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concentration of ICRF-193, 7.5 ȝM, PMA treated cells only display an average decrease 
in cell viability of 11%.  
The results of this assay reflect results presented in Figure 4.6a that demonstrated a 
G2/M arrest when cells were differentiated with PMA. The cytotoxic actions of ICRF-
193 to induce apoptosis, like VP-16 require an active cell cycle (Iwai et al., 1997; Li & 
Lui, 2001). However unlike VP-16, ICRF-193 requires progression through mitosis for 
DNA damage via accumulation of multiploid cells due to incomplete chromosome 
segregation (Iwai et al., 1997). Further to this studies quantifying ȖH2AX foci 
formation have shown that HeLa cells treated with ICRF-193 show an increase in 
ȖH2AX foci formation in S phase, late mitosis and early G1 (Park and Avraham, 2006). 
Therefore it may be inferred that the decrease in ICRF-193 sensitivity in PMA treated 
cells compared to non-PMA treated cells may be due to the inability of ICRF-193 to 
exert its DNA damaging effects in cells that are not undergoing a cell cycle (Figure 
4.6a). 
In addition, as discussed in Section 4.2.1, Figures 4.3, 4.3, 4.11 and 4.12 show that 
differentiation of both U937 and HL-60 cells results in down-regulation of topo IIα and 
topo IIȕ at both the transcript and protein level. ICRF-193 has been shown the target 
topo IIȕ preferentially (Isik et al., 2003), however the specificity of it is under question 
as it has also been shown to interact with topo IIα (Patel et al., 2000). A down-
regulation of topo IIα and topo IIȕ protein would then decrease the amount of target 
available for ICRF-193 to bind. Therefore it may be possible that a down-regulation of 
topo II may render ICRF-193 ineffective as seen in Figures 4.17 and 4.18.  
It is interesting to note that non-PMA treated HL-60 cells appear to be more sensitive to 
ICRF-193 than non-PMA treated U937 cells. When non-PMA treated HL-60 cells were 
exposed to 1 ȝM ICRF-193 they displayed an average 72% decrease in cell viability 
(Figure 4.18); in comparison non-PMA treated U937 cells only displayed an average 
32% decrease in cell viability when exposed to the same concentration of ICRF-193 
(Figure 4.17). This pattern is also exhibited at higher concentrations of ICRF-193 
(Figure 4.17 and 4.18). 
HL-60 is a p53 null cell line. p53 is a tumour suppressor protein involved in the up-
regulation of proteins involved in G1/S and G2/M checkpoint activation (Baus et al., 
2003). ICRF-193 has been shown to arrest or cause delay of cells in G2/M often leading 
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to cell death (Ishida et al., 1994). Interestingly ICRF-193 resistant cell lines have been 
shown to exert their resistance by bypassing these checkpoints (due to mutations in 
checkpoint proteins), therefore continuing their cell cycle (Nishida et al., 2001). 
However previous work has shown that HL-60 exerts its G2/M arrest in response to 
DNA damage via a p53 independent mechanism (Han et al., 1995), thus a resistance to 
ICRF-193 is not observed in HL-60 cells.  
 
4.4.3 Effect of ICRF-187 
ICRF-187, like ICRF-193 is part of a group of synthetic compounds named the 
bispdioxopiperzines. ICRF-187 acts as a Topo II inhibitor in a similar way to ICRF-
1λγ, by creating a ‘closed clamp’ structure. Topo II therefore is unable to complete its 
catalytic cycle without the formation of a double strand break (Section 1.8.3). The 
cytotoxic effect of ICRF-187 was compared in non-PMA and PMA treated U937 and 
HL-60 cells.  
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Figure 4.19 Comparing the cytotoxic effect of ICRF-187 on non-PMA and PMA 
treated U937 cells. 
 U937 cells were seeded at a density of 3 x 105 cells/ml with 5 ng/ml PMA or 0.1% 
DMSO (v/v) and allowed to incubate for 72 h. Media was then replaced with the 
addition of varying concentrations of ICRF-187 (0.0001, 0.001, 0.01, 1, 5, 10 and 20 
ȝg/ml) 0.1% DMSO (v/v) was used as the vehicle control. Cells were allowed to 
incubate for a further 72 h, after which an XTT assay was performed (Section 2.15).  
Results are reported as percentage of 0.1% DMSO (v/v) vehicle control. Results shown 
are the mean of three independent experiments ± standard error. ** = p < 0.01. See 
Appendix Tables A.15 for p values. 
The results in Figure 4.19 show that ICRF-187 exhibits a cytotoxic effect on non-PMA 
treated cells from a concentration of 5 ȝg/ml. Non – PMA treated U937 cells exhibit an 
average 31% decrease in cell viability when treated with 5 ȝg/ml ICRF-187 for 72 h. 
This decrease in cell viability is similar when non-PMA treated cells are treated with 
higher concentrations of ICRF-187 including 10 and 20 ȝg/ml. In comparison PMA 
treated U937 cells appear to be protected against the effects of ICRF-187 as there 
appears to be no decrease in cell viability even at the highest concentration of ICRF-
187.  
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Figure 4.20. Comparing the cytotoxic effect of ICRF-187 on non-PMA and PMA 
treated HL-60 cells. 
HL-60 cells were seeded at a density of 3 x 105 cells/ml with 5 ng/ml PMA or 0.1% 
DMSO (v/v) and allowed to incubate for 72 h. Media was then replaced with the 
addition of varying concentrations of ICRF-187 (0.0001, 0.001, 0.01, 1, 5, 10 and 
20ȝg/ml) 0.1% DMSO (v/v) was used as the vehicle control. Cells were allowed to 
incubate for a further 72 h, after which an XTT assay was performed (Section 2.15).  
Results are reported as percentage of 0.1% DMSO (v/v) vehicle control. Results shown 
are the mean of three independent experiments ± standard error. * = p < 0.05, ** = p < 
0.01, *** = p < 0.001. See Appendix Table A.16 for p values. 
 
The results in Figure 4.20 show that ICRF-187 exhibits a cytotoxic effect on non-PMA 
treated cells from a concentration of 0.01 ȝg/ml. Non – PMA treated HL-60 cells 
exhibit an average 10% decrease in cell viability when treated with 0.01 ȝg/ml ICRF-
187 for 72 h. This decrease in cell viability increases as the concentration of ICRF-187 
increases; at 5 ȝg/ml non-PMA treated cells display an average 67% decrease in cell 
viability upon treatment with the drug, a similar decrease in cell viability can be seen at 
higher concentrations of ICRF-187 including 10 and 20 ȝg/ml. In comparison PMA 
treated HL-60 cells appear to be protected against the effects of ICRF-187 as there 
appears to be no decrease in cell viability even at the highest concentration of ICRF-
187.  
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As discussed previously in Section 4.2.1, Figures 4.3, 4.4, 4.11 and 4.12 show that 
differentiation of HL-60 and U937 cells with PMA results in a decrease of topo IIα and 
topo IIȕ both at the mRNA and protein level. Indeed the protective effect that treatment 
of cells with PMA appears to elicit against the cytotoxic action of ICRF-187 (Figures 
4.19 and 4.20) may be due to a lack of target for the inhibitor to act upon, however this 
hypothesis is controversial, Fattman et al. (1996) report that ICRF-187 activity is 
inversely proportional to levels of topo II, whilst Hasinoff et al. (1997) and Sehested et 
al. (1998) infer resistance of cells to ICRF-187 is due to a decrease in topo II protein 
levels. 
Furthermore the exact mechanism by which ICRF-187 elicits its cytotoxic effects is still 
under investigation. Treatment of human leukemic CEM cells with ICRF-187 was 
shown to induce a G2/M decatenation checkpoint (Morgan et al., 2000), suggesting that 
ICRF-187 may induce a DNA damaging effect similar to that induced by ICRF-193. As 
suggested previously, the cell cycle arrest observed in PMA treated cells (Figure 4.6a) 
may be stronger than the ICRF-187 induced checkpoint, indeed treatment of cells with 
an enantiomer of ICRF-187, ICRF-154 results in cell cycle arrest followed by cell 
death. Thus the cell cycle arrest induced by PMA may be protecting against the cell 
death induced effects if ICRF-187.  
A difference in the potency of ICRF -193 and ICRF -187 was also observed in HL-60 
cells. Table 4.1 shows the LD50 values when HL-60 and U937 cells are treated with 
VP-16, ICRF-193 and ICRF-187. As can be seen a dose of 0.2ȝM of ICRF-193 was 
required to kill 50% of HL-60 cells. In comparison, a dose of 7ȝM was required to kill 
50% of HL-60 cells, thus suggesting that ICRF-193 is the more potent inhibitor. This is 
in agreement with previous work that has shown ICRF -193 is the most potent of the 
bispdioxopiperzines (Hasinoff et al., 1995). 
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Table 4.1 LD50 values for non-PMA treated U937 and HL-60 cells exposed to 72 h of 
treatment with the topo II poison, VP-16 and the topo II inhibitors, ICRF-193 and 
ICRF-187. 
     VP-16 
(μM) 
ICRF-193 
(μM) 
ICRF-187 
(μM) 
U937 3 N/A N/A 
HL-60 2 0.2 7 
 
 
Interestingly LD50 values could not be calculated for U937 non-PMA treated cells 
exposed to ICRF-193 and ICRF-187 as at all concentrations of the inhibitors a decrease 
in cell viability did not reach or exceed 50% (Figure 4.17 and 4.19). 
HL-60 cells appear to be more sensitive to the action of all three topo II drugs compared 
to U937 cells, as determined by LD50 values in Table 4.1. Indeed this may be due to a 
higher abundance of topo II within HL-60 cells compared to U937 cells, thus providing 
more target for the topo II drugs. Figure 4.21 compares the levels of topo IIα and topo 
IIȕ protein in non-PMA treated HL-60 and U937 cells.  
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Figure 4.21 Comparison of topo IIα and topo IIȕ protein levels in non-PMA 
treated HL-60 cells vs non-PMA treated U937 cells. 
Densitometry data used to generate Figures 4.12 and 4.13 was used to compare levels of 
topo IIα and topo IIȕ in non-PMA treated HL-60 cells vs non-PMA treated U937 cells.  
Results reported use arbitrary units generated from analysis of western blots using the 
densitometry software Syngene genetools 
Results shown are the mean of three independent experiments ± standard error. ** = p < 
0.01 
 
On average a significant increase (p=0.0055, student t-test) in the amount of topo IIα 
protein can be observed in HL-60 cells compared to U937 cells. In addition, on average 
there is a small increase in topo IIȕ protein in HL-60 cells compared to U937 cells, 
however the difference is not significant.  
A larger amount of topo IIα and topo IIȕ protein in HL-60 cells compared to U937 cells 
may explain the increased sensitivity to all three topo II drugs. Despite VP-16 and 
ICRF-193 being clinically important in the targeting α and ȕ topo II isoforms 
respectively, there is an increased amount of both isoforms in non-PMA treated HL-60 
cells, thus increasing the amount of target for each drug (Huang et al., 2001; Cowell et 
al., 2011). Again this data is in support of previous work that suggests the efficacy of 
topo II targeting chemotherapies can be measured by quantification of topo II protein 
levels (Dingemans et al., 1999). 
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It could be argued that due to the mechanism of the XTT assay (Section 2.15) that 
essentially measures mitochondrial function; some of the cytotoxic effects observed 
whilst investigating topo II inhibitors could be a result of the iron chelating capabilities 
of the inhibitors impairing mitochondrial function (Grausland et al., 2007. However 
very little cytotoxic effect was seen in PMA treated cells; who are shown to contain 
more mitochondria than monocytes (Monaco et al., 1982) and that their function is 
increased in differentiated cells as reflected by an increase in mitochondrial citrate 
carrier (Infantino et al., 2011) thus providing more target for the iron chelating 
capabilities of ICRF-193. This would then suggest that treatment with ICRF-193 is 
having little effect on mitochondrial function, and that the XTT assay is indeed an 
appropriate assay to use to measure the cytotoxic effects of ICRF-193. 
  
4.5 Summary  
The data in this Chapter reveals that levels of topo IIα and ȕ mRNA and protein are 
decreased when both HL-60 and U937 cells are differentiated with PMA. Moreover this 
result is also reflected when analysing mRNA levels of topo IIα and ȕ in CD14+ 
primary monocytes and in M-CSF differentiated CD14+ primary monocytes. Further to 
this, when comparing mRNA expression of topo IIα to topo IIȕ in U937 and HL-60 
cells, there appears to be no predominant isoform in non-PMA treated cells, with levels 
of mRNA expression between the two isoforms being similar, however in PMA treated 
cells levels of topo IIȕ message are much higher compared to levels of topo IIα 
message, suggesting a role not yet known for topo IIȕ in PMA induced differentiation.  
Cell cycle analysis of non-PMA and PMA treated cells demonstrated that upon 
differentiation with PMA cells experience a cell cycle block in G2/M phase. This is in 
support of previous studies that also report a G2/M block in PMA differentiated cells.  
Investigation into the effect of PMA treatment on sensitivity to the topo II poison, VP-
16 and topo II inhibitors, ICRF-193 and ICRF-187 revealed that PMA treated cells were 
protected from the cytotoxic effects of these drugs, and it is suggested that this may be 
due to the down-regulation of both topo II isoforms after PMA differentiation thus 
providing less target for the drug to induce its effects, or due to the PMA induced cell 
cycle blocking preventing processing of DNA damage. 
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Chapter 5 
 
The effects of topoisomerase IIȕ inhibition on multiple factors associated with 
macrophage differentiation and stimulation. 
 
5.1 Introduction 
The vertebrate immune system is comprised of two distinct mechanisms; the innate 
immune system and the adaptive immune system (Flajnik & Pasquier, 2004). 
The innate immune system provides immediate defence against sources of infection. It 
acts quickly, however it does not possess any immunological memory; it cannot mount 
a specialised response to a particular pathogen. Cells of the innate immune system 
include neutrophils, macrophages and dendritic cells (Janeway & Medzhitov, 2002; 
Bennouna et al., 2003; Mitchell et al., 2002). 
The innate immune response is however capable of recognising particular molecular 
patterns common within similar pathogens, these are referred to as pathogen associated 
molecular patterns (PAMPs) (Kingston & Mills, 2011). Examples of these include 
bacterial lipopolysaccharide (LPS), found in the cell wall of Gram-negative bacteria, 
virally derived double stranded RNA and lipoteichoic acid found in Gram-positive 
bacteria (Tang et al., 2012). Cells of the innate immune system are able to recognise 
these patterns via their pattern recognition receptors (PRRs); LPS for example, is 
recognised by Toll Like Receptor 4 (Mogensen, 2009). Binding of this PAMP to the 
PRR causes a cascade of intra-cellular signals, leading to the production of pro-
inflammatory cytokines, generation of reactive oxygen species and activation of 
phagocytosis which are used to launch a cytotoxic attack against pathogens, 
subsequently engulfing them in order for them to be destroyed by lysosomes found in 
the macrophage (MacMicking et al., 1997; BoseDasgupta & Pieter, 2014). 
The adaptive immune system in comparison, acts much slower than the innate immune 
system (Alper et al., 2007). It is often stimulated by the innate immune system, via 
actions of antigen presentation on the surface of antigen presenting cells such as 
macrophages. In contrast the adaptive immune system does possess immunological 
memory, and is the basis for vaccinations (Janeway et al., 2002; Chandra, 1997). 
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Both the innate and adaptive immune system, as a whole rely upon a signalling network 
for communication in order to generate and regulate the immune response. Cytokines 
are an integral part of this. These are small proteins released by the cell in response to 
stress stimuli, with pleotropic functions (Zhang et al., 2007; Mosser & Edwards., 2008). 
Indeed some cytokines have both a pro-inflammatory effect and an anti-inflammatory 
effect (see Section 1.13) (Scheller et al., 2011). 
A dysregulation of the innate immune system can lead to an over production of 
cytokines leading to chronic inflammation. This is seen in autoimmune diseases such as 
artherosclerosis, asthma and Type 1 Diabetes that are associated with and the result of 
chronic inflammation (Cook et al., 2004; Costa et al., 2010). Interestingly, 
topoisomerase II autoantibodies are detectable in serum from patients with systemic 
sclerosis, Type 1 Diabetes and juvenile Rheumatoid Arthritis (Grigola et al., 2000; 
Chang et al., 1996; Zuklys et al., 1991). The study by Grigola et al. (2000) identified 
autoantibodies specifically against topo IIα, however it was not reported whether topo 
IIȕ had been investigated also, leaving their report of isoform specificity open to 
question. Studies by Chang et al. (1996) and Zuklys et al. (1991) did not investigate 
autoantibody specificity and thus report detection of autoantibodies to topo II generally. 
Cytokine secretion in response to activation of the innate immune response relies on 
several important mechanisms; the transcription of the genes encoding the cytokine 
and/or their subsequent translation and secretion. The latter often relies on the cleavage 
of the cytokine by various proteases (that also require transcription) for activation 
and/or release into the extracellular environment (see Section 1.13) (Horiuchi et al., 
2010). It is the activation and up-regulation of transcription of these genes that is 
currently being investigated in cells of the innate immune system, specifically 
macrophages.  
As stated previously (Section 4.1), topo IIȕ knockout mice die perinatally due to 
neuronal defects (Yang et al., 2000; Lyu et al., 2006) and topo IIȕ has been associated 
with the activation and repression of genes related to neuronal survival (Tiwari et al., 
2012). Activity of topo IIȕ has also been shown to repress the transcription of genes in 
granulocytes regulated by all-trans retinoic acid in a time dependent fashion 
(McNamara et al., 2008). In addition studies have shown that topo II physically 
interacts with certain transcription factors, for example c-Jun and CREB (Kroll et al., 
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1993; Takemori et al., 2007) as well as HDAC 1 and 2, proteins involved in chromatin 
remodelling and gene silencing (Tsai et al., 2000; Johnson et al., 2001).  
A mechanism by which topo IIȕ  facilitates  transcription  was  proposed  by  Ju  et al. 
(β00θ). Cells stimulated with 17ȕ-estradiol, a steroid hormone, revealed that activation 
of the pS2 promoter (a gene encoding a nuclear hormone receptor) required recruitment 
of topo  IIȕ. They also showed using biotin d-UTP that DNA strand breaks were also 
present upon 17ȕ- estradiol  induction, and inferred that  these were topo IIȕ generated. 
Induction of the strand breaks then appeared to facilitate the recruitment of numerous 
transcription factors, causing an alteration in local chromatin architecture. It has been 
widely  documented  that  17ȕ-estradiol modulates the release of various pro-
inflammatory cytokines (Rogers et al., 2001; Kramer et al., 2004). Taken together, the 
requirement of  topo  IIȕ  activity  in  facilitation of gene expression  in  response  to 17ȕ-
estradiol,  and  17ȕ-estradiol regulating the secretion of pro-inflammatory cytokines it 
may be hypothesised  that  topo  IIȕ may  required  for  the  regulation of  transcription of 
other pro-inflammatory cytokines.  Interestingly Ju et al. (2006) also investigated other 
promoters that were responsive to external stimuli, MMP12 is an AP-1 regulated 
promoter, AP-1 is a transcription factor central to activation of genes involved in 
macrophage differentiation. Ju et al. (2006) showed that upon stimulation with TPA 
(PMA) topo IIȕ  recruitment  was  increased  at  the  εεP1β  promoter,  resulting  in 
changes in local chromatin architecture, similar to that described previously. Thus topo 
IIȕ may be involved in the regulation of gene activation of many other genes regulated 
by PMA induced AP-1 recruitment. 
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5.2 Aims 
In  order  to  investigate  whether  topo  IIȕ  plays  a  role  in  the  transcription  of  genes 
associated with macrophage differentiation and stimulation, a range of experiments 
were designed and performed;  
To determine the effects of down-regulation of  topo  IIȕ,  using  the  topo  IIȕ  specific 
inhibitor ICRF-193 on surface antigen expression, expression of differentiation 
associated transcription factors and cytokine expression and secretion.  
To investigate the effects of pre-treatment and co-treatment with ICRF-193 on cytokine 
expression and secretion in PMA treated cells. 
To utilise siRNA technology to create a transient topo IIȕ knockout version of the Uλγ7 
cell line; to examine the effects of this on TNFα and Iδ-1ȕ expression. 
To use wild-type  mouse  embryonic  fibroblasts  (WT  εEFs)  and  topo  IIȕ  stable 
knockout mouse embryonic fibroblasts (#5 MEFs) to determine the difference in 
secretion of IL-6 and IL-1α in response to various concentrations of δPS. 
 
5.3 Determining the effect of different lengths of exposure to 1 nM ICRF-193 on 
topo IIȕ protein level in U9γ7 cells. 
Previous studies have shown that exposure of cells to ICRF-193 leads to the 26S 
proteasome mediated degradation of topo IIȕ. Therefore in order to determine the effect 
of varying exposures of 1 nM ICRF-193 (2, 4, 6, 24, 48 and 72 h) on topo IIȕ, levels of 
the protein were quantified. The results are shown in Figure 5.1. 
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Figure 5.1 Semi Quantification of topo IIȕ post treatment with 0.1% DMSO (v/v) 
(a) and 1 nM ICRF-193 (b) for varying lengths of exposure. 
Cells were seeded at 3 x 105 cells/ml with 0.1% DMSO (v/v) (a) or 1 nM ICRF-193 and 
allowed to incubate for 2, 4, 6, 24, 48 or 72 h before harvesting. A whole cell protein 
extraction was then performed and quantified (see material and methods β.1η).  ζ0.λȝg 
of total protein was then loaded onto a 7.5% SDS gel and SDS PAGE was then 
performed to separate the proteins out by size (Section 2.16.4) this was followed by 
protein transfer onto nitrocellulose paper by wet western blot (Section 2.15.5). 
Nitrocellulose  blots  were  then  probed  with  an  antibody  to  topo  IIȕ  (Section  β.1θ.7). 
Lanes are labelled with exposure time to 0.1% DMSO (v/v) (a) or 1 nM ICRF-193 (b) 
Recombinant  topo IIȕ (ζ0.λȝg) was present  in  the lanes labelled ‘Recomb’ to act as a 
positive control. Quantification of protein was performed using the densitometry 
software, Syngene genetools See Appendix Figures B.1 and B.2 for GAPDH loading 
control. Results are expressed as percentage of 0.1% DMSO (v/v) treated samples (c). 
(a) 
   (b) 
(c) 
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The results in Figure 5.1 show that treatment of cells with 1 nM ICRF-193 for 2 h, 24 h 
72 h does not reduce levels of topo  IIȕ,  indeed  ICRF-193 appears to up-regulate the 
expression of topo IIȕ at these times. It may be possible at β h of treatment the cell is 
up-regulating topo IIȕ expression to try alleviate the effects of ICRF-193 on the existing 
topo IIȕ. This may also be suggested for the increase in topo IIȕ protein expression seen 
after 24 h of ICRF-193 exposure; the cell may be over-expressing topo IIȕ to counteract 
the depletion in topo IIȕ seen after θ h (Figure 5.1). Perez et al. (1997) report that upon 
72 h of treatment with 0.3 μM ICRF-193 an up-regulation of PKC is observed, 
furthermore McNamara et al., (2010) demonstrate that an up-regulation of PKC is 
accompanied by an up-regulation  of  topo  IIȕ  due  to  an  increase  in  protein  stability 
caused by the PKC mediated phosphorylation of topo  IIȕ.  Indeed  the  slight  up-
regulation of topo IIȕ seen after 7β h of 1 nM ICRF-193 treatment seen in Figure 5.1 
may be due to a similar mechanism.  
A down-regulation of  topo  IIȕ protein  expression  is  seen after θ h and 48 h of 1 nM 
ICRF-193 treatment, thus suggesting that ICRF-193 is causing the degradation of topo 
IIȕ and thus successfully inhibiting its actions. In addition the down-regulation of topo 
IIȕ protein expression  is maintained after cells have been  treated with PεA and δPS 
following the 6 h of pre-treatment with 1 nM ICRF-193 (see Appendix Figure B.3), 
therefore it is suggested that the results obtained from the following experiments with 
regards to a 6 hour pre-treatment are due to a down-regulation of  topo  IIȕ. Further  to 
this the protein expression of topo IIȕ after cells had been treated with PεA and δPS 
following 72 h of pre-treatment with 1 nM ICRF-193 does not appear any different to 
that of the control (see Appendix Figure B.4). This is in support of the measurement of 
topo IIȕ protein expression following treatment with 1 nM ICRF-193 for 72 h, in which 
levels of topo IIȕ appear to have recovered (Figure η.1). 
 
5.4 Effect of the topoisomerase II inhibitor, ICRF-193 on levels of macrophage cell 
surface antigens. 
Flow cytometry was utilised to determine the effects of 1 nM ICRF-193 pre-treatment 
prior to differentiation with 5 ng/ml PMA and stimulation with 10 ng/ml LPS on 
expression of the cell surface proteins, CD11b, HLA-DR and TLR4, all of which are 
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shown to be up-regulated during differentiation of monocytes to macrophages (Gordon, 
2005; Rey-Giraud, 2012; Traore et al., 2012).  
5.4.1 Effect of bacterial lipopolysaccharide on CD11b expression on PMA treated 
cells 
As previous studies to determine optimal conditions for differentiation (Chapter 3) used 
PMA it was necessary to determine the effect of PMA and LPS on CD11b surface 
expression. Bacterial Lipopolysachharide (LPS) is a major constituent of Gram-negative 
cell walls. (Triantafilou & Triantafilou, 2004; Leonardo et al., 2004; Ngkelo et al., 
2012).  Previous studies have shown that macrophages exposed to an acute stimulation 
by LPS display an increase in the cell surface marker, CD11b (Lichte et al., 2013).  
In order to determine if levels of the cell surface antigen, CD11b could be increased 
further, than when treated with PMA alone, LPS and PMA were simultaneously used to 
stimulate cells. Data presented in Figure 5.2 reveals that stimulation with LPS did not 
significantly increase cell surface expression of CD11b compared to PMA treatment 
alone. This suggests that maximal cell surface expression of CD11b is achieved using 5 
ng/ml PMA for 72 h. 
These results are in disagreement with Lichte et al., (2013) who demonstrated that 
CD11b expression on macrophages was increased in response to LPS. However the 
latter study only looked at acute stimuli by LPS (>3hrs) whereas stimulus to LPS for 72 
h as seen in Figure 3.4 can be considered a chronic stimulation. The difference in 
methodology between the studies makes it difficult to compare results. For the purposes 
of this study, as demonstrated by the results in both cell lines (Figure 5.2) simultaneous 
stimulation by LPS and PMA is not considered to have any further effect on CD11b 
expression.  
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Figure 5.2 Comparison of CD11b expression on LPS stimulated PMA treated cells 
and non LPS stimulated PMA treated cells. 
U937 cells were seeded at a density of 3 x 105 cells/ml and incubated with 5 ng/ml 
PMA, with and without 10 ng/ml LPS for 72 h. Cells were then labelled with anti-
human CD11b-APC conjugated antibody. Flow cytometry was performed using the 
Becton Dickinson flow cytometer (detailed in materials and methods). Results are 
presented as the mean fluorescence intensity of 1 x105 captured cells. 
The means of three independent experiments are shown +/- standard error. 
 
 
5.4.2 Effect of ICRF-193 pre-treatment on CD11b expression  
The  inhibition  of  topoisomerase  IIȕ  using  a  sub-lethal  dose  of  the  topo  IIȕ  specific 
inhibitor, ICRF-193 (as determined by a previous experiment, see Figure 4.16) prior to 
differentiation  and  stimulation was  used  to  determine  if  topo  IIȕ  played  a  role  in  the 
transcription of genes required for surface antigen expression associated with 
differentiation.  
CD11b cell surface expression is up-regulated during monocyte to macrophage 
differentiation and thus is often used as a macrophage differentiation marker (Garcia et 
al., 1999; Deszo et al., 2000; Murphy et al., 2008) due to the up-regulation of mRNA 
expression and protein during normal differentiation (Dziennis et al., 1995). CD11b is 
part of the ȕ intergrin εAC-1 complex. MAC-1 is a heterodimer consisting of CD11b, 
140 
 
the  α  subunit  and CD1κ,  the  ȕ  subunit  (Benimetskaya  et al., 1997; Klugewitz et al., 
1997). 
The role of this complex is involved in cellular adhesion (Gomes et al., 2010), which 
facilitates the recruitment of neutrophils to sites of infection (Moreland et al., 2002) and 
more recently has been shown to be a cell surface receptor recognising double stranded 
RNA (Zhou et al., 2013).  
Upon morphological examination of cells post ICRF-193, PMA and LPS treatment it 
appeared cells had indeed become adherent suggesting differentiation had occurred 
(data not shown).  
Flow cytometry using an antibody to CD11b was then used to determine if ICRF-193 
had any effect on the expression of this cell surface antigen on PMA and LPS treated 
U937 cells. The effect of different lengths of exposure to ICRF-193 before treatment 
with PMA and LPS was also investigated. The results of this experiment are shown in 
Figure 5.3. 
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Figure 5.3 Determining the effects of ICRF-193 on expression of surface antigen, 
CD11b 
U937 cells were seeded at a density of 3 x 105/ml in a 12 well tissue culture plate in 
complete media (detailed in materials and methods) with 1 nM ICRF-193 or the 0.1% 
DMSO (v/v). Cells were allowed to incubate for 2, 4, 6, 24, 48 or 72 h. Media was then 
changed and 5 ng/ml PMA and 10 ng/ml LPS was added. Cells were incubated for a 
further 72 h before harvesting. Cells were then labelled with anti-human CD11b - APC 
conjugated antibody. Flow cytometry was performed using the Becton Dickinson flow 
cytometer (detailed in materials and methods). Results are presented as the mean 
fluorescence intensity of 1 x105 captured cells as a percentage of the control sample. 
The means of three independent experiments are shown ± standard errors.  
 
Data revealed, that at 1 nM of ICRF-193, and at all time points of pre-treatment, 1 nM 
ICRF-193 had no effect on the expression level of CD11b on the cell surface (Figure 
5.3) (Appendix B.1). Several transcription factors are involved in the transcription of 
CD11b, these include SP1 and PU.1 which have been shown to bind to the CD11b 
promoter region (Chen et al., 1993; Pahl et al., 1993). Studies have yet to show that 
topo IIȕ  can  interact  with  these  transcription  factors.  Interestingly  though,  AP1,  a 
transcription factor which is known to be involved in the regulation of transcription of 
other  PεA  responsive  genes,  has  been  shown  to  interact with  topo  IIȕ  (Kroll  et al., 
1993) but this transcription factor is not present in the CD11b promoter region (Pahl et 
al., 1992). 
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It  is  most  likely  that  topo  IIȕ  does  not  play  a  role  in  the  up-regulation of genes 
associated with expression of the CD11b protein in response to PMA and LPS, 
however, the 72 h given for differentiation and stimulation following ICRF-193 
treatment may be too long for any significant results to be observed, or that changes 
may be time dependent. Indeed a study by Lyu et al. (β00θ) revealed that topo IIȕ was 
required for the latter stages of neuronal development but dispensable in the earlier 
stages.  Thus  suggesting  that  the  actions  of  topo  IIȕ  appear  to  be  tightly  restricted  to 
specific stages of development, which may also be reflected in differentiation.  
 
5.4.3 Effect of ICRF-193 pre-treatment on HLA-DR expression. 
HLA-DR is a Major Histocompatibility Complex Class II (MHC Class II) molecule. It 
is a glycosylated cell surface transmembrane protein that is found on antigen presenting 
cells including monocytes and macrophages. It is essential in the presentation of foreign 
(microbe derived) peptides to cells of the adaptive immune system (Perry et al., 2004). 
In order to examine the effects of topo IIȕ  inhibition on  the expression of  the surface 
antigen, HLA-DR, flow cytometry using an antibody to HLA-DR was used to 
determine the effects of different exposure times to ICRF-193 prior to stimulation of 
PMA and LPS treatment on U937 cells. The results of this experiment are shown in 
Figure 5.4. 
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Figure 5.4 Determining the effects of ICRF-193 on expression of surface antigen, 
HLA-DR 
U937 cells were seeded at a density of 3 x 105/ml in a 12 well tissue culture plate in 
complete media (detailed in materials and methods) with 1 nM ICRF-193 or the 0.1% 
DMSO (v/v). Cells were allowed to incubate for either 2, 4, 6, 24, 48 or 72 h. Media 
was then changed and 5 ng/ml PMA and 10 ng/ml LPS was added. Cells were incubated 
for a further 72 h before harvesting. Cells were then labelled with anti-human HLA-DR-
FITC conjugated antibody. Flow cytometry was performed using the Becton Dickinson 
flow cytometer (detailed in materials and methods). Results are presented as the mean 
fluorescence intensity of 1 x105 captured cells as percentage of the control sample. 
The means of three independent experiments are shown ± standard errors.  
 
 
An average 73% increase (p= 0.04, student t-test) in the expression of the cell surface 
antigen, HLA-DR was observed when cells were treated with ICRF-193 2 h prior to 
differentiation and stimulation compared to the control. No difference in HLA-DR 
protein expression was observed after 4, 6, 24, 48 and 72 h of exposure to ICRF-193 
before differentiation (Appendix B.2). An increase in HLA-DR protein levels would 
suggest that if topo IIȕ is playing a role it is not in the up-regulation of HLA-DR gene 
expression, as inhibition would have resulted in a decrease in HLA-DR protein 
expression rather than an increase as shown in Figure 5.4. Instead topo IIȕ may possibly 
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be playing a time dependent inhibitory role, as its inhibition with ICRF-193 for 2 h prior 
to differentiation results in an increase in HLA-DR expression on the cell surface. 
Regulation of HLA-DR expression is primarily controlled at a transcriptional level, by 
an atypical mechanism. An SXY module (from η’ end of region to γ’ end contains an S 
box, an X box and a Y box) is situated upstream of the transcription start site. It is here 
that a multi-protein complex is formed. The transcription factors cAMP response 
binding protein (CREB) and nuclear transcription factor Y (NFY) bind to the X box of 
the SXY module along with an unknown factor that binds to the S box. This creates a 
platform that the class II trans-activator (CIITA) can be recruited to. Recruitment of 
CIITA is required for the transcription of all MHC Class II genes (Reith et al., 2005). 
Interestingly topo II has been shown to associate with CREB, although the specific 
isoform was not determined (Kroll et al., 1993). If topo IIȕ is indeed playing a role here 
then  binding  of  topo  IIȕ  with  CREB  may  inhibit  HδA-DR gene transcription by 
inhibiting the ability of CIITA to be recruited to the SXY module. Inhibition of topo IIȕ 
may then decrease the association with CREB allowing a transient up-regulation of 
HLA-DR  expression  as  seen  in  Figure  η.ζ. Additionally  the  actions  of  topo  IIȕ  have 
been implicated in gene silencing. Huang et al., (2012) reported that treatment of 
murine neurons with topo II drugs resulted in the de-repression of the dominant allele of 
Ube3a. This de-repression effect was also mirrored in work by McNamara et al., (2008) 
who showed that retinoic acid resistant cells treated with the topo IIȕ inhibitor, ICRF-
193 became sensitive to the effects of retinoic acid. This was shown to be due to an up-
regulation of transcription in retinoic acid target genes. Taken together these studies 
suggest  that  topo  IIȕ  plays  a  role  in  the  regulation  of  transcription  through  gene 
silencing. Previous work in Figure 5.1 shows that there is still a substantial amount of 
topo IIȕ remaining in the cell after β h of ICRF-193 treatment and that degradation of 
the protein does not begin to occur until 4 h of ICRF-193 treatment. Indeed it is possible 
at this time that ICRF-193 is inhibiting the catalytic action of topo IIȕ, and detectable 
degradation has not yet taken place. However this does not explain why then an up-
regulation of HLA-DR expression is not observed when cells are treated with PMA and 
LPS at a time when there is a substantial amount of topo IIȕ degradation such as ζ h and 
6 h (Figure 5.1). It is possible that the up-regulation of HLA-DR expression after 2 h of 
ICRF-193 treatment prior to differentiation and stimulation may be the result of ICRF-
193 inducing an acute immune response that then attenuates the response to stimulation 
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with LPS; resulting in the cell up-regulating HLA-DR expression in order to present 
more of the LPS peptide to neighbouring cells. 
Thus in conclusion, cells treated with 1 nM ICRF-193 2 h prior to differentiation saw an 
increase in HLA-DR expression of 73%. This may be due to a silencing effect of topo 
IIȕ on the HδA-DR promoter region. Thus inhibition of topo IIȕ with ICRF-193 led to 
an up-regulation of HLA-DR surface antigen presentation. This effect however, was 
only seen when cells were treated 2 h prior to differentiation. Thus it is more likely an 
acute immune response to treatment with ICRF-1λγ  rather  than  a  topo  IIȕ  mediated 
effect. 
 
 5.4.4 Effect of ICRF-193 pre-treatment on TLR4 expression 
Toll like receptor 4 (TLR4) is found on the surface of macrophages as part of a complex 
with cell surface antigens, CD1ζ and εDβ (O’Neill et al., 2013).  It recognises LPS via 
presentation by MD2. Recognition and binding of LPS results in homodimerisation of 
TLR4 at the plasma membrane; leading to activation of NF-kB and the MAPK 
signalling pathway (details of this pathway can be found in Figure 1.8). This then 
results in the expression of inflammatory associated genes (Yan et al., 2006). TLR4 can 
also be endocytosed, activating an alternative pathway of transcription via the TRIF 
pathway (O’Neill et al., 2013). 
In  order  to  examine  the  effects  of  topo  IIȕ  inhibition  on  the  levels  of  the  toll  like 
receptor, TLR4, flow cytometry using an antibody to TLR4 was used to determine the 
effects of different exposure times to ICRF-193 prior to stimulation of PMA and LPS 
treatment on U937 cells. The results of this experiment are shown in Figure 5.5. 
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Figure 5.5 Determining the effects of ICRF-193 on expression of surface antigen, 
TLR 4 
U937 cells were seeded at a density of 3 x 105/ml in a 12 well tissue culture plate in 
complete media (detailed in materials and methods) with 1 nM ICRF-193 or the 0.1% 
DMSO (v/v). Cells were allowed to incubate for 2, 4, 6, 24, 48 or 72 h. Media was then 
changed and 5 ng/ml PMA and 10 ng/ml LPS and was added. Cells were incubated for 
a further 72 h before harvesting. Cells were then labelled with anti-human TLR4-PE 
conjugated antibody. Flow cytometry was performed using the Becton Dickinson flow 
cytometer (detailed in materials and methods). Results are presented as the mean 
fluorescence intensity of 1 x105 captured cells as percentage of the control sample. 
The means of three independent experiments are shown ± standard errors.  
 
No difference in TLR4 protein expression was observed after 2, 4, 6, 24, 48 and 72 h of 
exposure to ICRF-193 before differentiation compared to the 0.1% DMSO (v/v) 
(vehicle control) treated cells (Appendix B.3). 
Transcription of the TLR4 gene has been shown to involve the actions of the 
transcription factor PU.1. Roger et al., (2005) demonstrated that an overexpression of 
PU.1 in a murine cell line caused an increase in TLR4 promoter activity. However to 
date, there is no evidence to suggest that topo IIȕ interacts or associates with PU.1. It is 
most  likely  that  topo  IIȕ does not play  a  role  in  the  regulation of  the TδRζ gene. As 
discussed in Section 5.4.2, the results presented in Figure 5.5 may actually reflect the 
transient and time specific restriction of topo IIȕ action. Thus topo IIȕ may have little to 
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no effect on TLR4 expression after 72 h treatment with PMA but it may have an effect 
at a different time point in the differentiation process. 
Concomitant with visual morphological observations that suggested that ICRF-193 did 
not inhibit differentiation, no reduction in specific markers of differentiation were seen 
when cells were treated with ICRF-193 prior to differentiation with PMA. 
 
5.5 Effect of topoisomerase II inhibitor, ICRF-193 on expression of mRNA in a 
variety of transcription factors involved in macrophage activation. 
Hemaotopoesis gives rise to multiple different cell types, for example macrophages, 
dendritic cells and neutrophils (Ceredig et al., 2009). This cell fate is determined by the 
expression and repression of many specific genes (Lehtonen et al., 2007). 
The  role  of  topo  IIȕ  has  been  implicated  in  both  the  activation  of  transcription,  for 
example the activation of the AP-1 gene promoter in response to TPA (Ju et al., 2006) 
and in the silencing of genes, as demonstrated by Huang et al. (2012) who showed that 
inhibition of topo IIȕ unsilenced the dominant allele of Ubeγa. Additionally εcNamara 
et al. (β010) also revealed that inhibition of topo IIȕ lead to an up-regulation of retinoic 
acid  induced gene expression, and suggested  that  topo  IIȕ may act with  co-repressors 
such as HDAC to cause such gene silencing. Indeed topo IIȕ has previously been shown 
to physically interact with HDAC (Cowell et al., 2011).  
Therefore using qPCR, the effect of inhibition of topo IIȕ using 1 nM ICRF-193 pre-
treatment on genes that are normally up-regulated upon treatment with PMA and LPS 
were investigated. In this experiment cells were exposed to 6 h and 72 h of ICRF-193 
pre-treatment, thus representing an acute and chronic exposure respectively before 
being exposed to PMA and LPS.
 
 
 
 
 
 
  
5.5.1 POLR2A 
POLR2A is the gene that encodes the largest subunit (alpha) of the 12 subunits that 
make up the ubiquitous transcription factor, RNA polymerase II. RNA polymerase II is 
responsible for synthesising mRNA in eukaryotes. RNA polymerase II associates with 
various other proteins, namely the suppressor of RNA polymerase B regulatory proteins 
(SRB proteins) to form the RNA polymerase II holoenzyme. Along with various 
different protein associations throughout transcription, RNA polymerase II requires the 
actions of proteins involved in chromatin remodelling in order for successful 
transcription to occur (Chao et al., 1996). Samples were prepared as described in 
Section 5.5. RNA extraction was performed on samples that had been exposed to ICRF-
193 for 6 and 72 h, both this method and the protocol for cDNA synthesis are described 
in Section 2.17.  qPCR was performed with a hydrolysis probe to POLR2A. Details of 
the reaction conditions for the qPCR reaction can be found in Section 2.17.3. The 
results are shown in Figure 5.6. 
 
 
 
 
 
 
 
 
 
Figure 5.6 Determining the effects of 1 nM ICRF-193 on mRNA expression of 
POLR2A 
U937 cells were seeded at a density of 3 x 105/ml in a 12 well tissue culture plate in 
complete media (detailed in materials and methods) with 1 nM ICRF-193 or the 0.1% 
DMSO (v/v). Cells were allowed to incubate for either 6 or 72 h. Media was then changed 
and 5 ng/ml PMA and 10 ng/ml LPS was added. Cells were incubated for a further 72 h 
before harvesting. RNA extraction and cDNA synthesis was performed as detailed in 2.16. 
qPCR was then performed with a hydrolysis probe to POLR2A (details of qPCR 
conditions in Section 2.17.3). Fold expression was calculated using the comparative Δ/Δ 
Ct method. Data is presented as percentage of the 0.1% DMSO (v/v) treated control. The 
means of three independent experiments are shown ± standard error. 
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The results presented in Figure 5.6 show no difference in the level of POLR2A 
expression when U937 cells were treated with ICRF-193 6 h prior to differentiation and 
stimulation. When cells were treated with ICRF-193 for 72 h prior to differentiation, a  
a large increase in POLR2A expression was exhibited, however the results displayed 
did not reach significance when compared to the 0.1% DMSO (v/v) (vehicle control) 
treated cells (Appendix B.5). 
                                                                                                                                                                 
5.5.2 SP1 
Specificity Protein 1 (Sp1) is a zinc finger transcription factor encoded by the gene SP1. 
The activity of Sp1 has been associated with transcription of genes involved in murine 
development and macrophage differentiation. It acts by recruiting and forming a 
complex with other factors involved in transcription. Interestingly Sp1 is also suggested 
to play a role in the chromatin remodelling of the SV40 chromosome (Milavetz et al., 
2002). Samples were prepared as described in Section 5.5. RNA extraction was 
performed on samples that had been exposed to ICRF-193 for 6 and 72 h, both this 
method and the protocol for cDNA synthesis are described in 2.16.  qPCR was 
performed with a hydrolysis probe to SP1. Details of the reaction conditions for the 
qPCR reaction can be found in Section 2.17.3. The results are shown in Figure 5.7. 
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Figure 5.7 Determining the effects of 1 nM ICRF-193 on mRNA expression of SP1 
U937 cells were seeded at a density of 3 x 105/ml in a 12 well tissue culture plate in 
complete media (detailed in materials and methods) with 1 nM ICRF-193 or the 0.1% 
DMSO (v/v). Cells were allowed to incubate for either 6 or 72 h. Media was then 
changed and 5 ng/ml PMA and 10 ng/ml LPS was added. Cells were incubated for a 
further 72 h before harvesting. RNA extraction and cDNA synthesis was performed as 
detailed in Section 2.17. qPCR was then performed with a hydrolysis probe to SP1 
(details of qPCR conditions in Section 2.17.3). Fold expression was calculated using the 
comparative Δ/Δ Ct method. Data is presented as percentage of the 0.1% DMSO (v/v) 
treated control. The means of three independent experiments are shown ± standard 
error. 
 
 
The results presented in Figure 5.7 show no difference in the expression of SP1 when 
cells were treated with ICRF-193 6 h prior to differentiation and stimulation. 
Conversely, a large increase in SP1 expression was exhibited when cells were treated 
with ICRF-193 72 h prior to differentiation, however this was not significant when 
compared to the 0.1% DMSO (v/v) (vehicle control) treated cells (Appendix B.6). 
Collectively the results in Figure 5.6 and 5.7 show a trend with regards to an apparent 
increase in the mRNA expression of POLR2A and SP1 when U937 cells are treated 
with 1 nM ICRF-193 for 72 hours followed by differentiation. The trend observed, 
although non-significant may be due to a DNA damage response mediated through 
Ataxia Telangiectasia Mutated (ATM) and Ataxia Telangiectasia and Rad3 related 
(ATR) (Park & Avraham, 2006). DNA damage response requires the up-regulation of 
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transcriptional activity in order to transcribe DNA repair proteins for example BRCA1, 
PARP1 and MDC1 and their respective transcriptional regulators, for example AP-1 (Li 
et al., 2013; Kim et al., 2005; Stewart et al., 2003; Potapova et al., 2001; Rodriguez et 
al., 2010; Christmann & Kaina, 2013).  It is then postulated that the trend  seen in the 
increase in mRNA expression of POLR2A and SP1 after 72 h of treatment with ICRF-
193 (Figure 5.6 and 5.7) may have been the result of a prolonged exposure to ICRF-
193, leading to a DNA damage response. Indeed an increase in transcriptional activity 
as activated by a DNA damage response would require the activity of RNA polymerase; 
encoded for by POLR2A, as seen in Figure 5.6. 
Sp1 in addition has been shown to facilitate the repair of double strand breaks (dsb), 
although the induction of double strand breaks directly induced by ICRF-193 is 
controversial (Huang et al., 2001; Larsen et al., 2003). However intolerable strain on 
the DNA caused by the ICRF-193 induced closed clamp or collision of replicational 
and/or transcriptional machinery with the closed clamp may lead to generation of 
double strand breaks (Oestergaard et al., 2004). Therefore an extensive exposure to 
ICRF-193 may require the actions of Sp1 in dsb repair, ultimately leading to an up-
regulation of SP1. The results in Figure 5.7 reflect this to some extent by displaying a 
trend in the increase of SP1 mRNA expression after 72 h treatment with ICRF-193, 
however these results did not reach significance. Furthermore the results shown in 
Figure 5.1 reveal that after 72 h of treatment with 1 nM ICRF-1λγ  levels of  topo  IIȕ 
protein have returned back to normal levels, compared to a 0.1% DMSO (v/v) control. 
Therefore it is most likely that the trend demonstrated in Figures 5.6 and 5.7 with 
regards to an apparent increase in POLR2A and SP1 mRNA expression when cells were 
treated with 1 nM ICRF-193 prior to differentiation and stimulation is most likely not 
due  to  topo  IIȕ mediated effect but is due to a DNA damage response induced by a 
prolonged exposure to ICRF-193. 
This work supports a previous study by Perez et al. (1997) who reported an increase in 
protein kinase C (PKC) whole protein in response to 0.3 ȝε ICRF-193 after 72 h of 
treatment, and suggested this late up-regulation may be in response to DNA damage. 
Interestingly this study alludes to ICRF-193 inducing differentiation. Indeed it may be 
possible that treatment of cells with ICRF-193 results in a drive towards differentiation, 
however this may be a mechanism of protection; as shown in Chapter 4, differentiated 
cells are resistant to the cytotoxic effects of ICRF-193 treatment (Figures 4.16 & 4.17).  
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5.5.3 Early Growth Response Protein 2 
Early Growth Response Protein 2 (Egr2) is a zinc finger transcription factor encoded by 
the gene EGR2. It has been associated with the transcription of genes involved in 
differentiation, growth and neuronal development. Activity of EGR2 is modulated by 
the NAB family and is specifically associated with transcription of genes related to the 
response of extra-cellular signals (Kumbrink et al., 2010). EGR2 has previously been 
shown to be up-regulated in response to PMA and LPS stimulation (Baek et al., 2009; 
Zaman et al., 2012). 
Samples were prepared as described in Section 5.5. RNA extraction was performed on 
samples that had been exposed to ICRF-193 for 6 and 72h, both this method and the 
protocol for cDNA synthesis are described in Section 2.17.  qPCR was performed with 
a hydrolysis probe to EGR2. Details of the reaction conditions for the qPCR reaction 
can be found in Section 2.17.3. The results for this experiment are presented in Figure 
5.8. 
Figure 5.8 Determining the effects of 1 nM ICRF-193 on mRNA expression of 
EGR2 
U937 cells were seeded at a density of 3 x 105/ml in a 12 well tissue culture plate in 
complete media (detailed in materials and methods) with 1 nM ICRF-193 or the 0.1% 
DMSO (v/v). Cells were allowed to incubate for either 6 or 72 h. Media was then 
changed and 5 ng/ml PMA and 10 ng/ml LPS was added. Cells were incubated for a 
further 72 h before harvesting. RNA extraction and cDNA synthesis was performed as 
detailed in Section 2.17. qPCR was then performed with a hydrolysis probe to EGR2 
(details of qPCR conditions in Section 2.17.3). Fold expression was calculated using the 
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Δ/Δ  Ct  method.  Data  is  presented  as  percentage  of  the  0.1% DMSO (v/v) treated 
control. The means of three independent experiments are shown ± standard error. 
 
Statistical analysis of the data displayed in Figure 5.8 showed that there was no 
significant difference in EGR2 mRNA expression in cells treated with ICRF-193 for 6 h 
or 72 h prior to differentiation and stimulation by PMA and LPS when compared to the 
0.1% DMSO (v/v) (vehicle control) treated cells (Appendix B.7). 
 
5.5.4 NF-κB 
Nuclear factor kappa light-chain enhancer of activated B cells (NF-țB)  is a  family of 
transcription factors that include various heterodimers of p50, p52 and p65/RelA 
(Hayden., 2008). NF-țB  is  a  transcription  factor  primarily  associate  with  the  innate 
immune  system.  It  is  found  in  its  inactive  state  bound  to  IKαBα  in  the  cytosol. 
Activation via extracellular signalling leads to the phosphorylation and subsequent 
degradation  of  IKαBα,  leaving NF-țB  free  to  translocate  to  the  nucleus  and  act  as  a 
transcription factor (Hayden, 2008). 
NF-țB  is  involved  in  the  transcription  of  genes  encoding  chemokines,  cytokines  and 
adhesion molecules. Genes regulated by NF-țB  have  been  divided  into  two  distinct 
subgroups; those that require chromatin re-modification and those that do not (Saccani 
et al., 2001; Ramirez-Carrozzi et al., 2006). 
NF-țB gene expression and activity has previously been  shown  to be up-regulated in 
U937 and THP-1 cells when exposed to PMA and LPS stimulation (Baek et al., 2009; 
Sharif et al., 2007). 
Samples were prepared as described in Section 5.5. RNA extraction was performed on 
samples that had been exposed to ICRF-193 for 6 and 72 h, both this method and the 
protocol for cDNA synthesis are described in Section 2.17.  qPCR was performed with 
a hydrolysis probe to NF-țB. Details of the reaction conditions for  the qPCR reaction 
can be found in Section 2.17.3. The results for this experiment are presented in Figure 
5.9. 
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Figure 5.9 Determining the effects of 1 nM ICRF-193 on mRNA expression of NF-
κB 
U937 cells were seeded at a density of 3 x 105/ml in a 12 well tissue culture plate in 
complete media (detailed in materials and methods) with 1 nM ICRF-193 or the 0.1% 
DMSO (v/v). Cells were allowed to incubate for either 6 or 72 h. Media was then 
changed and 5 ng/ml PMA and 10 ng/ml LPS was added. Cells were incubated for a 
further 72 h before harvesting. RNA extraction and cDNA synthesis was performed as 
detailed in Section 2.17. qPCR was then performed with a hydrolysis probe to NF-țB 
(details of qPCR conditions in Section 2.17.3). Fold expression was calculated using the 
comparative Δ/Δ Ct method. Data is presented as percentage of the 0.1% DMSO (v/v) 
treated control. The means of three independent experiments are shown ± standard 
error. 
 
Statistical analysis of the data displayed in figure 5.9 showed that there was no 
significant difference in NF-țȕ mRNA expression in cells treated with ICRF-193 for 6 
h or 72 h prior to differentiation and stimulation by PMA and LPS when compared to 
the 0.1% DMSO (v/v) (vehicle control) treated cells (Appendix B.8). 
 
5.5.5 Toll Like Receptors 2 and 4 
Toll receptors are type 1 transmembrane proteins, they are involved in the mediation of 
the innate immune response. Toll like receptors respond to ‘foreign’ stimuli, resulting in 
the release of NF-țB  transcriptionally  regulated pro-inflammatory cytokines. To date, 
10 Toll like receptors have been identified. The most widely investigated are TLR2 and 
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TLR4. TLR2 responds to stimuli from lipoprotein, a commonly found in gram positive 
cell walls. TLR4 responds to stimuli from lipopolysaccharide, a component of the Gram 
negative cell membrane. Other TLRs such as TLR5 and TLR9 respond to stimuli from 
bacteria flagellin and foreign DNA respectively (Vasselon et al., 2002).TLR2 and TLR4 
mRNA expression have both previously been shown to be increased in response to 
PMA (Traore et al., 2012; Zarember et al., 2002).  
 
Samples were prepared as described in Section 5.5. RNA extraction was performed on 
samples that had been exposed to ICRF-193 for 6 and 72 h, both this method and the 
protocol for cDNA synthesis are described in Section 2.17.  qPCR was performed with 
hydrolysis probes to TLR2 and TLR4. Details of the reaction conditions for the qPCR 
reaction can be found in Section 2.17.3. The results for this experiment are presented in 
Figure 5.10. 
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Figure 5.10 Determining the effects of 1 nM ICRF -193 on mRNA expression of 
TLR2 and TLR4. 
U937 cells were seeded at a density of 3 x 105/ml in a 12 well tissue culture plate in 
complete media (detailed in materials and methods) with 1 nM ICRF-193 or the 0.1% 
DMSO (v/v). Cells were allowed to incubate for either 6 or 72 h. Media was then 
changed and 5 ng/ml PMA and 10 ng/ml LPS was added. Cells were incubated for a 
further 72 h before harvesting. RNA extraction and cDNA synthesis was performed as 
detailed in Section 2.17. qPCR was then performed using hydrolysis probes to TLR2 (a) 
and TLR4 (b) using 18S as the reference gene (details of qPCR conditions in Section 
β.17.γ) Fold expression was calculated using  the Δ/Δ Ct method. Data  is presented as 
percentage of the 0.1% DMSO (v/v) treated control. The means of three independent 
experiments are shown ± standard error. 
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Statistical analysis of the data displayed in figure 5.10 revealed that there was no 
significant difference in either TLR2 or TLR4 mRNA expression in cells treated with 
ICRF-193 for 6 h or 72 h prior to differentiation and stimulation by PMA and LPS 
when compared to the 0.1% DMSO (v/v) (vehicle control) treated cells (Appendix B.9 
& B10). 
 
5.5.6 TNFα 
In order to determine of ICRF-193 affected the expression of mRNAs encoding 
cytokines; that are released in response to extracellular stimuli (in this experiment LPS 
is used as the extracellular stimuli), levels of TNFA mRNA were quantified. This 
particular cytokine was investigated as it is the most potent and clinically important 
cytokine in the inflammatory response.  
Tumour Necrosis Factor α is a pro-inflammatory cytokine (Opree et al., 2000; Brabers 
et al., 2006; Malo et al., 2006) released by activated macrophages in response to 
extracellular stimuli (Heming et al., 2001). It is found as a transmembrane homotrimer 
in activated macrophages and is converted into a soluble homotrimer by the 
metalloproteinase,  TACE  (TNFα  converting  enzyme)  (Horiuchi  et al., 2010). 
Transcriptional regulation of the TNFA gene has been shown to involve multiple 
different transcription factors, for example NF-țB,  SP1  and  C/EBPȕ  (Collart  et al., 
1990; Pope et al., 2000; Barthel et al., β00γ). TNFα mRNA expression has previously 
been shown to be up-regulated in response to PMA and LPS stimulation (Liu et al., 
2000; Sharif et al., 2007). 
Samples were prepared as described in Section 5.5. RNA extraction was performed on 
samples that had been exposed to ICRF-193 for 6 and 72 h, both this method and the 
protocol for cDNA synthesis are described in Section 2.17.  qPCR was performed with 
a hydrolysis probe  to TNFα. Details  of  the  reaction conditions  for  the qPCR  reaction 
can be found in Section 2.17.3. The results are shown in Figure 5.11. 
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Figure 5.11 Determining the effects of 1 nM ICRF-193 on mRNA expression of 
TNFα 
U937 cells were seeded at a density of 3 x 105/ml in a 12 well tissue culture plate in 
complete media (detailed in materials and methods) with 1 nM ICRF-193 or the 0.1% 
DMSO (v/v). Cells were allowed to incubate for either 6 or 72 h. Media was then 
changed and 5 ng/ml PMA and 10 ng/ml LPS was added. Cells were incubated for a 
further 72 h before harvesting. RNA extraction and cDNA synthesis was performed as 
detailed in Section 2.17. qPCR was then performed using a hydrolysis probes to TNFA, 
using 18S as the reference gene (details of qPCR conditions in Section 2.17.3) Fold 
expression was calculated using the comparative Δ/ΔCt method. Data  is  presented  as 
percentage of the 0.1% DMSO (v/v) treated control. The means of three independent 
experiments are shown +/- standard error. 
 
Statistical analysis of the results shown in figure 5.11 showed that there was no 
significant difference in TNFα mRNA expression in cells treated with ICRF-193 for 6 h 
or 72 h prior to differentiation and stimulation by PMA and LPS when compared to the 
0.1% DMSO (v/v) (vehicle control) treated cells (Appendix B.11). 
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Figure 5.12 An overview of some of the genes quantified following pre-treatment 
with 1 nM ICRF-193.  
Collated data shows the quantification of EGR2 mRNA (a), NF-țB mRNA (b), TδRβ 
mRNA  (c),  TδRζ mRNA  (d)  and  TNFα mRNA  (e)  following  pre-treatment of cells 
with 1 nM ICRF-193 prior to differentiation and stimulation with PMA and LPS. 
Collated data is taken from Figures 5.8 – 5.11. 
 
 
 
 
160 
 
The results in Figure 5.12 show that although pre-treatment with 1 nM ICRF-193 prior 
to differentiation and stimulation does not significantly change the expression level of 
these key genes at either time point compared to controls, it does reveal an interesting 
trend whereby there is an increase in expression after 6 hours in all five genes 
examined.  
 
Figure 5.1 reveals that 6 h of treatment with 1 nM ICRF-193 results in a substantial 
degradation of topo IIȕ protein, thus suggesting that the results seen in Figure η.1β with 
regards to 6 h of 1 nM ICRF-193 pre-treatment may be due to inhibition of topo IIȕ. In 
contrast Figure 5.1 shows that 72 h of ICRF-1λγ treatment sees the recovery of topo IIȕ 
protein levels comparable to the levels shown in the 0.1% DMSO (v/v) control. The 
results in Figure 5.12 with regards to 72 h of ICRF-193 pre- treatment show little 
difference in mRNA expression of all genes compared to the control, thus reflective of 
the recovery of topo IIȕ protein.  
 
Increasing  evidence  suggests  a  role  for  topo  IIȕ  in  gene  regulation.  Interestingly  the 
action  of  topo  IIȕ  has  been  shown  to  be  required  for  the  up  and  down  regulation  of 
genes involved in neuronal development. Other studies support these findings by 
revealing  that  topo  IIȕ  is  involved  in  both  the  activation  and  repression  of  gene 
expression (Ju et al., 2006; McNamara et al., 2010; Huang et al., 2012).  
 
The trend in results shown in Figure 5.12 with regards to 6 h of 1 nM ICRF-193 pre-
treatment may  reflect  the  transient  and  global  actions  of  topo  IIȕ  in  gene  expression 
during  differentiation.  Indeed  the  results  show  that  inhibition  of  topo  IIȕ  drives  the 
expression of these genes. The mechanism by which these changes occur are not clear 
but the actions of topo IIȕ in both the activation and repression of genes suggests that 
topo  IIȕ  does  not  act  alone;  that  it  may  act  via  interactions  with  different  proteins 
involved in gene expression or repression. Ju et al., (2006) showed that activation of the 
psβ promoter by 17ȕ-estradiol resulted in the recruitment of multiple proteins including 
topo  IIȕ,  PARP-1, DNA-pK, Ku86 and Ku60 to the same DNA piece, and further 
suggested that these proteins may be forming a multi-protein complex. In addition, topo 
IIȕ has also been shown to associate with co-repressors such as HDACs (McNamara et 
al., 2010; Huang et al., 2012; Johnson et al., 2001). McNamara et al., (2010) suggest 
that silencing of retinoic  acid  induced  gene  expression  by  topo  IIȕ  may  require  the 
actions of co-repressors such as HDAC that act by reducing accessibility of the 
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chromatin, and that topo IIȕ may form a large co-repressor complex with these proteins 
similarly to the co-activator complex proposed by Ju et al., (2006). It may be postulated 
that the trend in the results in Figure 5.12, although non-significant may reflect a normal 
mechanism by which these genes are regulated by a transcriptional repressor complex 
that includes the physical interaction of topo IIȕ with the complex. Inhibition of topo IIȕ 
may then lead dissociation of the complex leading to a possible increase in chromatin 
accessibility and an increase in transcription that is to some extent exhibited by the 
trend seen in Figure 5.12. This is supported by work that shows that methylation of 
CpG  islands  in  the  TδRβ  promoter  causes  silencing  of  the  gene.  Topo  IIȕ  has 
previously been shown to be highly associated with sites of methylation, particularly 
H3k4 methylation (Tiwari et al., 2012). Thus suggesting that topo IIȕ along with other 
factors such as methyltransferases may repress the expression of TLR2. However, as the 
results did not reach significance, further work will be required to confirm this theory. 
 
The small increase in NF-țB expression seen after 6 h of 1 nM ICRF-193 pre-treatment, 
although non-significant, may  be  due  to  topo  IIȕ  being  involved  in  the  repression  of 
NF-țB, thus when topo IIȕ is inhibited, a small up-regulation of gene expression can be 
observed. However this small increase may also be a result of a DNA damage response 
induced by ICRF-193. An increase in NF-țB activation has been shown in response to 
DNA damage, in particular to double strand breaks (see Section 1.12.4 for more detail). 
The role of NF-țB in the DNA damage response is to promote a cell survival pathway. 
As discussed previously in this chapter, the induction of double strand breaks (dsbs) 
directly by ICRF-193 is controversial; however indirect mechanisms may lead to the 
formation of dsbs. Therefore after 6 h of ICRF-193 pre-treatment, followed by PMA 
and LPS stimulation, the small increase in NF-țB mRNA expression may be the result 
of activation of NF-țB by DNA damage and LPS stimulation. This may then lead to 
depletion in intracellular stores the cell responding by up-regulating NF-țB 
transcription.  
 
The trend in the results in Figure 5.12 are in agreement with Perez et al., (1997) who 
showed that treatment of U937 cells with 300 nM ICRF-193 lead to differentiation as 
measured by an up-regulation of CD11b expression and Nitric oxide synthesis. The 
study did not report changes in morphology in U937 cells treated with ICRF-193. 
Indeed at concentrations similar to that used by Perez et al. (1997) shown in Figure 4.16 
no morphological changes in cells were seen at this time (data not shown). The results 
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in Figure 5.12, although not significant do show that inhibition of topo IIȕ for θ h prior 
to differentiation with 1 nM ICRF-193 leads to a trend in the up-regulation of genes 
associated with differentiation. Taken together these results suggest that inhibition of 
topo IIȕ drives differentiation, suggesting that normally topo IIȕ may act to repress the 
transcription of these genes. 
As Figure 5.11 demonstrated an interesting increase in TNFα mRNA expression when 
cells were treated with ICRF-193 6 h prior to differentiation, it was then decided to 
investigate  the  TNFα  protein  secretion  from  cells  that  had  been  treated  with  1 nM 
ICRF-193 for varying exposure times prior to differentiation and stimulation. The 
results of this are shown in Figure 5.13. 
 
 
Figure 5.13 Comparing the effects of different exposure times to 1 nM ICRF-193 
prior to PMA and LPS treatment on TNFα protein secretion. 
U937 cells were seeded at a density of 3 x 105/ml in a 12 well tissue culture plate in 
complete media (detailed in materials and methods) with 1 nM ICRF-193 or 0.1% 
DMSO (v/v). Cells were allowed to incubate for 2, 4, 6, 24, 48 or 72 h. Media was then 
changed and 5 ng/ml PMA and 10 ng/ml LPS was added. Cells were incubated for a 
further 72 h before the supernatant was harvested. An EδISA to human TNFα was then 
performed (detailed in Section 2.18.1). Data is presented as percentage of the 0.1% 
DMSO (v/v) control. The means of three independent experiments are shown +/- 
standard error. * = p < 0.05. 
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The results show a small increase  in TNFα protein  secretion when  cells were  treated 
with ICRF-193 for 2 h prior to differentiation and stimulation, however this result was 
not significantly different to the 0.1% DMSO (v/v) control (see Appendix Table B.4). 
Very little difference in TNFα protein secretion was observed when cells were treated 
with ICRF-193 4, 6 and 24 h prior to differentiation and stimulation compared to their 
respective controls (Appendix Table B.4). Interestingly significant decreases were seen 
in TNFα protein  secretion when  cells were  treated with  ICRF-193 for 48 h and 72 h 
prior to differentiation and stimulation. An average decrease of βλ% was seen in TNFα 
protein secretion from cells treated with ICRF-193 for 48 h prior to differentiation and 
stimulation (p=0.028, student t-test)). An average decrease of 34% in TNFα  protein 
secretion was seen from cells treated with ICRF-193 for 72 h prior to differentiation and 
stimulation (p= 0.043, student t-test).  
 
TNFα protein exists as a transmembrane homodimer; upon stimulation of cells (in this 
case  by  δPS)  TNFα  is  cleaved  by  the  metalloproteinase,  TNFα  converting  enzyme 
(TACE) allowing its secretion into the extracellular environment (Horiuchi et al., 2010). 
Storage of TNFα as a transmembrane protein allows a rapid release of the cytokine in 
response to potential pathogenic stimuli (Stanley & Lacy, 2010). However, despite 
TNFα  being  stored  by  the  cell  for  such  events,  TNFα  mRNA  expression  is  seen  to 
increase when cells are stimulated (Suzuki et al., 2000), possibly to replenish secreted 
protein at the membrane, thus enabling a prolonged immune response.  
 
In order for TNFα to be secreted there are multiple steps that are required beforehand; 
transcription  of  the  TNFα  gene,  post  transcriptional  modifications  and  translation  of 
mRNA  and  synthesis  of  the  TNFα  protein,  transport  and insertion into the cell 
membrane and cleavage of transmembrane TNFα by TACE. 
 
Figure η.1γ shows very  little difference in protein secretion of TNFα when cells were 
treated with 1 nM ICRF-193 for 6 h prior to differentiation and stimulation. This is in 
contrast  to  results  shown  in  Figure  η.11  that  show  an  increase  in  TNFα  mRNA 
expression under the same conditions, however the results in Figure 5.11 did not reach 
significance. It is not known whether this increase in mRNA levels is mediated via 
increased transcriptional rate or due to an increase in mRNA stability i.e., some post-
transcriptional modification. In addition it is not known whether an increase in mRNA 
level is accompanied by an increase in translation and production of TNFα protein.  
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Indeed levels of mRNA do not always correlate with protein levels; Krämer et al. 
(1995) reported that an un-translated region in the TNFα mRNA was implicated in the 
predisposition of mRNA degradation by RNAses. Thus is it may be suggested that the  
increased amount of TNFα mRNA seen in Figure η.11 may not have all been translated, 
however, the results in Figure 5.11 did not reach significance, making it difficult to 
speculate. 
 
A decrease in TNFα protein secretion was observed when cells were treated with ICRF-
193 for 48 and 72 h prior to differentiation and stimulation. In contrast an increase in 
TNFα mRNA was observed when cells were  treated with  ICRF-193 for 72 h prior to 
differentiation and stimulation (Figure 5.11), however this result was not significantly 
different from the control. Indeed this increase in mRNA expression of TNFα after 7β h 
of pre-treatment with ICRF-1λγ is most likely not due topo IIȕ inhibition, as Figure η.1 
shows that after 72 h of exposure to 1 nM ICRF-1λγ levels of topo IIȕ have recovered 
back to levels comparable with the control. The decrease in protein secretion may be a 
result  of  previous  inhibition  of  topo  IIȕ  (after  θ  h) causing the down-regulation of 
transcription of another protein required for TNFα secretion, and thus due to translation 
of mRNA and protein synthesis, in addition to protein degradation of the residual 
protein the effects of this inhibition are not seen until this time (48 h and 72 h pre-
treatment). 
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Figure 5.14 Semi-quantification of TNFα  protein  expression  from  a  whole  cell 
lysate. 
Cells were treated with 0.1% DMSO (v/v) (Lane 1) or 1 nM ICRF-193 (Lane 2) for 6 h 
prior to differentiation and stimulation for 72 h with 5 ng/ml PMA and 10 ng/ml LPS 
respectively. Cells were harvested and whole cell extracts were performed as described 
in Section 2.16. 31.9 ȝg of whole protein was loaded onto an SDS gel and SDS PAGE 
was then performed followed by wet western blotting. Nitrocellulose blots were then 
probed with  antibodies  to  human TNFα  (a). Quantification of protein was performed 
using the densitometry software, Syngene genetools See Appendix Figure B.5 for 
GAPDH loading control. Results are expressed as percentage of 0.1% DMSO (v/v) 
treated samples (b). 
 
 
 
28kDa 
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The results from Figure 5.14 show that 6 h of 1 nM ICRF-193 pre-treatment causes an 
increase in TNFα protein expression compared to the 0.1% DMSO (v/v) control. This is 
in support of the results shown in Figure 5.14 that shows an increase in TNFα mRNA 
expression after 6 h of pre-treatment with 1 nM ICRF-193. However the increase in 
secreted  TNFα  is  small in comparison to the increase seen at the whole cell protein 
level, this is not unexpected as other mechanism are needed for its secretion for example 
the  actions  TACE,  the  enzyme  responsible  for  the  cleavage  of  TNFα  to  allow  its 
secretion into the extracellular environment. As it appears that despite an up-regulation 
of TNFα protein expression there is not an up-regulation of cleavage events leading to 
TNFα secretion. 
 
 
Figure 5.15 Comparing the effects of different exposure times to 1 nM ICRF-193 
prior to PMA and LPS treatment on TNFα protein secretion – raw data. 
Raw data used to generate Figure η.1γ. Amount of TNFα protein secreted in pg/ml was 
determined by y = mx +c of standard curve. A standard curve was generated for each 
independent experiment. Results shown are the means of three independent experiments 
are shown ± standard error.  
 
Figure 5.15 Shows ELISA raw data used to generate Figure 5.13. It shows that cells that 
had been in culture for longer prior to differentiation and stimulation (0.1% DMSO 
(v/v) and ICRF-193 treated) appear to secrete less TNFα in response to δPS than those 
cells that were in culture for less than 24 h before differentiation and stimulation. 
Interestingly, as reflected in Figures 5.13 and 5.14 cells that had been treated with 1 nM 
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ICRF-193 for 48 and 72 h prior to differentiation and stimulation appear to secrete even 
less  TNFα  than  their  0.1% DMSO (v/v) counterparts. Indeed cells that had been in 
culture for a total of 100, 124 and 148 h, despite being differentiated for the last 72 h of 
their time in culture may be undergoing a programmed cell death. This cell death may 
be  attenuated  by  TNFα  induced  apoptosis.  Secreted  TNFα  is  known  to  bind  to  the 
tumour-necrosis factor receptor-1 (TNFR1) found on the cell surface, this results in the 
recruitment  of  TNFα  associated  death  domain protein (TRADD), which in turn 
promotes the association of the TNFR1 complex with Fas associated death domain 
(FADD) inducing caspase-8 activation and cell death. The sum of this programmed cell 
death would ultimately  lead  to  a down  regulation of TNFα  secretion as seen in 0.1% 
DMSO (v/v) treated cells in Figure 5.15. In addition, as described previously in this 
chapter, a prolonged exposure to ICRF-193 may lead to a DNA damage response, 
possibly resulting in apoptosis, and therefore attenuating any apoptosis that may already 
be occurring. It could also be that inhibition of topo IIȕ at θ h caused a down-regulation 
of proteins involved in promoting cell survival when challenged with a pathogen, for 
example bacterial LPS. Indeed this down-regulation of protein expression may also still 
be occurring even when topo IIȕ has recovered (after 72 h of ICRF-193 treatment) and 
upon differentiation and stimulation the cell has been unable to promote a cell survival 
response and thus succumbed to apoptosis. Therefore the down-regulation  in  TNFα 
secretion seen after 48 h and 72 h of ICRF-193 pre-treatment followed by 
differentiation and stimulation with PMA and LPS is actually due to a reduction in 
viable cells able to secrete the cytokine.  
 
It may  also be postulated  that  topo  IIȕ may be  required  for  the  repression of TNFR1 
expression by association with a co-repressor complex. Treatment with ICRF-193 may 
then lead to disassociation of topo IIȕ from the complex, thus allowing transcription to 
occur and an up-regulation of TNFR1. An increase in TNFR1 at the cell surface would 
then increase the amount of  target  for TNFα  to bind and  thus  increase  the cascade of 
events leading to caspase activation and cell death. It should also be noted that 
prolonged treatment with ICRF-193 (48 and 72 h) could also generate post-translational 
modifications of key proteins involved in mediating apoptosis in this scenario such as 
TNFR1  which  could  account  for  the  further  decrease  in  TNFα  secretion  seen.  As 
described previously Figure η.1γ was generated by measuring secreted TNFα and not 
TNFα whole  protein.  Therefore  the protein measured required cleavage by TACE to 
facilitate its secretion. It would also be sensible to suggest a down regulation of TACE 
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may lead to a down regulation of secreted TNFα. Therefore it could be postulated that 
ICRF-193 may affect the expression of TACE. 
All of these scenarios are not mutually exclusive and taken together would lead to the 
attenuated down-regulation  of  TNFα  protein  secretion  when  cells  are  treated  with 
ICRF-193 for 48 and 72 h prior to differentiation.  
 
5.6 Effect of a co-treatment of ICRF-193, PMA and LPS on mRNA expression and 
protein secretion of the pro-inflammatory cytokines TNFα and IL-1ȕ. 
Results from Section 5.5 yielded some interesting results with regards to the effect of 
ICRF-1λγ treatment on TNFα mRNA expression and protein secretion. Therefore it was 
decided that the effect of this topo II inhibitor would be further investigated. In addition 
to  TNFα,  the  effect  of  ICRF-193 on IL-1ȕ,  another  important  pro-inflammatory 
cytokine was investigated.  
 
Research into the regulation of these cytokines is important as they play a crucial role in 
the inflammatory response. This response is the result of extracellular stimuli which in 
turn cause a cascade of intra and intercellular signals, leading to the secretion of pro-
inflammatory cytokines including, TNFα, Iδ-1ȕ and Iδ-6. It is highly regulated through 
negative feedback signals and anti-inflammatory cytokines and dysregulation of this 
process can lead to chronic inflammatory disease. Such diseases including autoimmune 
diseases are characterised by the hosts’ inability to recognise ‘self’. The cause of this is 
still to be fully elucidated. One mechanism, supported by the association of untreated 
Streptococcus Pyogenes throat infections and rheumatic heart disease suggests that 
microbes  display  molecular  mimicry  leading  to  the  host’s  immune  system  targeting 
‘self’ antigens and therefore causing a constant stimuli for pro-inflammatory producing 
cells. Another mechanism suggests the inactivity of endogenous anti-inflammatory 
cytokines (Karin et al., 2006). 
 
An example of a chronic inflammatory disease is Rheumatoid Arthritis (RA), affecting 
approximately 1% of the population in the developed world. It is a chronic 
inflammation of the synoivial membrane in diarthrodial joints, causing pain, stiffness 
and deformity (NICE; Brennan & McInnes, 2008). 
Previous work using a mouse model has shown the topo II poisons, etoposide and 
mitoxantrone can inhibit progression of collagen-induced arthritis (a model used to 
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study RA) in a dose dependent manner. Results were established by clinical observation 
and histological samples (Verdrengh et al., 2005) This is of particular importance as it 
suggests  that  Topoisomerase  II  α  and/or  ȕ  are  necessary  for macrophage and 
lymphocyte–associated joint inflammatory processes and that their inhibition can 
prevent this process. 
 
5.6.1 TNFα  
As  described  previously  TNFα  is  a  pro-inflammatory cytokine that is released by 
activated macrophages in response to extracellular stimuli (Opree et al., 2000; Brabers 
et al., 2006; Malo et al., 2006).  
Cells were exposed to a co-treatment of ICRF-193, 5 ng/ml PMA and 10 ng/ml LPS for 
72 h. In this experiment two concentrations of ICRF-193 were used: 1 nM, which has 
been  shown  to  cause  degradation  of  topo  IIȕ  (see  Figure  η.1)  and 150 nM that has 
previously been shown to inhibit and lead to the degradation of topo IIȕ (εcNamara et 
al., β010). qPCR and EδISA were performed to measure TNFα mRNA expression and 
protein secretion. The results are shown in Figures 5.16 and 5. 17 respectively. 
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Figure 5.16 Determining the effect of 1 nM and 150 nM ICRF-193, PMA, and LPS 
co-treatment on the expression of TNFα mRNA. 
U937 cells were seeded at a density of 3 x 105/ml in a 12 well tissue culture plate in 
complete media (detailed in materials and methods) with either 1 nM ICRF-193, 150 
nM ICRF-193 or 0.1% DMSO (v/v). 5 ng/ml PMA and 10 ng/ml LPS was also added. 
Cells were then allowed to incubate for 72 h before harvesting. RNA extraction and 
cDNA synthesis was performed as detailed in Section 2.17. qPCR was then performed 
using a hydrolysis probe to TNFA, using 18S as the reference gene (details of qPCR 
conditions in Section 2.17.3) Fold expression was calculated using the Δ/Δ Ct method. 
Data is presented as percentage of the 0.1% DMSO (v/v) treated control. The means of 
three independent experiments are shown ± standard error. 
 
 
The  results  presented  in  Figure  η.1θ  show  very  little  difference  in  TNFα  mRNA 
expression when cells were co treated with 1 nM ICRF-193, PMA and LPS for 72 h 
compared to the DMSO control (Appendix Table B.12). A slight, but non-significant 
increase in TNFα mRNA expression was exhibited when cells were co-treated with 150 
nM ICRF-193, PMA and LPS for 72 h (Appendix Table B.12). 
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Figure 5.17 Comparing the effects of different concentrations of 1 nM and 150 nM 
ICRF-193 when cells are co-treated with ICRF-19γ,  PMA  and  LPS  on  TNFα 
protein secretion 
U937 cells were seeded at a density of 3 x 105/ml in a 12 well tissue culture plate in 
complete media (detailed in materials and methods) with either 1 nM ICRF-193, 150 
nM ICRF-193 or 0.1% DMSO (v/v). 5 ng/ml PMA and 10 ng/ml LPS were also added. 
Cells were then allowed to incubate for 72 h before the supernatant was harvested. An 
ELISA to human TNFα  was  then  performed  (detailed  in  Section  β.1κ.1).  Data  is 
presented as percentage of the 0.1% DMSO (v/v) control. The means of three 
independent experiments are shown ± standard error. 
 
       
Figure 5.17 shows the cellular response to a 72 h ICRF-193 (1 nM & 150 nM), PMA 
and LPS co-treatment  in  terms  of  TNFα  secretion.  Statistical analysis of the results 
showed  that  there  was  no  significant  difference  in  TNFα  secretion  with  either 
concentration of ICRF-193 when compared to each other of the 0.1% DMSO (v/v) 
(vehicle control) treated cells (Appendix B.13). 
 
Figures 5.16 and 5.17 reveal that when cells were exposed to a co-treatment of 150 nM 
ICRF-193, PMA and LPS for 72 h there appeared an upward trend in the level of TNFα 
mRNA expression and protein secretion, however neither results reached significance. 
As described previously  in  this chapter,  topo  IIȕ has been  implicated  in  the activation 
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and repression of gene expression (Ju et al., 2006; McNamara et al., 2010; Huang et al., 
2012) and it has been postulated that it may act as part of a co-activator or co-repressor 
complex with regards to regulation of different genes (Ju et al., 2006; McNamara et al., 
2008). It may be postulated that the small increase in TNFα  mRNA  expression  as 
shown in Figure 5.16 may reflect a normal mechanism by which this gene is regulated 
by a transcriptional repressor complex that includes the physical interaction of topo IIȕ, 
however as this result did not reach significance it is difficult to speculate.  
 
δevels of topo IIȕ protein have previously been shown to be decreased following 48 h 
of 150 nM ICRF-193 treatment. This is due to ICRF-193 mediated inhibition of the 
topo IIȕ leading to the proteosomal degradation of the enzyme (εcNamara et al., 2008). 
Furthermore levels of topo IIȕ also maintain decreased following 7β h of treatment with 
150 nM ICRF-193, PMA and LPS (see Appendix Figure B.3). Thus inhibition of topo 
IIȕ may  lead  to  disassociation  of  the  inhibitory  complex,  leading  to  changes  in  local 
chromatin architecture thus facilitating an increase in TNFα mRNA expression.  
When cells were co-treated with 1 nM ICRF-193, PMA and LPS for 72 h, no effect in 
expression  of  TNFα  mRNA  was  exhibited  (Figure  η.1θ).  This  reflects  the  result  in 
Figure 5.1 that shows treatment of cells with 1 nM ICRF-193 resulted in the recovery of 
topo IIȕ protein levels to levels comparable in the 0.1% DMSO (v/v) control. However, 
in contrast, an increase in protein secretion was measured (Figure 5.17), although this 
result did not reach significance (Appendix B.13). This increase in protein secretion,  
may be the result of a previous up-regulation in TNFα mRNA caused by inhibition of 
topo IIȕ after the first θ h of ICRF-193 treatment, however the resultant up-regulation in 
protein secretion is not seen for a further 66 h. Indeed it is possible that if a sample had 
been taken at an earlier time point a greater increase in TNFα secretion may have been 
seen,  thus  suggesting  that  the  effects  of  topo  IIȕ  inhibition  are  very  much  transient. 
However, further work will be required to confirm this theory. 
 
Furthermore it may be postulated that differences seen between mRNA and protein 
levels  may  be  due  to  the  involvement  of  topo  IIȕ  in  the  regulation  of  other  genes 
involved  in  the  secretory  pathway of TNFα. TNFα protein exists as a transmembrane 
homodimer; upon stimulation of the cell (in this case by δPS) TNFα is cleaved by the 
metalloproteinase,  TNFα  converting  enzyme  (TACE)  allowing  its  secretion  into  the 
extracellular environment (Horiuchi et al., 2010). Storage of TNFα as a transmembrane 
protein allows a rapid release of the cytokine in response to potential pathogenic 
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stimuli. However, despite TNFα being stored by the cell for such events, TNFα mRNA 
expression is seen to increase when cells are stimulated (Suzuki et al., 2000), possibly 
to replenish secreted protein at the membrane, thus enabling a prolonged immune 
response.  
 
Additionally, as stated previously,  in order for TNFα to be secreted there are multiple 
steps that are required beforehand; transcription of  the  TNFα  gene,  translation  of 
mRNA  and  synthesis  of  the  TNFα  protein,  transport  and  insertion  into  the  cell 
membrane and cleavage of transmembrane TNFα by TACE. 
 
Thus the small increase  in  TNFα  protein  secretion  seen  in  Figure  η.17, although not 
significant (Appendix B.13) could be due to an up-regulation of TACE. Indeed an up-
regulation of TACE has been  shown  to  increase  the amount of TNFα  transmembrane 
protein that is cleaved (Guinea-Viniegra et al., 2009). In support of previous discussions 
it may be postulated that topo IIȕ may be part of a co-repressor complex that regulates 
the gene that encodes TACE. Therefore treatment of cells with ICRF-193 may lead to 
disassociation  of  topo  IIȕ  from  the  co-repressor complex, thus leading to the up-
regulation of TACE expression and therefore leading to an up-regulation  of  TNFα 
cleavage resulting in an increase in secretion. It may also be due to post-translational 
modification of TACE in response to exposure to ICRF-193 such that its activity 
increases thus resulting in increased TNFα secretion. Interestingly, in contrast, topo IIȕ 
could be driving the expression of genes involved in TNFα secretion.  Interestingly, in 
contrast, topo IIȕ could be driving the expression of genes involved in TNFα secretion. 
Perez et al. (1997) showed that treatment of U937 cells with 0.3 ȝε ICRF-193 for 72 h 
elicited an increase in PKC protein expression. Further to this McNamara et al. (2010) 
showed that an increase in PKCį protein expression correlated with an increase in topo 
IIȕ  protein expression, possibly by stabilisation of the protein by phosphorylation. 
However an up-regulation  of  topo  IIȕ  protein  expression  is  not  seen  following  a  co-
treatment with 150 nM ICRF-193, PMA and LPS (Appendix Figure B.3) it may be 
postulated that topo IIȕ is hyperphosphorylated due to an increase in PKC, and this in 
turn increases its enzymatic activity (DeVore et al., 1992; Matsumoto et al., 1999), thus 
leading to an increase in gene expression. Again further work will be required in order 
to support this hypothesis. 
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It is interesting to note that mRNA data from Figures 5.11 and 5.16 do not correlate. 
Figure 5.11 shows that 6 h of ICRF-193 treatment prior to differentiation and 
stimulation results in a significant increase in TNFα mRNA expression, in contrast a co-
treatment of cells with 1 nM ICRF-193, PMA and LPS for 72 h has little effect on 
TNFα  mRNA  expression.  It  may  be  that  pre-treatment of cells with ICRF-193 is 
‘priming’ the TNFα gene ready for transcription; for example by causing disassociation 
of a co-repressor complex. Indeed it has been shown the ICRF-193 may actually induce 
differentiation (Perez et al., 1997). Therefore pre-treatment of cells with ICRF-193 may 
drive the up-regulation of genes associated with macrophage like cells.  It is likely that 
the co-treatment of 1 nM ICRF-193 with PMA and LPS does not affect mRNA 
expression of TNFα as topo IIȕ is not being down-regulated at this time; as previously 
treatment of cells with 1 nM ICRF-193 for 72 h actually sees the recovery of topo IIȕ 
back to levels comparable with the 0.1% DMSO (v/v) control. 
 
In addition to this, protein data from Figure 5.13 and 5.17 do not correlate. A 72 h co-
treatment of 1 nM ICRF-193, PMA and LPS shows an up-regulation of protein 
secretion, in comparison a 72 h pre-treatment with 1 nM ICRF-193 causes a significant 
down-regulation in protein secretion. However a direct comparison between this data 
cannot be made. Cells used for the two sets of experiments were in culture for very 
different times; pre-treated cells were in culture for up to 148 h (72 h pre-treatment + 72 
h PMA and LPS treatment) whilst co-treated cells were only in culture for 72 h. 
Additionally  for  both  experiments  levels  of  topo  IIȕ  protein  were  shown  to  be 
comparable to levels in the 0.1% DMSO (v/v) control samples. However the down-
regulation  of  TNFα  following  7β  h of 1 nM ICRF-193 pre-treatment may be, as 
described previously, due to the effects of earlier inhibition of topo IIȕ at θ h effecting 
the gene expression of other proteins involved in TNFα secretion. It may also be due to 
pre-treatment with ICRF-193 driving apoptosis of the cells, thus seemingly causing a 
down-regulation  of  TNFα  secretion.  The  up-regulation  of  TNFα  secretion  observed 
when cells are co-treated with 1 nM ICRF-193 for 72 h may possibly be due the 
antagonism of the immune response by ICRF-193 itself. 
It could be suggested that possible LPS contamination of ICRF-193 and PMA could 
lead to an up-regulation  of  TNFα  mRNA  or  protein  secretion.  Following  these 
experiments, the stocks of ICRF-193 and PMA used were tested for LPS contamination, 
of which none was found (data not shown).  
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5.6.2 IL-1ȕ 
Interleukin -1ȕ is a pro-inflammatory cytokine produced by cells of the innate immune 
system (Opree et al., 2000; Brabers et al., 2006; Malo et al., 2006). It is produced as a 
35kDa inactive precursor, pro-IL-1ȕ in response to cell signalling induced by binding of 
Pattern associated molecular patterns (PAMPs). Processing of pro-IL-1ȕ is via cleavage 
by the pro-inflammatory protease, caspase-1. Caspase-1 is activated via recruitment to 
the inflammasome; a multi-protein complex consisting of ASC, NLPR3, PRR and pro-
caspase-1. The resulting cleavage of pro-IL-1ȕ  leads  to  the  secretion  of  active  Iδ-1ȕ. 
(Lopez-Castejon et al., 2011). 
Cells were prepared as described in Section 5.7.1. qPCR and ELISA were performed to 
measure IL-1ȕ  mRNA  expression and protein secretion. The results are shown in 
Figures 5.18 and 5.19, respectively.  
        
Figure 5.18 Determining the effect 1 nM and 150 nM ICRF-193, PMA, and LPS 
co-treatment on the expression of IL-1ȕ mRNA. 
U937 cells were seeded at a density of 3 x 105/ml in a 12 well tissue culture plate in 
complete media (detailed in materials and methods) with either 1 nM ICRF-193, 150 
nM ICRF-193 or the 0.1% DMSO (v/v). 5 ng/ml PMA and 10 ng/ml LPS was also 
added. Cells were then allowed to incubate for 72 h before harvesting. RNA extraction 
and cDNA synthesis was performed as detailed in Section 2.17. qPCR was then 
performed using a hydrolysis probe to IL1B, using 18S as the reference gene (details of 
qPCR conditions in Section 2.17.3) Fold expression was calculated using the 
comparative Δ/Δ Ct method. Data is presented as percentage of the 0.1% DMSO (v/v) 
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treated control. The means of three independent experiments are shown ± standard 
error. 
 
The results presented in Figure 5.18 reveal that there is no significant difference in IL-
1ȕ mRNA  expression  in  cells  that  had  been  co-treated with either 1 nM or 150 nM 
ICRF-193, along with PMA and LPS for 72 h or compared to the DMSO controls 
(Appendix Table B.14). 
 
Under the same conditions, using an ELISA to human IL-1ȕ,  protein  secretion  was 
quantified. The results are shown in Figure 5.19. 
 
 
 
Figure 5.19 Comparing the effects of different concentrations of ICRF-193 when 
cells are co-treated with ICRF-193, PMA and LPS on IL-1ȕ protein expression. 
U937 cells were seeded at a density of 3 x 105/ml in a 12 well tissue culture plate in 
complete media (detailed in materials and methods) with either 1 nM ICRF-193, 150 
nM ICRF-193 or 0.1% DMSO (v/v). 5 ng/ml PMA and 1ng/ml LPS were also added. 
Cells were then allowed to incubate for 72 h before the supernatant was harvested. An 
ELISA to human IL-1ȕ  was  then  performed  (detailed  in  Section  β.1κ.β).  Data  is 
presented as percentage of the 0.1% DMSO (v/v) treated control. The means of three 
independent experiments are shown ± standard error. * = p < 0.05. 
 
 
The results presented in Figure 5.19 reveal an increase in IL-ȕ protein secretion in cells 
that had been co-treated with 1 nM ICRF-193, PMA and LPS for 72 h, however this 
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result was not significantly different from the 0.1% DMSO (v/v) control (Appendix 
Table B.15). In comparison cells that had been co-treated with 150 nM ICRF-193, PMA 
and LPS for 72 h displayed a significant average decrease of 41% (p=0.03, student t-
test) in IL-1ȕ protein secretion.  
 
The results from Figure 5.18 suggest that co-treatment of cells with PMA, LPS and 1 
nM or 150 nM ICRF-193 has little effect on IL-1ȕ mRNA expression. However, it does 
appear to affect IL-1ȕ  protein  secretion,  and  the  effect  appears  to  be  dose  dependent 
with low doses eliciting a higher secretory response.  
 
A co-treatment of cells with 1 nM ICRF-193, PMA and LPS appears to increase protein 
expression. Previous work has shown an increase in serum levels of IL-1ȕ when mice 
were exposed to the topo II inhibitor, doxorubicin (Zhu et al., 2010). Sauter et al. 
(2011) later proposed that this response to doxorubicin could be due to activation of the 
inflammasome. Indeed it may be postulated that cells treated with 1 nM ICRF-193 may 
be eliciting an attenuated immune response mediated by the inflammasome, thus 
secreting more IL-1ȕ.  This  scenario  is more  likely  than  an effect caused by a down-
regulation of topo IIȕ protein, which as shown previously actually has recovered back to 
levels comparable with the 0.1% DMSO (v/v) control after treatment with 1 nM ICRF-
193 for 72 h. 
 
Conversely cells that were co-treated with 150 nM ICRF-193, PMA and LPS 
demonstrated a significant (p=0.03, student t-test) decrease in IL-1ȕ protein secretion. 
The  results  in Figures  η.1κ  and η.1λ  suggest  that  inhibition  of  topo  IIȕ with  150 nM 
ICRF-193 (McNamara et al., 2010) has little effect on mRNA expression of IL-1ȕ, thus 
suggesting it is not inhibiting IL-1ȕ gene expression, however it does appear to inhibit 
IL-1ȕ secretion. As described earlier Iδ-1ȕ exists in the cell in its inactive form, pro-IL-
1ȕ, once processed by  the protease, caspase-1 it is secreted from the cell. Indeed it is 
possible that topo IIȕ may regulate the expression of caspase-1. Therefore inhibition of 
topo IIȕ may lead to the down-regulation of caspase-1, resulting in a decrease in IL-1ȕ 
secretion. As discussed previously  topo  IIȕ  has  been  reported  to  play  a  role  in  the 
activation and repression of many genes (Lyu et al., 2006; Ju et al., 2006, Tiwari et al., 
2012). Tiwari et al. (β01β)  reported  that  topo  IIȕ  is  associated with  transcriptionally 
active sites of DNA, and that it actually exhibited a preference for binding to promoter 
regions of genes involved in neuronal development; interestingly an absence of topo IIȕ 
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in mice is associated with abnormalities in the cerebral cortex of the brain (Lyu et al., 
2003). Additionally knockdown of topo IIȕ in mouse embryos was shown to change the 
expression of 30% of developmentally regulated genes (Lyu et al., 2006). However as 
described in Section 1.13.2.1 the events leading to IL-1ȕ  secretion  are  not  quite  as 
simple as this hypothesis would suggest. Indeed due to the transient and global actions 
of  topo  IIȕ,  it may  be  involved  in  the  regulation  of  gene  expression  of  one  or more 
components involved in IL-1ȕ secretion. 
 
In addition an ICRF-193 dose of 150 nM may be leading to apoptosis of the cells, this 
would in turn lead to a decrease in IL-1ȕ protein secretion as seen in Figure η.1λ. 
 
 
5.7 Comparing cytokine expression of wild type mouse embryonic fibroblasts with 
topo IIȕ deficient mouse embryonic fibroblasts (#5). 
In order to support data collected on topo IIȕ down-regulation using ICRF-193, mouse 
embryonic fibroblasts  (εEFs)  that were  topo  IIȕ deficient due  to a stable knockdown 
were utilised to investigate the absence of topo IIȕ in production of the cytokines, Iδ-6 
and IL-1α compared to their secretion by wild type MEFs. 
MEFs have previously been shown to secrete IL-6 and IL-1α  in  response  to δPS and 
thus provided suitable targets for investigation (Tominaga et al., 1997). 
 
5.7.1 Comparing differences in IL-6 protein expression 
IL-6 is often described as a cytokine and a myokine (a cytokine related to muscle) 
(Muñoz-Cánores et al., 2013). It can act both in a pro-inflammatory and anti – 
inflammatory capacity and is secreted by immune cells and non-immune cells, such as 
osteoblasts and keratinocytes (Ishimi et al., 1990; Neuner et al., 1991; Scheller et al., 
2011). Exercise induced IL-6 secretion has been shown to elicit anti-inflammatory 
effects particular in chronic low grade systemic inflammatory diseases such as 
cardiovascular disease and Type II Diabetes (Peterson & Pederson, 2006; Pederson, 
2006). It is therefore an attractive target to investigate.  
In order to investigate the effect of topo IIȕ inhibition on IL-6, two different exposure 
times were used in addition to three different concentrations of LPS. 
As the proliferation rate of wild type MEFs and #5 MEFs was slightly different (data 
not shown) a cell count was performed when the supernatant was removed. Following 
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the ELISA, the amount of IL-6 secreted by the samples was divided by the cell number 
to give a final value in pg/ml/cell. The amount of IL-6 secreted in #5 MEFS as 
pg/ml/cell was then expressed as percentage of IL-6 secreted in pg/ml/cell of wild type 
MEFs. The results are shown in Figure 5.20 
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Figure 5.20 Determining the difference in levels of IL-6 protein in wild type 
mouse embryonic fibroblasts and topo IIȕ deficieny MEFs (#5).  
WT MEFs and #5 MEFs were seeded at a cell density of 3 x 105 cells/ml and 
allowed to incubate for 24 h, this was followed by the addition of 0.5, 1 and 5 ng/ml 
LPS was then added to both cell lines and cells were incubated for either 48 h (a) and 
72 h (b) before the supernatant was harvested. A cell count was also performed at 
this time. An ELISA to mouse IL-6 was then performed (see Section 2.18.3 for 
details). Using the cell count pg/ml per cell was calculated. Data is represented as 
percentage of WT MEF result. The means of two independent experiments are 
shown ± standard error for 0.5 and 1ng/ml (levels of IL-6 secretion in experiment 
were below levels of detection). The means of three independent experiments are 
shown ± standard error for 5 ng/ml. *** = p< 0.001 
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A significant average 82% decrease (p < 0.001, student t-test). in IL-6 secretion was 
seen in topo IIȕ knockout εEFs compared to wildtype εEFs after ζκ h of 5 ng/ml LPS 
stimulation (Figure 5.20a). A decrease was also observed when using 1ng/ml LPS for 
48 h, however this result was not significant (see Appendix Table B.16) this is most 
likely due to a low sample set (see Figure 5.20). There was very little difference 
observed in IL-6 secretion when cells were treated with 0.5 ng/ml LPS for 48 h. In 
contrast, no significant differences were seen when cells were exposed to all 
concentrations of LPS for 72 h. Indeed a small decrease was seen in cells treated with 5 
ng/ml for 72 h (Figure 5.20b), following the same trend demonstrated using the same 
LPS concentration in Figure 5.20a. 
 
The data in Figure η.β0a suggests that topo IIȕ is required for the secretion of Iδ-6, as 
topo IIȕ deficient cells are secreting significantly less Iδ-6 in response to 5 ng/ml LPS 
than the wild type cells. This is in agreement with previous work that has demonstrated 
that topo IIȕ is required for the transcription of certain genes to occur (Ju et al., 2006, 
Tiwari et al., 2012). The transcription of the IL-6 gene requires the cooperative effects 
of various transcription factors including AP-1, C/EBP and NF-țB (Grassl et al., 1999). 
Previous work by Ju et al. (2006) supports this result, as this study revealed that 
treatment with TPA (PMA) resulted in recruitment of  topo  IIȕ  to  the AP-1 regulated, 
MMP12 promoter, along with induction of a strand break. Thus suggesting topo IIȕ is 
involved in the regulation of transcription of AP-1 regulated genes. Additionally topo 
IIȕ  has  previously  been  found  to  associate  with  the  c-Jun subunit of the AP-1 
transcription factor (Kroll et al., 1993). Taken together, it may be suggested that topo 
IIȕ  cooperatively  acts  with  other  transcription  factors, in particular AP-1 at the IL-6 
gene in order to facilitate its transcription.  
 
The difference in results between 48 and 72 h may be due to the extended exposure of 
cells to LPS allowing the cells to subvert the inhibition of gene expression, possibly by 
recruitment of other transcription factors. Indeed multiple other transcription factors, for 
example, CREB, Notch1 and IRF-1 are involved in IL-6 gene expression (Sanceau et 
al., 1995; Grassl et al., 1999; Spooren et al., 2010; Wongchana & Palaga, 2012) 
however their recruitment appears to be cell specific, thus suggesting multiple modes of 
gene activation. The difference in IL-6 secretion between time points may also reflect 
the time specific action of topo IIȕ. δyu et al. (β00θ) showed that topo IIȕ was required 
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in the later stages of neuronal development and dispensable at the earlier stages. Indeed 
it is possible that topo IIȕ is required at the promoter region of Iδ-6 early in response to 
LPS, and therefore a down-regulation is not seen after 72 h. This also suggests that an 
even greater repression of IL-6 secretion may be seen after a shorter exposure to LPS. 
However as the data presented focuses on the secretion of IL-6 and not the mRNA 
expression of IL-θ then it is difficult to conclude that topo IIȕ is actually affecting Iδ-6 
gene expression, indeed its absence may cause the down-regulation of other genes 
associated with the expression and secretion of IL-6, conversely its absence could 
prevent the repression of genes involved in supressing IL-6 secretion. 
 
 
5.7.2 Comparing differences in IL-1α protein expression 
IL-1α is a pro-inflammatory cytokine produced mainly by macrophages and neutrophils 
but can also be expressed by epithelial cells and fibroblasts. IL-1α  is  produced  as  a 
31kDA precursor protein that requires the removal of the N terminal amino acids in 
order to become active. This occurs via cleavage by the protease calpain. IL-1α exists as 
is active in a membrane bound and soluble form.  
Cells were prepared as previously described in Figure 5.20 and an ELISA to mouse IL-
1α was  performed.  The  results  obtained  for  all  three  experiments  from  both  the wild 
type and #5 MEFs were below the limits of detection (data not shown), suggesting that 
either the doses of LPS used were too low to stimulate cells or indeed 48 h and 72 h was 
too long, and the IL-1α response was missed.  
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5.8 Knockdown of topoisomerase IIȕ in U9γ7 cells using siRNA 
In order to further establish the effects of an absence of topo IIȕ protein on TNFα and 
IL-1ȕ  secretion  in  PεA  and  δPS  treated  Uλγ7  cells,  small  interfering  RNA 
oligonucleotides (siRNA) were used to target topo IIȕ mRNA.  This should result in a 
lack of  topo  IIȕ mRNA  translation and  therefore protein  synthesis. This  accompanied 
with  the  normal  degradation  of  the  existing  topo  IIȕ  protein  due  to  its  finite  half-life 
results in a depletion of the protein. 
 
5.8.1 Determination of appropriate oligonucleotide to use 
Four siRNA oligonucleotides were obtained from Qiagen that targeted topo IIȕ. In order 
to determine which siRNA oligonucleotide would provide the optimal knockdown of 
topo IIȕ, protein quantification of topo IIȕ using SDS-PAGE and western blotting was 
performed following treatment with non-PMA treated U937 cells with each siRNA 
nucleotide. The results of this are shown in Figure 5.21. 
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Figure 5.21 Quantification of  topo  IIȕ protein  following  transfection with  siRNA 
oligonucleotides in non-PMA treated U937 cells. 
U937 cells were seeded at 1 x 105 cells/ml in a 12 well plate and allowed to incubate for 
24 h. siRNA oligonucleotides were then added (see materials and method) and cells 
were left to incubate for 4 h before media was changed. Cells were then left for a further 
48 h before harvesting. Whole cell extractions, SDS-PAGE, and western blots were 
performed as described in materials and methods Section 2.16. Blots were then probed 
with an anti-human topo IIȕ antibody (Section β.1θ.7) δanes are  labelled with siRNA 
treatment (a) Quantification of protein was performed using the densitometry software, 
Syngene  genetools,  data  is  presented  as  amount  of  protein  in  the  topo  IIȕ  targeting 
siRNA treated cells as a percentage of that in the negative siRNA treated cells (b). 
Results shown are representative of one sample set. See Appendix Figure B.6 for 
GAPDH loading control. 
(a) 
(b) 
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Figure 5.21 shows that siRNA oligonucleotides #3 and #4 appear to be the optimal 
siRNA oligonucleotides to use for topo IIȕ knockdown. Treatment of Uλγ7 cells with 
siRNA  #γ  and  #ζ  appear  to  cause  a  λλ%  and  λγ%  reduction  in  topo  IIȕ  protein 
expression compared to the negative control, respectively (Figure 5.21). The #1 and #2 
siRNA oligonucleotides also appear to induce a decrease in topo IIȕ protein expression, 
although not  as  effective  as #γ  and #ζ;  causing  a ηγ% and ζβ% decrease  in  topo  IIȕ 
protein expression compared to the negative control (Figure 5.21). 
 
5.8.β Quantification of topoisomerase IIȕ protein post siRNA experiment 
Following siRNA, PMA and LPS treatment, supernatant was removed from cells in 
order  to quantify TNFα  and  Iδ-1ȕ protein  secretion.  In  addition,  cells were harvested 
and protein extracted in order to quantify the levels of topo IIȕ post siRNA, PεA and 
LPS  treatment.  This  was  necessary  as  knockdown  of  topo  IIȕ  was  only  previously 
established after 48 h of incubation, in contrast this experiment requires a further 72 h 
of incubation. Quantification of topo IIȕ protein at this time would then ensure that any 
significant  result  that  may  be  observed  during  quantification  of  TNFα  and  Iδ-1ȕ 
secretion is due to a decrease in topo IIȕ protein. The results of this are shown in Figure 
5.22. 
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Figure 5.ββ Quantification of  topo  IIȕ protein  following  transfection with siRNA 
oligonucleotides and subsequent addition of PMA and LPS in U937 cells. 
U937 cells were seeded at 1 x 105 cells/ml in a 12 well plate and allowed to incubate for 
24 h. siRNA oligonucleotides were then added (see materials and method) and cells 
were left to incubate for 4 h before media was changed. Cells were then left for a further 
48 h before media was again changed with the addition of 5 ng/ml PMA and 10 ng/ml 
LPS. Cells were left for a further 72 h to incubate. Whole cell extractions, SDS-PAGE, 
(c) 
(b) 
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and western blots were performed as described in materials and methods Section 2.16. 
Blots were then probed with an anti-human topo IIȕ antibody (Section β.1θ.7) δanes are 
labelled with siRNA treatment, (a) western blot using protein from from experiments 1 
& 2. (b) Western blot using protein from experiment 3 Quantification of protein was 
performed using the densitometry software, Syngene genetools, data is presented as 
amount of protein  in  the  topo  IIȕ  targeting  siRNA (siRNA #γ  in black,  siRNA #ζ  in 
grey) treated cells as a percentage of that in the negative siRNA treated cells (c).  
 
Figure 5.22 shows that protein extracted from cells during experiment 1 revealed that 
topo  IIȕ  protein  expression  had  recovered,  additionally  the  level  of  topo  IIȕ  protein 
quantified was higher than the level found in the negative control. An 80% increase in 
topo  IIȕ  protein  expression  was  observed  when  cells  were  transfected  with  the  #γ 
siRNA oligonucleotide compared to the negative control. An even higher, 319% 
increase in topo IIȕ protein expression was seen in cells transfected with the #ζ siRNA 
oligonucleotide.  
 
Protein extracted from cells during experiment β, again showed an increase in topo IIȕ 
levels compared to the negative control. A 155% increase was observed in cells 
transfected with the #3 siRNA oligonucleotide compared to the negative control, whilst 
a 101% increase in topo IIȕ protein expression was seen in cells transfected with the #ζ 
siRNA oligonucleotide. 
 
In comparison, protein extracted from experiment γ showed that levels of topo IIȕ were 
still decreased compared to the negative control, but not as much as that seen in Figure 
η.ββb. A θ0% decrease in topo IIȕ protein expression was observed in cells transfected 
with the #3 siRNA oligonucleotide, whereas a 82% decrease was seen in cells 
transfected with the #4 siRNA oligonucleotide. 
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5.8.γ Effect of topoisomerase IIȕ knockdown on TNFα protein expression 
Following siRNA, PMA and LPS treatment, supernatant was removed from cells and 
TNFα protein secretion was quantified using an EδISA to human TNFα. The results are 
shown in Figure 5.23. 
 
Figure  5.βγ  Determining  the  effect  of  topoisomerase  IIȕ  targeted  siRNA 
transfection on expression of TNFα protein secretion. 
U937 cells were seeded at 1 x 105 cells/ml in a 12 well plate and allowed to incubate for 
24 h. siRNA oligonucleotides were then added (see materials and method) and cells 
were left to incubate for 4 h before media was changed. Cells were then left for a further 
48 h before media was again changed with the addition of 5 ng/ml PMA and 10 ng/ml 
LPS. Cells were left for a further 72 h to incubate before supernatant was removed and 
an ELISA to human-TNFα  was  performed.  Results  are  expressed  as  percentage  of 
negative control. Experiment 3 yielded results lower than the limits of detection and 
therefore results are shown as 0. 
 
 
Figure 5.23 reveals that in experiment 1, when cells are transfected with the #3 siRNA 
oligonucleotide, TNFα protein  secretion  is  decrease by  γζ% compared  to  the control. 
Conversely cells transfected with the #4 siRNA oligonucleotide demonstrated a 124% 
increase in TNFα secretion compared to the control.  
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In experiment 2, cells transfected with the #3 siRNA oligonucleotide displayed a 32% 
decrease in TNFα secretion compared to the control.  In comparison, cells treated with 
the #ζ siRNA oligonucleotide exhibited a β0% increase in TNFα secretion. 
Interestingly,  in  experiment  γ,  TNFα  secretion from cells treated with the #3 siRNA 
oligonucleotide and cells treated with the #4 siRNA oligonucleotide was below the 
detectable limits of the assay.  
 
5.8.4 Effect of topoisomerase IIȕ knockdown on IL-1ȕ protein expression. 
Following siRNA, PMA and LPS treatment, supernatant was removed from cells and 
IL-1ȕ protein secretion was quantified using an EδISA to human Iδ-1ȕ. The results are 
shown in Figure 5.24. 
 
Figure  5.β4  Determining  the  effect  of  topoisomerase  IIȕ  targeted  siRNA 
transfection on expression of IL-1ȕ protein secretion  
U937 cells were seeded at 1 x 105 cells/ml in a 12 well plate and allowed to incubate for 
24 h. siRNA oligonucleotides were then added (see materials and method) and cells 
were left to incubate for 4 h before media was changed. Cells were then left for a further 
48 h before media was again changed with the addition of 5 ng/ml PMA and 10 ng/ml 
LPS. Cells were left for a further 72 h to incubate before supernatant was removed and 
an ELISA to human-IL-1ȕ  was  performed.  Results are expressed as percentage of 
negative control.  
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Figure 5.24 Shows that IL-1ȕ secretion in experiment 1 in cells transfected with the #γ 
siRNA oligonucleotide is not largely different from the control, however cells 
transfected with the #4 siRNA oligonucleotide display a 108% increase in IL-1ȕ 
secretion.  
 
IL-1ȕ secretion in experiment β in cells transfected with the #γ siRNA oligonucleotide 
display an increase of 26%, whereas cells transfected with the #4 siRNA 
oligonucleotide exhibit a 68% increase compared to the control. 
 
Conversely, IL-1ȕ  secretion  in  experiment  γ  is  decreased  compared  to  the  control. A 
decrease of 83% in IL-1ȕ  secretion was  observed  from  cells  transfected with  the  #γ 
siRNA oligonucleotide, whilst cells transfected with the #4 siRNA oligonucleotide 
exhibited a 38% decrease in IL-1ȕ secretion compared to the control. 
 
Interestingly when investigating the correlation between topo IIȕ protein expression and 
TNFα and  Iδ-1ȕ  secretion  in  this  set  of  experiments,  there did  in  fact  appear to be a 
significant positive correlation between topo IIȕ protein expression and TNFα secretion 
in #4 siRNA treated cells (p=0.048, linear correlation) (Figure. 5.25a). In addition a 
significant  correlation  between  topo  IIȕ  protein  expression  and  Iδ-1ȕ  secretion in #3 
siRNA treated cells was also determined (p= 0.0345, linear correlation) (Figure. 5.25b). 
These results strengthen the other data in this chapter that suggest that topo IIȕ may be 
involved in the transcription of genes involved in both the TNFα and Iδ-1ȕ pathways of 
secretion. 
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Figure 5.β5 Correlation of topo IIȕ expression with TNFα secretion (a) and IL-1ȕ  
secretion (b).  
Percentage  of  topo  IIȕ  protein  expression  (compared  to  negative  control)  following 
treatment with the #4 siRNA oligonucleotide, PMA and LPS was plotted against 
percentage  of  TNFα  secreted  (compared  to  negative  control)  from  the  corresponding 
experiment  (a).  Percentage  of  topo  IIȕ  protein  expression  (compared  to  negative 
control) following treatment with the #3 siRNA oligonucleotide, PMA and LPS was 
plotted against percentage of IL-1ȕ  secreted  (compared  to  negative  control)  from  the 
corresponding experiment (b). Linear regression analysis was performed using 
GraphPad (Prism). 
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5.9 Summary  
The work in this Chapter reveals  that  inhibition of  topo  IIȕ using ICRF-193 has only 
small and mainly non-significant effects on factors associated with differentiation and 
stimulation. However some interesting trends have been identified such as the transient 
increases in the levels of NF-țB, EGRβ, TδRζ, TLR2 and TNFα mRNA after θ h 1 nε 
ICRF-193 exposure. In addition a small transient increase in TNFα  whole protein 
expression was seen. However it is also highlights the possible caveats of using a topo 
II drug to inhibit topo IIȕ. Use of the topo IIȕ inhibitor, ICRF-193, due to the possible 
DNA damaging effects and ultimately due to it being a foreign material to the cell 
leaves it difficult to determine if the effects seen when using ICRF-193 are due to topo 
IIȕ inhibition or dose and time dependent effects of treatment with ICRF-193 itself.  
 
The work using  the mouse embryonic  topo  IIȕ knockout cells  line does not have  this 
dis-advantage. Therefore the down-regulation of IL-6 secretion after 48 h of 5 ng/ml 
LPS treatment can be assumed to be due to an absence of topo IIȕ. 
 
In addition, the positive correlation seen between siRNA induced topo IIȕ depletion and 
TNFα  and  Iδ-1ȕ  secretion,  where  when  topo  IIȕ  is  decreased,  TNFα  and  Iδ-1ȕ 
secretion is also decreased is very interesting. Therefore further work will utilise 
Chromatin Immuno-precipitation (ChIP) to investigate the association of topo IIȕ with 
regions proximal to the TNFα and Iδ-1ȕ gene promoters. 
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Chapter 6 
 
The association of Topoisomerase IIȕ at discrete regions of interest within the 
TNFα and IL-1ȕ genes in non-LPS and LPS treated cells. 
 
6.1 Introduction 
There  is  increasing  evidence  to  suggest  that  topo  IIȕ  is  involved  in  the  regulation  of 
transcription and that this involvement includes its physical association at areas of 
transcriptional activity. For example, Pommier et al. (1992) reported that topo II 
induced double strand breaks in the p2 promoter of the c-myc gene in the plasmid, 
JB327. More recently, Ju et al. (2006) proposed a mechanism by which a topo IIȕ 
generated  double  strand  break  was  required  at  the  psβ  promoter  in  response  to  17ȕ-
estrdaiol in order for transcription to occur. Interestingly, Tiwari et al. (2012) reported 
that topo IIȕ is more highly associated with promoter regions than exon or introns, and 
association was up-regulated during differentiation from neuronal progenitor to terminal 
neuronal  state.  In  addition  to  association  at  promoter  regions,  topo  IIȕ  binding  sites 
were identified in DNAse hypersensitivity regions within the ȕ-globulin loci in chickens 
(Reitman & Felsenfeld, 1990).  
DNase I hypersensitivity regions are regions of chromatin which are sensitive to the 
cleavage activities of DNase I. DNase hypersensitivity sites are often found on 
chromatin that is ‘open’, and often associated with transcriptional activity. Identification 
of DNase hypersensitivity I aids in the understanding of DNA regulatory elements such 
as enhancer and promoter regions (Song et al., 2011; Thurman et al., 2012).  
In Chapter 5 it was shown that treatment of U937 cells with ICRF-193 led to significant 
perturbations in secreted levels of TNFα and Iδ-1ȕ (Figures η.1γ and η.1λ). TNFα and 
IL-1ȕ are the most potent cytokines released during the inflammatory response and are 
thus a great source of interest. The inflammatory response is triggered by binding of a 
pathogen associated molecular pattern (PAMP) to a pattern recognition receptor (PRR) 
on the cell surface, most notably a toll like receptor. One such PAMP is LPS, which is 
found in the cell wall of Gram-negative bacteria. Binding of LPS to TLR4 leads to a 
cascade of signalling events ultimately leading to the secretion of pro-inflammatory 
cytokines, including TNFα  and  Iδ-1ȕ.  Stimulation  of  cells  with  δPS  has  also  been 
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shown  to cause an  increase  in TNFα and  Iδ-1ȕ mRNA expression  (Cassatellas et al., 
1993; Reimann et al., 1994).  
In order to determine if topo IIȕ is associated with areas at, or within close proximity to 
the TNFα and Iδ-1ȕ promoter regions, ChIP-qPCR was used to compare relative levels 
of topo IIȕ association in non-LPS and LPS treated cells.  
 
6.2 Aim 
To identify regions in the IL-1ȕ and TNFα genes which contain putative topoisomerase 
II cleavage sites. 
To determine if topoisomerase IIȕ physically associates with the regions identified. 
To determine  if  there  is  a  change  in  topo  IIȕ  association  at  these  regions when PεA 
treated cells are stimulated with LPS compared to non-LPS stimulated cells. 
 
6.3 Designing primers to be used in qPCR following ChIP 
The aim of this section was to determine if topo IIȕ is physically assocaited with areas 
in or in close proximity to the TNFα and IL-1ȕ promoter which could indicate a role in 
the regulation of gene expression. In order to do this, ChIP-qPCR was utilised to 
analyse topo IIȕ interactions with DNA. This method combines ChIP with qPCR to 
determine if the protein of interest binds to the DNA site of interest. In order to identify 
whether topo IIȕ DNA binding sites are enriched in areas at or near to the TNFα and IL-
1ȕ promoter regions, primer pairs were used to amplify these regions of interest 
following protein unlinking and purification. These primer pairs were designed based 
on known DNAse hypersensitivity sites and putative topo IIȕ cleavage sites within the 
TNFα and IL-1ȕ genes, an outline of which is shown in Figure 6.1. 
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Figure 6.1 Designing primers towards areas of interest within the IL-1ȕ and TNFα 
genes.  
Using the NCBI database,  the  specific  loci  of  the  TNFα  and  Iδ-1ȕ  genes  were 
determined. Encode data (Rosenbloom et al., 2013) was then used to determine if any 
DNase hypersensitivity sites were located within the genes. A literature search was used 
to determine the sequence  of  any  possible  topo  IIȕ  binding  sites.  Using  BδAST 
software an alignment using the DNase hypersensitivity site sequences and putative 
topo  IIȕ cleavage site sequences was performed. BLAST primer design software was 
then used to generate primer sequences that included the DNase hypersensitivity 
sequence and putative topo IIȕ cleavage site sequence within their product. 
 
 
The UCSC genome browser, a database that collates genomic sequence data from 
vertebrate and invertebrate species including cell lines was used to examine the TNFα 
and IL-1ȕ genes  (Step  1,  Figure  θ.1). A  feature  of  the UCSC genome browser  is  the 
extensive range of tools to examine functional elements of the genome; including 
Use UCSC genome browser to determine DNase hypersensitivity sites within the gene 
Determine putative topo II cleavage sites using literature search (Figure 6.2) 
Use BLAST software to determine if putative topo II cleavage sites are 
found within the DNase hypersensitivity sites (Tables 6.1 and 6.2) 
Use DNase I hypersensitivity sequences that contain putative topo II cleavage 
sites to generate primers (using BLAST primer design software) 
196 
 
regions of methylation, CpG islands and DNase hypersensitivity sites, as determined by 
the public research project, ENCODE (Encylopedia of DNA Elements). This then 
enabled the identification of DNase hypersensitivity sites within the vicinity of the 
TNFα and Iδ-1ȕ promoter regions (Table. θ.1 and Table θ.β respectively). 
Once DNase hypersensitivity sites had been identified, a literature search was 
performed to identify any published topo IIȕ cleavage sites within these hypersensitivity 
regions. Previously studies using topo II poisons have shown that topo II preferably 
cleaves certain short sequences of DNA, however the sequences appear to differ 
depending on the poison used (Pommier et al., 1991; Marsh et al., 1996; Gao et al., 
2003). Data on putative topo II cleavage sites was collated (Figure 6.2) and revealed 
that there was a short sequence that was recurrent in multiple studies using different 
poisons; AGCT (Pommier et al., 1992; Cornarotti et al., 1996; Marsh et al., 1996). 
Using the nucleotide alignment tool in the NCBI blast software (blastn) the sequences 
of the DNase hypersensitivity sites previously identified were then aligned against this 
putative topo IIȕ cleavage site. The sites identified are highlighted in red in Table 6.1 
and θ.β. Only hypersensitivity sites that contained a putative topo IIȕ cleavage site were 
considered suitable targets to be used in the design of primers for qPCR. 
NCBI blast primer design software (Primer-blast) was used to generate primers. Primers 
were  designed  to  either  contain  the  putative  topo  IIȕ  cleavage site within the primer 
sequence or within the product. Primers were chosen that would generate products 
between 100-200bp in length, to ensure specificity. 
In  addition  to  primers  that  were  generated  to  include  sequences  that  topo  IIȕ  may 
associate to, primers were also designed that did not contain areas of DNase 
hypersensitivity  and putative  topo  IIȕ   cleavage sites, and were actually very close to 
the end of the TNFα and Iδ-1ȕ genes. These primers were designed as a control (Table 
6.3). 
Primer sequences generated for qPCR with TNFα and Iδ-1ȕ as the target are shown in 
Tables 6.1 and 6.2 respectively. 
  
Table 6.1 Location and sequences of DNase hypersensitivity regions within the IL-1ȕ gene. 
Locations of DNase hypersensitivity regions in the IL-1ȕ gene used to generate primers are reported in this table. DNase hypersensitivity sequences 
along with putative topo IIȕ cleavage sites (shown in red) are also reported. Additionally primer sequences generated as described in Figure 6.1 are 
also documented. Sequence identity will be used to describe the primers used when discussed in the text. 
Sequence 
ID 
DNase 
hypersensitivity 
site location 
DNase hypersensitivity sequence including putative topo IIȕ cleavage site Forward 
primer 
sequence 
Reverse 
primer 
sequence 
IL-1ȕ -1 Chromosome 2 
113,587,541 -
113,587,935bp 
TTGAATAAATTAGACCAATGAATAAAACAAACAAACAAATAAATAAATAAATAGGGAAGCG
GTTGCTCATCAGAATGTGGGAGCGAATGACAGAGGGTTTCTTAGAACCAAATGTGGCCGGTT
TCTGTCAGGCGGGCTTTAAGTGAGTAGGAGAGGTGAGAGAGGCCTGGCTCAACAAAAGGGC
TGGGGATTGGCCCTGAAAGGAGAGAGCTGACTGTCCTGGCTGATGGACAGGAGATCCTCTTA
GCACTACCCTAAGGCAGGCAGTTGGGCATTGGTGTAGACAACAGGAAAGTCCAGGCTATAGC
CGTACTCAAAAACTTTCTGTTCCCTTCTGCCAGCCCTAGGGATTGAGTCCACATTCAGCACAG
GACTCTCTGGGTACAGCTCTCTTTAGGAAGACACAAATTGCATGGTGAAGATCAGTTATATCC
TGGCCGCCTTTGGTCCCTCCCAGGAAGACGGGCATGTTTTCTGCTTGAGAGGTGCTGATGTAC
CAGTTGGGGA 
TTACTT
GGCACC
CTGTTT
GC 
ATTAC
AGGTC
AGTGG
AGACG
C 
IL-1ȕ -2 Chromosome 2  
113,589,441 -                 
113, 590,175bp 
AACTGGGAGAGGAGAGGCTGAGCTGGGAAAGTGGCTCCAAAGAGAGACACTCATTTTGATC
TTCCTCAGTCACAGCAGTGTCAATTGGAGGCCCTGGGATCACTCTTACTACCCGATTCCAAAG
AAACAGGATTTTCTTGGCCTGGCTGAGAGCAAATAGCTTCCCCCTGAGTGAGGCTGTCCTTCA
AAGTCAGCAGCCTTAGTTGCCCACACTCCTGTGCAGAGGCTTTGGCTACTGTGGCACGATGCC
AGGCAGATCACCACAGCTATGATGGGTCACCGCACTTGAAACTTTTGCCCGTTACAGCGGAG
AGATATAAGTTCCTGCTGGGCGGTAAAATTTCCCTACAAGGAACCACCTGGCATTGGGTGGG
ACGGATGTTGGGGCAAGGGGGGAAGACTGGGGAGGGGGATGGACACATTATCGCTCCAGCA
CTCTTGTTTCAGCCTCAACAACAGGAAGAGAGAACCCACAGGCAGTTAGGCCATGTCCATCA
AATGACCCCATATTGTGGAAGAATTGACATTGCACTATGCCCAAGAGACTTGGGTGGACATG
GTCCTGGGAGTGCTTGAGCCGTCTAATTTCTCAGGGTCAC 
AGCTAT
GATGG
GTTCAC
CGC 
AAACA
AGAGT
GCTGG
AGCGA 
IL-1ȕ -3 Chromosome 2 
113,590,981 -
113,591,370bp 
TCAGGTCATTCTCCTGGAAGGTCTGTGGGCAGGGAACCAGCATCTTCCTCAGCTTGTCCATGG
CCACAACAACTGACGCGGCCTGCCTGAAGCCCTTGCTGTAGTGGTGGTCGGAGATTCGTAGC
TGGATGCCGCCATCCAGAGGGCAGAGGTCCAGGTCCTGGAAGGAGCACTGCGGAGAGAGCG
AGGGAGGGAGCCTGGTGAGGTGGTCCTGCCAGGAACCATGCTTTGACATCAGAGAGTAGAA
AGCTCAGAGAGGAGGAAAGGGCTTGAAAGAATCCCGAGCTTCTAAAGATCATCC 
TCTGTT
CCCTTT
CTGCCA
GC 
AGCAG
AAACA
TGCCC
GTCT 
  
Table 6.β Location and sequences of DNase hypersensitivity regions within the TNFα gene.  
Locations of DNase hypersensitivity regions in the TNFα gene used to generate primers are reported in this table. DNase hypersensitivity sequences 
along with putative topo IIȕ cleavage sites (shown in red) are also reported. Additionally primer sequences generated as described in Figure 6.1 are 
also documented. Sequence identity will be used to describe the primers used when discussed in the text. 
 
Sequence 
ID 
DNase 
hypersensitivity 
site location 
DNase hypersensitivity sequence including putative topo IIȕ cleavage site Forward 
primer 
sequence 
Reverse 
primer 
sequence 
TNFα -1 Chromosome 6 
31,543,241-
31,543,390bp 
AAGGTGCAGGGCCCACTACCGCTTCCTCCAGATGAGCTCATGGGTTTCTCCACCAAGGAA
GTTTTCCGCTGGTTGAATGATTCTTTCCCCGCCCTCCTCTCGCCCCAGGGACATATAAAGG
CAGTTGTTGGCACACCCCAGCCAGCAGACGTCCCTCAGCAAGGACAGCAGAGGACCAGCT
AAGAGGGAGAGAAGCAACTACAGACCCCCCCTGAAAACAACCCTCAGACGCCACATCCC
C 
TGGGTT
TCTCCA
CCAAG
GAAG 
ATGTGG
CGTCTG
AGGGTT
G 
TNFα -2 Chromosome 6 
31,544,221 – 
31,544,370bp 
CAGGGAAAGAGCTGTTGAATGCCTGGAAGGTGAATACACAGATGAATGGAGAGAGAAAA
CCAGACACCTCAGGGCTAAGAGCGCAGGCCAGACAGGCAGCCAGCCAGCTGTTCCTCCTT
TAAGGGTGACTCCCCGATGTTAACCATTCTCCTTCTCCCCAACAGTTCCCCAGGGACCTCT
CTCTAATCAGCCCTCTGGCCCAGGCAGTCAGTAAGTGTCTCCAAACCTCTTTCCTAATTCT
GGGTTTGGGTTTG 
AGCTGT
TGAATG
CCTGGA
AGG 
GCCAGA
GGGCTG
ATTAGA
GAG 
TNFα -3 Chromosome 6 
31,543,068 –
31,543,302bp 
CAGTCAGTGGCCCAGAAGACCCCCCTCGGAATCGGAGCAGGGAGGATGGGGAGTGTGAG
GGGTATCCTTGATGCTTGTGTGTCCCCAACTTTCCAAATCCCCGCCCCCGCGATGGAGAAG
AAACCGAGACAGAAGGTGCAGGGCCCACTACCGCTTCCTCCAGATGAGCTCATGGGTTTC
TCCACCAAGGAAGGTTTTCCGCTGGTTGAATGATTCTTTCCCCGCCCTCCTCTC 
TTGATG
CTTGTG
TGTCCC
CA 
AACCAG
CGGAAA
ACCTTC
CT 
 
 
 
 
 
 
  
Table 6.3 Primer sequences for controls when investigating the IL-1ȕ and TNFα genes. 
Primers were generated using BLAST primer design software. They were designed against areas of the IL-1ȕ and TNFα genes that contain no DNase 
hypersensitivity sites, are non-coding (as determined by ENCODE data) and contain no topo IIȕ putative cleavage sites. Sequence identity will be used 
to describe the primers used when discussed in the text. 
 
Sequence Identification Forward Primer Reverse Primer 
IL-1ȕ control TTACTTGGCACCCTGTTTGC ATTACAGGTCAGTGGAGACGC 
TNFα control TGGGATCATTGCCCTGTGAG GGTGTCTGAAGGAGGGGGTA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 -5 -4 -3 -2 -1 +1 +2 +3 +4 +5 
VM-26 A Not T A A C A G/T C A/T G 
m-AMSA T G A A T A G C T A 
native C G A A C/T A A/G A/C T A 
 -5 -4 -3 -2 -1 +1 +2 +3 +4 +5 
VM-26 - - A/T - C T - - - - 
dn-EPI - - - - A A - - T T 
native C G A - C - - - - - 
 -5 -4 -3 -2 -1 +1 +2 +3 +4 +5 
pBR322 C - G - C A G C T G 
SV40  - G A - - A G C - - 
 -5 -4 -3 -2 -1 +1 +2 +3 +4 +5 
Common 
sequence 
C G A A C A G C T A/G 
(a) 
(b) 
(c) 
(d) 
Figure 6.2 Tables containing published data on putative topoisomerase II cleavage sites.  
(a) Pommier et al. (1991) used topoisomerase II extracted from the cell nuclei of the mouse leukemic cell line, L1210, they utilised SV40 DNA to identify 
putative topo II cleavage sites in the presence of tenoposide (VM-26), m-AMSA and no drug. (b) Cornarotti et al. (1996) used recombinant human topo IIȕ 
along with SV40 DNA in the presence of VM-26, doxorubicin derivative, dh-EPI and no drug to identify putative topo IIȕ cleavage sites. (c) Marsh et al. 
(1λλθ) used recombinant topo IIȕ along with HindIII-ECO-RI fragment, pBR322 and SVζ0 DNA to identify putative topo IIȕ cleavage sites in the presence 
of m-AMSA. (d) data from (a-c) was collated to determine the most common base pairs found at topo IIȕ cleavage sites. (+) and (-) represent the position of 
the base pair in respect of the topo II cleavage site, (+) being down stream and (-) being up stream of the cleavage site.  
  
6.4 Optimisation of sonication step for ChIP 
Sonication is the process in which ultrasound causes the production of small gaseous 
cavities (bubbles) within a sample. Continuous irradiation with ultrasound causes 
oscillation of the bubble causing their collapse which releases energy that is strong 
enough to induce shearing of DNA within a biological sample. Continuous sonication 
would eventually lead to shearing of the DNA into fragments less than 100 bp. 
However, the size of the fragments required for ChIP need to be between 100-500 bp. 
Therefore it was necessary to optimise the sonication conditions to ensure that the DNA 
fragments were within this size range (Figure 6.3). As sonication causes foaming and 
heating of samples it was performed in cycles of 15 second bursts, with the point of the 
sonicator held above the bottom of the microfuge tube containing the sample. The 
sample was also submerged in ice when sonication took place, and between cycles. 
These steps were employed to reduce protein and DNA degradation caused by 
excessive heat production. 
 
                          
                                     
 
 
 
 
 
 
 
 
 
 
Figure 6.3 Determining the amount of sonication cycles to generate the correct size of 
DNA fragments. 
Samples were prepared as described in materials and methods (Section 2.19). After addition 
of nuclear lysis buffer and protease inhibitors, sonication of the sample was performed. The 
samples were split into 5 tubes each in order to perform a different amount of sonication 
samples on each (0, 5, 7, 9 and 11 cycles). Each sonication step was performed at 25% for 
15 s on ice. Samples were then loaded on a 2% agarose gel and ran for 2 h at 75 V. Lane 1 
contains a sample that has undergone 0 cycles of sonication; Lane 2, 5 cycles of sonication,; 
Lane 3, 7 cycles of sonication; Lane 4, 9 cycles of sonication; Lane 5, 11 cycles of 
sonication; Lane 6 contains the 1kB ladder. 
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The smearing in lanes Figure 6.3 show the spread of different sizes of DNA fragments 
obtained using different numbers of cycles of sonication. The middle and most intense 
part of the smear shows at what size the majority of the DNA fragment are in the 
sample is at. In lane 1, there is a clear band at the top of the gel. This sample had not 
undergone any cycles of sonication, therefore the DNA remained intact as demonstrated 
by its size and lack of motility down the lane. The sample in lane 2 has undergone 5 
cycles of sonication and it appears the majority of the DNA is approximately 300-
700bp. Lane 2 and 4 contain samples that have undergone 7 and 9 cycles of sonication 
respectively. The majority of DNA is between 200-600bp.The sample in lane 5 has 
undergone 11 cycles of sonication, it appears the majority of DNA is under 500bp, with 
some being below 100bp in size. It was decided that 7 cycles of sonication would be 
sufficient in order to generate DNA between 150 and 500bps. 
 
6.5 Analysis of ChIP-qPCR data.  
The complete ChIP procedure can be found in materials and methods (Section 2.19) 
Immuno-precipitations from non-LPS/PMA and LPS/PMA treated U937 cells were 
performed  using  antibodies  to  topo  IIȕ    (target),  green  fluorescent  protein  (negative 
control) and Acetylated histone 3 (positive control). Green Fluorescent protein (GFP) 
was used as the negative control as the mammalian genome does not contain the GFP 
gene and so therefore cannot synthesise the protein. GFP was originally isolated from 
the jellyfish Aequarae victoria and is often used in molecular biology as a reporter 
protein. Therefore when using the GFP antibody no protein should be immune-
precipitated and thus no DNA should be in these samples. Acetylated histone 3 was 
used as the positive control as it is widely published commercially advertised to 
associate with the GAPDH gene (Calcagno et al., 2008; To et al., 2008).  
Data from the ChIP-qPCR has to be normalised for sources of variability between 
samples, including the amount of chromatin. This was carried out using the percent 
input method. With this method the signals obtained from the ChIP experiment are 
divided by signals obtained from an input sample. The input sample did not undergo 
any immune-precipitation and was diluted so that it represented 5% of the chromatin in 
samples that did undergo immune-precipitation. Analysis of the qPCR data is 
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represented as percentage of input, the calculation used to determine this is outlined in 
Figure 6.4. 
 
Figure 6.4 Calculating percentage of input using qPCR data. 
In log phase qPCR, the amount of DNA doubles with each cycle. This can be 
represented as 2Ct value, for example 3 cycles of PCR = 2 x 2 x 2 = 23. To calculate the 
ratio of input to sample, the input Ct value can be subtracted from the sample Ct value 
as 2(Sample Ct – Input Ct) is the same as 2(Sample Ct)/2(Input Ct). However before this step, the 
input ct value needs to adjusted for dilution. The chromatin contained in the input 
sample is equal to 5% of the chromatin in the samples that have undergone IP. 
Therefore the dilution factor is 20 (20 x 5% = 100%). As the calculations are based on 
Ct values, the dilution fold requires to be converted into Ct cycles. This is achieved by 
using Log2 (as 1 ct = 2 fold difference) of the dilution fold. Dividing the resulting 
number into 100 gives the quantity of DNA fragments amplified in non-INPUT samples 
as a percentage of DNA fragments amplified in INPUT samples. 
 
 
 
100 
% INPUT     =                                       
                                   
2
[SAMPLE Ct – (INPUT Ct – Log
2
INPUT dilution fold)]
 
  
                         
Figure 6.5 Determining if topo IIβ association increases at sites promximal to the promoter region of the IL-1ȕ gene when cells are PMA treated cells are 
stimulated with LPS. 
Cells were seeded at a cell density of 3 x105 cells/ml with 5 ng/ml PMA with and without 1 ng/ml LPS and allowed to incubate for 72 h before being harvested. Cells 
were fixed and ChIP was performed as described in material and methods (Section 2.19) Immuno-precipitations used in the ChIP utilised antibodies to topo IIȕ  
(target), Green fluorescent protein (negative control) and Acetylated histone 3 (positive control). qPCR was then performed using primers documented in Table 6.1, IL-
1ȕ-1 (a), IL-1ȕ-2 (b), IL-1ȕ 3 (c) and 6.3, IL-1ȕ control (d). A primer generated to GAPDH was used in the qPCR of the positive AcH3 control. Results are reported as 
percentage of input (no IP performed on this sample).  The means of three independent experiments are shown ± standard errors.  
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6.6. Association of topo IIȕ at regions of the IL-1ȕ gene  
Four primer pairs (Table 6.1 and 6.3) designed to amplify different regions of the IL-1ȕ 
gene were used in the qPCR reaction following ChIP with non-LPS and LPS treated 
samples. These primer pairs were used in the qPCR for the GFP sample (that should 
have no DNA). In addition, primers used to amplify GAPDH were used as a positive 
control, as AcH3 is known to associate highly with this gene (Calcagno et al., 2008; To 
et al., 2008). The results of the qPCR reaction are shown in Figure 6.5.  
Figure 6.5a shows the results from the qPCR experiment using the IL-1ȕ -1 primer pair 
(Table 6.1). There is no significant difference in topo IIȕ association between the non-
LPS treated samples and the LPS treated samples when using this primer pair. 
Additionally there is no significant difference between levels of topo IIȕ association and 
levels of GFP association (negative control), thus suggesting there is little or no 
detectable topo IIȕ associating at the region of the Iδ-1ȕ gene, the Iδ-1ȕ -1 primers are 
designed to amplify. 
Figure 6.5b shows the results collated from the qPCR experiment using the IL-1ȕ  -2 
primers (Table 6.1). The non – LPS treated samples appear to have a slightly higher 
topo  IIȕ  occupancy  than  the  δPS  treated  samples.  Similarly,  Figure  θ.ηc  shows  the 
results collated from the qPCR experiment using the IL-1ȕ -3 primers (Table 6.1) again 
revealing that non – LPS treated cells appear to have a slightly higher  topo  IIȕ 
occupancy than their LPS treated counterparts. However the results are not significantly 
different from the respective GFP negative controls or the AcH3 positive controls (see 
Appendix C). Thus suggesting there is little topo IIȕ associated at the region of the Iδ-
1ȕ gene that the Iδ-1ȕ -2 and IL-1ȕ -3 primers are designed to amplify. 
Results collated in Figure 6.5d show the data collated from the qPCR experiment using 
the IL-1ȕ – control primers (Table 6.3) There is a small increase in topo IIȕ association 
in non-LPS treated samples compared to LPS treated samples. However the results are 
not significantly different to the negative control (see Appendix C). This would suggest 
that topo IIȕ does not associate at the region of the Iδ-1ȕ gene that the Iδ-1ȕ -control 
primers are designed to amplify. This result is as expected as these control primers were 
designed to amplify regions which did not contain a DNase hypersensitivity or a 
putative  topo  IIȕ  binding  site  and  was  located  downstream  of  the  promoter  region 
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within the gene. This result is in agreement with Tiwari et al. (2012) showed that topo 
IIȕ preferentially targets promoter regions of genes rather than exons or introns. 
  
                             
Figure 6.6 Determining if topo IIȕ association increases at sites proximal and within the promoter region of the TNFα gene when PMA treated cells 
are stimulated with LPS. 
Cells were seeded at a cell density of 3 x105 cells/ml with 5 ng/ml PMA with and without 1ng/ml LPS and allowed to incubate for 72 h before being 
harvested. Cells were fixed and ChIP was performed as described in material and methods (Section 2.19) Immunoprecipitations used in the ChIP utilised 
antibodies to topo IIȕ (target), Green fluorescent protein (negative control) and Acetylated histone 3 (positive control). qPCR was then performed using 
primers documented in table 6.1, TNFα-1 (a), TNFα-2 (b), TNFα -3 (c) and 6.3, TNFα control (d). A primer generated to GAPDH was used in the qPCR of 
the positive AcH3 control. Results are reported as percentage of input (no IP performed on this sample).  The means of three independent experiments are 
shown +/- standard errors.  
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6.7 Association of topo IIȕ at regions of the TNFα gene  
Four primer pairs (Table θ.β and θ.γ) designed to amplify different regions of the TNFα 
gene were used in the qPCR reaction following ChIP with non-LPS and LPS treated 
samples. Again as previously described yhese primer pairs will also be used in the 
qPCR for the GFP sample (that should have no DNA). In addition, primers used to 
amplify GAPDH were used as a positive control, as AcH3 is known to associate highly 
with this gene (Calcagno et al, 2008; To et al, 2008). The results of the qPCR reaction 
are shown in Figure 6.6.  
Figure  θ.ηa  shows  the  results  collated  from  the  qPCR  experiment  using  the  TNFα-1 
primers (Table 6.2). The non – LPS samples treated appear to have a slightly higher 
topo  IIȕ  occupancy  than  the δPS  treated  samples.  Similarly,  Figures  θ.6b and Figure 
6.6c using  TNFα-β  and  TNFα-3 primers, (Table 6.2) shows that non – LPS samples 
treated appear to have slightly higher  topo  IIȕ occupancies than the respective LPS 
treated samples. The results in Figure 6.6 show a slight up-regulation  of  topo  IIȕ 
association at various sites of the TNFα gene in non-LPS stimulated cells compared to 
LPS stimulated cells. However these results are not significantly different from their 
respective GFP negative controls and AcH3 positive controls (see Appendix C). Thus 
suggesting  there  is  little  topo  IIȕ  associated  at  the  region  of  the  TNFα  gene  that  the 
TNFα-1, TNFα-β and TNFα-3 primers are designed to amplify. 
Interestingly the primer pair  that showed the most amount of topo IIȕ association was 
TNFα-control. Using this primer pair, although again not significantly different there 
was  an  increase  in  topo  IIȕ  association  in  non-LPS and LPS treated samples when 
compared to their respective negative controls. The primers used to amplify product in 
this data set (Figure 6.6d) were designed so that their product did not contain any 
DNase hypersensitivity sites or putative topo IIȕ binding sites. They were also designed 
to amplify a sequence downstream  of  the  promoter  region  of  the  TNFα  gene.  These 
results are in disagreement with Tiwari et al., (β01β)  who  showed  that  topo  IIȕ 
preferentially binds to promoter regions rather than exon or intronic regions. The 
increase in topo IIȕ association in δPS treated cells at this region compared to the other 
sites within the TNFα gene may be reflective of a re-localisation of topo IIȕ upon δPS 
stimulation, from a region of high transcriptional activity to that of relatively low 
transcriptional activity. Zwelling et al. (1988) suggest that PMA treatment may cause a 
re-localisation of topo IIȕ, whilst Cowell et al. (2011) show that treatment of cells with 
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the HDAC inhibitor, TSA causes re-localisation  of  topo  IIȕ  from  heterochromatin  to 
euchromatin.  
 
6.8 Discussion of results generated by ChIP-qPCR 
The innate immune response is the first line of defence against infection; therefore its 
actions must occur quickly. Both Il-1ȕ and TNFα are synthesised in inactive forms and 
must be cleaved by the proteases caspase 1 and TNFα converting enzyme  (TACE)  in 
order to be secreted. Therefore basal transcription of the IL-1ȕ  gene  and TNFα must 
occur in un-stimulated cells (Mauviel et al., 1988; Collart et al., 1990). Topo II has also 
been shown to associate with promoter regions (Tiwari et al., 2012), thus suggesting 
that as well as playing an active role in recruitment of transcription factors (Ju et al., 
2006) it may also play a role in the maintenance of an open chromatin state. It may be 
suggested again, that if topo IIȕ is acting on the Il-1ȕ and TNFα genes in non-stimulated 
cells,  it may  be  doing  so  to maintain  an  ‘open’  chromatin  structure  possibly  through 
interaction with other chromatin modifying proteins, and thus facilitating a rapid 
transcriptional response. Topo IIȕ  has  previously  been  shown  to  play  a  role  in  the 
modification of chromatin architecture; it has been shown to associate with HDAC, a 
protein involved in chromatin condensation; this association is suggested as mechanism 
by which topo IIȕ represses gene expression (McNamara et al., 2008). In addition topo 
IIα  has  been  shown  to  prime  developmental  genes  for  activation  upon  differentiation 
(Thakurela et al., 2013), it is possible that both isoforms are involved in changes in 
chromatin architecture. 
Results from Figure 5.18 and 5.19 suggest that a down-regulation of topo IIȕ with 150 
nM ICRF-193 has little effect on mRNA expression of IL-1ȕ  in  response  to  δPS, 
however it did significantly decrease the amount of IL-1ȕ protein secreted in response 
to LPS stimulation. However, it is suggested that treatment with 150 nM ICRF-193 may 
have caused a transient down-regulation of IL-1ȕ  mRNA  expression  at  an  earlier 
unobserved time-point and that the down regulation in protein secretion seen remained 
as a consequence of this (RNA extractions and removal of supernatant containing IL-1ȕ 
occurred at the same time). Il-1ȕ  transcription  occurs  rapidly  in  response  to  δPS 
(Suzuki et al., 2000), however a prolonged exposure to LPS has been shown to result in 
the down-regulation of IL-1ȕ mRNA expression  (Schilling  et al., 2001). Indeed a 72 
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hour exposure to LPS may be considered a chronic exposure, therefore a normal down-
regulation of IL-1ȕ  gene  expression may  be  occurring.  If  topo  IIȕ  is  involved  in  the 
activation of IL-1ȕ  transcription  in  response  to δPS,  then association of  topo  IIȕ with 
the IL-1ȕ gene would decrease along with a decline in requirement for transcription. In 
addition  the  results  from  Figure  θ.ηb  and  Figure  θ.ηc  together  suggest  that  topo  IIȕ 
associates with multiple parts of the IL-1ȕ  gene,  possibly  playing  different  roles  at 
different regions. 
Fig 6.6 a-c shows a general trend of reduced topo IIȕ occupancy in response to LPS. 
This is interesting as it may indicate that topo IIȕ is acting to repress TNFα transcription 
in the absence of TNFa and upon addition of LPS this repression is relieved. Previously, 
an  increase  in  TNFα mRNA  expression  has  been  shown  to  occur  in  reponse  to  δPS 
previously (Suzuki et al., 2000).  Although not significant, results in Figure 5.16 and 
η.17 showed an upward trend in TNFα mRNA expression in response to 1η0 nε ICRF-
193 more than that seen in response to PMA and LPS alone. This trend was also seen 
when cells were exposed to 1 nM ICRF-193 for 6 h prior to differentiation (Figure 
5.11). Again, it was suggested that this may be due to release of negative regulation of 
transcription  by  topo  IIȕ  inhibition  by  ICRF-193. However further analysis would be 
required to verify this. 
One caveat to the data presented in this Chapter was the high signal obtained for the 
GFP control. Although the human genome does contain the GFP gene, and thus no GFP 
protein, a low signal output is seen in these experiments. This is not unusual and 
represents background noise from the experiments (Cowell et al., 2012). However, 
average background signal in some of these experiments represents ~5% of input. This 
was thought to be as a result of prolonged exposure to primary antibody (see Material 
and Methods 2.19). 
In addition, an up-regulation of AcH3 association with GAPDH when cells are treated 
with LPS is also seen all experiments, thus suggesting an up-regulation of GAPDH gene 
expression. Xie et al. (2006) report that LPS induces an up-regulation of GAPDH 
mRNA expression in rat liver and lungs, and that this up-regulation may be important in 
the signalling pathway of LPS induced apoptosis. It is also suggested that GAPDH is 
not a suitable internal control for gene expression assays. Indeed it may be sensible to 
suggest that the down-regulation in  topo IIȕ association with regions of the IL-1ȕ and 
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TNFα genes seen when cells are treated with δPS may be a result of apoptosis induced 
by chronic LPS exposure.  
The results in this chapter most likely reflect the fleeting and transient nature of topo II 
activity; Ding et al. (2013) reported that the catalytic cycle of topo II took 0.84 s to 
complete. Previous ChIP work investigating topo IIȕ associations has utilised the topo 
II poison, etoposide to form a topo II –DNA complex in place of traditional cross-
linking by formaldehyde (Sano et al., 2008; Cowell et al., 2012). Traditional cross-
linking with formaldehyde acts by cross-linking all proteins with DNA at that particular 
moment of when it is added; in contrast etoposide is added to the cell culture for up to 
an hour, thus increasing the chances of forming topo II-DNA complexes, inevitably 
yielding better results.  Furthermore, this experiment investigated only one time point of 
LPS stimulation. Previous work has demonstrated that prolonged exposure to LPS 
results in a down-regulation of TNFα and Iδ-1ȕ gene expression (Schilling et al., 2001), 
taken together with previous work that suggests topo IIȕ is required at different stages 
of development (Lyu et al., 2006) future work using ChIP would investigate various 
time points of LPS stimulation, along with utilisation of topo II poisons. 
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Chapter 7 
Conclusions and Future Work 
 
7.1 Comparative Quantification of topo IIα and topoIIȕ in non-PMA and PMA 
treated cells 
The initial aim of this project was to determine  if  topo  IIȕ  was  required  for  the 
differentiation of monocytes into macrophages. Indeed previous work has shown that 
topo IIȕ is required for neuronal differentiation (δyu et al., 2006), it is so important in 
fact,  that  topo  IIȕ  knockout  embryos  are non-viable due to defects in neuronal 
development (Yang et al., β000). Studies have also shown that requirement of topo IIȕ 
for neuronal differentiation correlates with an increase in its expression (Tiwari et al., 
2012). 
Comparative quantification of topo  IIȕ  in  non-PMA (monocytes) and PMA treated 
(macrophage) HL-60 and U937 cells by Western Blot and q-RT-PCR revealed a 
decrease in topo IIȕ mRNA and protein expression when cells were differentiated with 
PMA (Figure 4.3 & 4.4). In addition this result was also reflected in primary monocytes 
differentiated with M-CSF compared to non-MCSF treated cells that also displayed a 
decrease  in  topo  IIȕ  mRNA  expression (Figure 4.10). This result is in disagreement 
with McNamara et al. (2010) who showed an increase in topo IIȕ protein expression in 
PMA treated NIH-3TC cells. However not only was a different cell line used but 
exposure of cells to PMA was for 2 h in comparison to the 72 h used in the experiments 
in this project. It may also suggest that levels of topo IIȕ change can either increase or 
decrease in a time-dependent manner during differentiation with PMA.  
Additionally comparative quantification of topo IIα in non-PMA and PMA treated HL-
60 and U937 cells revealed a down regulation of protein and mRNA expression of topo 
IIα when cells were treated with PεA (Figures 4.3, 4.4, 4.12 & 4.13). Indeed this down 
regulation has been attributed to the effects of cell cycle arrest induced by PMA that has 
previously been shown to result in a down-regulation topo IIα (Woessner et al., 1991). 
Furthermore a comparison of topo IIα and topo IIȕ mRNA levels revealed that relative 
levels of mRNA were similar in non-PMA treated cells, however in PMA treated cells 
topo IIȕ mRNA levels were significantly higher (Figure 4.7). This suggests that topo IIȕ 
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is the preferential isoform in PMA treated cells, and may reflect its importance in 
differentiated cells.  
It  would  be  interesting  to  quantify  topo  IIȕ  protein  and  message  expression  after 
varying lengths of exposure to PMA, not only in the aforementioned cell lines but in 
other PMA responsive cells such as the monocytic cell line THP-1. It may also be 
sensible to suggest that absolute quantification of topo IIα and topo IIȕ protein levels by 
the method described by Padget et al. (2000) be employed to determine the most 
abundant isoform after different exposure times of PMA. Furthermore it would also be 
useful to determine the phosphorylation state of topo IIȕ upon different exposure times 
of PMA; McNamara et al. (2010) postulate that an  increase  in  topo  IIȕ protein  levels 
upon 2 h of PεA treatment is mediated by an increase in PKCį phosphorylation of topo 
IIȕ. Phosphorylation of  topo  IIȕ may be analysed by western blotting using phospho-
specific antibodies or by ELISA. It would also be interesting to use a kinase activity 
assay to determine the kinase responsible for the (possible) phosphorylation of topo IIȕ 
at different times of PMA exposure. Aoyama et al. (1998) report that there was no 
change in the catalytic activity of topo IIȕ when HL-60 cells were treated with ATRA, 
however Plo et al. (β00β)  demonstrate  that  an  overexpression  of  PKCȗ  results  in  the 
phosphorylation of topo IIȕ and subsequent decrease in its catalytic activity. Therefore 
it may be useful to investigate the catalytic activity  of  topo  IIȕ  at  varying  exposure 
times of PMA by use of a de-catenation assay. Additionally research using primary 
monocytes would be advantageous; however successfully isolating enough CD14+ cells 
from PBMC samples, together with the invasive nature of obtaining whole blood 
samples makes it difficult to complete extensive studies. Such studies would lead to a 
clearer understanding of the fluctuation of topo IIȕ message and protein levels over time 
in  the  process  of  differentiation,  as  well  as  it’s phosphorylation status and catalytic 
activity. 
As the results appear to refute the hypothesis that topo IIȕ is required for differentiation 
with regards to a reduction in the expression of topo IIȕ in PεA treated cells compared 
to non-PMA treated cells; and as subsequent experiments in this thesis use PMA and 
LPS together to differentiate and stimulate cells, it would also be useful to examine the 
effect of treatment with PMA and LPS on topo IIȕ mRNA, protein and phosphorylation 
levels in addition to its catalytic activity. Stimulation of cells with LPS also leads to the 
up-regulation of expression of many genes encoding for proteins involved in the 
inflammatory response, for example cytokines such as TNFα and Iδ-1ȕ (Suzuki et al., 
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2000). Therefore it would be  interesting  to determine whether  topo  IIȕ  is  involved  in 
the up-regulation of transcription of such genes in response to LPS stimuli alone. It may 
also be interesting to use other biologically relevant molecules to stimulate cytokine 
expression, for example  TNFα  or  a  combination  of  IFNȖ and LPS. This would then 
establish  if  topo  IIȕ  acts  to  mediate  the  transcription  of  factors  involved  in  various 
pathways of signalling in response to different stimuli (Lin et al., 1995; Paulnock et al., 
2000). 
 
7.2 The effect of PMA treatment on the cytotoxicity of the topo II poison, VP-16 
and and the inhibitor, ICRF-193. 
The decrease  in  topo  IIα  and ȕ  protein  expression  in PεA  treated  cells  compared  to 
non-PMA treated cells lead to the investigation of the effect this had on the cytotoxicity 
of the topo II poison, VP-16 and the topo II inhibitor, ICRF-193. The XTT assay, an 
assay that measures cell viability was used to measure the proportion of cells that 
remained viable after treatment with the drugs, thus measuring the cytotoxic effects of 
these drugs. The results showed that cells treated with PMA prior to drug exposure were 
protected from the cytotoxic actions of VP-16 and ICRF-193 (Figure 4.14, 4.15, 4.17 & 
4.18). The mechanism by which they are protected from the cytotoxic effects of these 
drugs is thought to be multi-variable. But the first main factor is the decrease in the 
amount of topo IIα and ȕ protein in the cells. Down-regulation of the expression of topo 
II has been shown to render cells less sensitive to drugs which stabilise the topo II 
cleavable complexes. In some cell lines selected for resistance to anti topo II drugs, the 
levels of topo IIα have been shown to be reduced (Webb et al., 1991 & Eijdems  et al., 
1λλβ). In addition, levels of topo IIȕ rather than topo IIα have been found to serve as a 
marker for drug resistance in some cell lines (Brown et al., 1995 & Dereuddre et al., 
1997). Consequently, alterations in the relative amounts of the two isoforms could result 
in or contribute to resistance. The result corroborates the previous finding that both topo 
IIα and ȕ protein are decreased following 72 h exposure to PMA (Figure 4.12 & 4.13), 
thus decreasing the amount of target for the drugs to exert their effects. VP-16 and 
ICRF-193 preferentially target  topoIIα  and  ȕ,  respectively  and  as  both  isoform  are 
reduced in PMA treated cells then protection against both of these drugs would be 
expected and was indeed shown to be the case. 
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In addition it is proposed that the cell cycle block induced by PMA may decrease the 
amount of DNA damage caused by the drugs, via the collateral damage model. Previous 
studies have shown that VP-16 requires processing of cleavable complexes by the 
replication or transcription machinery to expose the induced double strand breaks (Li & 
Lui., 2001; Guo et al., 2007). ICRF-193 in comparison requires progression through 
mitosis to induce DNA damage via accumulation of multiploid cells due to inhibition of 
chromosome segregation. It is also proposed by Zwelling et al. (1988) that PMA 
induced VP-16 resistance may be due to PMA induced re-localisation of topo II in the 
nucleus to areas less susceptible to topo II interaction or to areas not associated with 
DNA. They could also not rule out the possibility of chromatin compaction preventing 
the formation of drug-stabilised cleavable complexes in the cells.  
It would be interesting to investigate whether treatment with PMA causes a sub-cellular 
redistribution  of  topo  IIȕ by employing immunofluorescence microscopy to compare 
the sub-cellular  localisation  of  topo  IIȕ  in  non-PMA and PMA treated cells.  Future 
work may also involve the measurement of cleavable complexes using the TARDIS 
(trapped in agarose DNA immune-staining) assay, as described by Willmore et al. 
(1998). Indeed if PMA is protecting the cell by causing a cell block and thus reducing 
cleavable complex processing then the amount of cleavable complexes observed should 
remain the same. It would also be interesting to compare the amount of double strand 
breaks generated in the presence of VP-16 in non-PMA and PMA treated cells. This 
could involve measuring a marker for dsbs, ȖHβAX using flow cytometry (εuslimovi 
et al., 2008). 
As topo IIȕ message is present in a higher amount in macrophage-like cells, then topo 
IIȕ  may  represent  a  better target for inhibiting activated synovial macrophages in 
Rheumatoid arthritis for example, whose secreted soluble products lead to joint 
destruction. At present mitoxantrone is used to ameliorate the inflammatory response in 
RA patients, this topo poison  targets α and ȕ equally. Thus it is important to quantify 
relative levels of α and ȕ in macrophages and to test whether they are more sensitive to 
beta inhibitors both in respect to their survival and to their secretion of pro-
inflammatory products such as iNOS and TNFα.  This type of study is an important step 
in understanding the molecular pharmacology of topo II poisons and inhibitors in 
macrophages. 
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7.3 The effects of 1 nM ICRF-193 pre-treatment on mRNA expression of proteins 
involved in differentiation and stimulation. 
As stated previously, the aim of this project was to determine if topo IIȕ was required 
for differentiation of monocytes into macrophages. As treatment of cells with 1 nM 
ICRF-193 for 6 h resulted in degradation of topo IIȕ, cells were exposed to ICRF for 6 h 
prior to the addition of PMA and LPS. The effect of down-regulation of topo IIȕ on the 
expression of genes involved in differentiation and stimulation was then investigated. 
Results revealed no significant change in the levels of mRNA for all genes studied 
including POR2A (5.6), SP1 (5.7), EGR2 (5.8), NF-țȕ (η.λ), TδRβ (η.10), TδRζ (η.10) 
and TNFα (η.11).  However a general trend emerged whereby levels of SP1, EGF2, NF-
kb, TLR2, TLR4 and TNFα mRNA were increased. The upwards trend in TNFα mRNA 
level was also mirrored by a slight up-regulation of whole cell TNFα protein. It could be 
hypothesised that in the monocyte–like state, topo IIȕ may regulate the transcription of 
these genes in a negative manner. It could be postulated that topo  IIȕ  may  form  a 
complex with other proteins associated with gene repression, for example HDACs to 
compact the area of chromatin containing these genes and thus preventing transcription. 
Inhibition of  topo  IIȕ may  then  lead  to disassociation of  the complex, resulting in the 
relaxation of the chromatin and increased access to these genes by transcription 
machinery and thus an increase in the levels of mRNA & protein. However, other 
studies on certain other genes (SP1 and NF-KB) suggest that their upregulation may be 
due to a DNA damage response induced by ICRF-193 treatment. For example Huang et 
al. (2001) have detected dsbs induced by treatment of cells with ICRF-193. In turn 
activation of NF-țB has been shown to occur in response to induction of dsbs as part of 
a pro-survival response. In addition to repeating these experiments again in order to 
determine if significance can indeed be reached, the yH2AX assay could be used to 
quantify DNA damage at the time points and doses of ICRF-193 used.  
 
As expected when ICRF-193 exposure was extended to 72 hours when levels of topo 
IIȕ  had  recovered  (Figure 5.1), no upward trend in the levels of EGR2 (5.8), NF-țȕ 
(5.9), TLR2 (5.10), TLR4 (5.10) and TNFα (η.11) mRNA was noted. However, levels 
of POLR2A and SP1 were increased although not significantly, Figure 5.6 and 5.7, 
repectively. It is proposed that this is a result of the DNA damage response as both 
genes may be required to facilitate the repair of DNA double strand breaks.  
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Interestingly though, unlike the increase  in  the  levels  of TNFα protein  seen  after  a  θ 
hour exposure, after a 48 and 72 hour exposure of ICRF-1λγ,  TNFα secretion was 
significantly decreased compared to controls (5.13). It is postulated that this may be due 
to an accumulation of DNA damage leading to apoptosis of cells, thus decreasing the 
amount of cells able to secrete TNFα. 
As these results did not support the  original  hypothesis  that  topo  IIȕ is required for 
macrophage differentiation, it may be interesting to use DNA microarray technology 
and exome sequencing to determine if ICRF-193 induced down-regulation of  topo IIȕ 
changes the gene expression, particularly the expression of protein encoding genes in 
cells that are undergoing differentiation with PMA, compared with non ICRF-193 
treated cells under the same conditions.  
7.4 The effects of co-treatment with ICRF-193, PMA and LPS on mRNA 
expression and protein secretion of the pro-inflammatory cytokines TNFα and IL-
1ȕ. 
An investigation into the effects of co-treatment with ICRF-193, PMA and LPS for 72 h 
on TNFα and IL-Iȕ gene expression and protein secretion utilised two different 
concentrations of ICRF-193, 1 nM and 150 nM.  
No significant change in the levels of TNFα or IL-Iȕ mRNA was seen in samples co-
treated with either 1 nM or 150 nM ICRF-193, PMA and LPS for 72 hours. At 1nM 
ICRF-193 a slight increase in the levels of TNFα and Iδ-Iȕ was observed although this 
did not reach significance.  This slight increase was also noted for TNFȕ at a dose of 
150 nM ICRF-193.  
It is postulated that co-treatment has little effect of the transcription of these genes as 
the response to PεA and δPS is mediated more quickly than inhibition of topo IIȕ by 
the drug. Indeed the slight increase in TNFα at both θ and 7β hour exposure and Iδ-1ȕ 
at 6 hr may be as a result of activation of an immune response and the subsequent 
secretion of these cytokines in response (Sauter et al., 2011).  
Unexpectedly though a significant decrease in the levels of secreted IL-1ȕ was seen 
after 72 hours (p = 0.03) (Figure 5.19). As levels of IL-1ȕ  are  not  altered  after  a  7β 
hours exposure,  this  suggests  that  topo  IIȕ  is  not  involved  in  the  regulation  of  Iδ-1ȕ 
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gene expression but may be involved in the regulation of gene expression of proteins 
involved in the IL-1ȕ pathway of secretion.  
Taken together the co-treatment results do not support the hypothesis that topo IIȕ plays 
a role in the transcription of TNFα or IL-1ȕ. However the results point to a complex 
control of secretion of these cytokines and this does not rule out the possibility that topo 
IIȕ may be involved in  the regulation of gene expression of other proteins involved in 
the  TNFα  and IL-Iȕ  pathways of  secretion,  for  example  in  the  regulation  of  TNFα 
converting enzyme expression. 
As many of the results in Chapter 5 follow a trend in which mRNA and protein 
secretion is up-regulated, although often not significantly following ICRF-193 
treatment, it is suggested that ICRF-193 possibly activates the inflammasome and thus 
stimulates an immune response, additionally, as described previously the DNA 
damaging effects induced by ICRF-193 may lead to an up-regulation of NF-țB 
activation and therefore may also effect the production of pro-inflammatory cytokines. 
Furthermore, it is possible that ICRF-193 may bind to cell surface receptors for 
example, TNF-R1, thus preventing activation of neighbouring cells or modulation of 
positive feedback loops. Taken together these possibilities suggest that the effects of 
ICRF-193 are far more extensive than previously reported, and that using ICRF-193 to 
measure the effects of topo IIȕ down-regulation on cytokine production may not be the 
most reliable method. Indeed a previous study has suggested that ICRF-193 itself can 
induce differentiation, however this study used different characteristics to measure 
differentiation, for example the NBT assay. They did however report that ICRF-193 led 
to an increase in the binding activity of the differentiation associated transcription 
factor, AP-1, however they did fail to report on the morphology of the cells following 
treatment with ICRF-193 (Perez et al., 1997), nevertheless this study supports the data 
shown in this thesis, suggesting inhibition of topo IIȕ not only affects the expression of 
transcription factors involved in differentiation but also increases their binding activity.  
These  results  partially  support  the  original  hypothesis  that  topo  IIȕ  is  required  for 
differentiation  of  monocytes  to  macrophages.  The  results  suggest  that  topo  IIȕ  is 
required for the actual function of macrophages in the immune response, in particular in 
the regulation of genes that encode pro-inflammatory cytokines,. 
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In order to strengthen this data it may also be useful to use DNA microarray technology 
and exome sequencing as described previously (Chapter 7.3) to determine if ICRF-193 
induced down-regulation  of  topo  IIȕ  changes  the  gene  expression  of  δPS  induced 
genes, compared with non ICRF-193 treated cells under the same conditions. 
 
7.5 The effect of  topo IIȕ directed siRNA knockdown on  the protein secretion of 
the pro-inflammatory cytokines, TNFα and IL-1ȕ 
In  light  of  previous  results  and  the  disadvantages  of  utilising  a  topo  IIȕ  inhibitor,  an 
investigation into the effect on TNFα and Iδ-1ȕ secretion was performed when topo IIȕ 
protein expression was knocked down by transfection  of  cells with  topo  IIȕ  directed 
siRNA oligonucleotides. The results from this showed in two out of three experiments 
performed, topo IIȕ protein expression had returned after treatment with PεA and δPS 
(Figure 5.22). However one experiment showed that  topo  IIȕ  protein  expression 
remained  decreased  after  PεA  and  δPS  treatment.  Correlation  of  topo  IIȕ  protein 
expression with TNFα and  Iδ-1ȕ  secretion  revealed a positive  correlation; when  topo 
IIȕ protein was decreased, TNFα and  Iδ-1ȕ secretion was  reduced (Figure 5.25). The 
TNFα results are in contrast to previous work utilising ICRF-1λγ as a topo IIȕ inhibitor 
that  showed  that  inhibition  of  topo  IIȕ  lead  to  an  increase  in TNFα  secretion (Figure 
5.17), although this result did not reach significance. The IL-1ȕ results however, are in 
agreement with previous work using ICRF-193 that also showed a decrease in IL-1ȕ 
secretion (Figure 5.19).  The  results  do  suggest  that  topo  IIȕ  is  involved  in  the  gene 
expression  of  proteins  involved  in  both  the  TNFα  and  Iδ-1ȕ  pathways of secretion. 
Further work would utilise qRT-PCR to determine the effect of siRNA-mediated topo 
IIȕ knockdown on the expression of TNFα and Iδ-1ȕ.  In addition the effect of siRNA 
treatment on PMA pre-treated cells would be investigated to determine  if  topo  IIȕ 
knockdown is possible at this time, form this further work measuring cytokine mRNA 
and protein expression would be investigated.  
One caveat in measuring the cytokine response to δPS and topo IIȕ inhibition in chapter 
5 was that only secreted protein was measured fro IL-1ȕ. This requires the cleavage 
action of proteases in order to be secreted into the extracellular environmentIt is 
suggested that further work would utilise western blotting to quantify IL-1ȕ  cellular 
protein levels and these results be combined with secreted protein levels to give a more 
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robust overview of IL-1ȕ  whole  protein  levels.  δevels  of  TNFα  in  co-treatment 
experimetns would also be investigated further. 
For future work it may be useful to dissect the pathways involved in the secretion of 
TNFα  and  Iδ- 1ȕ,  and  thus  thoroughly  investigate  the  role  of  topo  IIȕ  in  the  gene 
expression of the proteins involved in the pathways of secretion. Investigations would 
include measurement of mRNA levels and protein levels in the presence and absence of 
topo  IIȕ. Also  thorough  investigations of  topo  IIȕ upon stimulation of cells with δPS 
with regards to cellular localisation, activity and post-translational modifications may 
also be insightful. Additionally cleavage assays could be utilised to investigate whether 
topo IIȕ can bind and cleave at specific sequences of these genes.  
This result again partially supports the orginial hypothesis that topo IIȕ is required for 
differentiation of monocytes to macrophages.  The results support the work performed 
using ICRF-1λγ  that  shows  that  topo  IIȕ may be  required  for  regulation of  functional 
aspects of macrophages during the immune response, for example, in the  regulation of 
gene expression of pro-inflammatory cytokines or other proteins involved in the 
secretion of pro-inflammatory cytokines. 
7.6 Topo  IIȕ  association  at  discrete  locations  proximal  to  the  TNFα  and  IL-1ȕ 
promoters in non-LPS and LPS stimulated PMA treated U937 cells. 
The suggestion that topo IIȕ positively regulated the secretion of both TNFα and Iδ-1ȕ 
lead to the utilisation of ChIP - qPCR  to  investigate  the  association  of  topo  IIȕ  at 
regions  of  interest  proximal  to  the  TNFα  and  Iδ-1ȕ  promoters  in  non-LPS and LPS 
treated cells. Results showed that there was little association of topo  IIȕ at all regions 
examined on  the TNFα and  Iδ-1ȕ gene both  in non-LPS and LPS treated cells. There 
was a slight increase in association in non-LPS treated cells compared to LPS treated 
cells  on  the TNFα  and  Iδ-1ȕ  gene (Figure 6.5 & 6.6), however these results did not 
reach significance (Appendix C). This result neither supports nor refutes the original 
hypothesis. The trend seen is however worthy of further investigation as it suggests that 
topo  IIȕ may be involved in either the priming of the gene, ready for response to a 
stimuli or in the normal repression of gene transcription when there is no stimuli.  
One of the caveats with regards to sample preparation for the ChIP-qPCR is that cross-
linking of DNA with proteins is performed at one moment in time. The catalytic cycle 
of topo IIȕ has been shown to be only 0.κζ s (Ding et al., 2013), therefore the chances 
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of crosslinking multiple topo IIȕ homodimers at their sites of action at one given time is 
poor. Future work would utilise the topo II poison VP-16 (Cowell et al., 2011) in order 
to generate cleavable complexes thus capturing topo IIȕ at  its site of action for  longer 
than the length of its catalytic cycle. This would then increase the chances of seeing any 
association of  topo  IIȕ at  the regions of  interest. Another problem encountered during 
this experiment was the level of negative control (GFP – DNA association) being too 
high, possibly due to non-specific binding of the GFP antibody to proteins in the 
sample. Therefore no firm conclusions can be made from the data, as results obtained 
for topo IIȕ association may also be due to non-specific binding of that antibody also. If 
this experiment were to be repeated then an optimisation of antibody treatment would 
be carried out prior to processing of samples. 
Another limitation of this experiment is that only ζ discrete regions of the TNFα and Iδ-
1ȕ were investigated, thus this does not provide a full picture of topo IIȕ association at 
these genes. It may therefore be interesting to use ChIP-seq, a method by which all 
regions of DNA that the protein of interest is associated with is sequenced, to look at the 
global differences  in  topo  IIȕ association when PεA treated cells are stimulated with 
LPS compared to no-LPS. 
Future work may also consider investigating  the  association  of  topo  IIα  at  regions  of 
interest within the TNFα and Iδ-1ȕ genes. A previous study has shown that topo IIα is 
required for the priming of developmental genes in anticipation of response to stimuli. It 
is possible that topo IIα and topo IIȕ may work in concert to facilitate the transcription 
of genes that are transcribed in response to stimuli.  
 
7.7 The effect of an absence of topo IIȕ on LPS induced IL-6 expression in mouse 
embryonic fibroblasts 
It may be argued that when investigating the role of topo IIȕ in the expression of genes 
related to differentiation or stimulation, it is not ideal to treat cells with foreign material, 
for example, with ICRF-193 or siRNA, as this may cause the cell to elicit an immune 
response. Indeed the work in Chapter 5 with regards to NF-țB expression  and  Iδ-1ȕ 
secretion, ICRF-193 may induce both a DNA damage response and an immune 
response. Further work in Chapter 5 utilises a mouse embryonic fibroblasts cell line that 
has a stable topo IIȕ knockout (Errington et al., 1999) to investigate the secretion of IL-
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6 in response to varying concentrations of LPS. The results demonstrated that compared 
to the wild-type cells,  the topo IIȕ knockout cells secreted significantly less  Iδ-6 (p < 
0.001) (Figure 5.20). Thus suggesting that topo IIȕ is involved in the secretion of Iδ-6. 
However the results also show that this decrease is time dependent, with the significant 
decrease only being seen after 48 h of LPS stimulation, and not after 72 h. These results 
are in support of previous work that shows that topo IIȕ is required in the earlier stages 
of response to stimuli such as PMA (McNamara et al., 2010). Further work would 
utilise qRT-PCR to measure the mRNA levels of IL-6 after different exposure times to 
LPS to determine if topo IIbeta depletion actually effected the transcription of IL-6. 
This result partially supports the original  hypothesis  that  topo  IIȕ is required for 
differentiation of monocyte to macrophage. The result actually is heavily in support of 
previous work in this thesis that suggests that topo IIȕ is required for the regulation of 
pro-inflammatory  cytokine  secretion,  thus  it  appears  that  topo  IIȕ  is  required  for 
functional regulation of cells that secrete pro-inflammatory cytokines in the immune 
response.  
One limitation with regards to the experiments in Chapters 5 and 6 is that measurements 
were taken after 72 h of LPS treatment. Indeed this is considered a chronic exposure to 
LPS. It may be sensible to suggest that future work also considers investigating multiple 
different exposure times to LPS, for example taking samples after 30 s, 1 min, 5 min 
and 30 min of exposure, all of which are considered acute exposures. 
In addition, reintroducing topo IIȕ to the knockout cells and investigating whether this 
re-instates the secreted levels of IL-6 to those seen in the the wild-type cells is necessary 
to confirm the involvement of topo IIȕ. Further in vitro studies could then be carried out 
to identify whether topo IIȕ binds to this gene (ChIP and cleavage assays) and whether 
its presence can modulate the levels of transcription in an in vitro system.   
It may be sensible to suggest that due to the possibility of ICRF-193 or siRNA eliciting 
an immune or DNA damage response in cells, that utilisation of the MEF topo  IIȕ 
knockdown cell line may be a more reliable source to continue the investigation into the 
role of topo IIȕ in cytokine expression. In particular the future investigation of proteins 
and the genes that encode them that are involved in the immune or DNA damage 
response, for example SP1 and NF-țB.  However this model has its limitations, 
preferably a stable topo IIȕ knockdown monocyte or macrophage cell line would be 
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used. This could be achieved using stable short hairpin RNA (shRNA) that, due to its 
longevity with regards to stability would possibly mean that an acute immune response 
to transfection could be ruled out. A relatively new system, termed CRISPRi may also 
be used to silence the topo IIȕ gene, a highlight of this system is that it has minimal off 
target effects (Gilbert et al., 2013), ideal when examining factors related to the immune 
response. If possible, however, generation of a stable topo IIȕ knockout monocyte cell 
line would enable a more reliable source of investigation into the role of  topo  IIȕ  in 
macrophage differentiation. It would also be interesting to investigate the role of topo 
IIȕ in the differentiation of cells into granulocytes and dendritic cells.  
Taken together the results in this thesis suggest that the catalytic activity of Topo IIȕ is 
necessary  for  secretion  of  normal  levels  of  the  cytokines,  TNFα,  Iδ-1ȕ  and  Iδ-6 in 
response to LPS at certain time points. 
 
7.8 Conclusion. 
In  conclusion,  the  work  presented  in  this  thesis  demonstrates  that  topoisomerase  IIȕ 
may be involved in the regulation of gene expression of proteins involved in the TNFα 
and IL-1ȕ pathways of secretion. The results appear to vary depending on the technique 
used to down-regulate topo IIȕ. Additionally, results obtained when using the topo IIȕ 
inhibitor, ICRF-193, vary depending on when the cells were treated with the drug. For 
example when cells were treated with ICRF-193 prior to differentiation and stimulation, 
levels  of TNFα mRNA and cellular protein are increased, however levels of secreted 
TNFα  are  decreased. In contrast when cells are co-treated with ICRF-193, PMA and 
δPS, TNFα is increased at both the mRNA and secretory protein levels. However when 
using siRNA to down-regulate  topo  IIȕ  expression  prior  to  differentiation  and 
stimulation, TNFα secretion is seen to be decreased. Due to the caveats involved when 
using ICRF-193, in particular the DNA damaging effects, it would sensible to suggest 
that the results when using the siRNA are more reliable and therefore suggest that topo 
IIȕ is involved in the activation of TNFα gene transcription. Furthermore levels of Iδ-
1ȕ secretion are decreased when cells are co-treated with ICRF-193, PMA and LPS, and 
when  topo  IIȕ  is  down-regulated by  siRNAs, however unlike TNFα, no  difference  in 
IL-1ȕ mRNA expression is seen in co-treated cells, suggesting that topo IIȕ is possibly 
involved in the transcription of another protein involved in the IL-1ȕ secretory pathway.  
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Chronic Inflammatory diseases such as Rheumatoid Arthritis are the result of a 
dysregulation of the immune response, resulting in a chronic up-regulation of pro-
inflammatory cytokines, for example TNF? (Moelants et al., 2013). Therefore 
elucidating the exact mechanism, by which these cytokines are expressed including 
factors that regulate their transcription will aid in the generation of new therapies to 
treat chronic inflammatory disorders. Previous studies have shown that treatment of 
cells with sub-lethal doses of etoposide, targeting topo II leads to the down-regulation 
of TNF? and IL-6 secretion (Verdrengh et al., 2003). However the mechanism by 
which this is occurring has not been fully investigated. Further to this long term 
treatment with etoposide may result in the patient experiencing a whole host of 
unwanted side effects. Therefore it is equally as important to determine if down-
regulation  or  inhibition  of  topo  IIȕ  with  ICRF-193 leads to an increase in pro-
inflammatory cytokine production and thus increased inflammation.  
Elucidating the exact  involvement of topo IIȕ in the pathways of secretion may aid in 
the development of new treatments for chronic inflammatory diseases, possibly with the 
intention  of  directly  targeting  topo  IIȕ  in  activated  macrophages  to  inhibit  the 
transcription of genes involved in TNFα and Iδ-1ȕ secretion. For instance, low levels or 
pulses of non-toxic  quantities  of  topo  IIȕ  targeting  agents  could  be  delivered  to 
infiltrating macrophages in the joins of individual sufferers via nanocarriers, for 
example sterically stabilised micelles (Koo et al., 2011). Subsequent phagocytosis of 
the drug loaded particles by the macrophages would ensure this specific cell population 
was targeted. Once within the macrophage it is hypothesised that inhibition of the action 
of  topo  IIȕ  would  reduce  transcriptional  activity  and  thus  reduce  pro-inflammatory 
activity, thereby ameliorating the inflammatory response.  
Future studies will be necessary to examine this possibility but are important as they lay 
the foundation for the development of novel treatments based on modulating 
macrophage function that could in the future be translated into a clinical scenario. 
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Appendix A 
 
Efficiency = 10
-(1/slope)
 
 
For example, efficiency of Topo IIα (Fig 4.4a) = 10-(1/-3.335) 
= 1/-3.335 = -0.2999 
 
= 10
(0.299)
 
 
= 1.991 
 
= (1.991 – 1) X 100 = 99.1% (Efficiency of Primer) 
 
Figure A.1 Calculating the Efficiency of Primers.             
The calculations used in this flow diagram are based on the published method of efficiency 
calculation by Rutledge & Côté (2003).  
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Table A.1 p values from Figure 4.3 
 
Isoform p value 
α 0.0002 *** 
ȕ 0.0008 *** 
 
Table A.2 p values from Figure 4.4 
 
Isoform p value 
α 0.049 * 
ȕ 0.0018 ** 
 
Table A.3 p values from Figure 4.7 
 
Isoform p value 
α - 
ȕ 0.016 * 
 
Table A.4 p values from Figure 4.8 
 
Treatment p value 
No PMA 0.084 
PMA 0.015 * 
 
 
Table A.5 p values from Figure 4.12 
 
Isoform p value 
α 0.047 * 
ȕ 0.11 
 
Table A.6 p values from Figure 4.13 
 
Isoform p value 
α 0.0005 *** 
ȕ 0.005 ** 
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Table A.7 p values from 
Figure 4.14 
 Table A.8 p values from 
Figure 4.15     
 Table A.9 p values from 
Figure 4.16a Co-treat vs 
non-PMA 
 Table A.10  p values from 
Figure 4.16a Co-treat vs 
PMA 
 Table A.11 p values from 
Figure 4.16b Co-treat vs 
non-PMA 
 Table A.12 p values from 
Figure 4.16b Co-treat vs 
PMA 
VP-16 
concentration 
(uM) 
p value  VP-16 
concentration 
(uM) 
p value  VP-16 
concentration 
(uM) 
p value  VP-16 
concentration 
(uM) 
p value  VP-16 
concentration 
(uM) 
p value  VP-16 
concentration 
(uM) 
p value 
 0.01 0.39  0.01 0.6  0.01 0.26  0.01 0.17  0.01 0.89  0.01 0.74 
0.1 0.91  0.1 0.1  0.1 0.55  0.1 0.63  0.1 0.69  0.1 0.11 
1 0.007**  1 0.0001**
* 
 1 0.84  1 0.05*  1 0.0001**
* 
 1 0.001** 
2.5 0.015**  2.5 0.005**  2.5 0.26  2.5 0.07  2.5 0.005**  2.5 0.005** 
5 <0.0001**
* 
 5 0.005**  5 0.15  5 0.004**  5 0.005**  5 0.01** 
7.5 <0.0001**
* 
 7.5 0.02*  7.5 0.26  7.5 0.016*  7.5 0.024*  7.5 0.04* 
10 <0.0001**
* 
 10 0.007**  10 0.11  10 0.005**  10 0.007**  10 0.066 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A.13 p values from 
Figure 4.17 
 Table A.14 p values from 
Figure 4.18 
 Table A.15 p values from 
Figure 4.19 
 Table A.16 p values from 
Figure 4.20 
ICRF-193 
concentration 
(uM) 
p value  ICRF-193 
concentration 
(uM) 
p value  ICRF-187 
concentration 
(ug/ml) 
p value  ICRF-187 
concentration 
(ug/ml) 
p value 
 0.001 0.85   0.001 0.17   0.0001 0.52   0.0001 0.06 
0.01 0.42  0.01 0.01**  0.001 0.36  0.001 0.49 
0.02 0.43  0.02 0.32  0.01 0.37  0.01 0.004** 
0.04 0.27  0.04 0.15  0.1 0.23  0.1 0.07 
0.06 0.27  0.06 0.23  1 0.1  1 0.006** 
0.08 0.23  0.08 0.2  5 0.005**  5 0.0006** 
0.1 0.16  0.1 0.5  10 0.05*  10 0.006** 
1 0.04  1 <0.0001***  20 0.006**  20 0.005** 
2.5 0.001**  2.5 0.0001***     
5 0.003**  5 0.0003**       
7.5 0.01**  7.5 0.006**       
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Figure A.2 Western blot probed for GAPDH as loading control – Figure 4.11a. 
The nitrocellulose blot presented in Figure 4.11a was stripped as described in material 
and methods Section 2.16 and probed with an antibody raised to GAPDH. See Table 2.2 
for antibody details and Section 2.16.7 for probing method. The samples are in the same 
position as indicated in Figure 4.11a. 
 
 
 
                                       
 
Figure A.3 Western blot probed for GAPDH as loading control – Figure 4.11b. 
The nitrocellulose blot presented in Figure 4.11b was stripped as described in material 
and methods Section 2.16 and probed with an antibody raised to GAPDH. See Table 2.2 
for antibody details and Section 2.16.7 for probing method. The samples are in the same 
position as indicated in Figure 4.11b. 
 
 
 
                                       
 
Figure A.4 Western blot probed for GAPDH as loading control – Figure 4.12a. 
The nitrocellulose blot presented in Figure 4.12a was stripped as described in material 
and methods Section 2.16 and probed with an antibody raised to GAPDH. See Table 2.2 
for antibody details and Section 2.16.7 for probing method. The samples are in the same 
position as indicated in Figure 4.12a. 
 
 
  
                                       
 
Figure A.5 Western blot probed for GAPDH as loading control – Figure 4.12b. 
The nitrocellulose blot presented in Figure 4.12b was stripped as described in material 
and methods Section 2.16 and probed with an antibody raised to GAPDH. See Table 2.2 
for antibody details and Section 2.16.7 for probing method. The samples are in the same 
position as indicated in Figure 4.12b. 
 
 
 
 
  
 
 
 
 
 
Appendix B 
 
 
Table B.1 p values for 
Figure 5.3 
 Table B.2 p values for 
Figure 5.4 
 Table B.3 p values for 
Figure 5.5 
 Table B.4 values for Figure 
5.13 
ICRF-193             
pre-treatment (h) 
p value  ICRF-193             
pre-treatment 
(h) 
p value  ICRF-193             
pre-treatment 
(h) 
p value  ICRF-193             
pre-treatment 
(h) 
p value 
2 0.566  2 0.02*  2 0.15  2 0.15 
4 0.32  4 0.53  4 0.97  4 0.92 
6 0.3  6 0.76  6 0.94  6 0.49 
24 0.78  24 0.76  24 0.5  24 0.56 
48 0.37  48 0.42  48 0.11  48 0.02* 
72 0.7  72 0.94  72 0.01  72 0.015* 
   
 
 
 
 
 
 
 
  
 
 
Table B.5 p value from 
Figure 5.6 
 Table B.6 p value from 
Figure 5.7 
 Table B.7 p value from 
Figure 5.8 
 Table B.8 p value from 
Figure 5.9 
ICRF-193 
treatment (h) 
p value  ICRF-193 
treatment (h) 
p value  ICRF-193 
treatment (h) 
p value  ICRF-193 
treatment (h) 
p value 
 6 0.79   6 0.16   6 0.38  6 0.47 
72 0.12  72 0.29  72 0.85  72 0.85 
Table B.9 p value from 
Figure 5.10a 
 Table B.10 p value from 
Figure 5.10b 
 Table B.11 p value from 
Figure 5.11 
 Table B.12 p value from 
Figure 5.16 
ICRF-193 
treatment (h) 
p value  ICRF-193 
treatment (h) 
p value  ICRF-193 
treatment (h) 
p value  ICRF-193 
concentration 
(uM) 
p value 
6 0.46  6 0.38  6 0.1  1 0.37 
72 0.77  72 0.42  72 0.8  150 0.47 
 
 
Table B.13 p value from 
Figure 5.17 
  
 
Table B.14 p value from 
Figure 5.18 
  
 
Table B.15 p value from 
Figure 5.19 
  
ICRF-193 
concentration 
(uM) 
p value  ICRF-193 
concentration 
(uM) 
p value  ICRF-193 
concentration 
(uM) 
p value    
1 0.36  1 0.71  1 0.09    
150 0.48  150 0.47  150 0.02    
 
  
                              
Table B.16 p values from 
Figure 5.20a 
                               
Table B.17 p values from 
Figure 5.20b 
 
LPS 
concentration 
(ng/ml)      
p value  LPS 
concentration 
(ng/ml)      
p value  
0.1 0.95   0.1 0.69  
1 0.08  1 0.62  
5 <0.0001  5 0.36  
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Figure B.1 Western blot probed for GAPDH as loading control- Figure 5.1a.                           
The nitrocellulose blot presented in Figure 5.1a was stripped as described in material 
and methods Section 2.16 and probed with an antibody raised to GAPDH. See Table 2.2 
for antibody details and Section 2.16.7 for probing method. The samples are in the same 
position as indicated in Figure 5.1a. 
 
                                      
Figure B.2 Western blot probed for GAPDH as loading control- Figure 5.1b.                            
The nitrocellulose blot presented in Figure 5.1b was stripped as described in material 
and methods Section 2.16 and probed with an antibody raised to GAPDH. See Table 2.2 
for antibody details and Section 2.16.7 for probing method. The samples are in the same 
position as indicated in Figure 5.1b. 
 
 
Figure B.3 Western blot probed for Topoisomerase IIȕ                                                        
Samples prepared for this blot are as follows, Lane 1; 6 h pre-treatment with 0.1% 
DMSO (v/v), followed by 72 h treatment with 0.1% DMSO (v/v). Lane 2; 6 h pre-
treatment with 0.1% DMSO (v/v) followed by 72 h treatment with 5 ng/ml PMA and 10 
ng/ml LPS. Lane 3; 6 h pre-treatment with 1 nM ICRF-193 followed by 72 h treatment 
with 0.1% DMSO (v/v). Lane 4; 6 h pre-treatment with 1 nM ICRF-193 followed by 
72h treatment with 5 ng/ml PMA and 10 ng/ml LPS. Lane 5; 72 h co-treatment 150 nM 
ICRF-193, 5 ng/ml PMA and 10 ng/ml LPS. Lane 6; 72 h co-treatment 0.1% DMSO 
(v/v), 5 ng/ml PMA and 10 ng/ml LPS. Lane 7; Recombinant topo IIȕ. Cells were 
harvested by cell scraping and whole cell lysates were prepared as described in Section 
2.16.1. 31.9ȝg of whole protein was loaded onto a 10% SDS-PAGE gel, 
electrophoresis, western blotting and probing was performed as described in Section 
2.16.  
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Figure B.4 Western blot probed for Topoisomerase IIȕ – 72 h 1 nM ICRF-193 pre-
treatment.                                                                                                                                       
Samples prepared for this blot were as followed; Lane 1; 72 hour pre-treatment with 
0.1% DMSO (v/v) followed by 72 h treatment with 0.1% DMSO (v/v). Lane 2; 72 h 
pre-treatment with 0.1% DMSO (v/v) followed by 72 h treatment with 5 ng/ml PMA 
and 10 ng/ml LPS. Lane 3; 72 h pre-treatment with 1 nM ICRF-193 followed by 72 h 
treatment with 0.1% DMSO (v/v). Lane 4; 72 h pre-treatment with 1 nM ICRF-193 
followed by 72 h treatment with 5 ng/ml PMA and 10ng/LPS. Lane 5; Recombinant 
topo IIȕ. Cells were harvested by cell scraping and whole cell lysates were prepared as 
described in Section 2.16.1. 31.9ȝg of whole protein was loaded onto a 10% SDS-
PAGE gel, electrophoresis, western blotting and probing was performed as described in 
Section 2.16.  
 
                                       
Figure B.5 Western blot probed for GAPDH as loading control- Figure 5.14.                           
The nitrocellulose blot presented in Figure 5.14 was stripped as described in material 
and methods Section 2.16 and probed with an antibody raised to GAPDH. See Table 2.2 
for antibody details and Section 2.16.7 for probing method. The samples are in the same 
position as indicated in Figure 5.14. 
 
                                       
Figure B.6 Western blot probed for GAPDH as loading control- Figure 5.21.                           
The nitrocellulose blot presented in Figure 5.21 was stripped as described in material 
and methods Section 2.16 and probed with an antibody raised to GAPDH. See Table 2.2 
for antibody details and Section 2.16.7 for probing method. The samples are in the same 
position as indicated in Figure 5.21 
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Figure B.7 Western blot probed for GAPDH as loading control- Figure 5.22a.                         
The nitrocellulose blot presented in Figure 5.22a was stripped as described in material 
and methods Section 2.16 and probed with an antibody raised to GAPDH. See Table 2.2 
for antibody details and section 2.16.7 for probing method. The samples are in the same 
position as indicated in Figure 5.22a. 
 
                                                 
 
Figure B.8 Western blot probed for GAPDH as loading control- Figure 5.22b.                          
The nitrocellulose blot presented in Figure 5.22b was stripped as described in material 
and methods Section 2.16 and probed with an antibody raised to GAPDH. See Table 2.2 
for antibody details and Section 2.16.7 for probing method. The samples are in the same 
position as indicated in Figure 5.22b. 
 
                          
 
Figure B.9 Western blot probed for TNFα (whole blot from Figure 5.14)                             
Samples prepared for this blot are as follows, Lane 1; 6 h pre-treatment with 0.1% 
DMSO (v/v), followed by 72 h treatment with 0.1% DMSO (v/v). Lane 2; 6 h pre-
treatment with 0.1% DMSO (v/v) followed by 72 h treatment with 5 ng/ml PMA and 10 
ng/ml LPS. Lane 3; 6 h pre-treatment with 1 nM ICRF-193 followed by 72 h treatment 
with 0.1% DMSO (v/v). Lane 4; 6 h pre-treatment with 1 nM ICRF-193 followed by 
72h treatment with 5 ng/ml PMA and 10 ng/ml LPS. Lane 5; 72 h co-treatment 150 nM 
ICRF-193, 5 ng/ml PMA and 10 ng/ml LPS. Lane 6; 72 h co-treatment 0.1% DMSO 
(v/v), 5 ng/ml PMA and 10 ng/ml LPS. Please note Lanes 3 & 4 are denoted as Lanes 1 
and 2 in Figure 5.14. 
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Figure B.10 Western blot probed for TNFα – 72 h 1 nM ICRF-193 pre-treatment        
Samples prepared for this blot were as followed; Lane 1; 72 hour pre-treatment with 
0.1% DMSO (v/v) followed by 72 h treatment with 0.1% DMSO (v/v). Lane 2; 72 h 
pre-treatment with 0.1% DMSO (v/v) followed by 72 h treatment with 5 ng/ml PMA 
and 10 ng/ml LPS. Lane 3; 72 h pre-treatment with 1 nM ICRF-193 followed by 72 h 
treatment with 0.1% DMSO (v/v). Lane 4; 72 h pre-treatment with 1 nM ICRF-193 
followed by 72 h treatment with 5 ng/ml PMA and 10ng/LPS. Cells were harvested by 
cell scraping and whole cell lysates were prepared as described in Section 2.16.1. 
31.9ȝg of whole protein was loaded onto a 10% SDS-PAGE gel, electrophoresis, 
western blotting and probing was performed as described in Section 2.16.  
 
 
 
                                        
 
Figure B.11 Western blot probed for GAPDH as loading control- Figure B.8.                           
The nitrocellulose blot presented in Figure B.12 was stripped as described in material 
and methods Section 2.16 and probed with an antibody raised to GAPDH. See Table 2.2 
for antibody details and Section 2.16.7 for probing method. The samples are in the same 
position as indicated in Figure B.12. 
 
                                                                   
 
Figure B.12 Western blot probed for topoisomerase IIȕ                                                              
Wild type and topo IIȕ -/- mouse embryonic fibroblasts were grown to confluency and 
harvested using trypsin (Section 2.9).  Whole cell lysates were prepared as described in 
Section 2.16.7 25.7ȝg of whole protein was then loaded onto a SDS-PAGE gel, 
electrophoresis, western blotting and probing were performed as described in section 
2.16. The band on the left is wild type sample and the lack of band on the right is the 
topo IIȕ -/- sample. 
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Table C.1  p values from Figure 6.5   Table C.2  p values from Figure 6.6   
No LPS 
vs  
LPS 
p value  
(Primer pair 1) 
p value  
(Primer pair 2) 
p value  
(Primer pair 3) 
p value  
(Primer pair 4) 
 3535           
vs 
GFP 
p value  
(Primer pair 1) 
p value  
(Primer pair 2) 
p value  
(Primer pair 3) 
p value  
(Primer pair 4) 
3535 0.8 0.45 0.38 0.43  No LPS 0.74 0.48 0.49 0.98 
AcH3 0.11 0.11 0.08 -  LPS 0.76 0.98 0.13 0.21 
         
           
Table C.3 p values from Figure 6.6   Table C.4 p values from Figure 6.5   
GFP   
vs  
AcH3 
p value  
(Primer pair 1) 
p value  
(Primer pair 2) 
p value  
(Primer pair 3) 
p value  
(Primer pair 4) 
 3535   
vs  
AcH3 
p value  
(Primer pair 1) 
p value  
(Primer pair 2) 
p value  
(Primer pair 3) 
p value  
(Primer pair 4) 
No LPS 0.09 0.17 0.09  0.32  No LPS 0.06 0.69 0.92 0.29 
LPS 0.01 0.02 0.007 -  LPS 0.012 0.019 0.0075 - 
         
           
           
           
           
           
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table C.5  p values from Figure 6.6   Table C.6  p values from Figure 6.6   
3535          
vs 
GFP 
p value  
(Primer pair 1) 
p value  
(Primer pair 2) 
p value  
(Primer pair 3) 
p value  
(Primer pair 4) 
 No LPS 
vs  
LPS 
p value  
(Primer pair 1) 
p value  
(Primer pair 2) 
p value  
(Primer pair 3) 
p value  
(Primer pair 4) 
No LPS 0.74 0.72 0.54 0.45  3535 0.36 0.38 0.38 0.68 
LPS 0.28 0.015 0.24 0.36  AcH3 0.04 0.13 0.25 0.37 
         
           
Table C.7 p values from Figure 6.6   Table C.8 p values from Figure 6.6   
GFP   
vs  
AcH3 
p value  
(Primer pair 1) 
p value  
(Primer pair 2) 
p value  
(Primer pair 3) 
p value  
(Primer pair 4) 
 3535   
vs  
AcH3 
p value  
(Primer pair 1) 
p value  
(Primer pair 2) 
p value  
(Primer pair 3) 
p value  
(Primer pair 4) 
No LPS 0.14 0.09 0.36 0.23  No LPS 0.34 0.3 0.84 0.91 
LPS 0.14 0.09 0.36 0.23  LPS 0.002 0.01 0.048 0.25 
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Figure D.1 Scatter graphs for HL-60 cells (non-PMA treated) after flow 
cytometry using and antibody to CD11b 
Cells were seeded at 3 x 105 cells/ml and treated with 0.1% DMSO for 72 h. Cells 
were then harvested and washed before being probed with an antibody to CD11b – 
conjugated to APC. Flow cytometry was then performed, and the resulting scatter 
graphs (FL4-H is the channel of the flow cytometer capable of detecting and APC 
signal) are shown in this figure. The top left scatter graph is the control set of cells that 
were not treated with antibody. The other five scatter graphs depict the results of non-
PMA treated HL-60 cells when probed with an antibody to CD11b.  
  
 
Figure D.2 Scatter graphs for HL-60 cells (PMA treated) after flow cytometry 
using and antibody to CD11b. 
Cells were seeded at 3 x 105 cells/ml and treated with 5ng/ml PMA for 72 h. Cells were 
then harvested and washed before being probed with an antibody to CD11b – 
conjugated to APC. Flow cytometry was then performed, and the resulting scatter 
graphs (FL4-H is the channel of the flow cytometer capable of detecting and APC 
signal) are shown in this figure. The top left scatter graph is the control set of cells that 
were not treated with antibody. The other five scatter graphs depict the results of PMA 
treated HL-60 cells when probed with an antibody to CD11b.  
 
   
